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Abstract 
Melanoma is the fourth most common cancer in Australia (and 6th in the USA) leading to 
more than 1,500 preventable deaths each year. Over 136,000 Australians live with a 
previous melanoma diagnosis, and are at a significantly increased risk of developing 
subsequent primary melanomas. The overall 5-year survival for melanoma is high if the 
disease is detected early (91%) and removed through curative surgery, however 
metastatic melanoma has very poor prognosis, with 5-year patient survival of < 15%. Until 
relatively recently, metastatic melanoma patients, had no viable treatment options for 
disseminated melanoma, but with the advent of targeted therapies (e.g. BRAF inhibitors or 
BRAFi) – there is dramatic improvement in progression-free survival. Currently there is an 
unmet need for highly specific and predictive biomarkers of melanoma burden and 
treatment resistance. To address this need, this thesis focused on microRNAs (miRNAs) 
which have an inherent ability to behave in a tissue-specific manner. The biomarker 
potential of miRNAs is also high due to their stability in both tissue and blood. Melanoma 
progression markers have been used for many years, however it is clear from the survival 
rates that melanoma must be detected before disease progresses; thus highlighting that 
the current methods of progression detection are inadequate. 
 
miRNA microarrays (all known miRNAs present in miRBase v18) were used to 
comprehensively study the miRNA profile of melanoma in relation to other solid 
malignancies (e.g. breast, ovarian, prostate and colorectal cancer). The miRNAs enriched 
for melanoma were deemed to be ‘melanoma-related’ and were subsequently assessed 
(using a high-throughput sensitive method (Fluidigm Biomark HD)) as potential biomarkers 
for disease detection and prognosis in serum and tissue collected from biobanks in 
Australia and Germany. Target genes, from some of these miRNAs, were also identified 
(via a ‘pull-down’ procedure) which provided a unique insight into the regulation of key 
genes and pathways – important for melanomagenesis. 
 
This study has identified a seven-miRNA panel (‘MELmiR-7’) that has the ability to detect 
the presence of melanoma with high sensitivity and specificity which is superior to 
currently used markers for melanoma progression, recurrence, and survival. Using cutting-
edge techniques, this thesis also identified key genes involved in resistance to targeted 
therapies and pathways important to the melanocytic lineage and melanoma development. 
 
vii 
 
Overall, the findings discussed in this thesis may lead to more precise measurement of 
disease progression allowing for better treatments and an increase in overall survival. 
Armed with an improved surveillance methodology, we hope to see better clinical 
management of metastatic disease, which in turn could increase objective clinical 
responses and survival times. Given the advances presented in this thesis, future 
melanoma treatment regimens should consider the utility of miRNAs as a prognostic aid in 
the clinical setting. 
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Chapter 1 
Introduction 
1.1- Significance of the project 
Melanoma is the fourth most common cancer in Australian men and women, causing 
more than 1,500 preventable deaths each year. Over 136,000 Australians live with a 
previous melanoma diagnosis, and are at a significantly increased risk to develop 
subsequent primary melanomas [1]. While some melanomas are particularly deadly 
(nodular, amelanotic, and those diagnosed at greater thickness), all melanomas are 
potentially dangerous [2]. The overall 5-year survival for melanoma is high if the 
disease is detected early (91%) and removed through curative surgery, however 
metastatic melanoma has very poor prognosis, with 5-year patient survival of < 15%. 
Until relatively recently, metastatic melanoma patients, had no viable treatment 
options for disseminated melanoma, but with the advent of targeted therapies - we 
are witnessing dramatically improved progression-free survival. However, these 
dramatic response rates have not translated into vast improvements in overall 
survival. This can be attributed to inherent and acquired resistance to these new 
therapies. Therefore, other than primary prevention, early detection of primary 
lesions offers the best hope through curative surgery. Moreover, if targeted therapies 
could be offered at a lower disease burden, i.e., early detection of melanoma 
metastases, prior to clinically evidence disease – then one would expect to see a 
significant increase in overall survival. A key element in facilitating early diagnosis 
and/or new therapeutic options is the identification of new biomarkers and functional 
targets for this disease. This study aims to address the hypothesis that microRNAs 
(miRNAs) will provide a rich source of melanoma-specific markers and targets. 
 
1.2- Melanoma background 
Melanoma is defined as a malignant neoplasm that arises from melanocytes of the 
skin and other organs. In normal healthy skin, melanocytes (melanin-producing cells) 
are maintained for many years and are resistant to apoptosis (programmed cell-
death) due to the high expression of the anti-apoptotic gene BCL2 [3, 4]. Due to this 
“non-renewal”, melanocytes are susceptible to malignant transformation if normal 
DNA repair or cell-cycle control mechanisms are damaged due to repeated insult by 
1
 
 
ultra-violet radiation (UVR). In the majority of sporadic melanoma cases, UVR can 
cause irreversible DNA damage or a change in gene expression in the melanocytes 
that sets off a cascade of events, which after repeated prolonged UVR exposure, 
leads to uncontrolled cell proliferation. If this condition is left undiagnosed and the 
nascent tumour is not surgically removed, tumour cell infiltration of the lymphatic and 
circulatory systems (Figure 1.1) may occur leading to metastasis to distal organs. 
 
There are four main classes of cutaneous melanoma: superficial spreading 
melanoma (SSM), lentigo maligna melanoma (LMM), acral lentiginous melanoma 
(ALM), and nodular melanoma (NM). SSM is the most common of all melanomas 
and is often seen in the younger age-group. It is generally an in situ or thin 
melanoma as it is confined to the epidermis although SSM can invade into the 
dermis if not surgically removed. Lentigo maligna melanoma are also often confined 
to the epidermis, however, usually they are found in chronically sun-damaged skin 
(e.g. face, ears, and arms) of the older age group. ALM also usually begins as an in 
situ melanoma that grows superficially (within the epidermis) prior to invasion. It 
differs from SSM and LMM as it presents on skin surfaces such as on the palms of 
hand and soles of feet. Lastly, NM is an invasive form of primary melanoma which 
presents as an elevated lump on the skin surface and which has begun to invade 
Figure 1.1 Diagram of a 
skin cross-section 
showing proliferation of 
malignant melanocytes 
and their proximity to the 
lymphatic and 
circulatory systems. 
 
2
 
 
through into the dermis. Due to this invasion, it is considered the more aggressive 
form of melanoma. 
1.3- Melanoma genomics 
UVR is the leading risk factor in the development of cutaneous melanoma (~90%); 
which can also be found in non-UVR exposed body sites; with the remaining 10% of 
melanoma cases being due to an inheritable predisposition in families. Mutations in 
genes such as CDKN2A (~35-50% of all familial cases), CDK4 (<1%) (reviewed in  
[5]) and BAP1 (<1%) have been identified as causative in some families and are 
classed as high-penetrance genes [6]. Low to medium penetrance genes, like MC1R 
[7] and MITF [8], have been successfully identified and more recently, genes 
involved in protection of telomere length (shelterin complex e.g. POT1, ACD, and 
TERF2IP) have been found to be melanoma associated [9, 10]. The remaining 90% 
of ‘sporadic’ melanomas are caused by the complex interplay of genomic copy 
number alterations  involving  focal, regional, and whole chromosome amplifications 
and deletions, and loss-of-heterozygosity (LOH) [11]; somatic mutations [12], 
methylation status [13], and gene expression alterations [14, 15]. To date a large 
number of studies have catalogued these events which have resulted in some 
ground-breaking discoveries which have ultimately led to the development of 
mutation-specific targeted therapies for melanoma patients. A prime example are the 
BRAF V600E inhibitor drugs (e.g. dabrafenib and vemurafenib) which inhibit the 
mutant BRAF protein (~50% of all melanoma tumours harbour a V600 mutation). 
There have been some dramatic responses to this therapy in patients, some with 
long-term progression-free survival, however most patients develop resistance to 
therapy (either acquired or innate resistance) so there is still much to be learned to 
devise better therapies. Due to the genomic complexities of melanoma, there was a 
great need to perform a large-scale, comprehensive, and integrated analysis to try 
and uncover the precise mechanisms involved in melanomagenesis. Current multi-
centre consortia (TCGA and ICGC) studies are underway and nearing completion, 
which harness the power of current high-throughput technologies, such as next-
generation sequencing (NGS)) [16]. In a study of 333 melanoma tissues, the TCGA 
consortium established a framework whereby cutaneous melanoma could be 
classed based upon a genomic classification of the most frequently mutated genes: 
mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type) [16]. The hope is 
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that these studies will allow for better therapeutic options to be devised for metastatic 
melanoma patients (Stage III and IV).  
1.4- Melanoma diagnosis 
Melanoma is diagnosed by a complete physical examination. A practitioner, usually a 
dermatologist, will visually inspect the entire surface of the body. If any suspicious 
lesions are noted, the physician will utilize a dermoscope, which magnifies the skin 
lesion and allows for inspection of the dermo-epidermal junction. Photographs of 
pigmented lesions are taken as a reference point for follow-up visits to determine if 
the margins (shape) have changed, which indicates that the lesion is likely malignant 
as opposed to benign. The physician will palpate the regional lymph nodes near any 
suspicious lesion and assess whether any further tests are necessary. Often, if the 
regional nodes are inflamed, then the patient is referred to have a chest x-ray 
followed by a CT scan or MRI for a closer inspection of potential metastases. 
Following these examinations, a skin biopsy is taken which will show whether or not 
the lesion was benign or malignant and, if malignant, how deep the tumour had 
penetrated the skin and whether there are any signs of ulceration. Using all of these 
pieces of information, the tumour is staged (0-IV), which impacts upon the level of 
treatment given to the patient.  
1.5- Melanoma staging and treatment 
The American Joint Committee on Cancer (AJCC) published the 7th edition of the 
AJCC staging Manual in 2009 which was implemented in 2010 [17-19]. The 8th 
edition is currently being drafted and will be implemented in 2017. There are vast 
numbers (~40,000) of patients contained within the AJCC database which makes for 
a highly significant dataset. According to this updated dataset, melanoma is grouped 
into the following stages (Staging descriptions were sourced from 
http://www.melanomacenter.org). 
1.5.1- Melanoma in situ, or Stage 0 melanoma 
Melanoma in situ, or Stage 0 melanoma (Figure 1.2), is very early stage disease 
which involves the epidermis but has not reached the underlying dermis. Treatment 
generally involves minor surgery to remove the tumour and a limited surgical margin 
(5 mm) of the ‘normal-appearing’ skin. Following removal of the margins, the 
likelihood of local recurrence of the disease is small. Patients with melanoma in situ 
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Figure 1.2 Depiction of the various stages of melanoma. Sourced from 
www.roche.co.uk/home/disease-areas/cancer/skin-cancer.html 
 
 
should receive a physical examination, including a skin examination, every 6 months 
for one to two years following surgery and at least annually for years 3, 4, and 5. 
 
1.5.2- Stage I melanoma 
Stage I melanomas (Figure 1.2) are localized tumours and are characterized by 
tumour thickness, presence and number of mitoses, and ulceration status. There is 
no evidence of regional lymph node or distant metastasis. There are two subclasses 
of Stage I melanoma.  
• Stage IA (T1aN0M0) 
 T1a: the tumour is no more than 1.0 mm thick, with no ulceration 
and no mitoses 
 N0: the tumour has not spread to nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
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tumour  
 
• Stage IB (T1bN0M0 or T2aN0M0) 
 T1b: the tumour is no more than 1.0 mm thick, with ulceration or 
presence of > 1 mitoses 
 T2a: the tumour is 1.01-2.0 mm thick, with no ulceration 
 N0: the tumour has not spread to nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour 
 
1.5.2.1. Stage I treatment 
Stage I tumours are removed surgically via a “wide local excision” procedure. The 
width of the margin taken depends on the thickness of the primary tumour and it is 
often recommended for the sentinel lymph node to be biopsied (SLNB) in Stage I 
tumours >1mm and for ulcerated tumours of any thickness. The results of the biopsy 
will help devise the best course of treatment. The future clinical management of the 
disease is the same as Stage 0 disease. 
1.5.3- Stage II melanoma 
Stage II melanomas (Figure 1.2), similar to Stage I melanoma, is also characterized 
by tumour thickness and ulceration status and there is no evidence of regional lymph 
node or distant metastasis. There are three subclasses of Stage II melanoma. 
• Stage IIA (T2bN0M0 or T3aN0M0) 
 T2b: the tumour is 1.01-2.0 mm thick, with ulceration 
 T3a: the tumour is 2.01-4.0 mm thick, with no ulceration 
 N0: the tumour has not spread to nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour  
 
• Stage IIB (T3bN0M0 or T4aN0M0) 
 T3b: the tumour is 2.01-4.0 mm thick, with ulceration 
 T4a: the tumour is greater than 4.0 mm thick, with no ulceration 
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 N0: the tumour has not spread to nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour  
 
• Stage IIC (T4bN0M0) 
 T4b: the tumour is greater than 4.0 mm thick, with ulceration 
 N0: the tumour has not spread to nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour 
 
1.5.3.1. Stage II treatment 
Stage II melanomas undergo the same surgical treatment as Stage I tumours, along 
with a SLNB. The difference in treatment is that most patients have some form of 
adjuvant therapy which usually involves a systemic treatment, with interferon alpha 
therapy being the most common, which assists the patient to develop an immune 
response against the tumour (reviewed in [20]). The success of adjuvant therapy is 
highly variable with most patients having limited benefit [20]. However, data from a 
large nodal biopsy study, found that staging of intermediate-thickness or thick 
primary melanomas provided prognostic information and identified patients with 
nodal metastases [21]. The authors concluded that these data support the notion 
that nodal biopsies prolonged distant disease-free survival and melanoma-specific 
survival for patients with nodal metastases from intermediate-thickness melanomas 
[21]. 
The future clinical management of the disease is the same as Stage 0 and I disease. 
1.5.4- Stage III melanoma 
Stage III melanomas (Figure 1.2) are those that have spread to regional lymph 
nodes or have developed in transit metastasis or satellites, yet display no evidence 
of distant metastasis. There are three subclasses of Stage III melanoma. 
• Stage IIIA (T1-T4a N1aM0 or T1-T4aN2aM0) 
 T1-T4a: the tumour is not ulcerated and ranges in size from less 
than 1.0 mm to more than 4.0 mm thick. 
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 N1a: micro-metastasis is diagnosed in 1 nearby lymph node 
 N2a: micro-metastasis is diagnosed in 2-3 nearby lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour  
 
• Stage IIIB (T1-T4bN1aM0, T1-T4bN2aM0, T1-T4aN1bM0, T1-T4aN2bM0, or 
T1-T4a/bN2cM0) 
 T1-T4a: the tumour is not ulcerated and ranges in size from less 
than 1.0 mm to more than 4.0 mm thick. 
 T1-4b: the tumour is ulcerated and ranges in size from less than 
1.0 mm to more than 4.0 mm thick 
 N1b: macro-metastasis is diagnosed in 1 nearby lymph node 
 N2b: macro-metastasis is diagnosed in 2-3 nearby lymph nodes 
 N2c: presence of in-transit metastases or satellite metastases 
 M0: the tumour has not spread to sites distant from the primary 
tumour  
 
• Stage IIIC (T1-4bN1bN0, T1-4bN2bM0, T1-4aN3MO or T1-4bN3MO) 
 T1-T4a: the tumour is not ulcerated and ranges in size from less 
than 1.0 mm to more than 4.0 mm thick. 
 T1-4b: the tumour is ulcerated and ranges in size from less than 
1.0 mm to more than 4.0 mm thick 
 N1b: macro-metastasis is diagnosed in 1 nearby lymph node 
 N2b: macro-metastasis is diagnosed in 2-3 nearby lymph nodes 
 N3: metastasis in 4 or more lymph nodes, the presence of 
matted lymph nodes, or the combination of in-transit/satellite 
metastases and metastatic lymph nodes 
 M0: the tumour has not spread to sites distant from the primary 
tumour 
1.5.4.1. Stage III treatment 
The treatment for Stage III melanoma is complicated to say the least and relies 
heavily on the accuracy of the clinical staging of the disease. Surgery is performed in 
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the same manner as for Stage I and II tumours however only small, easily 
removable, and recurrent tumours are removed and in patients who have a limited 
number of in-transit tumours. It is common for patients to have a therapeutic lymph 
node dissection (TLND) which removes all regional lymph nodes from the area 
where cancerous lymph nodes are found which reduces the possibility of further 
spread through the lymphatic system. In addition to the surgical procedures, Stage III 
patients receive the same type of adjuvant therapy as Stage II patients but some (i.e. 
with unresectable tumours) may qualify for early access to therapy which is usually 
only made available to Stage IV patients. The clinical management of Stage III 
disease is of the utmost importance for identification of distant metastases to vital 
organs.  
Following treatment, Stage III patients are subjected to the standard physical 
examinations including computer tomography (CT) scans and serum lactate 
dehydrogenase (LDH) testing every 3 months for the first year, every 4 months in the 
second year, every 6 months in the third-fifth year, and then yearly for every 
subsequent year post 5 years. The frequency of these tests is necessary for early 
detection of distant metastases however they are a burden to the patient, along with 
an even greater burden to the healthcare system.  
1.5.5- Stage IV melanoma 
Stage IV melanomas (Figure 1.2) are associated with metastasis beyond the 
regional lymph nodes to distant sites in the body; commonly to vital organs like the 
lungs, abdominal organs, brain, and bone.  
Primary characteristics of Stage IV melanoma include: 
• Location of the distant metastases 
• Number and size of tumours 
• Serum LDH level. Elevated LDH levels usually indicate that the tumour has 
spread to internal organs.  
 
Stage IV melanomas do not include any T or N classification and are classified 
based on their M Stage. 
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• M1a: the tumour has metastasised to distant skin, the subcutaneous layer or 
to distant lymph nodes. Serum LDH is normal. 
• M1b: the tumour has metastasised to the lungs. Serum LDH is normal. 
• M1c: the tumour has metastasised to vital organs other than the lungs and 
serum LDH is normal, or there are any distant metastases with elevated LDH 
 
1.5.5.1. Stage IV treatment 
Targeted therapy for the treatment of metastatic melanoma has heralded an 
increase in progression free and overall survival. Support of this has been seen in 
recent clinical trials in Stage III unresectable and Stage IV melanoma patients, 
treated with ipilimumab (targets CTLA-4),[22] vemurafenib (targets BRAF 
V600E/K),[23] combined dabrafenib (targets BRAF V600E/K) and trametinib (targets 
MEK1 and MEK2) [24] or anti-PD1 pembrolizumab [25]. An improved overall survival 
and response rate in patients with lower disease volume (M1a/M1b) has been 
observed as compared to those with distal disease (M1c). One observation after 
drug treatment is the dramatic reduction in tumour load, giving patients much needed 
relief. However, in many cases this is short-lived (a few months) with progressive 
disease returning. Alternatively, treatments often focus instead on relieving 
uncomfortable symptoms caused by the disease. They include: 
• Surgery to remove cancerous tumours or lymph nodes that have 
metastasised to other areas of the body, if they are few in number and are 
causing symptoms. 
• Radiation therapy is generally reserved for advanced cases where surgery is 
complicated or likely to have no effect on the patients’ quality of life. 
 
1.6- Melanoma Patient Survival 
According to recent data from the AJCC Staging committee, the survival rates for 
patients diagnosed with Stage I-III disease, even at 20 years, is much greater for 
Stage I-III than for IV, with the prognosis for Stage IV patients remaining poor (Figure 
1.3). Other than primary prevention, early detection offers the best hope through 
curative surgery. Early detection of melanoma metastases in patients originally 
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Figure 1.3: 
Survival rates for 
patients with 
AJCC Stages I-IV 
melanoma. [18] 
 
diagnosed with Stage II/III disease has the potential to greatly increase the chances 
of long-term survival of patients.  
 
Melanoma progression markers have been used for many years with varying levels 
of success. However it is clear from the survival rates shown in Figure 1.3 that 
melanoma must be detected before disease progresses thus highlighting the point 
that the current methods of progression detection are inadequate. 
1.7- FDA approved biomarkers for cancer 
There are only a handful of approved biomarkers [26] being used for diagnosis 
and/or clinical staging of late stage disease. In order for a biomarker to attain current 
FDA approval, it must be “proven” in the clinical setting with the main emphasis on 
statistical robustness of the findings. Moreover, the biomarkers should be highly 
sensitive and specific to the cancer. Many of the historically approved biomarkers 
would most likely not meet these criteria (e.g. serum PSA). Some of these FDA 
approved biomarkers include: HER2/neu (breast cancer), CA-125 (ovarian cancer), 
and PSA for screening and monitoring of prostate cancer. 
1.7.1- HER2/neu 
HER2/neu is overexpressed in 15-20% of invasive breast cancers, and is associated 
with increased tumour aggressiveness and reduced survival rates [27]. 
Measurement of the expression levels of HER2 is necessary to classify the tumour in 
order to decide on the appropriate treatment regimen. The results are highly specific 
11
 
 
and sensitive, however the results are determined by the judgement of the 
pathologist. In most cases HER2 status is defined as negative, borderline, or 
positive, with no formal statistical analysis done. 
1.7.2- CA-125 
CA-125 has been shown to be effective in predicting prognosis after treatment, and 
for detecting the recurrence of ovarian cancer. It is important however to note that 
CA125 is not specific to ovarian cancer and has been observed in serum of 
individuals with endometriosis [28] as well as in other cancer types. CA-125 levels 
>35 U/ml are considered to be elevated, however ovarian cancer is only diagnosed 
after a series of CA-125 measurements over time and in combination with a pelvic 
examination along with sonography. Thus the biomarker test itself is insufficient to 
lead to a diagnosis of ovarian cancer. 
1.7.3- Serum PSA 
Serum PSA is normally present at relatively low levels in men, and increased levels 
of this protein can be indicative of prostate cancer. It is also common to have 
elevated levels of PSA due to prostate infection, irritation, and benign prostatic 
hypertrophy. In the past, most doctors considered a serum PSA level below 4.0 
ng/mL as normal. However prostate cancer has been diagnosed in ~15% of men 
with a PSA level at or below 4.0 ng/mL [14]. The PSA test remains a common 
screening tool mainly due to its high sensitivity, albeit its low specificity. 
With the ever increasing use of high-throughput tools like microarrays, many 
potentially useful biomarkers for cancer have been identified; however, most are yet 
to be approved by the FDA. Those that have not undergone testing in a clinical 
setting are simply classed as an ASR (analyte-specific reagent) for research 
purposes only. 
1.8- Biomarkers for melanoma 
 
1.8.1- Currently used serum and plasma biomarkers 
Serum LDH levels have been reported to be elevated in serum of melanoma 
patients. In Stage II patients, serum LDH is highly sensitive (95%) and specific 
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(83%), however the sensitivity and specificity decrease as the disease progresses 
(Stage III: 87% specificity and 57% sensitivity) [29-32]. S100B is another serological 
marker that was identified to be elevated in Stage III and IV melanoma patients [33, 
34]. S100B has been measured in all stages of disease with varying concentrations 
dependent upon stage: 0-9% in Stage I/II, 5-98% in stage III, and 40-100% in Stage 
IV (reviewed in [35]). In another study of melanoma patients before and after sentinel 
lymph biopsy, the sensitivity and specificity of S100B to predict whether the SLN had 
tumour present was 13% and 83% respectively [36]. Thus the use of serum LDH and 
S100B are mainly used for tumour surveillance rather than primary diagnosis (see 
Chapter 3 for discussion points). 
1.8.2- Prognostic molecular biomarkers 
A vast number of molecular biomarkers (including but not limited to; tyrosinase, 
gp100, TRP-1, TRP-2, and MART-1) have been studied to predict the outcome of 
progressive disease or progression-free survival (reviewed in [37]). However some 
markers are expressed at low levels in normal tissues thus producing false positive 
results [38, 39]. Immunohistochemistry (IHC) is often used to detect micrometastasis 
in SLN following biopsy or sentinel lymphadenectomy which is important for 
determining staging and prognosis. Antibodies to such proteins as S100p, HMB45, 
and MART-1 are in routine use for IHC diagnosis, however a number of 
histopathologically-negative SLNBs from Stage III patents subsequently develop 
recurrent disease [37].  
1.8.3- Circulating tumour cells 
Circulating tumour cells (CTCs) hold great promise for use as biomarkers for 
detecting and monitoring metastases in many malignancies including melanoma. In 
one of the earliest reports of CTCs in melanoma, De Giorgi et al. [40] used a size-
filtration technique to identify CTCs in the peripheral blood of 87 cutaneous 
melanoma patients in comparison with patients with benign melanocytic naevi, non-
melanoma skin cancer, and healthy controls. The authors identified CTCs in 29% of 
patients with primary invasive melanoma and 62.5% of those with metastatic 
melanoma [40]. Whilst these are positive findings, further refinement is needed to 
improve the sensitivity. In other studies, “melanoma-specific” cell surface markers 
have been utilised which have increased the sensitivity of detection in melanoma 
13
 
 
patients [41]. Another report, a different combination of cell-surface markers, 
revealed a high degree of heterogeneity amongst the CTC population [42]. Taken 
together, these findings are very promising but further investigations are required to 
test their true efficacy in the clinic. 
1.8.4- Summary 
Despite the limitations of some of these tests, they continue to be used routinely 
(particularly S100B and LDH) as there are currently no effective biomarkers that are 
sensitive or specific enough to be beneficial for early diagnosis of malignancies. 
Therefore the use of a minimally-invasive blood test for early detection of distant 
metastases or recurrence could greatly increase the chances of survival of 
melanoma patients. This notion will be expanded upon in Chapters 3 and 4. 
1.9- microRNAs 
 
1.9.1- Definition 
MicroRNAs (miRNAs or miRs) are small ~22 nucleotide long sequences that are 
central regulators of gene expression and can act both in a positive and a negative 
way to control protein levels in the cell. Firstly, miRNAs are transcribed by RNA 
polymerase II (Pol II) to form precursor molecules (pri-miRNA) that are 
approximately 3-4kb in length which are 5’-capped and poly-adenylated. These 
precursor molecules are then cleaved by the enzyme DROSHA (along with DGCR8, 
a dsRNA binding protein, which is required for proper DROSHA function) to produce 
a stem-loop structure of approximately 70bp in length (pre-miRNA) (Figure 1.4). 
Exportin-5 and Ran-GTP then transport the pre-miRNA from the nucleus into the 
cytoplasm where it binds to the DICER/TRBP complex which cleaves the pre-miRNA 
to form a duplex of two complementary strands termed mature and mature-star 
(mature:mature*)(Figure 1.4). The duplex is processed further with usually one 
strand being incorporated into the RNA-induced silencing complex (RISC) (Figure 
1.4). The predominant or more highly expressed strand (mature) is thought to be 
incorporated into the RISC complex with the other strand (mature-star) being 
degraded or not expressed. In some cases both strands are expressed equally and 
both have the potential to be incorporated into the RISC complex. It is within the 
RISC complex that the miRNA binds to its target gene (primarily at the 3’UTR of 
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mRNA although they can bind to all areas of the transcript). If the miRNA binds with 
perfect complementarity then AGO2 is directed to cleave the mRNA which leads to 
mRNA degradation. However in most cases the binding of the mRNA to the target 
gene is imperfect which leads to silencing of the gene by preventing translation. As 
miRNAs primarily bind imperfectly to mRNAs, they have to potential to bind to and 
regulate the functions of 1000s of genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following text (sections 1.9.2 through to 1.9.6) was adapted from an 
“invited review” that I co-wrote which was published late 2011 (just prior to the 
commencement of this PhD project in Jan 2012) for the journal “Melanoma 
Research” [15]. 
1.9.2- Identification of microRNA 
miRNAs were first discovered in Caenorhabditis elegans [43] when it was shown that 
lin-4 tightly regulated the protein abundance of LIN-14. Many years later, let7 was 
found to be expressed not only in C. elegans [44] but also in numerous other species 
including humans [45]. However, the importance of miRNAs was not realised until 
Calin et al. [46] discovered frequent deletions of miR-15 and miR-16 in B-cell chronic 
Figure 1.4: miRNA biogenesis pathway. Source: http://www.sigmaaldrich.com/  
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lymphocytic leukaemia. Since that seminal study, particular miRNAs have been 
shown to be oncogenic [47-49], or conversely, tumour suppressive [50, 51] in a wide 
variety of cancers. Given their role in modulating gene expression, it is not surprising 
that miRNAs have been shown to be closely involved in regulating a wide variety of 
biological processes, including proliferation, apoptosis, cell-cycle control and 
differentiation. Lewis et al. [52] stated in 2005 that one-third of all human protein-
coding genes may be regulated by miRNAs. It is likely that this statement could be 
extrapolated further and feel with time it may be shown that every gene in the 
genome (coding and noncoding) can be regulated directly or indirectly by the action 
of miRNAs. 
 
1.9.3- microRNA and cancer 
Many studies have utilized miRNA expression arrays together with quantitative RT-
PCR (qRT-PCR) assays to analyze miRNA expression in different cell types and 
cancerous tissues.  Very quickly, it became evident that miRNAs were able to 
discriminate between cell and/or cancer types. In 2007, Gaur et al. [53] performed 
Taqman-based miRNA PCR assays using the well established NCI-60  cancer cell 
line panel along with normal tissue types. At the time, only 241 miRNAs were known; 
however, the authors were able to discriminate between many of the malignancies, 
including melanoma (eight cell lines). Three particular miRNAs were shown to be 
highly expressed in melanoma: mir-146, mir-204 and mir-211. Notably, this was the 
first report on the importance of mir-211 as a melanoma-associated miRNA. On the 
basis of their findings, the authors highlighted the future potential of miRNAs as 
diagnostic and prognostic markers as well as potential therapeutic targets for many 
malignancies. 
Recent evidence from our laboratory and others, has demonstrated that this 
approach is also applicable to melanoma. 
 
1.9.4- microRNA expression profiling in melanoma 
 
1.9.4.1. Potential pigment cell-specific microRNAs 
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Work in this laboratory over the past 5 years has identified miRNAs associated with 
melanocytic neoplasia by determining the global miRNA expression profiles of a 
large panel of melanoma cell lines (n = 51) and pooled primary (normal cells) 
melanocyte cultures (n = 4) [54]. Unsupervised hierarchical clustering of samples 
showed that the normal melanocyte samples clustered distinctly from the melanoma 
cell lines. Using the statistical method analysis of variance, we found four highly 
significant (p < 0.001) miRNAs that were differentially expressed between 
melanocytes and melanoma cells. Moreover, miR-211 had the largest mean 
expression difference between melanocytes and melanoma cells. 
Others have used commercial custom qRT-PCR assays and identified many 
miRNAs differentially expressed between melanoma samples and melanocytes [55-
57]. Interestingly, Segura et al. [57] compared immortalised melanocytes with 
primary melanocytes and melanoma cell lines (n = 14), which allowed them to study 
miRNAs differentially expressed in different stages of transformation. A significant 
limitation of their study is that they used qRT- PCR assays for only 11 miRNAs, as 
they were focusing on genomic regions frequently gained or lost in advanced 
melanomas. 
Other teams directed their efforts towards specific potential targets, such as well 
known melanoma-related factors. For example, Igoucheva and Alexeev [58] used a 
custom microarray to search for miRNAs targeting KIT, a known proto-oncogene 
with activating mutations in melanoma, and Muller et al. [59] focused on miRNAs 
targeting ITGB3, which is often downregulated in melanoma. 
Although many of the expression studies published thus far are not directly 
comparable, one common finding that has emerged from several reports is that the 
most consistently downregulated miRNA in melanoma is miR-211.  
 
1.9.4.2. microRNA discovery 
We recently  expanded on our initial microarray profiling of miRNA in the  pigment  
cell lineage by utilizing next-generation  sequencing (Illumina GAII) in a panel (n= 12) 
of normal (melanoblast and melanocyte), pre-cancer (naevus cell line) and malignant 
melanoma subtypes (acral, mucosal, cutaneous  and uveal) [60]. We identified 539 
17
 
 
of the 847 canonical miRNAs (mature and mature star) that were present in the 
international database/registry, miRBase [61] v12 (September 2008), to be 
expressed in at least one of the samples. In addition, we identified 722 expressed 
sequences predicted to be novel miRNAs. These   sequence tags were filtered 
further using CID-miRNA [62], which reduced the list to 389 novel candidate 
miRNAs. The majority of these are now present in the current miRBase registry 
(v18), which hosts more than 1400 human miRNAs. We proposed that some of the 
novel miRNAs identified may be specific to the melanocytic lineage. Moreover, 
although previous and subsequent studies identified miRNAs that have important 
biological consequences for melanoma development, with ever increasing power to 
detect miRNAs using deep sequencing technologies, there are likely to be many 
other miRNAs whose functions remain to be elucidated. 
 
1.9.5- microRNAs as diagnostic/prognostic markers and potential 
therapy targets  
The increasing availability of datasets linking specific miRNAs to cancer progression 
will likely continue to facilitate the use of miRNAs as powerful diagnostic and 
prognostic markers. We may also see them used in a melanoma setting as 
therapeutic agents or as targets for specialised therapies. Low levels of miR-29c 
have been associated with disease outcome in melanoma [63]. miR-29c is 
responsible for the downregulation of the methyltransferases DNMT3A/B, and its 
absence in melanoma leads to hypermethylation and silencing of tumour-related  
genes. In a series of Stage I–IV cutaneous melanomas, Nguyen et al. [63] utilised 
overall survival data to show that miR-29c expression is a significant predictor of 
improved disease-free survival. 
miRNAs have recently been  shown to circulate in a highly stable, cell-independent 
form in the blood [64-70] either contained within exosomes [68, 69, 71, 72] or bound 
to Ago2, the key effector protein of miRNA-mediated  silencing [70]. Tumour cells 
have also been shown to release miRNAs into the circulation [64] and the expression 
of miRNAs in plasma and serum is often altered  in cancers, including melanoma, B-
cell lymphoma,  ovarian or lung  cancer,  to name  just  a few [64, 67, 68, 71],[73-79]. 
To date, the identification of circulating melanoma-specific miRNAs has been limited 
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to a small number of studies. Recently, Kanemaru et al. [79] have shown, in a set of 
94 melanoma patients and 20 healthy controls, that miR-221 levels measured in 
serum samples by qRT-PCR could be used as a tumour marker. They proposed the 
use of this gene as a diagnostic marker, as melanoma patients had significantly 
higher miR-221 levels than control participants and the levels in patients correlated 
with tumour thickness. The authors also presented data showing a decrease in miR-
221 expression after surgical removal of the primary tumour, which suggests that 
miR-221 could be used to follow up the patients as a potential prognostic marker. 
Lodygin et al. [80] showed that in prostate cancer patients, methylation  of the  miR-
34a locus could be detected in circulating tumour DNA and suggested  it could be 
used as a potential  diagnostic tool for tumour dissemination. They showed that 
restoring epigenetically silenced miR-34a expression in prostate tumour cells has the 
potential to suppress colony formation and to activate senescence. Of importance 
here is that the authors screened a panel of 44 melanoma cell lines for miR-34a 
locus methylation and found that a high proportion of samples were 
hypermethylated. Thus, by inference, miR-34a methylation could also be a useful 
serum biomarker of tumour burden in melanoma patients. 
Although the melanoma-related studies summarised above have found some truly 
interesting and highly relevant results, they remain significantly underpowered, as 
they have small sample sizes and have not used the most up-to-date array platforms 
that utilise current versions of mirBase. As discussed earlier, there  are now more 
than 1400 human miRNAs that have been deposited into miRBase (v18), for which 
more than 200 were discovered after deep sequencing a panel of pigment  cell types 
including melanoma [60]. Because of the vast number of previously unidentified 
miRNAs present across this panel of samples, we propose that many of these could 
be specific to the melanocytic lineage and as such could be useful as potential 
blood-based and tissue-based biomarkers for melanoma. 
 
1.9.6- Future Directions  
As yet, a miRNA that is truly melanoma specific remains to be identified, but we have 
highlighted that several miRNAs may be useful as new diagnostic and prognostic 
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markers for melanoma progression. Specific miRNAs could be used, alone or in 
combination to differentiate between benign and malignant lesions, or between 
invasive lesions with poor versus favourable outcomes. Others might have utility as 
serum/plasma biomarkers of relapse or tumour burden. Some miRNAs may also 
make excellent candidates for use in targeted therapies for melanoma, either being 
used to abrogate oncogenic signalling, or themselves being the target of treatment if 
they are oncomiRs providing the growth stimulus. Studies investigating the various 
roles of miRNAs in melanocytes and melanoma are gaining momentum and should 
continue to provide fertile ground for both clinical and basic research. 
*********end of invited review*************** 
1.9.7- Current directions for miRNA research in melanoma 
Since completion of the invited review in late 2011, [15] there has been a lot of 
activity in the melanoma miRNA field. As the primary focus of this PhD project is to 
identify melanoma-related miRNA markers that may be expressed in melanoma 
patient serum/plasma, along with specific therapeutic gene targets, I will focus the 
remainder of this review on literature relating to these topics. 
1.9.7.1. miRNA target gene identification in melanoma 
Most studies of melanoma associated miRNAs have focused on those miRNAs that 
target oncogenes [54, 59, 63, 81-92] with the central dogma indicating that said 
miRNAs would have low expression thus causing the oncogenes to be over-
expressed.  On the other hand, a few studies [57, 58, 93-97] have focussed on 
oncogenic miRNAs associated with melanoma and one of particular relevance (to 
this PhD project) identified the miR-506-514 cluster to be consistently over-
expressed in nearly all melanomas tested (33 metastatic melanoma tumour biopsies) 
[97].  This is consistent with current data produced in this project (see Chapter 2). 
Whilst the authors highlighted the important of this cluster in melanoma, they did not 
present any data to suggest which genes (confirmed targets) the cluster was 
targeting. 
1.9.7.2. Serum miRNA expression in melanoma 
Following commencement of this PhD project there have been a number of studies 
investigating the utility of miRNAs to serve as melanoma blood and tissue 
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biomarkers [15, 98-103]. Notably, there were two key studies that identified a panel 
of miRNAs that were related to melanoma recurrence - a common event in 
melanoma patients. In the initial study, Friedman et al. [99] screened 355 miRNAs in 
sera from 80 melanoma patients using a previously characterised panel of miRNAs 
expressed in sera. Measurable expression was available for 170 miRNAs and using 
Cox proportional hazard models for recurrence free survival, 5 miRNAs (miR-150, 
miR-15b, miR-199a-5p, miR-33a, and miR-424) were selected and validated in an 
independent set of 50 sera collected from primary melanoma patients. The 5 miRNA 
signature was able to classify the patients into high and low recurrence risk. The 
authors propose that this panel of miRNAs could be useful for predicting risk of 
recurrence which would be important for patient surveillance. Although this study did 
highlight the potential use of this subset of miRNAs for diagnostic purposes, the 
study is limited in the sense that they only surveyed 355 miRNAs of the 2500 human 
miRNAs in miRBase [61]). In addition, the panel of miRNAs selected for validation 
may not be specific to melanoma and could simply be a consequence of the body’s 
response to tumourigenic processes (a notion discussed in Chapter 3). The authors 
also did not use any healthy controls with no known history of melanoma. As such, 
the use of this panel would be limited to prior diagnosis of melanoma and could not 
be used to identify unknown primary or unidentified metastases. In a follow-up study, 
the authors expanded upon their original study by examining the clinical utility of 
miRNAs in large cohorts of melanoma patients to assess for prognosis and 
recurrence. [98] Refinement of their miRNA-signature enabled prediction of 
recurrence-free survival (RFS) and overall survival (OS). The authors concluded that 
a single miRNA (miR-15b) could improve patient stratification as well as disease 
surveillance.[98]  
 
1.10- Rationale of this study 
The objective of this project was to use miRNA microarrays to comprehensively 
study the miRNA profile of melanoma (generally) in relation to other malignancies. 
These findings will be used to measure the expression levels of melanoma-
specific/over-expressed miRNAs in serum from melanoma patients with varying 
stages of disease i.e. to further refine those miRNAs that distinguish between these 
distinct sets of patients. The project will also identify a number of gene targets that 
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will be important for understanding the mechanisms by which the melanoma 
developed or disseminated. Understanding these fundamentals will be important for 
defining a set of new diagnostic and/or prognostic biomarkers and for designing 
rational treatments for this insidious disease. 
1.11- Specific aims and hypotheses of this study 
 
Hypotheses:  
1) A melanoma-specific panel of miRNAs can be identified following a 
comprehensive assessment of miRNA expression profiles in a range of 
solid malignancies. 
2) This melanoma-specific miRNA panel will correlate with disease 
progression in melanoma tissues and patient-derived serum. 
3) Identification of gene targets of melanoma-specific miRNA will aid 
understanding of melanoma development. 
 
Aim (1): To identify melanoma specific miRNAs for use as diagnostic and 
prognostic markers.  
 
The use of melanoma progression markers has been used for many years with 
varying levels of success. However it is clear from the survival rates (5-year survival 
of Stage IV patients is ~11%) that melanoma must be detected before disease 
progresses thus highlighting the point that the current methods of progression 
detection are inadequate.  
 
Aim (2): To measure elevated levels or presence of melanoma-specific 
miRNAs in serum/plasma from early and late stage melanoma patients. 
 
The development of a specific panel of miRNAs based on use of a minimally 
invasive test would be of advantage to both the patient and the clinician as this may 
allow for a more accurate staging of disease progression so that a more appropriate 
“stage-specific” treatment could be devised. A ‘non-invasive’ test also has the 
potential to detect disease progression in early stage patients. This early detection 
would otherwise go undetected with conventional follow-up regimens.  
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Aim (3): To correlate miRNA expression levels with tumour progression. 
 
In order to elucidate if the panel of miRNAs will be useful for clinical staging/ early 
detection, it will be necessary to correlate expression levels with current disease 
staging at time of blood collection along with survival data. The analysis of survival 
data will highlight if certain miRNAs will be useful to predict clinical outcome. 
 
Aim (4): To identify gene specific targets of miRNAs relevant to melanoma 
development. 
 
Identification of gene specific targets will be important for understanding the 
mechanisms by which the melanoma developed or disseminated. Understanding 
these fundamentals is, and will be, important for defining a set of new diagnostic 
and/or prognostic biomarkers and for designing rational treatments for this disease. 
 
1.12- Account of research progress linking the research papers 
 
This project has used miRNA microarrays to comprehensively study the miRNA 
profile of melanoma in relation to other malignancies (Aim 1). The reasoning behind 
this was to identify (if present) a melanoma-specific or melanoma-related panel of 
miRNAs that could be used to more accurately stage melanomas and improve the 
detection of metastatic deposits before they are clinically evident (i.e. detectable via 
medical imaging or palpation) – to fast-track access to targeted therapy which is 
currently offered to clinically staged patients (Stage IV and unresectable Stage III; 
Aims 2 and 3). Along with the identification of a panel of melanoma-related miRNAs, 
these data were also used to link melanoma-related miRNAs with the regulation of 
protein-coding genes (Aim 4).  Identification of these miRNA-mRNA pairings, I 
believe, are fundamentally important in understanding the complex processes 
involved in melanomagenesis and may provide an insight/new perspective into the 
design of novel therapies. 
The initial key experiment involved culturing sufficient quantities of cell lines (n = 99) 
(see Chapter 2) to harvest total RNA (including miRNA) for the miRNA microarrays 
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performed by LC Sciences. The data generated were then analysed by comparing 
two major groups (‘melanomas’ and ‘other’ cancers) with the sole purpose of finding 
miRNAs significantly enriched for melanoma. These data specifically addressed Aim 
1 of the study by identifying a panel of miRNAs that could be deemed melanoma-
related or ‘melanoma-specific’ and had the potential to be used in a diagnostic and 
prognostic setting. This data-rich resource (presented in Chapter 2) enabled the 
identification of 233 miRNAs which, given their differential expression compared with 
other cancers, appear to have a relationship with melanoma. These data 
underpinned the entire project (as evident in Chapters 2 [104], 3 [105], and 5 
(manuscript under review), and will serve as a benchmark for future projects for 
years to come. As discussed in Chapter 2, the top two miRNAs that were 
significantly enriched for melanoma were miR-211 and miR-514a. Since miR-211 
was well known in to be associated with melanoma, miR-514a was selected for 
functional validation, as to date, no gene-specific targets have been identified. Using 
a biotin-labelled pull-down procedure to identify binding targets of miR-514a, 
numerous melanoma-related genes were identified which gave the first indication 
that focusing on ‘melanoma-specific’ miRNAs may yield relevant melanoma-gene 
targets. miR-514a was subsequently found to bind to and regulate the tumour 
suppressor gene NF1 along with a key cell cycle regulator CDK2. Further 
investigations revealed that the expression of miR-514a influenced cell proliferation 
rates and colony formation. The role of miR-514a was next investigated in relation to 
BRAF inhibitor sensitivity (in part due to its regulation of NF1 – with loss of this gene 
involved in resistance to PLX4032 targeted therapy). High levels of miR-514a were 
subsequently found to decrease the sensitivity of BRAFi with the effect being 
reversed when miR-514a expression was down-regulated. Resistance to BRAFi 
therapy is a common event and may be due to the dynamic expression levels of 
miR-514a observed in melanoma. 
The data presented in Chapter 2 was next used to identify a panel of melanoma-
related miRNAs which were presented in Chapter 3.  Specimen collection was a 
large proportion of this study which took close to 3 years to complete and involved 
establishing a number of key collaborations to order to gain access to melanoma and 
healthy control biobanks. A total of 255 serum and 86 tissue specimens from 
melanoma patients (Stages I-IV) and 130 sera from control participants (no 
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observable melanoma at time of collection) were recruited from the Princess 
Alexandra Hospital (PAH), the Australian Cancer Study (ACS), the Melanoma 
Institute of Australia (MIA), and the University of Tubingen (see Chapter 3 and 4 for 
recruitment details). This multicentre study discovered a number of important 
findings that may contribute to better treatment regimens and improved outcome for 
patients.  
 
Specifically, in the study discussed in Chapter 3, a seven-miRNA panel (‘MELmiR-7’) 
detected the presence of melanoma with high sensitivity (93%) and specificity 
(≥82%) and in serially collected Stage IV patients, members of the ‘MELmir-7’ panel 
confirmed tumour progression in 100% of cases. Lastly, the ‘MELmiR-7’ panel 
significantly outperformed the currently used serological markers for monitoring 
melanoma and were better at predicting progression, recurrence, and survival. Since 
commencement of this study there have been a number of studies investigating the 
utility of miRNAs to serve as melanoma blood and tissue biomarkers [15, 98-103]. 
One of which is discussed in Chapter 4 [101].  
 
In this study, in collaboration with members of the MIA, we used global expression 
profiling of both mRNA (whole genome) and miRNA in matched fresh-frozen 
metastatic melanomas (AJCC Stage III) which were classed as GP (good prognosis) 
and PP (poor prognosis). Four miRNAs were found to be associated with prognosis 
(miR-142-3p, miR-142-5p, miR-146b-5p, and miR-150-5p), some of which were 
identified by Segura et al. [106]. These miRNAs were subsequently validated by real-
time PCR and later (as part of this PhD project) in an independent cohort of FFPE 
tumours (AJCC Stage III and IV) and serum derived from melanoma patients (AJCC 
Stage III and IV). The comparison of the miRNA panels derived from both studies 
was the primary purpose for this inclusion of this collaborative project (see the 
Discussion in Chapter 6). 
 
Finally, the study discussed in Chapter 5 relates to miR-4731 and its regulation of 
genes important for the melanocytic lineage and progression of melanoma. miR-
4731 was identified as being significantly enriched for melanoma (compared with 
other solid cancers) (Chapter 2) along with being found in serum from melanoma 
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patients and expressed less abundantly in metastatic melanomas from Stage IV 
patients relative to stage III patients (Chapter 3). Binding targets of miR-4731 were 
identified via a biotin-labelled mRNA pull-down of direct gene targets. This procedure 
was performed in parallel with the pull-down with the miR-514a duplex (Chapter 2). 
Validation of miR-4731 binding targets revealed a host of genes associated with the 
cell cycle (e.g. CCNA2, ORC5L, and PCNA) and melanosome pathways (e.g. 
RAB7A, CTSD, and GNA13). Furthermore, members of the synovial sarcoma X 
breakpoint family (SSX) (melanoma growth promoters) were also down-regulated 
(e.g. SSX2, SSX4, and SSX4B) as a result of miR-4731 overexpression. 
Lastly, Chapter 6 (Discussion and Future Directions) discusses the role of each 
Chapter (2-5) in relation to each other and within the context of studies I have 
previously been involved in, together with the proposed future directions of the major 
findings presented in this thesis. 
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Chapter 2 
miR-514a regulates the tumour suppressor NF1 and modulates BRAFi 
sensitivity in melanoma 
 
Mitchell S. Stark, Vanessa F. Bonazzi, Glen M. Boyle, Jane M. Palmer, Judith Symmons, 
Catherine M. Lanagan, Christopher W. Schmidt, Adrian C. Herington, Robert Ballotti, 
Pamela M. Pollock, Nicholas K. Hayward. miR-514a regulates the tumour suppressor NF1 
and modulates BRAFi sensitivity in melanoma. Oncotarget. 2015 Jul 10; 6(19):17753-63 
 
2.1. Relevance to thesis aims 
This chapter touches on all aims of the thesis. Specifically, at the time of study design, the 
complete repertoire of miRNAs expressed in humans (miRBase v18) was assessed using 
miRNA microarrays in a panel of melanoma cell lines and ‘other’ solid malignancies. In 
addition to these cell lines, a pool of melanocytes, a melanoblast, a congenital naevus, 
and RNA from melanoma-patient derived serum/plasma were also assayed. In relation to 
Aim 1, a total of 233 miRNAs were found to be differentially expressed (p ≤ 0.05; ≥ 2 fold) 
when ‘melanomas’ were compared with ‘other’ cancers. These data therefore successfully 
identified a panel of ‘melanoma-specific’ or melanoma-related that were useful for 
diagnostic and prognostic purposes (see Chapter 3). A small number of serum/plasma 
samples were initially assessed to elucidate if miRNA expression were at detectable levels 
prior to performing the larger serum cohort studies detailed in Chapter 3 which addresses 
Aim 2. 
 
This chapter focuses on a ‘melanocyte-specific’ miRNA (miR-514a-3p or miR-514a) that 
was enriched in melanoma (69% expression; mean 204 fold) compared to other cancers 
(3% expression). This miRNA is a member of a cluster of miRNAs that have been 
previously been shown to initiate melanocyte transformation and promote tumour growth. 
As such the study of this particular miRNA was well suited to address Aim 4. The 
expression of miR-514a was later found to be related to cell proliferation and colony 
formation with over-expression leading to reduced proliferative and colony forming ability. 
In addition a great number of target genes were identified via miRNA-mRNA pull-down 
experiment. NF1 was selected for functional validation as it has had a long history of a 
being a tumour suppressor in melanoma and more recently has been implicated in 
resistance to BRAFi-targeted therapy for melanoma. In the data presented in Chapter 2, 
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miR-514a was proven to bind to NF1 and in turn regulate its protein expression. Together 
with other pull-down genes like CDK2, it was shown that the expression of miR-514a 
modulated the BRAFi sensitivity in BRAFV600E melanoma cell lines. These data therefore 
contribute and satisfy Aim 4 of the thesis.  
 
2.2. Contribution of candidate 
I developed the concept and initial study design which was agreed upon and refined by my 
supervisors. I performed the majority of the experimental work, data analysis and 
interpretation, and writing of the manuscript. 
 
2.3. Statement of Contribution of Co-Authors 
The authors listed below have certified* that: 
1. they meet the criteria for authorship in that they have participated in the conception, 
execution, or interpretation, of at least that part of the publication in their field of 
expertise; 
2. they take public responsibility for their part of the publication, except for the responsible 
author who accepts overall responsibility for the publication; 
3. there are no other authors of the publication according to these criteria;  
4. potential conflicts of interest have been disclosed to (a) granting bodies, (b) the editor 
or publisher of journals or other publications, and (c) the head of the responsible 
academic unit, and 
5. they agree to the use of the publication in the student’s thesis and its publication on the 
QUT ePrints database consistent with any limitations set by publisher requirements.  
 
In the case of this chapter: 
 
Publication title and date of publication or status: miR-514a regulates the tumour 
suppressor NF1 and modulates BRAFi sensitivity in melanoma. Published online April 
23rd 2015, Oncotarget.  
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ABSTRACT
To identify ‘melanoma-specific’ microRNAs (miRNAs) we used an unbiased 
microRNA profiling approach to comprehensively study cutaneous melanoma in 
relation to other solid malignancies, which revealed 233 differentially expressed (≥ 
2 fold, p < 0.05) miRNAs. Among the top 20 most significantly different miRNAs 
was hsa-miR-514a-3p. miR-514a is a member of a cluster of miRNAs (miR-506-514) 
involved in initiating melanocyte transformation and promotion of melanoma growth. 
We found miR-514a was expressed in 38/55 (69%) melanoma cell lines but in only 
1/34 (3%) other solid cancers. To identify miR-514a regulated targets we conducted 
a miR-514a-mRNA ‘pull-down’ experiment, which revealed hundreds of genes, 
including: CTNNB1, CDK2, MC1R, and NF1, previously associated with melanoma. NF1 
was selected for functional validation because of its recent implication in acquired 
resistance to BRAFV600E-targeted therapy. Luciferase-reporter assays confirmed NF1 
as a direct target of miR-514a and over-expression of miR-514a in melanoma cell lines 
inhibited NF1 expression, which correlated with increased survival of BRAFV600E cells 
treated with PLX4032. These data provide another mechanism for the dysregulation 
of the MAPK pathway which may contribute to the profound resistance associated 
with current RAF-targeted therapies.
INTRODUCTION
Melanoma is a multifaceted disease that exhibits all 
the usual ‘hallmarks’ of cancer [1] shared across a wide 
range of malignancies. However, despite these similarities 
in the tumourigenic process, most cancers exhibit a set of 
characteristics unique to the tumour or the tissue/cell of 
origin. 
microRNAs (miRNAs) are ~22 nucleotide long 
sequences that are central regulators of gene expression 
and can act both in a positive and a negative way to 
control protein levels in the cell. If a miRNA binds with 
perfect complementarity to its target mRNA, then AGO2 
is directed to cleave the mRNA, which leads to mRNA 
degradation. However, in most cases the binding of the 
mRNA to the target gene is imperfect, which leads to 
silencing of the gene by preventing or reducing translation. 
As miRNAs primarily bind imperfectly to mRNAs, they 
have the potential to bind to and regulate the functions of 
thousands of genes. Due to these intrinsic characteristics, 
a single miRNA or ‘cluster’ of miRNAs has the ability 
to control gene expression across a multitude of different 
signaling pathways. In melanoma, numerous miRNAs 
have been implicated in tumour development [2] and some 
have been shown to being relatively ‘tissue-specific’. This 
notion of miRNA tissue specificity was first explored by 
Gaur et al [3] using the NCI-60 cell line cancer panel. 
Even with only eight melanoma cell lines included, it 
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was evident miRNA expression was able to discriminate 
melanoma from other cancer types. Since this seminal 
paper, there have been a limited number of studies that 
have harnessed the power of miRNA for melanoma 
diagnostics [4-6], although some have utilized next-
generation sequencing for the discovery of ‘tissue-specific’ 
miRNAs [7, 8].
In the current study we sought to expand our current 
understanding of ‘melanoma-specific’ miRNA expression 
by performing a comprehensive microarray analysis of 
melanoma compared to a range of other solid tumour 
types, and to follow up key microRNAs which may be 
critical to aspects of melanoma biology.
Here, in the largest study to date, we identified a 
significant number of miRNAs (n = 233) with known 
and novel relationships to melanoma. One particular 
miRNA, miR-514a-3p (miR-514a) is a member of a 
cluster of miRNAs on chrXq27.3 that has been implicated 
in the malignant transformation of melanocytes, along 
with the promotion of tumour formation [9]. Using a 
‘pull-down’ procedure [10, 11] we revealed hundreds of 
miR-514a-regulated genes including some melanoma 
associated genes: CTNNB1, CDK2, MC1R, and NF1. We 
subsequently confirmed that miR-514a has the ability to 
bind to NF1 and inhibit its translation. Furthermore, we 
show that miR-514a expression is involved in modulating 
cell proliferation rates along with BRAFi (PLX4032) 
sensitivity in melanoma.
RESULTS
‘Melanoma-specific’ miRNA discovery profiling in 
melanoma
Comprehensive analysis of a large panel of 
melanoma cell lines identified distinct ‘tissue-specific’ 
miRNA expression compared to other solid malignancies. 
We used miRNA microarrays (miRBaseV18) to study the 
miRNA profile of cutaneous melanoma (n = 55), uveal 
melanoma (n = 7), and RNA derived from melanoma 
patient serum/plasma (n = 3) in relation to ‘other’ solid 
cancers (n = 34). Normal pigment cells (melanocytes 
and melanoblasts) and pre-malignant cells (nevocytes) 
were also included as controls (‘Discovery cohort’). In 
this ‘Discovery’ set, a total of 233/1898 differentially 
expressed (≥2 fold, p < 0.05; See Materials and Methods) 
miRNAs were identified when ‘melanomas’ were 
compared to ‘other’ cancers (Supp Figure 1 and Supp 
Table 1). Supp Table 2 summarizes the top up- and down-
regulated miRNAs (by at least 10-fold), which have either 
known or novel relationships with melanoma.
‘Lineage-specific’ miRNA validation
Notably, the top two miRNAs up-regulated in 
melanoma were hsa-miR-211-5p (miR-211) and hsa-
miR-514a-3p (miR-514a) with profound average fold-
changes of 276 and 204 respectively compared to other 
solid malignancies (Supp Tables 1 and 2). It is well known 
that miR-211 is deemed to be a lineage specific miRNA 
[12] however, we provide the first reported evidence that 
miR-514a also fits into this category. Supp Table 1 shows 
relatively high expression of miR-514a in melanocytes 
(MELA) and melanoblasts (QF1160MB), no detectable 
expression in a congenital nevus (MM653), detectable 
expression in 69% and 43% of cutaneous and uveal 
melanoma cell lines respectively, and expression in only 
1/34 ‘other’ solid cancers. To test the robustness of the 
array data, quantitative real-time PCR validation was 
performed with these miRNAs along with a selection of 
other miRNAs from the array (Supp. Figure 2 and Supp 
Table 3). Supp. Figure 2 highlights that the array and real-
time PCR data are well correlated. 
MITF regulation of ‘lineage-specific’ miRNAs
MITF is a melanocyte lineage specific transcription 
factor which has previously been shown to regulate miR-
211 levels via its host gene TRPM1 [13]. As miR-514a 
is part of a melanocyte-specific cluster of miRNAs [9] 
and is highly expressed along with miR-211 levels, we 
sought to investigate whether this tissue-specificity could 
be considered MITF-dependent. Using an inducible MITF 
system [14] we measured the expression levels of miR-
514a along with other highly expressed lineage-specific 
miRNAs; miR-204-5p, miR-211-5p, mir-506-3p, miR-
508-3p, miR-509-3p, and miR-509-5p. miR-211 was 
confirmed as being under transcriptional control of MITF 
following MITF induction in two melanoma cell lines 
(C-32 and HT144). The 6-7-fold increase in miR-211 in 
these cell lines following MITF induction was statistically 
significant (p = 0.01; Figure 1). Some of the miR-506-
514 cluster members had modest (1.4-1.8 fold) but 
significantly increased expression after MITF induction 
in the C-32 cell line (miR-514a; p = 0.001, miR-508-3p; 
p = 0.0003, miR-509-3p (p = 0.05), and miR-509-5p (p 
= 0.002)), however they were not significantly increased 
in HT144. We thus conclude that the effect observed in 
C-32 is likely to be indirect, rather than through direct 
transcriptional regulation of the miR-506-514 cluster 
by MITF. Additionally, miR-204 which differs by one 
nucleotide to miR-211 is regulated independently to miR-
211 as there was no difference in expression following 
induction with MITF (Figure 1).
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Target gene identification via biotin-labeled 
miRNA duplex ‘pull-down’ of mRNA transcripts
Due to the high levels of miR-514a in melanoma 
compared to other cancers, we sought to identify its 
specific target genes by performing a whole-genome 
mRNA expression array following a biotin-labeled 
miRNA duplex pull-down of bound mRNAs (See 
Materials and Methods). This comprehensive approach 
revealed hundreds of genes that were ‘pulled-down’ as 
compared to a negative scrambled control miRNA duplex 
(Neg-Scr)(Supp Table 4). Supp. Figure 3 shows the lists 
of genes associated with the key words: ‘MELANOMA’, 
‘BRAF’, and ‘MITF’; along with the genes common to all. 
The common genes pulled-down by miR-514a included 
ATF4, BIRC3, CDK2, CREB1, CTNNB1, ERBB3, EZH2, 
FOS, IL18, KDM5B, MC1R, NF1, SPRY4, STAT1, TSC1, 
and TSC2.
Dual-luciferase reporter assays confirm binding of 
miR-514a to NF1
In order to validate the robustness of the ‘pull-
down’ assay we selected NF1 for follow up and sought 
to confirm direct binding of miR-514a to the transcript. 
Using the miRanda prediction algorithm, the top two 
highly conserved (Figure 2a-2b) putative binding sites 
of miR-514a were located in the coding region of NF1 
(NM_000267), in exons 9 and 23 respectively (see 
Materials and Methods and Figure 2). Coding region 
binding is not commonly reported in the literature but an 
increasing number of studies attest to its relevance e.g. 
Figure 1: Figure shows the miRNA expression of the known lineage-specific miRNA, miR-211-5p along some other 
highly expressed miRNAs with known associations with melanoma. In MITF-inducible melanoma cell lines (C-32 and HT144), 
miR-211-5p expression was significantly upregulated as compared to LacZ induced cell lines. Members of the miR-506-514 cluster show 
only mild upregulation in MITF-induced C-32 when endogenous levels were expressed which indicates that the cluster is likely to be 
independently regulated. No basal or induced expression was observed in HT144 (MITF or LacZ). Error bars represent SD from four 
technical replicates. ns = non-significant. *p < 0.05, **p < 0.01, ***p < 0.005.
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[15-17]. As dogma suggests, there were binding sites 
in the 3’UTR but these were below the default binding 
threshold (binding threshold = 140) of the prediction 
algorithm, along with 79 (binding threshold = 100) 
other potential binding sites across the length of the NF1 
transcript (NM000267) (Supp Table 5). It was not feasible 
to assess all of the binding sites so we chose to focus 
on the best hits. To assess the function of these binding 
sites, a cDNA sequence spanning this region was cloned 
upstream of a luciferase reporter construct. Mutation of 
either the first, or the second, or both putative miR-514a-
binding sites (Figure 2c) led to an increase in reporter 
activity in MM253 and C-32 (Figure 2d) cells compared to 
the reporter containing the cloned wild-type NF1 sequence 
which relied on endogenous miR-514a expression. Figure 
2d shows that both binding sites are required and have 
an additive effect on recovery of luciferase signal (mean 
3.5-fold increase in signal compared to wild-type). To 
further confirm that miR-514a was involved, a miR-514a 
mimic along with a negative control (miR-Neg-scr) was 
co-transfected with NF1-mutant constructs (both sites) 
(Figure 2c). Figure 2e highlights that overexpressed miR-
514a successfully bound to the NF1 wild-type construct, 
which resulted in a reduction in luciferase signal. 
Furthermore, mutation of both of these sites prevented 
binding of miR-514a in both MM253 and a non-melanoma 
cell line, HEK293T (which has no endogenous expression 
of miR-514a) (Figure 2e). These data provide strong 
evidence for miR-514a direct binding to NF1 mRNA. 
Figure 2: a. Schematic diagram of the two predicted miR-514a-3p binding sites in Exon 9 (Ex9) and Exon 23 (Ex23) of NF1. Shown 
underneath Ex9 and Ex23 are the mutations made in the NF1 cDNA fragment for luciferase assays (bolded and underlined). b. Multiple 
species alignment of the miR-514a binding. Underlines = miR-514a binding sites. Shading and stars = nucleotide conservation present in 
the alignment. c. Diagram of mutations generated in NF1 cDNA fragment. Black crosses = mutation of binding site. d. Dual-Luciferase 
Reporter (DLR) assays. MM253 and C-32 were transfected with constructs shown in panel C, as well as pGL4.75 [hRluc/CMV] to 
normalize the data. (e) MM253 and HEK293T were co-transfected with miR-514a mimic and miR-Neg-scr together with NF1 wildtype 
and mutant constructs (Both). Error bars show standard error of the mean (SEM) from a triplicate experiment; ns = non-significant. **p < 
0.01, ***p < 0.005. 
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Inhibition of miR-514a increases protein 
expression of NF1 along with increased cell 
proliferation
We selected melanoma cell lines (MM253 and 
MM96L) that had detectable NF1 protein to assess if 
NF1 expression could be altered following manipulation 
of miR-514a. Inhibition of miR-514a with a Locked-
Nucleic Acid (LNA) resulted in an increase of NF1 protein 
expression (1.3-2.6 fold higher) (Figure 3a) compared to a 
negative srambled control (LNA-Neg-scr). We next sought 
to investigate the effect of inhibition of miR-514a on cell 
proliferation given the prior reports on growth rate and 
increased NF1 expression. Contrary to the expected result, 
we found that inhibition of miR-514a led to a significant 
increase in cell proliferation (Figure 3B) in MM253 (p = 
0.002; mean 3 fold) and MM96L (p = 3.17e-008; mean 4 
fold) as measured by SRB assay.
Inhibition of miR-514a increases protein 
expression of CDK2 and other cell cycle 
progression markers
To investigate why we observed a marked increase 
cell proliferation even in the presence of increased 
NF1 protein, we selected an additional gene for target 
confirmation (CDK2; Supp Table 4). CDK2 also showed 
increased expression upon inhibition of miR-514a (2.3-8.2 
fold higher) (Figure 3c). As CDK2 is a well known cell 
cycle progression marker, this prompted an investigation 
into additional cell cycle and apoptosis markers. Indeed, 
measurement of the cell cycle proteins E2F1 (1.8-13.2 fold 
higher) and cyclin-D1 (1.6-3.2 fold higher), and the anti-
apoptosis marker, BCL2 (1.4-4.2 fold higher), revealed 
that these too were increased upon inhibition of miR-514a 
(Figure 3c). 
Overexpression of miR-514a leads to down-
regulation of NF1 protein and a decrease in cell 
proliferation and colony formation
Transient transfection of 5 nM of a miR-514a 
mimic, or a miR-Neg-scr (for comparison) into MM253 
and MM96L, showed a reduction of NF1 protein levels 
(0.80- 0.56 fold) after 72 hours (Figure 4a), which was 
observed up to 6 days post-transfection (data not shown). 
Interestingly, despite a reduction in protein levels, NF1 
mRNA was increased in MM96L (data not shown), 
whereas in MM253, the mRNA expression was reduced 
(data not shown), mirroring the protein expression (Figure 
4a). These data indicate that the binding of miR-514a to 
NF1 mRNA is dynamic, and, in different cell contexts, 
can reduce as well as increase expression. These data 
also highlight that the only reliable measurement for an 
effect of miRNA binding is via protein expression which 
is in keeping with miRNAs being post-transcriptional 
modifiers. Nevertheless, with the combination of the 
luciferase assays (Figures 2d-2e) and the western blot 
analysis affecting NF1 expression upon miR-514a 
depletion (Figure 3a) and over-expression (Figure 4a), 
Figure 3: a. NF1 expression is increased following transfection in with a miR-514a inhibitor (LNA-miR-514a) as compared to a negative 
scrambled control (LNA-Neg-scr). NF1 relative expression is normalized to the loading control (GAPDH). Numbers indicated relative fold 
change. NF1 (~300kDa) and GAPDH (37kDa) were run and quantified on the same gradient gel b. MM253 and MM96L were transfected 
with LNA-miR-514a and LNA-Neg-scr with proliferation measured at day 6 post transfection. c. Cell cycle (E2F1, CDK2, and Cyclin D1) 
and apoptosis-related (BCL-2) proteins are increased following transfection with LNA-miR-514a as compared LNA-Neg-scr. All proteins 
are normalized to the loading control (GAPDH) and compared to their respective negative control. Numbers indicated relative fold change. 
E2F1 (70kDa), CDK2 (33 kDa), Cyclin D1 (36kDa) and GAPDH (37kDa). Error bars show standard error of the mean (SEM) from 2 
biological triplicate experiments; P values as indicated, ***p<0.005  , **** p<0.001.  
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we provide strong evidence for miR-514a-mediated direct 
regulation of NF1 protein levels.
As inhibition of miR-514a promoted cell 
proliferation, we next sought to investigate the effect of 
overexpression of miR-514a. Indeed, cell proliferation 
was significantly decreased in both MM253 (p = 0.0005; 
2.1-fold less) and MM96L (p = 7.40e-005; 1.3-fold less) 
(Figure 4b). This was subsequently confirmed in an in 
vitro clonigenicity assay, with both cell lines having 
markedly reduced colony formation upon overexpression 
of miR-514a (Figure 4c).
miR-514a expression levels modulate BRAFi 
sensitivity in BRAFV600E melanoma cell lines
With loss of NF1 [18-21] and more recently an 
increase of CDK2 (in association with MITF) [22] in 
melanomas being involved in the resistance to BRAF-
inhibitor (BRAFi) therapy, we next sought to investigate 
whether miR-514a might be involved in this process. 
Furthermore, cell proliferation rates have also been shown 
to be involved in BRAFi sensitivity [23]. Firstly, to confirm 
that NF1 downregulation is involved in inducing BRAFi 
resistance in MM253 and MM96L (both are BRAFV600E) 
cell lines, we silenced NF1 expression via specific siRNAs 
(4x siNF1). We observed > 50% NF1 mRNA knockdown 
even after 6 days post transfection of siRNAs (data not 
shown). With NF1 knockdown confirmed, we repeated 
the experiment with the siRNAs and compared growth 
rates to cells treated with either miR514a or a scrambled 
miRNA control (miR-Neg-scr), in the presence of various 
concentrations of PLX4032 (See Materials and Methods). 
The siNF1 treatment resulted in significantly increased cell 
viability compared to miR-Neg-scr (see Supp Table 6 for 
P values) (Figure 5a) with the effect being most apparent 
in MM253. These data confirm the published association 
of NF1 loss being involved in reduced BRAFi sensitivity 
[18-21]. In the presence of miR-514a, cell viability was 
significantly increased in both MM253 (at 1-100 nM) and 
MM96L (at 1-10 nM) (see Supp Table 6 for P values) 
when compared to miR-Neg-scr. There was no significant 
difference in MM96L when siNF1 was compared with 
miR-514a, whereas in MM253, particularly at higher drug 
dosage (10-100nM), the differences between siNF1 and 
miR-514a, were highly significant (p < 0.00001) (Figure 
5a), indicating that the mode of BRAFi resistance was 
different, possibly due to other targeted genes of miR-
514a. Next we sought to measure the effect of reducing 
miR-514a levels via a LNA on BRAFi sensitivity. In the 
presence of PLX4032, using the same LNA specific to 
miR-514a (LNA-miR-514a), we showed that inhibition 
of miR-514a resulted in significantly greater BRAFi 
sensitivity in MM253 and MM96L (Figure 5b) at the 10 
(p = 0.0002 and p = 4.89e-006 respectively) and 100 nM 
(p = 2.21e-005 and p = 1.79e-007 respectively) dosage 
as compared to a negative control (LNA-Neg-scr) (Supp 
Table 6). 
DISCUSSION
MicroRNAs have been proven to be powerful 
regulators of protein coding gene expression in almost 
all facets of cell biology. In cancer, their dysregulation 
can be far reaching, spanning a multitude of different 
signaling pathways due to the number of genes being 
directly and indirectly regulated. In melanoma, the 
comprehensive analysis of miRNAs has been limited, 
with most studies performed using only a few hundred 
miRNAs [2]. Newly characterized miRNAs have seen 
the expansion of miRBASE (curated miRNA database), 
largely due to the advent of deep sequencing technologies. 
Figure 4: a. NF1 expression is reduced following transient transfection of miR-514a-3p (miR-514a) mimic (5 nM) as compared to miR-
Neg-scr control. Numbers indicated relative fold change. NF1 (~300 kDa) and GAPDH (37 kDa) were run and quantified on the same gel. 
b. MM253 and MM96L were transiently transfected with miR-514a mimic (5 nM) and miR-Neg-scr with proliferation measured at day
6 post transfection. Error bars show standard error of the mean (SEM) of 3 biological triplicates; P values as indicated, ****P < 0.001. c. 
MM253 and MM96L were transiently transfected with miR-514a mimic (5 nM) and a negative control (miR-Neg-scr) with colonies stained 
with crystal violet 14 days post transfection. This assay was repeated twice in duplicate and representative results are shown.
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As most of the newly identified miRNAs have no known 
association with melanoma, here we sought to survey a 
large panel of melanoma cell lines in relation to other solid 
malignancies to strengthen prior studies into melanocyte-
specific miRNAs and to identify those that were 
previously unknown to be involved in melanomagenesis. 
Identification of a panel in a comprehensive manner such 
as this has the ability to open new avenues for research 
in this burgeoning field, which may provide a greater 
understanding of this complex disease.
In our analysis we identified 233 miRNAs that were 
statistically significantly differentially expressed (P < 
0.05, ≥2 fold) when melanoma (n = 55) was compared 
with other solid cancers (n = 34). Several of the identified 
miRNAs have a known association with melanoma, 
however a number have no known association. The main 
premise of the study was to identify a panel of melanocyte-
specific miRNAs (or more predominantly melanoma-
expressed) and these are more readily observed in the up-
regulated group of miRNAs. However, it is worth noting 
that many of the down-regulated miRNAs have been 
previously associated with cancers including melanoma. 
Our dataset confirms and strengthens the associated loss 
of the miR-200 family (including miR-141) [24, 25] along 
with the frequently silenced miRNA, miR-205 (Supp 
Table 2) [26-30].
Figure 5: a. siNF1, miR-514a-3p (miR-514a), and a negative control (miR-Neg-scr) were transfected into melanoma cell lines MM253 
and MM96L with an endogenous BRAFV600E mutation. Following 24hr incubation, PLX4032 (BRAFi) was added to all wells (except 
miR-only or PLX4032 = 0 nM)) with concentrations as indicated. A proliferation assay was performed at day 5 post BRAFi addition. Line 
graphs show the effect of siNF1 and 514a and miR-Neg-scr respectively, as a % cell viablity in relation to titrated PLX4032 concentrations. 
b. LNA-miR-514a and LNA-Neg-scr were transfected and drug added as in Panel a. Lines graphs show that the cells are more sensitive to
BRAFi when miR-514a is inhibited. Error bars show standard error of the mean from 3 biological triplicate experiments.**p < 0.01, ***p 
< 0.005, ****p < 0.001.
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Lineage-specific miRNA expression
It has been well documented that miR-211 is a 
lineage-specific miRNA which is highly expressed in 
the melanocytic lineage and has been associated with 
melanoma cell invasiveness [12, 13, 31] via its direct 
regulation of POU3F2 (BRN2), IGF2R, TGFBR2, NFAT5, 
and NUAK1. Interestingly, whilst we observe miR-211 
to be highly expressed in the melanocytic lineage, as 
compared to other cancers (highest fold change observed), 
we have previously reported that miR-211 is often down-
regulated in melanoma relative to melanocytes [12]. miR-
211 expression is largely driven by its co-regulation with 
TRPM1 (Melastatin; miR-211 is located in intron 6) via 
MITF [12, 13, 31], and we have subsequently strengthened 
this association using an inducible MITF system [14] 
(Figure 1).
The miRNA with the next highest fold change in 
expression was miR-514a, which is a member of a cluster 
of miRNAs on chromosome X (miR-506-514). Most 
members of this cluster were found to be expressed in 
melanoma (compared to ‘other’ cancers) along with miR-
514a (see Supp Table 1 and 2) however their observed fold 
changes ranged from 204 (miR-514a) through to 2.5 (miR-
513a-5p) and, as such, it could be concluded that they are 
independently regulated. We assessed whether MITF may 
play a role in their regulation as was observed with miR-
211. Our data suggest that MITF does not directly control 
the expression of this cluster as we observed only a mild 
up-regulation in a cell line with endogenous expression 
and no induced expression in a cell line that had no 
detectable expression. Therefore, it still remains to be 
elucidated precisely how this cluster is regulated. 
The miR-506-514 cluster has been shown to be 
involved in melanocyte transformation along with the 
promotion of melanoma growth [9]. Prior to this study, 
members of this cluster had also been reported to be over-
expressed in melanoma [32], however, we provide the 
first documented evidence of this cluster being lineage-
specific. Streicher et al. [9] elegantly showed that the 
whole cluster was required to initiate cancer formation 
and its over-expression in melanoma was independent of 
mutations in BRAF and NRAS (oncogenes highly mutated 
in melanoma). Whilst we and others have observed the 
miR-506-514 cluster to be up-regulated in melanoma, 
individual members of the cluster (miR-506 and miR-507) 
have been shown to be lost during metastatic colonization 
despite being up-regulated in early melanoma progression 
[32]. 
Collectively, the miR-506-514 cluster is involved 
in malignant transformation; however we have shown 
that individual members of the cluster are expressed 
at different levels. In steps to elucidate the network of 
genes involved, here we selected miR-514a as it showed 
the highest fold change difference between melanomas 
compared with other cancers (204 fold), which was 
suggestive of its importance within the cluster. In addition, 
no confirmed gene targets of miR-514a have been reported 
in melanoma to date. To address this, we performed an 
unbiased approach (biotin-labeled miRNA duplex ‘pull-
down’ of mRNA transcripts) to identify precise target 
genes, rather than relying on target prediction algorithms 
which have high false positive rates upon experimental 
validation [10]. This focused approach yielded a large 
number of transcripts that were common to two transfected 
cell lines. Melanoma associated genes were indentified 
(via key words: melanoma, BRAF, and MITF) which 
produced a refined gene list (n = 16) common to all. One 
stand-out gene was the tumour-suppressor NF1.
Loss of NF1 function, a well-known tumour-
suppressor gene in melanoma, has been implicated on 
multiple occasions in resistance to PLX4032 targeted 
therapies [18-21] in BRAF-mutant melanoma. This loss 
can be attributed to a high frequency of inactivating 
mutations [33, 34], which occur in ~10% of all 
melanomas, along with proteasomal degradation, which 
has been observed in glioma [35, 36]. However, we have 
now confirmed that miR-514a has the ability to directly 
bind to NF1 transcripts, which can lead to altered NF1 
protein expression. 
Furthermore, as miR-514a is expressed in ~70% 
of melanoma samples tested, we believe that miR-
514a binding could be an important regulator of NF1, 
and as such warrants further investigation. Moreover, 
we have also demonstrated that over-expression and 
inhibition of miR-514a, not only leads to altered NF1 
protein expression, but also contributes to altered BRAFi 
sensitivity in vitro. Studies of sequential biopsies taken 
during response and later at recurrence may reveal that 
miR-514a does indeed play a key role in the resistance 
mechanisms observed in melanoma patients undergoing 
targeted therapy with the common BRAF inhibitor 
(PLX4032).
It is clear that direct binding of miR-514a to NF1 
is not the sole mechanism this miRNA plays in BRAFi 
resistance given the number of ‘pull-down’ target genes 
that are also predicted to be involved (Supp Figure 3) 
in the process and those as yet to be associated. One of 
these ‘pull-down’ genes, CDK2, was subsequently shown 
to be induced when miR-514a was inhibited. CDK2 is 
a cell cycle gene involved in G1/S transition and cell 
cycle progression. Taken together, these data highlight 
the important roles that miRNAs play in the control of 
biological processes. As a single miRNA can control 
a diverse range of different pathways simultaneously, 
by inference, a network of miRNAs would therefore 
have the potential to regulate a multitude of different 
genes. It could be postulated that targeted-therapy of a 
few key melanoma-specific miRNAs may allow better 
management of melanoma progression. In combination 
with currently used targeted therapies of the MAPK, 
PI3K, and mTOR pathways, pharmacological intervention 
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of miRNAs may allow for more durable outcomes in late 
stage melanoma patients.
MATERIALS AND METHODS
Cell Culture, Total RNA extraction, microRNA 
microarray profiling and quantitative RT-PCR 
validation
Cell lines used along with culturing, STR profiling, 
RNA extraction, microarray profiling and qRT-PCR are 
described in the supplementary methods. 
MITF inducible melanoma cell lines and lineage-
specific miRNA Taqman Assays
MITF inducible cell lines were cultured, 
induced with tetracycline, and then harvested for 
RNA as previously described [14]. Please refer to the 
supplementary methods for details on quantitative Real-
Time PCR. 
Biotin pull-downs and microarray hybridizations 
and data analysis
Please refer to the supplementary methods for a 
detailed description of the ‘pull-down’ methodology. 
Site-directed mutagenesis and dual-luciferase 
reporter assays
Please refer to the supplementary methods for 
detailed description of constructs used and transfection 
conditions. 
Transient transfections and cell viability assays
Please refer to supplementary methods for details 
on miRNA mimics, LNAs, transfection conditions, and 
BRAFi dosages.
Western blot and mRNA analysis
Please refer to the supplementary methods for 
details on protein extraction, western blotting, antibodies, 
and mRNA primer assays.
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miR-514a regulates the tumour suppressor NF1 and modulates 
BRAFi sensitivity in melanoma 
Supplementary Material and Methods 
Cell Culture and Total RNA extraction 
Ethical approval was granted by the QIMR Berghofer's Human Research Ethics 
Committee (HREC) approval number P1237. 
All melanoma (cutaneous and uveal) cell lines (Supp Table 3) were established and have 
been previously described (Dutton-Regester et al., 2012; Pavey et al., 2004). All other 
solid cancer cell lines (Supp Table 3) were kind donations from investigators at QIMR 
Berghofer. Most of the solid cancer cell lines are available from the cell line repositories 
ATCC or CellBank Australia. 
All cell lines were cultured in RPMI (#31800-089, Life Technologies, Foster City, CA, 
USA) supplemented with 10% FBS (Life Technologies, Foster City, CA, USA), HEPES, 100 
U/ ml penicillin and 100 µg/ml streptomycin (Life Technologies, Foster City, CA, USA ) 
and incubated at 37°C (5% CO2). All cell lines were periodically authenticated via short 
tandem repeat profiling according to the manufacturer’s instructions (AmpFISTR 
Profiler Plus ID kit; Life Technologies, Foster City, CA, USA). Primary human 
melanoblasts (QF1160MB) and melanocytes (MELA) were established from human 
neonatal foreskin and cultured as described (Cook et al., 2003; Leonard et al., 2003). 
Cells were harvested from the plate and column-purified using the miRNeasy Kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. 
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Serum/plasma collection and Total RNA extraction 
Serum and plasma were processed using standard methodologies and Total RNA was 
extracted using the Plasma/Serum Circulating RNA Purification Kit (#30000; Norgen 
Biotek, Ontario, Canada) according to manufacturer’s instructions. 
microRNA microarray profiling and data analysis 
5 µg of Total RNA was shipped to LC Sciences (Houston, USA) for miRNA profiling using 
a custom array platform (µParaflo® technology) containing 1898 miRNAs (miRBase 
V18)(Griffiths-Jones et al., 2006). All QC, labeling (Cy-3), hybridization, scanning, signal 
background subtraction and global normalization (LOWESS) were performed by LC 
Sciences as per technical note: (www.lcsciences.com/documents/application-
notes/Tech-Bull-MicroRNA-Microarray-Data-Analysis.pdf). 
Advanced data analyses were performed in Genespring GX12.5 (Agilent Technologies, 
Santa Clara, USA) using the LOWESS normalized signal intensity values. All values <30 
were considered ‘background expression’ (personal communication with LC Sciences) 
and changed to 0.01 prior to log2 transformation. So as to identify ‘melanocyte-specific’ 
miRNAs that were potentially more relevant to melanoma, samples were classified as 
either ‘melanoma’ or ‘other cancers’ (melanocytes, melanoblasts, nevocyte, and serum 
derived samples were excluded from these categories). To identify differentially 
expressed miRNAs, a Mann-Whitney U-test (unpaired) was applied to a ‘volcano-plot’ 
analysis with thresholds set at p<0.05 and ≥2 fold. The gene list derived from these 
analyses was then applied to all samples in an unsupervised manner using hierarchical 
clustering (Euclidean similarity with average linkage). 
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miScript quantitative RT-PCR validation 
Briefly, all samples included on the microarray along with an extended cohort of 
melanoma cell lines (as described in (Boyle et al., 2011)) were reverse transcribed using 
the miScript II RT Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s 
instructions. Real-time PCR was subsequently performed with a miScript SYBR Green 
PCR Kit (QIAGEN, Hilden, Germany); with the miRNA primer assays (QIAGEN, Hilden, 
Germany) hsa-miR-211-5p (#MS00003808), hsa-miR-514-3p (#MS00031948), and 
RNU-6 (#MS00033740), using the 7900HT Fast Real Time PCR System (Life 
Technologies, Foster City, CA, USA). Data were analyzed in Microsoft Excel using the 
ΔCT method compared to RNU6 which was assessed in every sample. 
MITF inducible melanoma cell lines and lineage-specific miRNA Taqman Assays 
RNA from the MITF inducible cells was used as templates for Taqman miRNA-specific 
cDNA synthesis as per manufacturer’s instructions (Life Technologies, Foster City, USA). 
Taqman miRNA assays were performed using miRNA-specific primers for miR-211-5p 
(000514), miR-514a-3p (001147), miR-204-5p (000508), miR-506-5p (001050), miR-
508-3p (001052), miR-509-3p (002236), and miR-509-5p (002235) (along with RNU6 
(001973) as an endogenous control) using the 7900HT Fast Real Time PCR System 
(Applied Biosystems, Foster City, USA) as per manufacturer’s instructions. Data were 
analyzed in Microsoft Excel using the ΔCT method compared to RNU6 which was 
assessed in every sample. The ΔΔCT was then applied with the induced cell line (MITF 
and LacZ inducible (control)) and the Negative non-induced cell lines (MITF and LacZ 
non-induced (control)). An ‘array expression-like value’ was produced by using ΔΔCT2. 
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Biotin pull-downs and microarray hybridizations and data analysis 
Synthetic biotinylated microRNA-duplexes were designed for miR-514a (Sequence 1: 
/5Phos/rUrArCrUrCrUrGrGrArGrArGrUrGrArCrArArUrCrArCrG Sequence 2: 
/5Phos/rArUrUrGrArCrArCrUrUrCrUrGrUrGrArGrUrArGrA/3Bio/) along with a 
scrambled control (Sequence 1: 
/5Phos/rUrArUrCrCrCrCrUrUrUrGrCrCrUrGrCrUrUrUrUrCrC/3Bio/ Sequence 2: 
/5Phos/rUrArArGrCrUrArGrArCrCrGrGrArGrGrArGrGrGrC) according to specifications 
detailed in the methodology devised by Cloonan and colleagues (Martin et al., 2014; 
Wani and Cloonan, 2014) and purchased from Integrated DNA Technologies (Coralville, 
USA). A step-by-step methodology (Wani and Cloonan, 2014) was followed with the 
following exceptions optimized to specific melanoma cell lines: Lyophilized miRNA 
duplexes were resuspended to a final concentration of 50 µM. 500,000 cells in 2.5mls of 
media (RPMI/10% FBS/no PenStrep) were seeded into 9-wells of 6-well plates (i.e. 1.5 
plates). 1.8 µL of each 50 µM duplex (miR-514a and miR-Scr-control (NEG-scr)) was 
added to 500µL of Opti-MEM® I (Life Technologies, Foster City, USA) and 4 µL of 
Lipofectamine® 2000 (Life Technologies, Foster City, USA) per well and allowed to 
incubate for 20mins. 500 µL of transfection mix was then added to each well. Precise 
modifications of the Cloonan protocol (Wani and Cloonan, 2014) are detailed in the 
Supplementary Methods below. 
 Biotinylated cRNA was prepared with the Illumina TotalPrep RNA Amplification Kit 
(Ambion, Austin, TX, USA). Labelled cRNA was hybridized to HumanHT-12 v4 BeadChip 
Arrays (Illumina Inc, San Diego, CA, USA), and then washed and scanned according to 
standard Illumina protocols. Data were extracted in GenomeStudio (Illumina) using 
default analysis settings and no normalization method.  Resulting data were imported 
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into GeneSpring GX v12.5 (Agilent Technologies, Santa Clara, CA, USA).  Expression 
values were normalized using quantile normalization with default settings. 
The gene-lists were filtered firstly by the following criterion: present in at least 2 cell-
lines with a fold change of >1.3 fold up-regulated as compared to Neg-Scr. Next, using 
PubMatrix (http://pubmatrix.grc.nia.nih.gov/) the following keywords were used to 
find associations: ‘Melanoma’, ‘BRAF’, ‘MITF’, and ‘proliferation’. 
Biotin pull-downs and microarray step-by-step methods 
Biotin pull-downs and microarray hybridizations were modified to work with existing 
transfection conditions for melanoma cell lines. The protocol follows a step-by-step 
guide which was originally published by the Cloonan lab (Martin et al., 2014; Wani and 
Cloonan, 2014). 
MATERIALS  &  REAGENTS  
• Cell line of choice  
• Fetal Bovine Serum  
• Phosphate Buffer Saline  
• Opti-MEM ® Reduced Serum Media   
• Transfection Reagent  
• Biotin tagged miRNA duplexes (Integrated DNA Technologies)  
• Dynabeads ® MyOne Streptavidin C1 (Invitrogen cat. no. 650-01)  
• Buffer Kit (Ambion cat.no. AM9010)  
• Sigma-IGEPAL ® CA-630 (Sigma Aldrich cat. no. I8896)  
• DL-Dithiothreitol  
• Yeast tRNA (Invitrogen cat.no.15401-011)  
• Bovine Serum Albumin (BSA)  
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• SUPERase•In™ (Ambion cat. no.AM2694)  
• Complete Mini Protease Inhibitor EDTA free (Roche cat.no. 11836170001)  
• RNase/DNase free water  
• RNeasy kit  
• Illumina ® TotalPrep RNA Amplification kit (Ambion cat. no. AMIL1791)  
• Illumina HumanHT-12 v4 Expression BeadChip.  
• Dry Ice  
 EQUIPMENT  
• Cell scrapers  
• 6-well tissue culture plates (P6) 
• Centrifuge capable of spinning 50mL falcon tubes at 1000g  
• 50mL Falcons  
• Rotating mixer  
• DynaMag™-2 magnet; magnetic separator (Life technologies cat. no. 123-21D)  
• Bench top Microcentrifuges; one set at 4oC and one at room temperature, both should 
be capable of  
doing at least 10,000g  
• Eppendorf LoBind® tubes; 1.5mL  
• Nanodrop 1000 spectrophotometer (Thermo Scientific)  
• Illumina Bead Array Reader.  
• Filter tips (10ul, 20ul, 200μl and 1000μl)  
 REAGENT SET UP  
• Biotin tagged miRNA duplexes: Resuspend lyophilized miRNA duplexes to a final 
concentration of  
200uM. Make working dilution at 50uM.  
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▲ CRITICAL Repeat freeze thaw cycles should be avoided.
• Bead Wash Buffer (Once prepared is stable at room temperature for several months):
5mM  Tris-Cl pH 7.5  
0.5mM EDTA 
1M NaCl. 
• Solution A (Once prepared is stable at room temperature for several months):
0.1M  NaOH 
0.05M  NaCl in RNase/DNase free H2O. 
• Solution B (Once prepared is stable at room temperature for several months):
0.1M NaCl in RNase/DNase free H2O. 
• Bead Blocking Solution: Prepare RNase/DNase free water containing
1ug/µL BSA 
1ug/µL Yeast tRNA.  
▲ CRITICAL This solution must be made fresh on the day of use.
• Cell Lysis Buffer : Prepare a solution with final concentrations of the following in
RNase/DNase free 
H2O 
10mM  KCl, 
1.5mM MgCl2, 
10mM  Tris-Cl pH 7.5, 
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5mM  DTT,  
0.5%  Sigma-IGEPAL ® CA-630,  
60U/ML SUPERase•In  and  
1x Complete Mini protease inhibitor.  
▲ CRITICAL SUPERase In and PIC must be added on the day of use. Then, the solution 
must be kept on ice at all times.  
 
• Wash Buffer: Prepare a solution with final concentrations of the following in 
RNase/DNase free  
H2O 
10mM KCl, 
1.5mM MgCl2, 
10mM Tris-Cl pH 7.5,  
5mM DTT,  
0.5% Sigma-IGEPAL ® CA-630,  
60U/ML SUPERase•In,  
1x Complete Mini protease inhibitor   
 ▲ CRITICAL This solution must be made fresh on the day of use and must be kept on 
ice at all  
times.  
  PROCEDURE  
Step 1-6: Transfecting the Biotin tagged miRNA duplexes into cells. (Day 1)  
● TIMING 24.5 h, 30 mins hands-on  
1. For each miRNA to be tested, seed 5x105 cells in 2.5mL media + 10% FCS, no 
Pen/strep per P6 (at least 8-9 P6 per point tested).  
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Optional: Set up 1x P6 dish with 5x105 cells as a mock transfection control if desired. 
2. Prepare the transfection mix according to the classical Lipofectamine protocol (Mix1
= 1.8ul of miRNA duplex 50uM + 250ul Optimem, Mix2 = 4ul Lipofectamine + 250ul 
Optimem). 
3. Incubate each mix separately for 5min at room temperature.
4. Mix 1 + 2 and Incubate at room temperature for 20min to allow the transfection
complexes to form. 
5. Add 500ul of the transfection complexes to each of the P6. Swirl the plate gently to
ensure that the complexes are distributed uniformly across the plate. 
6. Incubate the cells with the transfection complexes at 37ºC and 5% CO2 for 24 h.
Step 7-20: Bead washing and blocking. Bead preparation can be started on the day of 
transfection (day 1) on a rotating mixer at 4º overnight, or can be done on the day of cell 
harvesting (day 2) for 2  h at room temperature. 
● TIMING 17.5  h if started on day 1, 2.5  hs if started on day 2, 30 mins hands-on
7. Resuspend Dynabeads ® MyOne Streptavidin C1 in its bottle by vortexing. Transfer
200µL (100µL of bead suspension per point) to a 2mL LoBind tube. 
8. Place the tube with the bead suspension on the DynaMag™-2 magnet for 2 minutes.
9. Using a pipette, aspirate and discard supernatant before removing tube from the
DynaMag™-2 magnets. 
10. Add 200µl of bead wash buffer to the beads. Pipette several times to ensure the
beads are washed sufficiently. 
11. Repeat steps 8 -10 twice more for a total of three washes.
12. RNase Freeing Beads: After the third wash resuspend the beads in 200µl Solution
A. Mix well by pipetting several times. Let beads incubate at room temperature for 2 
minutes. 
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13. Place the tube containing the bead solution on the DynaMag™-2 magnet for 2 
minutes.  
14. Using a pipette, aspirate and discard supernatant before removing tube from the 
DynaMag™-2 magnets.  
15. Repeat steps 12-14 once more.  
16. Resuspend beads in 200µl Solution B. Mix well by pipetting several times.  
17. Place the tube containing the bead solution on the DynaMag™-2 magnet for 2 
minutes.  
18. Using a pipette, aspirate and discard supernatant before removing tube from the 
DynaMag™-2 magnets.  
19. Resuspend beads in 400µl Bead blocking solution. Pipette several times to mix.  
20. Place the tube containing the bead on a rotating mixer at 4ºC overnight if starting 
on day 1, or  
allow mixing at room temperature for 2h if starting on day 2.  
 Steps 21- 36 Harvesting and lysing transfected cells (Day 2)  
● TIMING 1 h , 30 mins hands-on  
21. Prepare cell Lysis Buffer and keep buffer on ice till required.  
▲ CRITICAL this buffer must be made fresh on the day of use.  
22. Retrieve transfection plates from step 6 of the protocol. Aspirate and discard media.  
23. To each P6 well, add 1 mL of PBS and using a cell scraper gently lift off the cells from 
the plate.  
24. Using a pipette transfer the cells to a 50mL falcon tube. Note: Cells from each of the 
9xP6 should be pooled at this stage.  
25. Centrifuge the falcon tubes containing the harvested cells at 1800rpm for 5 minutes 
at room temperature.  
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26. Aspirate and discard the supernatant. Add 1mL of PBS to the cell pellet and then
pipette gently to wash and resuspend the cells. Transfer into a 1.5ml Eppendorf tube. 
27. Centrifuge the tube at 10 000rpm for 5 minutes at room temperature.
28. Aspirate and discard supernatant.
29. Add 150µl cell lysis buffer to each pellet and gently pipette to resuspend cells.
30. Put cells in lysis buffer at -80oC for 20 mins.
31. Allow the cells to thaw out at room temperature.
▲ CRITICAL this freeze thaw step allows for better lysis of cells.
32. Centrifuge tube at 13,000rpm in a bench top centrifuge set at 4ºC for 5 minutes.
33. Transfer the cleared cell lysate to a clean 1.5mL LoBind tube, leaving behind the soft
pellet. The final volume of cleared lysate should be ~140µl-150ul. 
34. Transfer 20µL of this cleared lysate to a clean 1.5mL LoBind tube and keep on ice.
This lysate will serve as the control lysate RNA which can be extracted with the 
miRNeasy mini kit (elution in 30µl). 
Note: If processing a mock transfected control, carry out steps 22-33 of protocol on the 
mock transfection plate and keep mock control lysate on ice for later use. 
35. Add NaCl to the cleared lysate to give a final concentration of 1M. For example, add
32.5µL of 
5M NaCl to 130µL of lysate, giving a final concentration of 1M NaCl in 162.5ul. 
36. Place the tube containing cleared lysate and NaCl on ice.
Steps 37-44 Bead Preparation 
● TIMING 15 mins, 15 mins hands-on
37. Prepare wash Buffer and keep buffer on ice till required.
▲ CRITICAL This buffer must be made fresh on the day of use.
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38. Place the tube with the beads from step 20 on the DynaMag™-2 magnets for 2 
minutes.  
39. Aspirate and discard supernatant using a pipette.  
40. Add 200µl of wash buffer and Resuspend beads by pipetting several times.  
41. Place tube on the DynaMag™-2 magnets for 2 minutes.  
42. Aspirate the supernatant using a pipette and discard. Remove the tube from the 
DynaMag™-2  
magnets.  
43. Repeat steps 40-42  
44. Resuspend beads in 600µl of wash buffer.  
Steps 45-52 Target mRNA capture and post capture bead washing  
● TIMING 45 mins, 15 mins hands-on  
45. Add the 130µl cell lysate + NaCl from step 36 to the 100µl prepared beads from 
step 45. Place tubes on a rotating mixer at room temperature and incubate for 45 
minutes.  
46. Place the tube containing the cell lysate + Beads on the DynaMag™-2 magnets for 2 
minutes.  
47. Aspirate supernatant using pipette and discard. Remove the tube from the 
DynaMag™-2 magnets.  
48. Wash beads in 100µl wash buffer. Mix well by pipetting several times.  
49. Place the tube containing Beads + wash buffer on the DynaMag™-2 magnets for 2 
minutes.  
50. Aspirate supernatant using pipette and discard. Remove the tube from the 
DynaMag™-2 magnets.  
51. Repeat steps 48 -50 three times.  
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▲ CRITICAL These washes are essential and are important for the removal of non-
specifically bound products from the beads.  
52. Once the washes are complete, resuspend the beads in 30µL of RNase/DNase free
H2O, store on ice and proceed immediately to the next step.  
▲ CRITICAL The target mRNAs are captured on these beads. Do not discard.
Steps 53-59 Target mRNA and control lysate RNA purification  
● TIMING 1 h, 30 mins hands-on
53. Target mRNAs are purified off the Dynabeads® MyOne Streptavidin C1 using a
Qiagen RNeasy kit according to manufacturer’s RNA clean-up protocol. RNA should be 
eluted twice in 30µl RNase/DNase free water. The final volume of RNA will be 60µl. 
54. Alongside the captured target mRNAs also purify the control lysate RNA from step
34 of this protocol. Make up the volume of the control lysate to 100µL by adding 90µL of 
RNase /DNase free water. Purify the control samples using a Qiagen miRNeasy kit 
according to manufacturer’s RNA clean-up protocol. The control RNA can be eluted in 
30-50µL of RNase/DNase free water. 
■ PAUSE POINT Samples can now be stored at -80ºC. Alternatively, continue with
quantification of RNA. 
 Step 60 Target mRNA and control RNA Quantification 
● TIMING 45mins, 20 mins hands-on
60. The target mRNA and the control lysate RNA can now be quantified on the
Nanodrop 1000 spectrophotometer and on an Agilent 2100 Bioanalyser using the 
Agilent RNA 6000 Pico kit using manufacturer’s protocol. 
■ PAUSE POINT Samples can now be stored at -80ºC or continue on with RNA
amplification. 
 Step 61- 62 Target mRNA Labeling and Amplification 
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● TIMING 23 h, 2 h hands-on  
61. Amplify and label 160-500ng of captured target mRNA using Illumina® TotalPrep 
RNA Amplification kit according to manufacturer’s instructions. Also amplify and label 
160-500 ng of control RNA.  
▲ CRITICAL Carry out the 16 hour incubation for the IVT step.  
62. Quantify the amplified RNAs on the Nanodrop 1000 spectrophotometer.  
Step 63-65 Hybridization of samples onto Illumina® Human HT-12 array and 
scanning  
● TIMING 18 h s, 2 h s hands-on  
63. Hybridize 750ng of amplified cRNA onto an Illumina® Human HT-12 array 
following manufacturer’s protocol.  
64. Scan the arrays using an Illumina BeadArray Reader.  
65. Extract the expression measurements using the GenomeStudio software.  
 
Site-directed mutagenesis and dual-luciferase reporter assays 
Putative binding sites were identified using the miRanda target prediction software 
(version August 2010)(Enright et al., 2003). A partial sequence of the cDNA of NF1 
(NF1; NM_000267) from positions 1279–3542, which includes two putative miR-514a-
binding sites (site 1 in exon 9, 1342-1360bp; site 2 in exon 23, 3420– 3435 bp), flanked 
by AvrII sites, was cloned into the pGL4.10 vector (Promega, Madison, WI, USA) 
downstream of the luciferase gene. Site-directed mutagenesis of the putative binding 
sites was carried out using a QuickChange II XL site-directed mutagenesis kit 
(Stratagene, CA, USA). Melanoma cell lines with endogenous expression of miR-514a (C-
32, MM253, and HT144) were seeded onto 96-well plates at 25 000 cells per well and 
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co-transfected with 400 ng of pGL4.10 NF1 WT, Ex9_Mut, Ex23_Mut or both vector and 
20 ng pGL4.75 expressing Renilla luciferase. Luciferase activity was measured using the 
Dual-Luciferase Reporter Assay System as per the manufacturer’s instructions 
(Promega, Madison, WI, USA). Firefly luciferase activity was normalized to 
corresponding Renilla luciferase activity and expressed as a percentage of the control. 
To confirm that the mutated binding sites were related to miR-514a expression, MM253 
and HEK293T was co-transfected with 5 nM of miR-514a-3p mimic or Negative Allstars 
control (miR-Neg-scr) (QIAGEN, Hilden, Germany) along with 400 ng of pGL4.10 NF1 
WT and pGL4.10 NF1 Mut (Ex9 and Ex23) and 20 ng pGL4.75 expressing Renilla 
luciferase. 
Transient transfection of miRNA  mimics,  miRNA inhibitors, siRNAs and cell viability 
assays 
A highly efficient transfection reagent allows the use of low amounts of mimic thus 
reducing the possibility of off-target effects. Adding too much miRNA mimic can 
overload the RNA-induced silencing complex (RISC)(Khan et al., 2009) 
miR-514a-3p mimic (#MSY0002883), Negative Allstars control (#1027280; miR-NEG-
scr), and siRNAs (FlexiTube GeneSolution GS4763 for NF1) were purchased from 
QIAGEN (Hilden, Germany). miRNA inhibitors (miRCURY LNA™ microRNA Power 
Inhibitors # 427206-04 and 199020-04) were purchased from Exiqon (Vedbaek, 
Denmark). A final concentration of 5 nM of mimic, siRNAs and Negative control and 50 
nM of LNA’s were reverse-transfected into melanoma cell lines (30,000 cells/6-well and 
4,000 cells/well; MM96L and MM253 using Lipofectamine® RNAiMAX (Life 
Technologies, Foster City, USA) and harvested for RNA, protein at 72 hrs or measured 
for cell viabilities 6-days post transfection (equal to 5 days post BRAFi addition). 
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Melanoma cell lines were selected based upon transfection ability along with having 
detectable (by Western blot) endogenous NF1 protein levels (data not shown). NF1 
mRNA expression was determined (relative to RNU6) using a QuantiTect Primer Assay 
(#QT00065016; QIAGEN) as described previously. Cell viability assays were performed 
and determined using a modified sulforhodamine B (SRB; Sigma, St Louis, USA) assay 
(Vichai and Kirtikara, 2006). Briefly, siRNAs, miRNA mimic, Negative control or LNA’s 
were reverse-transfected with melanoma cell lines and seeded into a 96-well plate then 
incubated at 37ºC with 5% CO2 for 24hr. A serial 10-fold dilution series (100 nM-0.01 
nM) of PLX4032 (Selleckchem, Houston, USA) in DMSO was added across each plate. 
Plates were fixed on day 6 with methylated spirits prior to performing the SRB assay 
and read at 564 nm using a plate reader (Molecular Devices, Sunnyvale, USA). 
Western blot and mRNA analysis 
Cells were lysed in ice-cold lysis buffer containing 20 mM HEPES, pH 7.8, 0.42 M NaCl, 
0.5% NP40, 25% glycerol, 0.2 mM EDTA, 1.5 mM MgCl2, 0.1 mM PMSF and protease and 
phosphatase inhibitors. Samples (60 μg total protein) were resolved on 4–15% Mini-
PROTEAN TGX gels (Bio-Rad, Hercules, USA) and transferred to PVDF membranes using 
a Trans-Blot®Turbo™ (Bio-Rad, Hercules, USA). The following antibodies were used to 
detect NF1 (#A300-140A; Bethyl Laboratories, Montgomery, USA) and GAPDH (#2118S, 
Cell Signaling Technology, Danvars, USA) at 1:1000 and 1:5000 dilutions respectively 
along with a HRP-linked anti-rabbit secondary at 1:2000 (#7074S, Cell Signaling 
Technology, Danvars, USA). Cell-cycle and apoptosis related proteins were detected 
with the following antibodies: rabbit anti-E2F1 (#3742S), rabbit anti-CDK2 (#2546S), 
mouse anti-cyclin D1 (#2926P) and rabbit anti-BCL2 #2876S (Cell Signaling 
Technology, Danvars, USA), at 1:1000 dilution. Enhanced chemiluminescence (ECL) 
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detection of antibody binding was quantified using the Fuji LAS-4000 (GE Healthcare 
Life Sciences, Buckinghamshire, England). 
NF1 mRNA expression analysis 
RNA was reverse transcribed using the miScript II RT Kit (QIAGEN, Hilden, Germany) 
using the ‘HiFlex’ Buffer thus enabling both mRNA and miRNA to be analyzed in the 
same sample. The primer assays were used as described NF1 (#QT00065016) along 
with (RNU-6). Real-time PCR was performed and analyzed as previously stated.  
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SUPPLEMENTARY TABLE LEGENDS 
Supplementary Table 1 
All miRNA genes (n=233) listed have a P value ≤0.05 with a fold change (FC) ≥2 when 
55 melanoma cell lines were compared with 34 other solid malignancies. P values were 
generated using a Mann-Whitney U test (unpaired) with multiple testing corrections 
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(Benjamini-Hochberg). Normalised expression data of 233 miRNAs genes in all samples 
present on the microarray. Samples are grouped based upon tissue type. Normalised 
expression data is conditionally formatted (in Microsoft Excel) to assist in data 
visualisation. 
Supplementary Table 2 
All miRNAs genes that were ≥10 fold up and downregulated from those listed in 
Supplementary Table 1 are summarized here along with their relevance to melanoma. 
Supplementary Table 3 
Summary of all cell line names and associated tissue type that were used in the 
discovery (microarray) and validation cohorts (qRT-PCR). 
Supplementary Table 4 
List of all genes that we upregulated in 2/2 melanoma cell lines following a biotin-
labelled miR-514a duplex pulldown of mRNA transcripts. 
Supplementary Table 5 
List of all possible binding sites of miR-514 in the NF1 transcript (5’UTR, coding, and 
3’UTR) using the miRanda prediction algorithm. Binding threshold is set to 100 
(default=140). 
Supplementary Table 6 
Table of P values associated with BRAFi sensitivity for the melanoma cell lines MM96L 
and MM253 (Figure 5A-B). T-tests were performed with comparisons were made 
between siNF1 vs miR-514a; siNF1 vs siNF1+miR-514a; siNF1 vs miR-Neg-scr; miR-
67
514a vs miR-Neg-scr; LNA-miR-514a vs LNA-Neg-scr. All tests were corrected for 
multiple comparisons using the Sidak-Bonferroni method and those that still remained 
significant are noted (*). 
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SUPPLEMENTARY FIGURE 1 
Unsupervised hierarchical cluster tree (Euclidean similarity with average linkage) of all 
miRNA genes and samples (Supplementary Table 1). Distinct separation can be 
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observed for most melanoma (cutaneous) samples (brown) compared with other solid 
malignancies (green). Controls (melanocytes and melanoblsts) (red), uveal melanoma 
(UMM) (pink), melanoma patient-derived serum (blue) and nevocyte (grey) are also 
present in the tree.  
 
 
SUPPLEMENTARY FIGURE 2 
The top 3 upregulated miRNAs were validated using qRT-PCR with all samples present 
on the microarray along with an extended cohort of melanoma cell lines 
(Supplementary Table 3). For comparative purposes the array data was also plotted to 
highlight the high correlation between the array and qRT-PCR. 
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SUPPLEMENTARY FIGURE 3 
The Venn diagram graphically represents the filtered gene lists derived from keyword 
searches (‘Melanoma’, ‘BRAF’, ‘MITF’) compared to the common 2/2 gene list 
(Supplementary Table 4). 
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PAN
CͲ1
CAPAN
Ͳ1
CAPAN
Ͳ2
PL45
22rV
Ͳ1
ALVA
Ͳ1
LN
CAP
PCͲ3
Du145
CAKIͲ1
CAKIͲ2
786ͲO
SN
12KͲ1
SW
839
1
hsaͲm
iRͲ211Ͳ5p
3.43EͲ07
3.97EͲ09
276.8409
up
9.567844
8.338625
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.976384
6.731961
7.307253
2.425548
8.178769
8.227442
Ͳ6.64386
8.656941
Ͳ6.64386
7.665374
4.033297
Ͳ6.64386
5.299895
2.472384
Ͳ6.64386
9.186001
6.998863
4.966862
9.59944
Ͳ6.64386
6.498162
Ͳ6.64386
Ͳ6.64386
7.109354
8.953699
10.15491
8.896058
Ͳ6.64386
3.574063
7.981245
5.17853
2.237802
Ͳ6.64386
Ͳ6.64386
3.249517
Ͳ6.64386
1.536495
1.856038
5.695843
2.032444
5.023652
1.806176
4.477686
Ͳ6.64386
6.448804
4.743825
1.805841
Ͳ6.64386
1.561802
Ͳ6.64386
Ͳ6.64386
6.408644
2.478694
5.24932
Ͳ6.64386
6.023411
7.317211
7.749643
Ͳ6.64386
Ͳ6.64386
6.33625
6.955968
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.757622
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.007435
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2
hsaͲm
iRͲ514aͲ3p
2.96EͲ07
3.12EͲ09
204.0894
up
6.027062
5.4094434
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.87142
1.905415
2.627304
Ͳ6.64386
8.701356
6.119935
Ͳ6.64386
6.62798
Ͳ6.64386
Ͳ6.64386
4.357038
Ͳ6.64386
8.810731
4.838033
Ͳ6.64386
3.860971
Ͳ6.64386
3.851385
2.85417
5.395762
6.362243
Ͳ6.64386
3.154754
5.634016
5.321238
7.499312
Ͳ6.64386
3.578395
Ͳ6.64386
6.099684
2.497809
3.188892
Ͳ6.64386
4.175937
4.385721
4.257319
4.449385
Ͳ6.64386
4.508215
2.464201
5.3455
Ͳ6.64386
5.893532
Ͳ6.64386
3.312099
5.846663
6.304078
Ͳ6.64386
7.43031
Ͳ6.64386
2.505209
6.008565
Ͳ6.64386
3.689572
4.933208
Ͳ6.64386
1.865788
5.455324
Ͳ6.64386
Ͳ6.64386
4.846149
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.082333
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3
hsaͲm
iRͲ509Ͳ3p
5.15EͲ07
6.24EͲ09
139.3508
up
5.443304
5.9087563
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.286472
Ͳ6.64386
1.67461
Ͳ6.64386
7.44893
5.394606
Ͳ6.64386
5.603515
Ͳ6.64386
Ͳ6.64386
3.949232
Ͳ6.64386
7.842879
4.181335
Ͳ6.64386
3.222479
Ͳ6.64386
2.576763
2.692707
5.357101
4.618399
Ͳ6.64386
1.782786
4.408914
5.160773
6.077965
2.398025
2.005816
Ͳ6.64386
6.142268
2.825383
3.012735
Ͳ6.64386
2.160986
4.630996
3.938957
3.70642
Ͳ6.64386
3.272403
2.96979
4.956399
Ͳ6.64386
5.598628
Ͳ6.64386
2.757507
5.646413
4.919769
Ͳ6.64386
6.536786
Ͳ6.64386
Ͳ6.64386
5.793404
Ͳ6.64386
4.090097
4.274489
Ͳ6.64386
2.690343
4.893715
Ͳ6.64386
Ͳ6.64386
4.701985
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.391121
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4
hsaͲm
iRͲ204Ͳ5p
5.50EͲ06
1.39EͲ07
93.67072
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.85038
Ͳ6.64386
Ͳ6.64386
8.494253
5.984643
Ͳ6.64386
4.201002
7.071479
3.847751
2.475301
6.993068
7.007788
Ͳ6.64386
5.661485
3.251923
2.578395
Ͳ6.64386
5.155586
5.661107
4.376426
6.959186
4.044051
5.347513
Ͳ6.64386
6.037827
Ͳ6.64386
4.236114
Ͳ6.64386
4.606415
6.621423
4.745949
Ͳ6.64386
3.446389
7.020266
5.514987
4.591778
Ͳ6.64386
2.816338
5.536885
3.223186
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.953235
3.231376
6.69409
Ͳ6.64386
Ͳ6.64386
5.476918
7.898109
6.097333
2.156921
2.786275
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.249072
8.03134
5.044138
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.99203
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.310708
Ͳ6.64386
Ͳ6.64386
1.383379
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.529457
1.94839
Ͳ6.64386
Ͳ6.64386
4.072122
5
hsaͲm
iRͲ509Ͳ5p
2.29EͲ06
4.59EͲ08
65.2407
up
4.121795
4.024321
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.828511
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.122147
3.81269
Ͳ6.64386
3.855866
Ͳ6.64386
Ͳ6.64386
3.005816
Ͳ6.64386
7.587602
2.579299
Ͳ6.64386
2.207529
Ͳ6.64386
2.177155
1.444779
3.463507
4.07783
Ͳ6.64386
2.218885
3.870645
3.379972
5.424317
Ͳ6.64386
2.578395
Ͳ6.64386
4.749701
Ͳ6.64386
1.915874
Ͳ6.64386
2.067877
3.331803
2.921036
2.945886
Ͳ6.64386
2.413579
2.039624
3.201097
Ͳ6.64386
3.59565
Ͳ6.64386
1.657042
3.17366
4.349231
Ͳ6.64386
5.505111
Ͳ6.64386
Ͳ6.64386
3.566993
Ͳ6.64386
Ͳ6.64386
2.207026
Ͳ6.64386
Ͳ6.64386
3.61686
Ͳ6.64386
Ͳ6.64386
3.068738
1.468353
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6
hsaͲm
iRͲ513b
1.08EͲ05
3.13EͲ07
61.25974
up
5.927318
6.2692003
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.562168
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.635098
4.653568
Ͳ6.64386
4.055804
Ͳ6.64386
Ͳ6.64386
2.392839
Ͳ6.64386
7.398111
2.981397
Ͳ6.64386
3.699382
Ͳ6.64386
3.207529
2.936632
3.999103
4.152988
Ͳ6.64386
Ͳ6.64386
4.494887
4.626283
5.458506
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.491903
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.804843
3.68913
3.72839
3.060057
Ͳ6.64386
3.597025
Ͳ6.64386
3.565131
Ͳ6.64386
4.391032
Ͳ6.64386
2.951763
4.797355
5.20664
Ͳ6.64386
6.419285
Ͳ6.64386
Ͳ6.64386
4.351725
Ͳ6.64386
2.482681
3.420621
Ͳ6.64386
2.053608
4.767038
Ͳ6.64386
Ͳ6.64386
3.958416
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7
hsaͲm
iRͲ509Ͳ3Ͳ5p
3.46EͲ06
7.48EͲ08
55.9232
up
4.956314
3.74426
1.315536
Ͳ6.64386
Ͳ6.64386
3.621098
3.383598
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.491903
3.976515
Ͳ6.64386
3.261123
Ͳ6.64386
Ͳ6.64386
2.179845
Ͳ6.64386
6.528954
2.326533
Ͳ6.64386
2.377454
Ͳ6.64386
2.377454
Ͳ6.64386
2.803847
3.258856
Ͳ6.64386
1.695323
3.458667
4.379972
4.759333
Ͳ6.64386
1.968341
Ͳ6.64386
5.865582
Ͳ6.64386
1.833412
Ͳ6.64386
2.434005
3.392185
2.788932
2.72632
Ͳ6.64386
2.413579
1.825112
3.281417
Ͳ6.64386
4.577653
2.303706
1.649486
3.34031
3.978706
Ͳ6.64386
5.451814
Ͳ6.64386
1.66696
3.957558
Ͳ6.64386
2.289186
2.433796
Ͳ6.64386
Ͳ6.64386
4.172859
Ͳ6.64386
Ͳ6.64386
3.782944
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.362729
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.840736
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
8
hsaͲm
iRͲ145Ͳ5p
1.31EͲ04
6.27EͲ06
54.31673
up
5.114636
2.1095593
9.000869
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.287151
6.423821
6.67024
6.146394
5.304625
7.409776
Ͳ6.64386
Ͳ6.64386
3.662425
Ͳ6.64386
2.112731
5.910406
5.437071
2.198209
4.633793
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.312295
Ͳ6.64386
Ͳ6.64386
4.833411
6.588595
3.228208
Ͳ6.64386
6.108431
6.103805
Ͳ6.64386
2.891472
4.382573
6.451994
4.745949
Ͳ6.64386
3.431997
2.979439
7.947738
1.530936
2.460451
Ͳ6.64386
Ͳ6.64386
4.553304
Ͳ6.64386
Ͳ6.64386
6.424684
Ͳ6.64386
6.418253
Ͳ6.64386
4.741088
Ͳ6.64386
3.424244
2.474875
Ͳ6.64386
5.233637
2.170752
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.719216
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.497067
3.18407
8.10399
Ͳ6.64386
Ͳ6.64386
2.142371
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
9
hsaͲm
iRͲ146aͲ5p
3.50EͲ10
5.54EͲ13
36.32244
up
1.009903
0.98576665
Ͳ4.21723
Ͳ3.66633
Ͳ6.64386
Ͳ6.44142
0.75525
1.267154
0.902034
0.680086
1.246149
0.740482
1.289293
0.909741
Ͳ0.43894
0.552894
0.841362
0.065384
Ͳ0.25668
0.233533
0.426201
0.658126
0.181775
0.196682
0.536398
0.442993
0.536455
0.672175
Ͳ0.54378
0.422394
1.330454
1.103481
0.849041
Ͳ0.17403
1.002604
1.685111
1.096932
0.377159
Ͳ2.21137
Ͳ0.02034
0.239234
Ͳ2.31681
0.382166
0.195626
Ͳ0.05243
0.432967
0.776714
Ͳ1.58265
1.226
Ͳ6.64386
0.020057
1.344018
0.846475
Ͳ0.37093
1.19293
Ͳ1.80808
0.809991
1.43952
Ͳ1.23066
1.606611
0.350817
0.705192
1.342729
1.465251
Ͳ6.56534
Ͳ6.64386
1.08683
0.674821
Ͳ6.45354
Ͳ1.82476
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ5.08523
Ͳ6.64386
Ͳ6.64386
Ͳ2.28631
Ͳ1.58891
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.45031
Ͳ6.64386
Ͳ6.64386
Ͳ4.77339
Ͳ3.06346
Ͳ0.54362
Ͳ5.72723
Ͳ4.38872
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ4.00243
Ͳ6.64386
0.060697
0.578215
Ͳ2.24512
Ͳ5.18149
Ͳ1.50689
10
hsaͲm
iRͲ508Ͳ3p
7.57EͲ05
3.03EͲ06
31.90864
up
4.935213
5.1265917
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.711765
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.140268
4.243619
Ͳ6.64386
3.836238
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.014381
1.901227
Ͳ6.64386
2.480547
Ͳ6.64386
2.323006
2.117205
3.324679
3.022789
Ͳ6.64386
Ͳ6.64386
4.010652
3.348945
5.204229
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.968341
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
1.482914
2.44544
2.643502
2.765314
Ͳ6.64386
2.363826
Ͳ6.64386
2.784762
Ͳ6.64386
4.136218
Ͳ6.64386
1.641276
4.459817
4.665172
Ͳ6.64386
6.116775
Ͳ6.64386
Ͳ6.64386
4.571355
Ͳ6.64386
Ͳ6.64386
2.674804
Ͳ6.64386
Ͳ6.64386
4.28017
Ͳ6.64386
Ͳ6.64386
2.401639
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.796837
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
11
hsaͲm
iRͲ506Ͳ3p
1.47EͲ04
7.38EͲ06
27.69136
up
3.952683
3.767367
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.382897
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.74049
4.230009
Ͳ6.64386
3.668781
Ͳ6.64386
Ͳ6.64386
2.335124
Ͳ6.64386
7.026389
2.019872
Ͳ6.64386
2.576763
Ͳ6.64386
2.081998
2.059489
3.515502
3.700861
Ͳ6.64386
Ͳ6.64386
3.317491
2.658273
5.033297
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.047293
Ͳ6.64386
2.700145
Ͳ6.64386
Ͳ6.64386
2.488966
2.213817
2.317855
Ͳ6.64386
2.740389
Ͳ6.64386
1.827132
Ͳ6.64386
2.80607
3.19894
1.571976
3.592373
4.144801
Ͳ6.64386
5.175683
Ͳ6.64386
Ͳ6.64386
3.742309
Ͳ6.64386
2.529865
2.407324
1.776456
Ͳ6.64386
3.498019
Ͳ6.64386
Ͳ6.64386
3.316965
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.989258
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.45304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.003427
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
12
hsaͲm
iRͲ513cͲ5p
1.56EͲ04
7.97EͲ06
26.93033
up
4.768651
4.823789
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.359317
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.485617
3.520137
Ͳ6.64386
3.623693
Ͳ6.64386
Ͳ6.64386
2.042342
Ͳ6.64386
6.54118
1.859407
Ͳ6.64386
2.377454
Ͳ6.64386
1.944494
1.766707
3.187176
3.160292
Ͳ6.64386
Ͳ6.64386
3.276464
3.619799
4.668781
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.268465
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.826145
2.153696
1.928813
Ͳ6.64386
2.485132
Ͳ6.64386
2.169848
Ͳ6.64386
3.334998
Ͳ6.64386
1.560067
3.907678
3.923279
Ͳ6.64386
5.439473
Ͳ6.64386
Ͳ6.64386
3.890026
Ͳ6.64386
Ͳ6.64386
2.559327
Ͳ6.64386
Ͳ6.64386
3.354376
Ͳ6.64386
Ͳ6.64386
2.953095
1.313557
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.232482
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
13
hsaͲm
iRͲ4731Ͳ5p
1.47EͲ04
7.29EͲ06
24.1787
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
2.538497
Ͳ6.64386
Ͳ6.64386
1.718651
1.929867
1.880114
2.03873
1.553304
2.397184
2.733876
Ͳ6.64386
1.77958
1.849697
2.458146
2.044754
1.901227
2.455456
2.576763
2.448334
2.266423
Ͳ6.64386
1.980725
2.338291
1.511827
Ͳ6.64386
2.067877
2.410346
2.212267
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.201002
Ͳ6.64386
1.745949
Ͳ6.64386
Ͳ6.64386
2.185879
1.991425
Ͳ6.64386
1.633646
3.29912
Ͳ6.64386
2.02975
1.988357
1.721181
2.323145
1.585225
2.202807
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.922329
Ͳ6.64386
1.912157
Ͳ6.64386
2.273336
Ͳ6.64386
Ͳ6.64386
1.93775
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.538404
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.716003
2.074275
Ͳ6.64386
Ͳ6.64386
2.658734
Ͳ6.64386
Ͳ6.64386
2.455456
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
14
hsaͲm
iRͲ508Ͳ5p
6.88EͲ07
9.42EͲ09
21.59629
up
1.954803
1.6063751
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.293207
1.511701
Ͳ0.11617
Ͳ0.08803
0.381594
3.183747
0.348167
1.33393
0.975476
Ͳ6.64386
0.917407
1.362635
0.353773
3.506962
0.44893
0.492198
0.551091
0.75997
0.492198
Ͳ0.22616
1.046081
1.354764
Ͳ6.64386
0.406256
0.475403
Ͳ6.64386
1.733003
Ͳ6.64386
Ͳ6.64386
0.022964
2.446782
Ͳ6.64386
0.837973
Ͳ6.64386
0.146095
1.098707
0.691131
Ͳ6.64386
Ͳ6.64386
Ͳ0.14
0.306132
1.232635
Ͳ6.64386
1.301306
0.927425
0.277089
0.865987
1.529192
0.246858
2.023088
0.322475
0.229163
0.960992
0.942766
Ͳ6.64386
1.086853
0.06549
Ͳ6.64386
0.583252
Ͳ6.64386
Ͳ6.64386
0.374173
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.036887
Ͳ6.64386
Ͳ6.64386
Ͳ0.02334
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.16203
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.17127
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.098067
Ͳ6.64386
0.030618
0.61361
Ͳ6.64386
Ͳ6.64386
0.264787
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
15
hsaͲm
iRͲ363Ͳ3p
0.001081
8.32EͲ05
17.00228
up
1.670399
4.032822
Ͳ6.64386
0.396108
Ͳ6.64386
Ͳ6.64386
5.634797
Ͳ6.64386
3.95029
3.103766
4.133842
5.706069
Ͳ6.64386
Ͳ6.64386
5.26628
Ͳ6.64386
4.252383
Ͳ6.64386
6.0304
6.124855
Ͳ6.64386
Ͳ0.37059
Ͳ6.64386
0.76691
5.332428
2.772552
1.564576
Ͳ6.64386
4.763939
3.25529
5.947007
6.625402
0.351426
2.986527
Ͳ6.64386
Ͳ6.64386
3.532663
3.019576
Ͳ0.46222
3.372072
0.590045
5.836208
5.828738
Ͳ6.64386
2.003751
4.663546
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.667418
2.443535
3.278007
Ͳ6.64386
Ͳ0.31545
2.641887
1.526647
3.648958
0.55668
Ͳ6.64386
5.190659
3.598185
2.696951
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.36732
6.356567
Ͳ6.64386
Ͳ6.64386
0.247875
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.557857
2.838171
0.493941
Ͳ6.64386
Ͳ 6.64386
1.585411
0.549626
1.831164
Ͳ6.64386
Ͳ0.68733
2.522894
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.28612
Ͳ6.64386
0.238658
Ͳ6.64386
Ͳ6.64386
2.735347
16
hsaͲm
iRͲ551bͲ3p
0.002793
2.75EͲ04
13.10246
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.743657
Ͳ6.64386
Ͳ6.64386
7.193308
Ͳ6.64386
Ͳ6.64386
2.138266
2.993876
Ͳ6.64386
4.077966
4.313411
6.922732
Ͳ6.64386
2.710029
Ͳ6.64386
1.720414
Ͳ6.64386
Ͳ6.64386
2.924141
3.4013
2.535674
3.855194
2.458667
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.077966
2.407239
1.931815
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.518539
3.498865
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.05701
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.825737
4.150423
Ͳ6.64386
6.815022
Ͳ6.64386
4.39075
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.40763
Ͳ6.64386
2.00129
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.221254
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
17
hsaͲm
iRͲ4708Ͳ3p
0.001086
8.76EͲ05
12.24264
up
2.314327
Ͳ6.643856
Ͳ6.64386
2.808709
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.212267
2.503551
1.931815
2.123619
Ͳ6.64386
2.931815
Ͳ6.64386
2.97513
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.164261
3.222479
2.926347
3.34977
3.266423
2.059489
Ͳ6.64386
2.957201
2.734219
Ͳ6.64386
2.035456
Ͳ6.64386
2.448334
1.982988
Ͳ6.64386
2.28681
2.401301
Ͳ6.64386
2.20538
1.511827
2.620418
2.66868
1.72839
1.784423
Ͳ6.64386
2.413579
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.889717
2.844353
Ͳ6.64386
2.261749
1.512011
2.942228
2.553304
Ͳ6.64386
3.752192
Ͳ6.64386
2.919223
Ͳ6.64386
2.445122
Ͳ6.64386
Ͳ6.64386
2.805961
Ͳ6.64386
1.389921
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.122669
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.831909
Ͳ6.64386
1.614013
Ͳ6.64386
1.59619
Ͳ6.64386
1.655234
2.612709
Ͳ6.64386
Ͳ6.64386
2.863205
Ͳ6.64386
Ͳ6.64386
1.944494
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
18
hsaͲ m
iRͲ510
0.001869
1.69EͲ04
11.33646
up
2.956903
3.3233538
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.9648
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.966085
2.812691
Ͳ6.64386
2.453768
Ͳ6.64386
Ͳ6.64386
2.275003
Ͳ6.64386
6.827363
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.904776
2.990368
Ͳ6.64386
Ͳ6.64386
2.248449
2.284815
4.024194
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.9132
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.453189
2.505998
Ͳ6.64386
Ͳ6.64386
2.203361
Ͳ6.64386
1.963472
Ͳ6.64386
2.484142
Ͳ6.64386
Ͳ6.64386
1.646413
2.942648
1.583677
4.296603
Ͳ6.64386
Ͳ6.64386
1.809845
Ͳ6.64386
Ͳ6.64386
1.559328
Ͳ6.64386
Ͳ6.64386
2.142464
Ͳ6.64386
Ͳ6.64386
2.703739
1.891506
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.769032
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.797092
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
19
hsaͲm
iRͲ584Ͳ3p
9.67EͲ05
4.02EͲ06
10.36175
up
0.337103
0.24824145
Ͳ0.39406
3.020222
Ͳ6.64386
1.51221
0.375817
1.38456
1.092794
1.063505
1.229361
1.410219
Ͳ6.64386
1.70969
2.221707
Ͳ6.64386
0.663951
1.167812
1.180937
1.318822
Ͳ6.64386
0.357517
Ͳ0.03649
Ͳ0.13434
1.257732
0.9157
Ͳ0.05604
0.997781
0.523383
0.211439
1.653443
1.607367
0.989046
0.963511
0.695098
0.174913
Ͳ6.64386
0.989046
0.240351
1.701764
Ͳ6.64386
Ͳ6.64386
0.662236
Ͳ6.64386
Ͳ6.64386
0.892174
0.263645
0.101428
2.069631
Ͳ6.64386
Ͳ0.25378
0.732785
0.522323
Ͳ6.64386
1.601312
Ͳ6.64386
0.035589
0.997223
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.532521
1.183734
Ͳ6.64386
Ͳ6.64386
1.067889
1.930494
Ͳ6.64386
0.076509
Ͳ6.64386
Ͳ6.64386
1.556834
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.072131
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.26544
Ͳ0.19949
Ͳ6.64386
Ͳ6.64386
Ͳ0.25368
0.143596
Ͳ6.64386
0.712379
Ͳ0.12789
Ͳ6.64386
Ͳ6.64386
0.970899
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.12298
20
hsaͲm
iRͲ5701
0.008838
0.001197
10.01555
up
Ͳ6.64386
Ͳ6.643856
2.315536
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.171625
3.956063
Ͳ6.64386
4.3544
Ͳ6.64386
5.293871
Ͳ6.64386
2.802663
3.968341
3.15252
Ͳ6.64386
4.754938
1.944494
2.237276
3.910238
1.870494
Ͳ6.64386
3.489739
2.054498
2.582216
Ͳ6.64386
3.879804
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.915874
1.926865
Ͳ6.64386
3.731643
1.643502
3.121458
Ͳ6.64386
2.022789
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.58897
1.806878
Ͳ6.64386
3.607524
1.948418
2.367114
3.442745
1.992531
2.835514
Ͳ6.64386
3.802184
5.967913
Ͳ6.64386
2.799844
4.697525
4.487845
3.770668
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.423022
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.804616
Ͳ6.64386
Ͳ6.64386
2.090961
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.662385
Ͳ6.64386
2.884379
1.393869
Ͳ6.64386
Ͳ6.64386
2.717432
Ͳ6.64386
Ͳ6.64386
3.008001
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
21
hsaͲm
iRͲ4655Ͳ3p
0.007966
0.001032
9.83113
up
1.686386
1.8025779
Ͳ6.64386
3.237196
2.125487
2.792995
Ͳ6.64386
Ͳ6.64386
1.720414
2.162514
1.553304
Ͳ6.64386
3.376426
1.690807
Ͳ6.64386
2.525823
1.67461
2.16864
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.275003
Ͳ6.64386
Ͳ6.64386
1.602213
2.022789
Ͳ6.64386
2.310032
Ͳ6.64386
2.497809
Ͳ6.64386
2.067877
Ͳ6.64386
Ͳ6.64386
1.894341
2.46924
1.993876
Ͳ6.64386
1.968341
2.592618
1.808561
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.61397
2.041608
Ͳ6.64386
2.349212
2.433312
1.852507
Ͳ6.64386
2.234312
1.846712
Ͳ6.64386
2.452844
1.576763
Ͳ6.64386
2.382515
2.488439
1.696831
Ͳ6.64386
1.819783
1.912137
1.852825
1.994706
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.365773
Ͳ6.64386
Ͳ6.64386
2.078555
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.993318
1.847035
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.88352
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.553304
1.719941
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
22
hsaͲ m
iRͲ3909
0.001779
1.60EͲ 04
9.591683
up
1.622365
Ͳ 6.643856
Ͳ6.64386
3.388807
2.38155
3.010189
Ͳ6.64386
Ͳ6.64386
2.501773
2.028213
Ͳ6.64386
1.50891
3.376426
1.775696
Ͳ6.64386
1.77958
2.275003
2.103051
2.009989
2.164261
1.529457
2.081998
2.243976
Ͳ6.64386
Ͳ6.64386
1.649519
1.778863
Ͳ6.64386
1.980725
Ͳ6.64386
Ͳ6.64386
2.179845
2.523556
1.764808
2.579984
Ͳ6.64386
Ͳ6.64386
2.935773
Ͳ6.64386
Ͳ6.64386
2.218941
Ͳ6.64386
Ͳ6.64386
2.048683
Ͳ6.64386
2.0503
2.125055
Ͳ6.64386
1.676787
2.754089
Ͳ6.64386
1.513147
1.871826
Ͳ6.64386
Ͳ6.64386
2.000331
1.66696
1.852452
Ͳ6.64386
Ͳ6.64386
2.078702
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.88213
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.380439
1.779878
Ͳ6.64386
Ͳ6.64386
1.556152
Ͳ6.64386
1.514219
Ͳ6.64386
1.904391
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.645963
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.529457
1.597686
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
23
hsaͲm
iRͲ 514aͲ5p
0.004085
4.44EͲ04
8.814804
up
3.311048
3.0809364
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.211314
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.476136
2.866462
Ͳ6.64386
3.4013
Ͳ6.64386
Ͳ6.64386
2.929867
Ͳ6.64386
6.402306
2.295506
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.999368
3.104714
2.597025
Ͳ6.64386
Ͳ6.64386
2.506761
Ͳ6.64386
4.5846
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.690807
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.966046
1.505998
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.069104
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
3.606188
Ͳ 6.64386
4.887111
Ͳ 6.64386
Ͳ6.64386
1.891427
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
2.645543
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.719724
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
24
hsaͲm
iRͲ3937
7.27EͲ05
2.87EͲ06
8.556762
up
0.287374
Ͳ0.2398757
0.101121
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.01078
Ͳ6.64386
0.869747
1.418631
Ͳ0.24607
1.435851
0.242148
0.732553
Ͳ6.64386
2.229138
0.988392
0.719205
0.479842
0.315556
0.928019
0.52526
0.988392
1.356862
0.395567
0.548263
0.943304
0.75427
Ͳ0.33043
0.403429
Ͳ6.64386
0.910389
Ͳ6.64386
0.098016
Ͳ0.1086
0.421351
Ͳ6.64386
Ͳ0.10472
0.379875
0.935924
1.008802
0.619158
0.080108
0.139123
1.251426
Ͳ0.18141
0.764261
Ͳ6.64386
Ͳ0.09371
Ͳ6.64386
1.214615
1.306921
Ͳ0.05193
0.627575
Ͳ6.64386
1.164772
1.034934
Ͳ0.21454
1.193652
Ͳ6.64386
1.115431
0.39892
Ͳ6.64386
Ͳ0.34329
0.199005
0.297841
Ͳ6.64386
Ͳ0.5144
Ͳ6.64386
0.158317
Ͳ6.64386
0.570552
0.157826
Ͳ6.64386
Ͳ0.04281
Ͳ6.64386
Ͳ0.08304
Ͳ6.64386
Ͳ6.64386
0.727682
Ͳ6.64386
Ͳ0.23964
Ͳ6.64386
Ͳ0.71205
Ͳ6.64386
Ͳ6.64386
0.228517
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.23449
0.882965
Ͳ6.64386
0.374808
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.343056
Ͳ6.64386
Ͳ0.12328
Ͳ6.64386
0.010698
25
hsaͲm
iRͲ4321
0.008674
0.00117
8.399978
up
Ͳ6.64386
Ͳ6.643856
1.537929
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.499586
1.955122
2.212267
1.992589
1.775696
3.23683
Ͳ6.64386
2.968341
3.727801
2.632738
Ͳ6.64386
1.846712
2.510418
2.326533
1.944494
2.553304
2.212267
3.611251
1.35167
Ͳ6.64386
1.990367
2.734219
1.782786
1.53022
2.802663
2.501773
Ͳ6.64386
1.849697
Ͳ6.64386
1.894341
2.379972
Ͳ6.64386
2.890339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.028348
Ͳ6.64386
2.72076
Ͳ6.64386
1.720097
Ͳ6.64386
1.583677
Ͳ6.64386
1.929108
2.646413
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.925062
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.710911
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.486498
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.48175
Ͳ6.64386
2.739938
1.389328
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.319669
Ͳ6.64386
1.938251
Ͳ6.64386
Ͳ6.64386
1.850285
Ͳ6.64386
2.005586
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
26
hsaͲm
iRͲ3184Ͳ5p
0.001423
1.23EͲ04
8.294511
up
1.045734
0.80164886
1.027001
Ͳ6.64386
Ͳ6.64386
1.189056
1.291404
0.326966
Ͳ0.00637
0.126744
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.33562
Ͳ6.64386
Ͳ6.64386
Ͳ0.26162
Ͳ6.64386
Ͳ0.37691
Ͳ6.64386
1.454517
Ͳ0.02827
Ͳ6.64386
Ͳ0.26927
1.152402
1.185354
Ͳ0.4053
1.575594
0.713285
1.582305
1.137077
Ͳ0.12836
0.809715
0.032107
0.957745
0.592822
1.657334
0.667696
0.450062
1.326291
0.824305
0.277583
0.272687
2.066646
Ͳ0.27601
1.193075
Ͳ0.03388
0.447726
0.573443
1.159811
0.347728
1.350637
Ͳ0.19294
0.412978
0.085067
0.275602
1.83608
Ͳ0.30542
Ͳ6.64386
Ͳ6.64386
0.549093
2.008834
Ͳ6.64386
0.15067
0.779337
Ͳ0.079
Ͳ6.64386
2.504118
Ͳ6.64386
1.786995
0.098104
Ͳ6.64386
Ͳ0.09365
Ͳ6.64386
Ͳ0.05903
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.018002
Ͳ6.64386
0.060974
Ͳ0.31646
Ͳ6.64386
Ͳ0.93137
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.915355
Ͳ6.64386
Ͳ6.64386
0.593781
1.004049
Ͳ6.64386
0.37043
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.7087
Ͳ6.64386
0.006339
Ͳ6.64386
Ͳ6.64386
27
hsaͲm
iRͲ146aͲ3p
0.006231
7.35EͲ04
8.144401
up
Ͳ6.64386
3.575995
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.633031
Ͳ6.64386
Ͳ6.64386
3.366535
Ͳ6.64386
3.977802
1.583677
4.366682
Ͳ6.64386
2.622566
Ͳ6.64386
2.36427
Ͳ6.64386
5.318224
3.904776
Ͳ6.64386
3.159525
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.880285
Ͳ6.64386
Ͳ6.64386
2.182935
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.028348
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.391841
2.147273
Ͳ6.64386
5.737136
Ͳ6.64386
2.350487
Ͳ6.64386
2.483549
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.80604
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
28
hsaͲm
iRͲ654Ͳ5p
0.009938
0.001386
7.699157
up
2.058109
Ͳ6.643856
2.408645
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.20273
Ͳ6.64386
2.503551
Ͳ6.64386
1.756837
Ͳ6.64386
2.836238
Ͳ6.64386
3.182935
Ͳ6.64386
1.630983
Ͳ6.64386
1.816338
2.177155
2.266423
2.305376
2.266423
1.654233
Ͳ6.64386
1.700861
1.852864
1.602213
2.458667
1.954666
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.418374
1.692399
Ͳ6.64386
1.670964
Ͳ6.64386
1.58089
Ͳ6.64386
3.4013
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.38692
2.082512
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.037806
Ͳ6.64386
Ͳ6.64386
2.166552
3.064291
2.433796
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.239257
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.058539
Ͳ6.64386
Ͳ6.64386
1.38989
3.629358
Ͳ6.64386
Ͳ6.64386
1.563829
Ͳ6.64386
2.62473
1.5234
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
29
hsaͲm
iRͲ140Ͳ5p
0.002789
2.73EͲ04
7.660998
up
2.137185
0.5802835
0.755263
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.743652
0.668376
2.646044
Ͳ6.44EͲ04
2.184562
0.64496
Ͳ6.64386
1.02822
4.165497
Ͳ6.64386
0.814644
1.566197
1.387125
1.465212
Ͳ0.16121
Ͳ0.46378
0.153446
Ͳ6.64386
0.179467
0.094407
Ͳ6.64386
0.312143
0.43001
0.712074
1.021975
1.771575
Ͳ6.64386
2.219034
Ͳ6.64386
0.881999
Ͳ6.64386
2.187344
0.419059
4.448525
Ͳ6.64386
Ͳ0.10872
2.79119
0.018925
Ͳ6.64386
1.874906
Ͳ6.64386
1.62178
1.023404
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.273364
Ͳ0.31645
3.960163
0.081099
0.487315
0.032988
Ͳ6.64386
Ͳ6.64386
1.016756
Ͳ6.64386
0.449078
0.26834
Ͳ6.64386
1.589768
Ͳ0.12718
0.399423
Ͳ0.09217
6.44EͲ04
Ͳ6.64386
Ͳ6.64386
0.044574
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.237376
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.01081
Ͳ6.64386
Ͳ6.64386
1.33224
Ͳ6.64386
Ͳ0.6777
1.365246
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.61502
Ͳ6.64386
Ͳ6.64386
0.410566
Ͳ6.64386
Ͳ0.28162
Ͳ6.64386
1.333742
1.340586
30
hsaͲm
iRͲ3972
0.002615
2.54EͲ04
7.432085
up
Ͳ6.64386
Ͳ6.643856
1.730574
2.461204
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.005816
Ͳ6.64386
1.775696
Ͳ6.64386
Ͳ6.64386
2.105845
Ͳ6.64386
2.525823
1.764808
2.261749
1.606633
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.146678
Ͳ6.64386
Ͳ6.64386
1.649519
1.990367
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.243976
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.775696
Ͳ6.64386
1.652839
Ͳ6.64386
1.620418
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.174792
1.568954
1.914581
Ͳ6.64386
2.431674
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.621818
Ͳ6.64386
2.419164
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.378217
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
31
hsaͲm
iRͲ593Ͳ5p
4.55EͲ05
1.70EͲ06
7.19713
up
1.190245
Ͳ0.4629576
Ͳ0.24198
2.423111
Ͳ6.64386
Ͳ6.64386
0.160991
0.168744
2.319402
1.113145
0.147791
0.825863
1.410825
1.374299
Ͳ0.0746
1.142337
1.935487
1.026161
0.554353
1.315966
0.783869
Ͳ0.23451
Ͳ0.37767
0.180527
0.511754
Ͳ0.44716
0.365737
0.439738
0.334204
Ͳ0.10702
0.464264
0.0042
0.22238
0.069788
Ͳ6.64386
Ͳ0.03663
Ͳ6.64386
0.557667
Ͳ0.40826
0.825863
Ͳ0.05268
Ͳ0.15105
0.348213
Ͳ6.64386
0.692238
Ͳ0.10934
Ͳ0.17404
1.041435
0.178164
0.933157
0.401805
0.701874
Ͳ0.03187
0.05787
1.051626
Ͳ0.06815
0.906353
Ͳ0.31404
Ͳ6.64386
0.339133
0.464155
1.969645
Ͳ6.64386
0.784381
0.851177
Ͳ6.64386
Ͳ0.37137
0.212732
Ͳ0.3476
Ͳ0.00421
Ͳ6.64386
Ͳ6.64386
0.477841
Ͳ0.24152
Ͳ6.64386
Ͳ0.24128
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.37345
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.34406
Ͳ6.64386
Ͳ6.64386
0.135857
0.288535
Ͳ0.12484
0.4195
Ͳ0.40958
0.153252
Ͳ6.64386
0.062902
Ͳ0.35335
Ͳ6.64386
Ͳ6.64386
0.802016
Ͳ0.18623
Ͳ0.3937
Ͳ6.64386
1.181824
32
hsaͲm
iRͲ218Ͳ2Ͳ3p
7.74EͲ04
5.43EͲ05
7.18456
up
0.753784
0.19149634
Ͳ0.34533
1.911279
1.581305
Ͳ6.64386
Ͳ0.01725
0.199752
Ͳ0.17107
0.001572
Ͳ6.64386
0.354394
1.141955
Ͳ0.02268
Ͳ6.64386
0.518865
0.594467
0.30468
0.101992
Ͳ6.64386
Ͳ0.00588
0.033648
0.24397
0.283626
Ͳ6.64386
0.45154
Ͳ6.64386
0.016018
0.481913
0.02558
0.274939
0.207444
0.998203
0.207444
Ͳ6.64386
0.057495
0.114474
0.620002
0.054492
Ͳ0.17795
0.282261
Ͳ0.06998
Ͳ6.64386
0.683271
0.090116
0.446575
Ͳ0.11278
0.366594
0.370268
Ͳ6.64386
Ͳ0.04654
0.22001
0.246803
Ͳ0.21469
0.003009
Ͳ0.00157
Ͳ0.00588
Ͳ6.64386
0.433872
3.391594
0.66142
Ͳ0.04985
0.007376
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.453658
0.583982
Ͳ6.64386
0.305129
Ͳ6.64386
0.064949
Ͳ6.64386
Ͳ6.64386
Ͳ0.10237
Ͳ6.64386
0.036928
Ͳ0.03788
Ͳ6.64386
Ͳ6.64386
0.047711
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 0.00335
Ͳ6.64386
Ͳ0.46747
Ͳ6.64386
Ͳ6.64386
0.225168
0.040803
Ͳ6.64386
Ͳ6.64386
0.490267
Ͳ6.64386
0.605554
Ͳ0.25295
Ͳ6.64386
Ͳ0.04376
0.064715
33
hsaͲm
iRͲ138Ͳ5p
0.001269
1.06EͲ04
7.184394
up
0.644178
0.39080095
2.58545
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ2.15003
1.009811
2.691948
2.666147
1.929534
Ͳ0.39617
Ͳ6.64386
0.804946
0.993342
Ͳ0.60105
1.83296
0.954708
2.539424
0.155292
0.669389
Ͳ0.0737
Ͳ0.14962
Ͳ1.65867
Ͳ0.53306
1.524838
0.070155
0.441541
2.156418
Ͳ0.99301
2.536457
2.431488
Ͳ6.64386
0.652777
0.144014
0.123475
0.022986
0.898813
0.808035
Ͳ0.55936
1.099109
Ͳ0.86167
0.666459
0.203818
0.423036
1.352861
Ͳ0.67058
0.9975
Ͳ6.64386
Ͳ6.64386
Ͳ1.50506
Ͳ0.93702
1.007142
0.771703
2.598925
0.50904
Ͳ0.10473
0.376618
Ͳ1.65458
Ͳ6.64386
Ͳ0.10657
1.819374
0.677375
0.961728
2.624326
Ͳ6.64386
0.589961
0.227179
Ͳ6.64386
3.085054
Ͳ6.64386
Ͳ6.64386
Ͳ2.23135
Ͳ6.64386
Ͳ6.64386
Ͳ2.29576
Ͳ6.64386
Ͳ6.64386
Ͳ0.23384
Ͳ0.69755
Ͳ1.99141
Ͳ6.64386
Ͳ0.8784
Ͳ1.0374
Ͳ6.64386
0.874126
Ͳ6.64386
0.527021
Ͳ6.64386
0.702765
Ͳ0.8369
Ͳ6.64386
Ͳ6.64386
Ͳ1.38943
Ͳ6.64386
Ͳ6.64386
1.835145
1.341335
0.51021
Ͳ0.04238
Ͳ0.02336
0.701427
34
hsaͲm
iRͲ4722Ͳ3p
0.006789
8.18EͲ04
7.179308
up
2.660731
1.6949203
1.83491
Ͳ6.64386
Ͳ6.64386
3.246363
1.606966
1.677323
2.212267
Ͳ6.64386
2.169975
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.077966
2.16864
2.175999
1.771944
1.870494
1.622566
2.305376
Ͳ6.64386
1.730181
1.824606
Ͳ6.64386
Ͳ6.64386
2.052875
Ͳ6.64386
Ͳ6.64386
1.849697
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.733876
1.912846
Ͳ6.64386
Ͳ6.64386
2.190734
1.654857
1.769032
Ͳ6.64386
2.250317
2.597025
2.000203
1.778319
2.701025
2.136218
Ͳ6.64386
Ͳ6.64386
1.951268
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
2.403926
Ͳ6.64386
Ͳ6.64386
2.484548
Ͳ6.64386
2.858559
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.652839
Ͳ6.64386
Ͳ6.64386
1.704353
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.30743
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.831228
Ͳ6.64386
1.511483
2.094793
Ͳ6.64386
Ͳ6.64386
2.081998
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
35
hsaͲm
iRͲ658
0.010971
0.001607
6.930552
up
1.744402
Ͳ6.643856
1.963234
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.94136
Ͳ6.64386
Ͳ6.64386
2.820408
Ͳ6.64386
2.9183
Ͳ6.64386
4.038731
Ͳ6.64386
3.944325
Ͳ6.64386
Ͳ6.64386
1.652437
1.981397
3.39075
2.688655
2.742782
3.266423
2.277669
Ͳ 6.64386
2.700861
2.627304
Ͳ6.64386
2.130613
2.182935
2.697694
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.733876
Ͳ6.64386
2.60393
2.219646
Ͳ6.64386
1.632855
1.769032
2.264416
Ͳ6.64386
3.700861
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.963749
2.768404
Ͳ6.64386
1.583677
Ͳ6.64386
2.037806
1.83202
Ͳ6.64386
2.576828
2.948944
2.352876
2.249827
2.344642
1.819678
1.775883
Ͳ6.64386
Ͳ6.64386
1.94872
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.817748
Ͳ6.64386
Ͳ6.64386
2.991425
Ͳ6.64386
2.039933
Ͳ6.64386
2.142371
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.83491
1.499588
Ͳ6.64386
1.621572
2.455381
1.946662
1.745949
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
36
hsaͲm
iRͲ3944Ͳ3p
0.010203
0.001441
6.720376
up
1.804629
Ͳ6.643856
1.868077
2.41794
3.1906
2.849627
Ͳ6.64386
1.911133
1.67461
1.880114
Ͳ6.64386
Ͳ6.64386
2.397184
1.60061
Ͳ6.64386
2.073311
Ͳ6.64386
2.261749
1.606633
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.35167
2.08764
Ͳ6.64386
Ͳ6.64386
2.08764
1.576024
2.034837
2.179845
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.968341
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.643502
Ͳ6.64386
2.609398
1.660219
1.645601
2.570362
1.86252
2.349212
2.477812
Ͳ6.64386
1.951268
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.752404
Ͳ6.64386
1.886947
Ͳ6.64386
Ͳ6.64386
2.14429
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.674498
1.833412
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.654639
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.829009
Ͳ6.64386
1.709423
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.792491
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
37
hsaͲm
iRͲ4539
0.021122
0.003405
6.615453
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
3.676588
3.587583
Ͳ6.64386
1.874763
1.646743
Ͳ6.64386
1.758123
Ͳ6.64386
Ͳ6.64386
2.940327
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.816338
2.048831
1.622566
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.485132
2.332857
2.08764
2.190734
2.034837
2.077966
2.982988
Ͳ6.64386
2.354583
1.816338
Ͳ6.64386
1.993876
1.649331
Ͳ6.64386
1.982968
Ͳ6.64386
1.536495
Ͳ6.64386
Ͳ6.64386
2.016574
1.696024
1.994962
Ͳ6.64386
3.52544
Ͳ6.64386
1.603344
Ͳ6.64386
1.924714
1.537129
2.109956
1.710029
1.834988
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.973584
Ͳ6.64386
1.667274
2.048438
Ͳ6.64386
2.342912
Ͳ6.64386
Ͳ6.64386
1.993876
2.156007
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.86185
1.362842
Ͳ 6.64386
Ͳ6.64386
1.923982
1.857458
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.66696
Ͳ6.64386
1.76725
Ͳ6.64386
Ͳ6.64386
38
hsaͲm
iRͲ146bͲ5p
9.66EͲ07
1.42EͲ08
6.577508
up
1.153703
1.263122
Ͳ2.17661
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.145823
1.894079
1.391502
2.490393
2.759545
3.1
Ͳ0.86278
2.106095
0.167804
1.96906
1.198324
Ͳ0.08844
Ͳ1.13311
1.657414
2.705193
2.134176
2.152864
2.31585
2.50552
Ͳ0.13175
1.418012
3.883183
Ͳ1.21855
3.335671
2.459659
1.810727
1.753273
0.634516
0.962596
2.30157
2.008806
0.681934
Ͳ1.20122
1.483812
1.107128
Ͳ1.34871
1.101242
0.252865
Ͳ0.19941
0.995821
1.229673
Ͳ2.247
2.186313
Ͳ6.64386
3.359154
2.254069
Ͳ0.0707
1.004351
1.317521
Ͳ0.41115
3.595688
2.163417
Ͳ1.05141
2.014916
1.95013
1.34201
Ͳ2.09061
3.403166
Ͳ2.54104
Ͳ3.15514
Ͳ0.00359
Ͳ1.95144
Ͳ0.99791
Ͳ0.76976
Ͳ1.44732
Ͳ6.64386
Ͳ3.042
Ͳ0.29841
Ͳ1.98623
Ͳ2.23537
Ͳ1.30553
Ͳ1.21326
Ͳ1.3941
Ͳ0.4805
Ͳ1.6783
Ͳ2.811
2.41869
Ͳ1.92023
Ͳ2.44451
Ͳ1.61838
3.674078
Ͳ1.8726
Ͳ1.30066
Ͳ0.04595
Ͳ1.8189
Ͳ2.39317
Ͳ2.08182
Ͳ2.85722
Ͳ6.64386
Ͳ6.64386
Ͳ2.7066
1.19332
2.094551
0.003581
Ͳ1.67342
Ͳ0.29307
39
hsaͲm
iRͲ362Ͳ3p
2.02EͲ04
1.08EͲ05
6.514883
up
1.049444
0.03130359
Ͳ0.52539
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.630247
1.570194
2.124862
Ͳ0.00961
2.977727
3.323587
Ͳ6.64386
2.17685
2.120467
0.820269
0.314762
1.327718
3.467115
1.729931
1.41436
1.345648
Ͳ6.64386
Ͳ0.76398
0.94986
0.190135
1.596905
1.199285
1.240761
2.372006
1.753155
3.273295
Ͳ6.64386
1.758368
0.105809
1.876129
0.891352
1.018369
Ͳ0.78161
1.20834
Ͳ6.64386
0.0521
2.07695
Ͳ6.64386
Ͳ6.64386
Ͳ0.18105
Ͳ0.53513
1.129692
1.373233
Ͳ6.64386
Ͳ0.3391
0.878676
2.194195
Ͳ6.64386
3.512422
Ͳ6.64386
1.26422
2.040863
Ͳ6.64386
Ͳ6.64386
2.621593
Ͳ0.87198
Ͳ0.57695
1.735142
Ͳ6.64386
Ͳ6.64386
1.822511
0.491312
Ͳ0.5727
Ͳ6.64386
1.13174
Ͳ6.64386
Ͳ6.64386
0.300689
Ͳ0.83353
Ͳ0.66971
0.797013
0.51097
Ͳ0.89308
Ͳ6.64386
Ͳ6.64386
Ͳ0.8175
Ͳ0.60644
0.092862
Ͳ6.64386
Ͳ6.64386
Ͳ0.79504
0.328764
2.293468
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.48253
Ͳ6.64386
Ͳ6.64386
Ͳ0.16007
Ͳ0.23054
Ͳ6.64386
Ͳ6.64386
Ͳ0.18646
0.00955
40
hsaͲm
iRͲ501Ͳ3p
6.88EͲ07
9.19EͲ09
6.462504
up
Ͳ0.04149
Ͳ0.3935417
Ͳ6.64386
0.566726
0.707267
Ͳ6.64386
0.990683
0.24985
1.211054
0.393117
1.36887
1.242593
1.012726
1.357554
Ͳ0.15308
0.592234
0.81791
1.013953
0.817837
0.851952
0.914878
0.884182
0.551394
0.453547
0.489164
0.27576
0.792551
0.414856
0.32467
1.252677
Ͳ0.40777
0.982029
0.415938
Ͳ0.00254
1.014687
1.041295
0.191696
1.587346
Ͳ6.64386
Ͳ0.70152
0.679058
Ͳ0.03458
Ͳ0.2492
Ͳ6.64386
Ͳ0.10275
Ͳ0.03891
0.002537
Ͳ6.64386
0.257224
0.826784
0.092868
0.529334
0.970807
Ͳ 0.01579
1.548945
Ͳ0.06571
0.611809
0.957035
Ͳ6.64386
Ͳ0.02924
1.419287
0.485318
Ͳ0.09384
0.543918
Ͳ6.64386
Ͳ0.15248
0.399888
Ͳ6.64386
Ͳ0.13319
Ͳ0.40231
0.846134
Ͳ0.23685
Ͳ6.64386
Ͳ6.64386
Ͳ0.06653
Ͳ0.23945
Ͳ0.19113
0.18026
Ͳ6.64386
Ͳ0.63404
Ͳ6.64386
Ͳ0.38771
Ͳ6.64386
Ͳ6.64386
Ͳ0.37871
Ͳ6.64386
0.031662
Ͳ0.8245
Ͳ0.40881
Ͳ0.28466
Ͳ6.64386
Ͳ0.39406
Ͳ0.26217
Ͳ6.64386
0.721419
Ͳ6.64386
Ͳ6.64386
0.27576
Ͳ0.61483
Ͳ6.64386
0.113395
Ͳ6.64386
41
hsaͲm
iRͲ3907
7.04EͲ06
1.93EͲ07
6.43762
up
0.407779
Ͳ0.2290613
0.039712
1.441719
0.555098
2.104108
Ͳ0.00357
Ͳ0.50757
0.35148
0.513231
Ͳ0.27001
0.979512
0.847438
Ͳ0.34596
Ͳ6.64386
Ͳ0.12851
1.176802
0.474963
0.151053
1.045854
0.303386
0.064599
0.472787
Ͳ0.22171
0.075846
0.22142
0.373507
0.310004
0.643246
Ͳ0.6716
Ͳ6.64386
Ͳ0.19601
0.906695
Ͳ0.31148
0.341514
0.199477
0.813384
0.829528
0.046969
1.281091
1.012604
0.279927
Ͳ0.4174
0.279819
Ͳ0.05618
0.238514
0.785967
0.66601
0.256323
0.830999
Ͳ0.19554
0.766518
Ͳ0.48458
0.901228
Ͳ6.64386
Ͳ0.44942
1.374939
Ͳ0.17253
0.788991
Ͳ6.64386
0.257968
1.629869
Ͳ6.64386
Ͳ6.64386
0.596402
0.588584
0.066512
Ͳ6.64386
Ͳ0.49911
0.098714
0.068972
Ͳ0.14795
Ͳ6.64386
Ͳ6.64386
Ͳ0.48103
Ͳ0.6068
Ͳ0.56134
Ͳ0.32806
Ͳ0.07688
0.304174
Ͳ0.07162
Ͳ6.64386
Ͳ6.64386
Ͳ0.93392
Ͳ6.64386
Ͳ6.64386
Ͳ0.53614
Ͳ0.47125
Ͳ0.81218
Ͳ6.64386
Ͳ0.22573
0.504847
Ͳ6.64386
0.003557
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.35148
Ͳ6.64386
Ͳ0.17843
Ͳ6.64386
Ͳ6.64386
42
hsaͲm
iRͲ3189Ͳ5p
0.010122
0.001419
6.377651
up
Ͳ6.64386
Ͳ6.643856
1.45304
Ͳ6.64386
Ͳ6.64386
3.050908
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.670661
1.894341
Ͳ6.64386
2.940327
Ͳ6.64386
Ͳ6.64386
1.77958
2.005816
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.710029
1.622566
1.807877
Ͳ6.64386
1.398976
Ͳ6.64386
1.700861
Ͳ6.64386
1.782786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.026057
2.005816
1.752922
1.931815
Ͳ6.64386
2.103501
Ͳ6.64386
1.53022
1.784396
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.151642
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.394582
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.752404
1.622566
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.747571
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.934975
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.757084
Ͳ6.64386
1.424021
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
43
hsaͲm
iRͲ199bͲ5p
0.010553
0.001518
6.022791
up
1.615446
Ͳ6.643856
6.128034
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.367513
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.671948
Ͳ6.64386
Ͳ6.64386
4.891106
6.602264
Ͳ6.64386
2.207529
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.461673
Ͳ6.64386
Ͳ6.64386
4.138266
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.731641
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.316702
2.153696
2.394476
2.609398
1.778863
3.134667
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.405049
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.456572
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
44
hsaͲm
iRͲ4436bͲ5p
0.029436
0.005087
5.61163
up
2.203663
3.1531773
1.868077
3.307713
2.647795
Ͳ6.64386
1.566365
1.85858
2.005816
1.918588
2.318838
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.16864
Ͳ6.64386
1.901227
1.710029
1.751849
2.042342
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.700861
1.604936
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.720414
2.026057
Ͳ6.64386
Ͳ6.64386
1.855866
1.995308
2.300538
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.490692
Ͳ6.64386
2.485132
1.971042
Ͳ6.64386
1.977546
2.069104
Ͳ6.64386
Ͳ6.64386
1.688233
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.178669
1.870494
1.638283
Ͳ6.64386
3.589765
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.794982
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.945388
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.444354
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.808561
1.885094
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.841564
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.890852
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.977076
Ͳ6.64386
45
hsaͲm
iRͲ548q
0.004951
5.61EͲ04
5.547026
up
4.724566
2.6128526
Ͳ6.64386
Ͳ6.64386
0.834807
Ͳ6.64386
1.827107
1.208036
0.391592
1.158975
0.479862
Ͳ6.64386
Ͳ6.64386
1.448836
Ͳ6.64386
1.596097
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.956709
Ͳ0.05418
1.065363
1.186829
Ͳ0.1889
1.660684
0.095199
1.651981
Ͳ6.64386
1.820669
Ͳ6.64386
Ͳ6.64386
1.148192
Ͳ6.64386
0.459659
0.856011
Ͳ6.64386
Ͳ0.02099
0.343229
Ͳ6.64386
0.595207
0.23552
0.596716
Ͳ6.64386
1.453653
Ͳ6.64386
0.307426
1.887009
Ͳ6.64386
Ͳ6.64386
2.184525
0.047264
1.205819
1.064172
0.297207
0.316666
Ͳ6.64386
0.713404
3.422221
1.532171
1.470456
1.741076
2.550242
Ͳ 6.64386
0.268635
Ͳ6.64386
1.380864
Ͳ6.64386
0.126431
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.2812
Ͳ6.64386
Ͳ0.17576
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.514708
Ͳ6.64386
0.020693
Ͳ6.64386
Ͳ6.64386
0.305784
Ͳ6.64386
Ͳ0.4424
Ͳ6.64386
0.088136
1.719862
1.241288
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.195652
Ͳ6.64386
0.920622
Ͳ6.64386
0.453472
Ͳ6.64386
46
hsaͲm
iRͲ498
0.01123
0.001651
5.406655
up
0.613397
0.35078126
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.45227
Ͳ0.44354
0.703961
0.734379
Ͳ0.37004
Ͳ0.68263
Ͳ6.64386
1.466462
Ͳ6.64386
1.249504
0.744603
Ͳ0.42455
Ͳ6.64386
Ͳ0.05186
1.231719
1.149256
1.407569
1.798759
Ͳ6.64386
1.382477
1.594654
0.240561
Ͳ0.16501
0.28827
Ͳ0.32035
Ͳ0.033
0.31642
Ͳ6.64386
0.639657
1.158889
1.071965
0.300653
0.187122
0.407568
0.882102
0.945225
Ͳ0.70235
0.335907
0.633128
Ͳ6.64386
0.25416
0.078364
Ͳ0.38149
Ͳ6.64386
1.804784
0.58314
0.032266
1.174908
Ͳ0.31578
0.735952
Ͳ0.16562
0.079528
2.743253
Ͳ6.64386
0.716155
1.564524
1.209008
Ͳ6.64386
Ͳ0.15306
1.129669
0.207004
Ͳ0.30137
Ͳ0.32752
Ͳ6.64386
Ͳ0.38352
0.811382
Ͳ6.64386
Ͳ0.07902
0.533046
Ͳ0.64828
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.738774
Ͳ6.64386
0.597978
Ͳ6.64386
Ͳ6.64386
0.688343
Ͳ0.21244
Ͳ6.64386
Ͳ6.64386
Ͳ0.49983
Ͳ6.64386
0.178969
1.57818
0.800637
Ͳ6.64386
1.738887
Ͳ6.64386
Ͳ6.64386
0.284186
Ͳ0.41504
Ͳ6.64386
0.464598
Ͳ6.64386
47
hsaͲm
iRͲ4781Ͳ5p
0.014003
0.002132
5.305426
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.649406
Ͳ6.64386
1.670661
Ͳ6.64386
1.553304
Ͳ6.64386
2.733876
Ͳ6.64386
3.129164
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.294992
2.294992
Ͳ6.64386
2.731091
Ͳ6.64386
4.052875
2.413579
2.128498
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.054498
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.011754
1.728875
Ͳ6.64386
Ͳ6.64386
3.422726
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.207582
Ͳ6.64386
Ͳ6.64386
2.367207
2.039768
Ͳ6.64386
Ͳ6.64386
1.746264
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.991425
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
48
hsaͲm
iRͲ5587Ͳ5p
3.80EͲ04
2.30EͲ05
5.271441
up
Ͳ0.02248
Ͳ6.643856
Ͳ6.64386
0.980069
0.673864
Ͳ6.64386
Ͳ0.432
Ͳ0.23496
0.398287
0.30044
Ͳ0.08289
Ͳ0.42203
0.969234
0.583374
Ͳ6.64386
1.096081
0.022139
Ͳ0.40615
Ͳ6.64386
0.273967
1.446518
1.027914
1.261966
1.252345
Ͳ6.64386
0.373196
1.123562
Ͳ0.1885
0.325102
0.205803
Ͳ6.64386
0.139975
1.177583
Ͳ6.64386
0.91349
0.885402
0.405409
1.493085
Ͳ0.64793
Ͳ0.58938
1.139101
0.433706
Ͳ6.64386
0.356534
0.487525
Ͳ0.63634
Ͳ0.18671
Ͳ6.64386
Ͳ6.64386
1.284061
0.580487
0.572873
0.168321
0.378119
Ͳ0.22911
1.213785
0.346982
0.2075
1.694382
0.282984
0.703354
0.592039
0.403931
Ͳ0.20404
0.529084
0.362646
0.136202
Ͳ6.64386
Ͳ0.24705
Ͳ6.64386
0.540705
0.353457
Ͳ6.64386
Ͳ6.64386
Ͳ0.16102
Ͳ0.73228
Ͳ6.64386
Ͳ0.58663
Ͳ6.64386
0.127603
Ͳ0.14654
Ͳ0.58321
Ͳ6.64386
Ͳ6.64386
Ͳ0.51228
Ͳ6.64386
0.306409
Ͳ0.84422
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
0.27669
0.055635
Ͳ6.64386
0.744297
Ͳ6.64386
Ͳ6.64386
0.893264
Ͳ0.22272
Ͳ0.45182
Ͳ0.27656
Ͳ6.64386
49
hsaͲm
iRͲ501Ͳ5p
0.002222
2.07EͲ04
5.113965
up
0.382961
0.24888206
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.457531
0.942831
2.289852
0.294547
2.256879
2.654033
Ͳ6.64386
2.360902
0.816581
0.366807
1.144001
1.579209
2.52706
1.473833
1.233032
0.468845
Ͳ0.01827
Ͳ6.64386
1.336146
1.662354
0.100374
0.795863
0.236747
1.811345
0.153814
2.396767
Ͳ6.64386
Ͳ0.16266
0.74349
1.256879
1.170116
1.774819
Ͳ6.64386
Ͳ6.64386
0.034548
Ͳ0.44443
0.04935
Ͳ6.64386
Ͳ0.47078
Ͳ0.37998
Ͳ0.43381
Ͳ6.64386
0.037639
Ͳ6.64386
Ͳ6.64386
1.405229
1.338347
Ͳ6.64386
2.39802
Ͳ6.64386
Ͳ6.64386
1.427392
Ͳ6.64386
Ͳ6.64386
2.200916
1.015558
1.104801
1.312882
Ͳ6.64386
Ͳ6.64386
1.643141
0.018042
0.626438
Ͳ6.64386
1.860471
Ͳ0.27604
Ͳ6.64386
Ͳ0.06022
Ͳ6.64386
Ͳ0.1324
0.042315
1.141789
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.18704
Ͳ6.64386
Ͳ0.7111
Ͳ0.55467
Ͳ0.56331
0.045923
0.277644
0.210256
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.32571
Ͳ0.38505
0.152152
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
50
hsaͲm
iRͲ4323
9.31EͲ04
7.02EͲ05
4.921013
up
0.862403
0.67593205
Ͳ0.01187
Ͳ6.64386
Ͳ6.64386
0.949436
0.214302
0.811122
0.487525
0.209503
1.20572
0.725824
0.925389
0.640935
Ͳ0.03714
0.935383
0.415375
0.609908
0.521428
0.390957
0.119589
0.202051
0.684562
Ͳ6.64386
1.139741
0.011773
1.006585
Ͳ6.64386
0.85977
0.411848
1.189139
0.684562
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.756412
0.48287
Ͳ6.64386
Ͳ6.64386
0.916321
0.308033
Ͳ6.64386
Ͳ6.64386
0.180709
Ͳ0.0595
0.244824
0.86531
0.36436
0.512611
Ͳ6.64386
0.233239
0.360827
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.389678
0.201203
Ͳ6.64386
Ͳ6.64386
0.309924
0.215404
0.398647
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.361724
Ͳ6.64386
Ͳ0.11366
0.11273
Ͳ 6.64386
0.287203
Ͳ6.64386
Ͳ6.64386
Ͳ0.08444
Ͳ6.64386
Ͳ6.64386
0.346792
Ͳ0.28301
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.13669
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.25953
Ͳ6.64386
Ͳ6.64386
0.318381
0.704551
0.032227
Ͳ6.64386
0.117525
0.226177
51
hsaͲm
iRͲ3944Ͳ5p
0.001908
1.74EͲ04
4.912326
up
Ͳ0.07347
Ͳ6.643856
0.556597
1.914465
1.140051
1.596411
0.041846
0.199597
0.219838
0.089914
Ͳ0.10942
Ͳ0.03119
1.142835
0.145837
Ͳ0.11608
0.669943
0.332313
0.610614
0.986802
Ͳ6.64386
0
0.082462
0.258312
0
0.51611
0.072756
0.068834
Ͳ0.01763
0.411558
0.187923
0.669943
0.964581
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.258312
Ͳ6.64386
0.205845
Ͳ6.64386
0.357848
0.430522
0.098532
Ͳ6.64386
Ͳ0.07638
0.751644
0.068543
0.730418
Ͳ6.64386
0.426189
1.70169
0.191927
0.018846
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.2123
0.527247
0.446705
Ͳ6.64386
0.408517
0.434261
0.182175
Ͳ6.64386
Ͳ6.64386
0.165375
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.07083
Ͳ0.05719
Ͳ6.64386
Ͳ6.64386
Ͳ0.30658
Ͳ6.64386
0.424537
Ͳ6.64386
Ͳ6.64386
0.222403
Ͳ6.64386
Ͳ0.20403
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.61205
Ͳ0.07159
Ͳ6.64386
0.086479
Ͳ0.01598
Ͳ6.64386
Ͳ6.64386
0.01415
0.201134
Ͳ6.64386
Ͳ6.06EͲ04
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.866733
Ͳ6.64386
0.364656
Ͳ6.64386
0.404724
52
hsaͲm
iRͲ4665Ͳ5p
0.047031
0.008772
4.908286
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
3.14478
3.852629
1.726251
2.015556
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.50891
3.222098
Ͳ6.64386
Ͳ6.64386
2.410346
1.627304
2.231376
1.606633
Ͳ6.64386
1.576763
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.476682
Ͳ6.64386
Ͳ6.64386
1.67461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.733876
Ͳ6.64386
1.745949
Ͳ6.64386
Ͳ6.64386
1.697042
Ͳ6.64386
Ͳ6.64386
2.048683
Ͳ6.64386
1.938565
2.397906
Ͳ6.64386
2.261749
2.320926
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.881687
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.121249
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.476174
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.138266
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.836791
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.796292
Ͳ6.64386
1.967334
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
53
hsaͲm
iRͲ4469
0.026951
0.004558
4.714384
up
0.128324
Ͳ6.643856
0.307695
1.740383
0.844431
2.013662
Ͳ6.64386
Ͳ6.64386
0.181342
0.131589
0.107342
Ͳ6.64386
1.924381
Ͳ6.64386
Ͳ0.02485
Ͳ6.64386
0.955066
0.738108
Ͳ6.64386
0.636228
0.338752
0.129299
1.085127
Ͳ6.64386
Ͳ6.64386
0.787017
0.592257
Ͳ6.64386
0.693908
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.200214
Ͳ6.64386
0.35332
0.707734
1.871275
1.361206
Ͳ6.64386
0.440308
1.080337
0.660429
Ͳ6.64386
0.51889
Ͳ6.64386
1.057159
0.963837
Ͳ6.64386
0.675372
2.116589
Ͳ6.64386
0.019879
Ͳ6.64386
0.575836
Ͳ6.64386
1.117117
0.773155
0.422583
0.904074
Ͳ6.64386
0.682731
0.273039
Ͳ6.64386
Ͳ6.64386
0.357441
0.299222
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.381964
0.131533
0.931415
Ͳ6.64386
Ͳ6.64386
0.717924
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.193302
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.02016
0.859534
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.771403
Ͳ6.64386
Ͳ6.64386
1.854534
Ͳ6.64386
Ͳ6.64386
0.129299
Ͳ 6.64386
0.483523
Ͳ6.64386
Ͳ6.64386
54
hsaͲm
iRͲ628Ͳ3p
0.02025
0.003233
4.679494
up
2.064265
0.34417018
0.545545
0.903429
Ͳ6.64386
Ͳ6.64386
0.877551
0.510874
1.022373
0.085095
0.761287
0.70994
Ͳ6.64386
0.888666
Ͳ0.35419
Ͳ6.64386
Ͳ6.64386
0.228724
0.268505
Ͳ6.64386
1.124463
Ͳ0.115
Ͳ6.64386
Ͳ0.19746
1.137198
1.832223
Ͳ6.64386
1.252031
0.311391
0.526511
0.672777
0.513359
Ͳ6.64386
Ͳ0.28019
Ͳ6.64386
Ͳ0.35419
Ͳ6.64386
Ͳ6.64386
0.580085
0.449889
0.251159
0.215175
0.818826
1.852684
0.773189
Ͳ0.09043
0.564389
1.197294
0.651936
Ͳ6.64386
Ͳ0.37164
0.880275
Ͳ6.64386
Ͳ0.32382
0.688989
Ͳ6.64386
0.692352
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.811032
2.299847
Ͳ0.10288
0.455528
0.508792
Ͳ6.64386
0.486231
0.341551
Ͳ6.64386
1.230772
Ͳ6.64386
Ͳ6.64386
0.53393
Ͳ0.5036
Ͳ6.64386
Ͳ6.64386
Ͳ0.3855
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.343689
Ͳ6.64386
0.299007
Ͳ6.64386
0.656049
Ͳ6.64386
1.086114
Ͳ6.64386
0.645185
0.23709
0.547219
Ͳ6.64386
0.297886
Ͳ6.64386
Ͳ0.22453
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.343204
55
hsaͲm
iRͲ3619Ͳ3p
0.008931
0.001214
4.414144
up
0.320403
0.33194706
6.95EͲ04
2.66388
0.372971
1.171391
0.397703
0.451646
Ͳ6.64386
0.297475
Ͳ0.11909
Ͳ6.64386
1.202838
Ͳ6.64386
0.01607
Ͳ6.64386
Ͳ6.64386
0.337549
0.056859
Ͳ6.64386
Ͳ0.09854
Ͳ0.23605
Ͳ6.64386
Ͳ6.64386
0.036828
0.139273
Ͳ6.64386
1.068252
0.884016
0.202838
0.189163
0.084194
1.260554
Ͳ6.95EͲ04
Ͳ0.01183
0.202838
0.84124
0.302374
0.087361
0.132449
0.0257
0.081532
Ͳ0.14154
0.633678
Ͳ0.06464
0.470685
0.80045
0.521852
0.793927
1.191821
Ͳ6.64386
0.465873
Ͳ0.01643
Ͳ6.64386
Ͳ0.00349
0.308829
0.557503
Ͳ0.13436
Ͳ6.64386
Ͳ6.64386
0.53079
1.097293
Ͳ6.64386
Ͳ0.10895
0.52027
Ͳ6.64386
0.789957
Ͳ0.43746
Ͳ6.64386
0.787801
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.05138
Ͳ6.64386
0.552061
0.043058
0.14352
Ͳ6.64386
Ͳ6.64386
Ͳ0.11294
Ͳ6.64386
0.153785
0.070656
0.286999
Ͳ0.29138
Ͳ6.64386
0.219914
0.158454
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.194517
Ͳ0.01365
Ͳ0.15378
Ͳ6.64386
Ͳ6.64386
Ͳ0.12474
56
hsaͲm
iRͲ20bͲ3p
0.030173
0.005262
4.286351
up
Ͳ6.64386
1.8994781
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.914071
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.078765
Ͳ6.64386
Ͳ6.64386
2.652839
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.380357
3.458445
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.74856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.121588
Ͳ6.64386
3.234774
3.448334
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.110786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.72839
2.72632
Ͳ6.64386
Ͳ6.64386
2.164467
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.652437
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.913886
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.978492
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
57
hsaͲm
iRͲ584Ͳ5p
2.00EͲ06
3.68EͲ08
4.172919
up
Ͳ0.04799
0.41171163
Ͳ0.95495
Ͳ1.25762
Ͳ0.11169
Ͳ6.64386
Ͳ0.67521
2.04569
2.233487
2.287226
2.429656
1.4154
Ͳ1.74259
2.235054
2.618875
Ͳ0.16625
2.362864
2.811761
1.470836
2.25162
1.94535
Ͳ0.31392
1.519989
Ͳ0.32297
0.485571
2.501649
Ͳ0.05506
1.844372
0.425591
Ͳ0.25613
1.062822
0.925522
Ͳ0.81203
0.871388
2.147464
1.826789
0.181677
2.817329
0.785312
1.91566
0.563118
Ͳ0.00826
0.631226
0.67291
Ͳ0.25987
1.783688
2.123983
Ͳ1.38961
3.100487
Ͳ1.43527
Ͳ0.41514
1.058757
1.273622
0.857162
2.302874
1.28515
Ͳ0.17642
Ͳ0.02206
Ͳ0.19259
Ͳ2.10081
Ͳ0.05908
1.287133
2.021619
1.384186
Ͳ0.94274
Ͳ0.2238
2.06158
1.205542
Ͳ2.11206
0.339281
Ͳ1.9669
Ͳ1.97147
Ͳ0.12923
Ͳ2.19906
Ͳ1.36654
Ͳ0.22361
Ͳ1.1889
0.111553
Ͳ0.70777
Ͳ1.75242
0.605017
Ͳ2.49486
Ͳ1.61417
Ͳ1.12702
Ͳ1.88147
Ͳ0.04992
Ͳ0.63315
0.00821
Ͳ6.64386
1.550514
Ͳ0.03072
0.120257
Ͳ1.92653
1.737357
Ͳ2.25523
0.666247
Ͳ 1.9677
Ͳ2.08126
Ͳ1.72739
Ͳ2.41422
Ͳ1.71889
Ͳ1.7076
58
hsaͲm
iRͲ3194Ͳ3p
0.002812
2.83EͲ04
4.127772
up
2.198076
0.13595347
0.654285
2.048882
0.497745
2.680135
0.556485
0.45094
Ͳ0.5258
Ͳ0.48809
Ͳ0.20748
Ͳ6.64386
0.90433
Ͳ6.64386
Ͳ0.73473
Ͳ6.64386
Ͳ0.5258
0.074429
Ͳ0.00881
Ͳ0.30435
1.048778
Ͳ6.64386
Ͳ0.13348
Ͳ0.23133
0.175845
1.525924
Ͳ0.42988
0.928578
1.230468
0.260547
Ͳ0.42083
0.088909
0.246969
Ͳ0.00224
0.178076
0.100639
0.533366
0.747662
0.358722
0.002235
0.571362
Ͳ0.60271
0.575684
2.20164
0.854577
0.679366
0.924871
1.856458
0.890004
1.067065
Ͳ6.64386
0.652586
Ͳ0.12363
Ͳ0.44014
1.370394
0.091152
1.020208
Ͳ0.43825
Ͳ6.64386
Ͳ6.64386
0.187583
2.543251
Ͳ6.64386
Ͳ0.35541
0.611766
Ͳ0.12074
0.210266
1.836014
Ͳ6.64386
1.254622
0.118414
Ͳ0.34595
Ͳ0.09362
Ͳ0.70261
Ͳ0.5692
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.35395
Ͳ6.64386
Ͳ 0.21851
0.011837
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.453486
0.058644
0.605375
Ͳ0.96558
Ͳ6.64386
0.076276
1.075438
Ͳ6.64386
Ͳ0.46464
Ͳ6.64386
Ͳ0.54203
Ͳ6.64386
Ͳ0.16422
Ͳ0.51701
Ͳ6.64386
Ͳ0.33723
0.045755
59
hsaͲm
iRͲ1914Ͳ5p
0.0043
4.75EͲ04
4.031873
up
0.017343
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.454737
Ͳ6.64386
Ͳ0.06781
Ͳ0.07503
0.474684
Ͳ0.28653
Ͳ0.24346
1.310711
0.689223
Ͳ6.64386
1.029944
0.306845
0.006878
Ͳ6.64386
Ͳ0.0235
0.306295
0.17505
0.989105
0.564093
Ͳ6.64386
0.213041
0.84085
Ͳ6.64386
0.527915
Ͳ0.13453
0.629406
0.404142
0.098761
0.009863
0.112647
0.664561
0.509112
0.33238
Ͳ6.64386
Ͳ0.26381
0.307263
0.344237
Ͳ6.64386
0.410484
Ͳ0.2645
0.358693
0.755928
0.281157
0.48081
Ͳ6.64386
0.326409
Ͳ0.1516
Ͳ6.64386
0.360515
Ͳ6.64386
0.467159
0.208998
0.494193
0.3582
Ͳ6.64386
0.397566
0.221445
0.065562
Ͳ6.64386
0.220416
Ͳ0.00691
Ͳ6.64386
Ͳ0.1994
0.267521
Ͳ6.64386
Ͳ6.64386
0.37827
Ͳ6.64386
Ͳ0.39382
0.550279
Ͳ6.64386
Ͳ6.64386
Ͳ0.18827
0.007472
Ͳ0.33384
0.142771
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.22322
Ͳ6.64386
Ͳ0.17961
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.095245
0.126042
Ͳ6.64386
Ͳ6.64386
0.327414
Ͳ0.20036
0.827127
Ͳ0.1567
0.137127
0.351397
Ͳ6.64386
60
hsaͲm
iRͲ596
3.88EͲ04
2.39EͲ05
4.02502
up
0.048813
Ͳ0.4662519
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.114971
0.172012
0.218927
0.361819
0.484413
Ͳ0.18102
0.984595
0.144926
Ͳ6.64386
Ͳ0.04289
0.359105
0.233015
Ͳ0.10621
0.1476
0.715823
0.949313
0.69168
0.791772
Ͳ0.38602
0.005391
0.681526
Ͳ0.26333
0.279566
0.132253
Ͳ0.00541
0.558413
0.144325
Ͳ6.64386
Ͳ6.64386
0.311576
Ͳ6.64386
0.819577
Ͳ0.4238
0.014416
0.47194
0.006473
Ͳ0.49224
Ͳ6.64386
0.368935
0.24892
Ͳ0.18485
0.498524
0.115179
0.730388
0.647236
0.612679
Ͳ6.64386
0.39348
Ͳ 0.10335
0.958135
0.287729
0.03235
0.235505
Ͳ6.64386
0.644765
0.107741
0.219309
Ͳ0.24452
0.368946
0.071876
0.576589
Ͳ0.61572
Ͳ0.02993
Ͳ0.41605
Ͳ6.64386
0.074736
Ͳ0.38728
Ͳ0.60853
Ͳ0.39435
Ͳ6.64386
Ͳ6.64386
Ͳ0.0176
Ͳ6.64386
0.460191
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.73282
Ͳ6.64386
Ͳ0.32601
0.295649
Ͳ6.64386
Ͳ0.6892
Ͳ6.64386
Ͳ0.36715
0.410176
0.402473
0.035745
Ͳ0.40422
Ͳ0.07782
Ͳ6.64386
0.881409
Ͳ0.17925
Ͳ6.64386
Ͳ0.34429
Ͳ6.64386
61
hsaͲm
iRͲ4665Ͳ3p
5.11EͲ04
3.26EͲ05
4.010174
up
0.408096
Ͳ0.1053094
Ͳ0.37741
1.401577
1.394912
1.860285
Ͳ0.10605
0.40322
0.172519
0.902985
0.407846
Ͳ0.07069
1.262534
1.06681
Ͳ6.64386
1.522111
0.321382
0.795155
0.072833
0.159919
0.760563
0.136072
1.403845
0.358464
0.255966
Ͳ6.64386
0.918911
Ͳ0.46652
1.083298
Ͳ0.40797
0.368636
1.443373
Ͳ0.00358
Ͳ0.02911
Ͳ0.17078
0.841743
Ͳ0.15861
0.844417
Ͳ6.64386
0.176993
0.389358
Ͳ0.47235
Ͳ6.64386
Ͳ0.0593
Ͳ0.04867
0.520836
0.818983
0.529621
0.909111
1.457375
0.594665
0.011056
Ͳ6.64386
0.30577
Ͳ0.54567
0.966349
Ͳ0.05657
0.914509
Ͳ6.64386
Ͳ0.00418
0.438961
0.391545
Ͳ6.64386
Ͳ6.64386
0.088377
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.131757
Ͳ0.11605
Ͳ6.64386
0.135644
Ͳ6.64386
Ͳ0.53711
Ͳ0.11182
Ͳ6.64386
Ͳ0.09081
0.261419
Ͳ6.64386
0.255571
Ͳ6.64386
Ͳ0.31803
Ͳ6.64386
Ͳ6.64386
0.001775
Ͳ6.64386
0.169606
Ͳ6.64386
Ͳ0.61954
0.158913
Ͳ0.06044
0.42192
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.20036
Ͳ0.15439
0.943427
Ͳ0.34763
Ͳ0.04497
0.024231
Ͳ0.00178
62
hsaͲm
iRͲ557
0.002559
2.45EͲ04
3.978653
up
0.20205
Ͳ6.643856
Ͳ0.32536
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.066583
1.29923
Ͳ0.08759
0.795373
0.49208
1.158169
Ͳ6.64386
1.605955
1.500986
Ͳ0.09903
Ͳ6.64386
1.283699
1.417494
1.168673
1.16091
1.431708
Ͳ0.17058
0.762776
1.354152
0.385509
0.041492
0.172171
Ͳ6.64386
0.529555
Ͳ6.64386
0.142532
1.18898
0.849218
1.190918
1.240217
Ͳ0.08842
0.172171
1.426086
0.780217
Ͳ0.11734
Ͳ0.00725
0.059969
Ͳ0.13333
0.533799
Ͳ6.64386
Ͳ0.2323
Ͳ6.64386
0.950249
1.105057
Ͳ6.64386
0.942786
Ͳ0.37259
0.955209
0.540642
0.33277
2.217266
Ͳ6.64386
0.743349
1.080375
0.689246
Ͳ6.64386
Ͳ6.64386
0.09154
Ͳ6.64386
Ͳ0.49944
Ͳ0.01963
0.274982
0.353653
0.638623
Ͳ0.44602
Ͳ0.14987
0.575996
Ͳ0.25421
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.642714
Ͳ6.64386
0.175779
Ͳ6.64386
Ͳ0.59538
Ͳ0.20374
Ͳ0.24757
Ͳ0.02506
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.379664
0.79611
0.703118
Ͳ0.15386
1.342736
Ͳ6.64386
Ͳ6.64386
0.00721
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
63
hsaͲm
iRͲ3677Ͳ5p
0.046873
0.008704
3.970655
up
1.749937
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
2.756678
3.719678
1.591239
1.973276
1.764808
Ͳ6.64386
1.894341
Ͳ6.64386
2.515829
Ͳ6.64386
Ͳ6.64386
2.182935
Ͳ6.64386
1.88624
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.437827
Ͳ6.64386
2.218885
Ͳ6.64386
2.110786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.690807
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.633646
Ͳ6.64386
1.732521
2.299685
Ͳ6.64386
1.924714
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.69387
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.725398
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.948172
Ͳ6.64386
Ͳ6.64386
64
hsaͲm
iRͲ646
0.028359
0.004856
3.96194
up
Ͳ6.64386
Ͳ6.643856
1.656573
Ͳ6.64386
2.116217
2.929093
Ͳ6.64386
1.605944
Ͳ6.64386
1.758123
Ͳ6.64386
Ͳ6.64386
2.267901
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.627304
2.103051
Ͳ6.64386
1.981397
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.649519
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.067877
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.816338
Ͳ6.64386
1.703643
Ͳ6.64386
1.80607
3.510505
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.172525
1.606633
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.052173
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
65
hsaͲm
iRͲ602
4.35EͲ05
1.56EͲ06
3.929173
up
2.137033
0.3584721
Ͳ0.9142
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.276087
0.239407
0.509466
1.008333
0.300113
Ͳ0.41058
0.200318
0.276267
Ͳ6.64386
1.177703
Ͳ0.03306
0.100189
0.28229
Ͳ0.18317
0.989385
0.75492
1.157622
0.703081
0.434529
0.062142
0.55768
0.160789
0.418286
0.488811
0.133309
0.487771
Ͳ0.25098
Ͳ6.64386
Ͳ0.34996
0.300113
0.656871
1.141337
Ͳ0.21267
Ͳ0.27475
Ͳ0.5745
Ͳ0.25167
Ͳ0.31428
Ͳ6.64386
Ͳ0.01818
0.050851
Ͳ0.25823
0.483446
0.257731
0.223619
0.877465
0.188804
Ͳ0.08623
0.628568
Ͳ0.6437
0.934798
0.228172
Ͳ0.20377
0.31761
0.434797
1.294263
0.404831
0.275907
0.351025
Ͳ0.10716
Ͳ6.64386
Ͳ0.21308
Ͳ0.31907
Ͳ0.14246
0.023501
Ͳ6.64386
0.210692
Ͳ0.08935
Ͳ6.64386
Ͳ0.3822
Ͳ0.61437
Ͳ6.64386
Ͳ0.2165
Ͳ0.42205
0.531524
0.050411
Ͳ0.63806
Ͳ6.64386
Ͳ0.68721
Ͳ6.64386
Ͳ6.64386
Ͳ0.15486
Ͳ0.69847
Ͳ0.44128
Ͳ0.38886
0.067853
0.707289
0.180835
0.146984
Ͳ6.64386
Ͳ6.64386
Ͳ0.55161
0.017954
Ͳ 0.34903
Ͳ6.64386
Ͳ6.64386
Ͳ0.09768
66
hsaͲm
iRͲ660Ͳ5p
4.69EͲ04
2.94EͲ05
3.816789
up
1.389605
Ͳ0.2766528
Ͳ0.45951
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.75822
1.516689
1.813366
Ͳ0.58216
2.628808
2.537374
Ͳ6.64386
1.378484
1.427538
0.345151
0.274946
0.86137
2.887901
1.225714
1.655146
1.051568
Ͳ1.02991
Ͳ1.63026
0.614489
Ͳ0.18827
1.24774
0.963549
1.289384
2.267019
0.828901
2.67921
Ͳ6.64386
1.374482
0.297927
2.047033
0.724564
1.300482
Ͳ0.66806
0.775329
Ͳ0.89031
0.498288
1.743105
Ͳ1.6516
Ͳ0.24795
0.195873
Ͳ0.07238
0.194574
1.276407
Ͳ6.64386
Ͳ0.58492
1.239491
2.227064
Ͳ1.79176
3.242075
Ͳ6.64386
0.683635
1.976575
Ͳ6.64386
Ͳ0.38475
2.409599
Ͳ1.33429
Ͳ0.09945
1.606928
Ͳ1.30455
Ͳ6.64386
1.293999
0.349586
0.114335
Ͳ6.64386
1.521238
Ͳ0.62505
Ͳ0.96191
0.521607
Ͳ0.08578
Ͳ0.41074
0.423315
1.086422
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.4319
Ͳ0.92565
Ͳ0.20583
Ͳ1.39832
Ͳ0.47443
0.068922
0.135646
2.200852
Ͳ0.8113
Ͳ1.12446
Ͳ6.64386
Ͳ0.81978
Ͳ0.8902
Ͳ6.64386
Ͳ1.60916
Ͳ0.55675
Ͳ1.04529
Ͳ6.64386
Ͳ6.64386
Ͳ0.49739
0.135735
67
hsaͲm
iRͲ4785
0.033194
0.005929
3.763893
up
2.446105
Ͳ6.643856
Ͳ6.64386
2.809727
3.091106
Ͳ6.64386
Ͳ6.64386
2.204067
Ͳ6.64386
1.577551
1.775696
1.463106
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.231376
1.937839
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.627304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.618399
Ͳ6.64386
2.339179
Ͳ6.64386
1.912846
1.67461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.692932
Ͳ6.64386
Ͳ6.64386
1.88624
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.696831
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.68898
Ͳ6.64386
68
hsaͲm
iRͲ181aͲ3p
0.022309
0.003667
3.537355
up
Ͳ6.64386
Ͳ0.4152006
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.928323
0.595931
1.247061
1.527962
Ͳ6.64386
1.98941
1.983641
Ͳ6.64386
2.817999
3.602057
3.679036
0.840578
Ͳ6.64386
Ͳ6.64386
2.126489
Ͳ6.64386
Ͳ0.05218
2.191128
1.062542
Ͳ0.4066
1.046357
0.974364
0.969966
2.014223
Ͳ6.64386
2.618514
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.277555
1.018706
2.020167
0.00162
Ͳ6.64386
1.895522
1.02888
Ͳ6.64386
0.270284
Ͳ0.00162
0.770905
1.05953
Ͳ6.64386
Ͳ0.27884
0.48422
0.032009
0.558335
1.136612
0.003902
2.626405
0.579291
Ͳ6.64386
Ͳ6.64386
0.03518
Ͳ0.00649
Ͳ6.64386
0.719127
2.500526
1.313047
1.129112
1.203198
Ͳ6.64386
1.205043
Ͳ0.05383
Ͳ0.06503
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.811272
Ͳ6.64386
Ͳ6.64386
Ͳ0.05756
0.608035
0.227713
Ͳ6.64386
Ͳ6.64386
0.712045
Ͳ6.64386
0.0808
1.443001
0.995747
1.668469
0.396995
Ͳ0.26736
Ͳ0.16321
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.51825
Ͳ0.09105
Ͳ6.64386
Ͳ6.64386
0.90911
69
hsaͲm
iRͲ5008Ͳ5p
0.011546
0.001703
3.408319
up
0.246205
Ͳ6.643856
Ͳ6.64386
0.369215
0.752276
Ͳ6.64386
Ͳ0.64841
Ͳ0.21058
0.121085
0.398907
0.018515
Ͳ0.44092
1.040542
0.28155
Ͳ6.64386
0.839032
0.536123
0.311923
Ͳ0.33391
0.382833
0.67274
0.208793
0.987819
0.328092
Ͳ6.64386
Ͳ0.117
0.525968
Ͳ0.57935
0.763419
Ͳ0.41033
Ͳ6.64386
Ͳ0.46388
0.732929
0.379397
0.72372
0.67844
0.743454
1.229082
Ͳ0.45736
Ͳ0.14114
0.767454
Ͳ0.14908
Ͳ6.64386
0.00959
Ͳ0.69642
0.350597
0.693922
Ͳ0.42708
0.427401
0.777497
Ͳ0.00965
Ͳ0.18924
Ͳ0.38438
0.427401
Ͳ0.39505
0.906915
Ͳ0.18976
0.406442
1.20503
Ͳ6.64386
0.468146
0.343252
Ͳ0.24592
Ͳ6.64386
Ͳ0.38074
0.647204
0.136226
Ͳ6.64386
0.1105
0.059157
0.561754
0.404263
Ͳ6.64386
Ͳ 0.65392
0.209074
Ͳ 0.49715
Ͳ6.64386
0.073504
Ͳ6.64386
Ͳ 0.11806
Ͳ6.64386
Ͳ 0.32909
Ͳ6.64386
Ͳ 6.64386
0.298734
Ͳ 6.64386
0.438989
Ͳ 6.64386
Ͳ0.88503
0.063027
Ͳ0.12239
0.551782
0.277209
Ͳ6.64386
0.939611
Ͳ6.64386
Ͳ6.64386
Ͳ0.0946
Ͳ0.51493
Ͳ0.40141
0.036165
Ͳ0.52764
70
hsaͲm
iRͲ3178
1.96EͲ06
3.51EͲ08
3.343691
up
2.120543
1.587894
Ͳ1.09404
Ͳ1.95516
Ͳ2.89814
Ͳ1.1176
1.221234
Ͳ0.03726
1.08057
1.41347
Ͳ0.13665
Ͳ0.09599
0.233593
2.299709
Ͳ2.21342
2.645003
Ͳ0.00466
Ͳ0.41367
Ͳ0.30282
Ͳ0.11081
1.360891
0.228715
1.339248
0.270386
1.558156
0.363258
1.087596
0.013385
0.377614
0.950192
1.40906
1.394164
1.053396
Ͳ0.55507
1.437874
0.673524
0.935701
1.189826
Ͳ1.0602
Ͳ1.0142
0.85243
Ͳ0.79532
Ͳ0.19004
0.477708
1.864929
Ͳ0.50639
0.636035
1.280549
Ͳ1.14159
Ͳ1.39482
1.272355
1.678021
Ͳ0.6214
0.004647
0.750851
1.083421
Ͳ1.22566
1.14296
1.151491
0.466109
0.750863
1.64197
2.111278
0.09264
0.45637
0.296417
0.566608
0.721299
Ͳ0.69276
Ͳ1.136
Ͳ1.30811
Ͳ1.23783
Ͳ1.84403
Ͳ1.16687
Ͳ2.08029
Ͳ1.64857
Ͳ1.24189
1.130392
Ͳ3.24729
Ͳ0.2918
Ͳ0.08344
0.725314
Ͳ2.55331
Ͳ2.3116
Ͳ0.3338
Ͳ3.71363
Ͳ0.17547
Ͳ1.76389
Ͳ2.36265
Ͳ0.07641
Ͳ0.9057
1.481607
Ͳ1.64249
Ͳ3.33348
Ͳ2.43846
Ͳ2.62165
Ͳ 0.38149
0.04358
Ͳ0.40601
Ͳ3.62918
0.297528
Ͳ2.10691
71
hsaͲm
iRͲ500b
4.14EͲ06
9.15EͲ08
3.306766
up
0.288773
0.05087909
Ͳ1.32422
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.860639
0.930881
2.033058
Ͳ0.00776
1.80805
2.025913
0.589479
1.908912
0.718631
0.233376
1.603008
1.45293
2.16944
1.624036
0.39871
0.411649
Ͳ0.29786
Ͳ0.51306
0.34537
1.103315
0.501348
0.444645
1.254479
1.557751
0.282844
2.059693
Ͳ0.49472
0.656338
1.199641
1.279192
1.138028
1.970851
0.368024
Ͳ0.25242
0.367528
Ͳ0.07932
0.993956
Ͳ0.36078
Ͳ0.58045
0.311513
0.26353
Ͳ0.89251
0.915902
0.04266
Ͳ0.95607
0.889406
1.745027
Ͳ6.64386
2.509256
Ͳ0.77402
Ͳ0.24596
1.407174
Ͳ6.64386
Ͳ6.64386
1.942504
0.120067
0.093263
0.565939
Ͳ6.64386
Ͳ0.50983
1.587205
Ͳ0.27081
Ͳ0.02029
Ͳ0.81289
1.678479
Ͳ0.16075
Ͳ0.89257
Ͳ0.76764
Ͳ0.03948
Ͳ0.75686
Ͳ0.20214
0.651844
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.00772
Ͳ1.14402
Ͳ1.01341
Ͳ0.73456
Ͳ1.04122
Ͳ0.76941
Ͳ0.40017
0.737688
Ͳ0.5267
Ͳ1.19818
Ͳ6.64386
Ͳ0.46491
Ͳ0.61697
Ͳ0.18603
Ͳ6.64386
Ͳ0.7552
Ͳ1.03815
Ͳ1.11233
Ͳ1.3041
0.158146
Ͳ1.01738
72
hsaͲm
iRͲ500aͲ3p
2.81EͲ06
5.78EͲ08
3.288926
up
0.724195
0.6457457
Ͳ1.37618
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.159355
0.620885
1.848357
Ͳ0.09952
1.600026
1.716706
0.799105
1.984972
0.689823
0.901583
1.269247
1.673858
1.942901
1.07285
0.822945
1.47096
Ͳ0.5706
Ͳ0.6895
0.724725
0.524607
0.360221
0.472189
1.096689
1.452614
0.826729
1.920793
Ͳ0.23212
0.128235
0.082862
1.564292
1.539591
2.029409
Ͳ1.09416
0.165175
0.10368
Ͳ0.21546
1.031779
Ͳ0.71858
Ͳ0.73932
0.377524
0.050206
Ͳ0.28968
1.15377
Ͳ1.00411
Ͳ1.01649
0.914304
1.592865
Ͳ1.05032
2.583018
Ͳ1.47721
0.47096
2.101667
Ͳ6.64386
Ͳ1.3863
2.063474
Ͳ0.20735
0.308674
0.98994
Ͳ6.64386
Ͳ1.5865
1.302935
Ͳ0.29063
Ͳ0.2312
Ͳ1.29603
0.745365
Ͳ0.54332
Ͳ1.15173
0.137234
Ͳ0.45693
Ͳ0.73668
0.262104
0.635447
Ͳ6.64386
Ͳ6.64386
Ͳ1.51767
Ͳ0.32365
Ͳ0.88103
Ͳ1.778
Ͳ0.65816
Ͳ0.82601
Ͳ1.0066
Ͳ0.88236
0.200388
Ͳ0.81164
Ͳ1.4787
Ͳ1.52326
Ͳ1.00641
Ͳ1.19415
Ͳ0.05202
Ͳ6.64386
Ͳ0.6545
Ͳ0.77697
Ͳ1.38271
Ͳ1.5218
0.086288
Ͳ0.7328
73
hsaͲm
iRͲ4467
1.45EͲ05
4.59EͲ07
3.269783
up
3.628005
1.2570895
Ͳ0.7929
Ͳ6.64386
Ͳ0.54429
0.744139
0.727626
Ͳ0.70362
0.196938
1.157169
0.460807
0.660999
1.082295
1.404223
Ͳ1.26938
3.224739
Ͳ0.27255
Ͳ0.55718
Ͳ0.34052
0.100911
1.805682
0.452727
1.685224
0.951533
1.008766
0.571777
0.579002
0.977625
Ͳ0.71268
0.663983
0.507022
0.670869
0.799782
Ͳ0.0661
0.79729
0.760367
0.06272
0.780468
Ͳ0.20582
0.871308
0.431687
0.191109
Ͳ0.02762
Ͳ0.03591
Ͳ0.35511
Ͳ0.03324
0.63379
0.641377
Ͳ 6.64386
Ͳ0.24229
1.704767
0.920832
Ͳ0.72406
0.358425
Ͳ0.54154
0.904493
0.468324
0.388413
2.375445
Ͳ6.64386
2.414363
1.456439
0.715162
Ͳ0.17654
Ͳ0.54585
0.543535
Ͳ0.25395
0.057026
Ͳ0.81942
Ͳ0.62552
Ͳ0.087
Ͳ0.39658
Ͳ6.64386
Ͳ0.93781
Ͳ0.62202
Ͳ0.82666
Ͳ0.26451
Ͳ0.84538
Ͳ6.64386
Ͳ0.07193
0.025051
Ͳ0.18721
Ͳ6.64386
Ͳ6.64386
Ͳ0.37629
Ͳ6.64386
Ͳ0.00485
Ͳ0.96283
Ͳ0.04954
Ͳ1.01362
0.229545
1.81485
Ͳ0.45367
Ͳ1.36249
0.83718
Ͳ6.64386
0.004832
Ͳ0.28947
0.162511
Ͳ0.66263
Ͳ0.29723
Ͳ0.88197
74
hsaͲm
iRͲ1914Ͳ3p
5.84EͲ04
3.84EͲ05
3.166935
up
0.84823
Ͳ0.2159368
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.040369
0.162662
0.005521
Ͳ0.00404
0.83658
Ͳ0.34813
Ͳ0.01851
1.375717
0.693688
Ͳ6.64386
1.576265
0.338845
0.179741
Ͳ6.64386
Ͳ0.18078
0.669841
0.649082
0.569142
0.606647
Ͳ0.1778
0.072746
0.858318
0.250848
0.742597
0.048604
0.498262
0.030722
Ͳ6.64386
Ͳ0.00404
0.277045
0.73433
Ͳ0.04717
0.471295
Ͳ6.64386
Ͳ0.29653
0.721261
0.271986
Ͳ0.1532
0.399634
0.203815
0.507694
0.96467
Ͳ0.02925
0.376138
Ͳ6.64386
0.376122
0.686395
Ͳ6.64386
0.179741
Ͳ6.64386
0.77892
Ͳ0.13751
0.287117
1.457628
0.178681
0.453071
0.587292
0.5779
Ͳ6.64386
0.190089
Ͳ0.09787
Ͳ6.64386
Ͳ0.57339
Ͳ0.01299
Ͳ0.20678
Ͳ0.45399
0.519081
Ͳ6.64386
Ͳ0.55822
0.556077
Ͳ6.64386
Ͳ6.64386
0.0357
Ͳ6.64386
Ͳ0.09058
Ͳ6.64386
0.220781
Ͳ0.53814
Ͳ6.64386
Ͳ0.1864
Ͳ0.37989
Ͳ0.06051
Ͳ6.64386
Ͳ0.66092
Ͳ0.07781
0.219593
0.600334
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.18159
Ͳ6.64386
0.373448
Ͳ0.4161
Ͳ0.02496
0.004031
Ͳ0.07004
75
hsaͲm
iRͲ637
5.32EͲ04
3.42EͲ05
3.097873
up
0.392579
Ͳ0.4318808
0.555582
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.16426
Ͳ0.22461
0.22794
1.443532
0.336143
0.123351
Ͳ 0.01812
1.419284
Ͳ6.64386
1.822295
0.527501
Ͳ0.30667
Ͳ0.33102
0.102593
1.372168
1.372168
1.30886
1.599578
0.537268
0.36039
1.467306
0.601848
0.025971
0.055536
0.41383
0.481697
Ͳ0.34743
Ͳ6.64386
0.303296
0.845817
Ͳ6.64386
0.507232
0.193383
0.631038
0.511361
0.815585
Ͳ0.33449
Ͳ6.64386
1.024523
Ͳ0.2447
0.554465
Ͳ0.50394
0.007435
Ͳ6.64386
1.392075
0.49532
Ͳ6.64386
0.291228
Ͳ6.64386
1.002434
0.517116
Ͳ0.05411
1.63904
Ͳ0.07434
0.781452
0.96048
0.114168
Ͳ6.64386
0.254662
0.057431
Ͳ0.05633
Ͳ6.64386
Ͳ0.51408
Ͳ0.12504
Ͳ6.64386
0.743579
Ͳ0.30181
Ͳ0.77803
Ͳ0.12104
Ͳ6.64386
Ͳ0.38494
Ͳ0.51598
Ͳ6.64386
1.064406
Ͳ6.64386
0.263587
Ͳ6.64386
Ͳ0.00747
Ͳ0.51367
Ͳ0.43985
Ͳ0.13495
Ͳ0.87738
Ͳ0.45114
Ͳ0.44396
0.418176
1.1025
Ͳ6.64386
0.063997
0.093548
Ͳ6.64386
Ͳ6.64386
0.102078
Ͳ0.64661
Ͳ6.64386
Ͳ0.21998
Ͳ6.64386
76
hsaͲm
iRͲ3195
8.82EͲ10
3.25EͲ12
3.056716
up
3.203342
1.7877938
Ͳ0.61173
Ͳ0.59318
Ͳ2.10032
Ͳ0.67746
1.114636
0.645115
0.318216
1.277813
0.648897
0.710931
0.295672
2.504041
Ͳ1.54265
2.689655
Ͳ0.42
Ͳ0.58774
0.274424
Ͳ0.8817
0.340888
0.531374
1.439598
0.684738
1.54453
1.04836
0.079116
0.001761
0.385765
0.748118
1.638054
1.937169
0.942494
Ͳ0.02307
1.734798
0.624602
0.538518
1.121046
Ͳ0.83335
Ͳ0.5182
Ͳ0.12405
Ͳ0.42703
Ͳ0.20699
0.313257
1.050683
0.171203
0.655911
1.635114
0.425841
0.554085
1.699007
1.285017
Ͳ0.40078
0.029824
0.838966
0.403611
Ͳ0.41519
1.661423
1.237815
Ͳ0.16495
1.213184
1.948769
1.996301
0.200976
Ͳ0.33378
Ͳ0.00176
0.836218
0.528817
Ͳ1.3929
Ͳ1.55659
Ͳ0.73793
Ͳ0.51208
Ͳ1.51197
Ͳ1.62436
Ͳ0.47854
Ͳ2.1456
Ͳ2.03514
Ͳ0.52765
Ͳ1.45498
Ͳ0.75694
Ͳ0.58456
Ͳ0.84265
Ͳ2.30066
Ͳ1.8196
Ͳ1.32128
Ͳ0.71641
Ͳ0.84472
Ͳ0.97677
Ͳ1.09336
Ͳ0.47804
Ͳ1.56451
0.021825
Ͳ0.00714
Ͳ1.45649
Ͳ1.15938
Ͳ1.72827
Ͳ1.07696
Ͳ0.13285
Ͳ0.90393
Ͳ0.83349
Ͳ0.26976
0.076009
77
hsaͲm
iRͲ612
0.018014
0.002819
2.968695
up
1.180798
0.45037535
Ͳ0.29333
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.164727
Ͳ6.64386
0.132091
1.883434
Ͳ0.37159
0.520049
Ͳ6.64386
1.814597
Ͳ6.64386
2.129305
0.462737
Ͳ0.12304
Ͳ6.64386
0.678386
1.347402
0.884668
1.68761
1.347402
1.255006
0.039886
0.942614
0.713687
Ͳ0.32268
0.172126
0.169947
0.626856
0.033798
Ͳ6.64386
Ͳ0.06719
0.079786
Ͳ0.52193
0.522623
0.398485
0.283157
0.211923
Ͳ0.07941
0.488741
Ͳ0.58403
Ͳ0.03569
Ͳ6.64386
0.318255
Ͳ0.63428
Ͳ0.20104
Ͳ6.64386
1.810544
0.937461
Ͳ0.89446
0.82543
0.069936
0.861154
0.513412
Ͳ0.39052
1.241231
Ͳ6.64386
0.209545
1.681727
0.232631
0.393094
Ͳ6.64386
1.03813
Ͳ6.64386
Ͳ6.64386
Ͳ0.57807
0.539497
Ͳ6.64386
1.084164
1.22438
Ͳ1.1076
0.783449
Ͳ6.64386
Ͳ0.77883
Ͳ6.64386
Ͳ6.64386
0.861209
Ͳ6.64386
Ͳ0.38006
Ͳ6.64386
Ͳ0.86231
Ͳ0.48598
Ͳ6.64386
0.240934
Ͳ0.52363
Ͳ0.5011
Ͳ6.64386
Ͳ0.03461
0.348404
0.100579
1.192184
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.3297
Ͳ0.3851
Ͳ0.08983
Ͳ0.17568
Ͳ0.62721
78
hsaͲm
iRͲ4654
0.047201
0.008845
2.915873
up
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
2.196418
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.901227
2.312295
Ͳ6.64386
Ͳ6.64386
2.110786
Ͳ6.64386
Ͳ6.64386
1.696831
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.825383
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.017135
1.646413
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.775877
Ͳ6.64386
Ͳ6.64386
1.633646
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.557858
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.522671
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
79
hsaͲm
iRͲ152
0.001604
1.39EͲ04
2.903808
up
1.110426
0.44751042
2.1679
Ͳ6.64386
Ͳ6.64386
Ͳ1.94476
Ͳ1.86329
1.229338
Ͳ1.56918
0.097274
1.656495
1.222992
Ͳ6.64386
Ͳ6.64386
0.979149
Ͳ0.0455
1.259054
2.264337
3.012576
Ͳ2.5474
1.318176
0.11058
Ͳ6.64386
Ͳ0.88942
Ͳ2.01658
2.24429
1.934972
0.139425
0.525729
1.906538
2.169008
2.132392
Ͳ0.32185
1.902247
Ͳ1.9463
Ͳ1.9911
2.273124
0.902342
Ͳ1.12944
1.946681
2.022036
Ͳ0.98327
0.542085
2.027023
0.530515
1.710973
1.428679
0.752016
1.478116
Ͳ6.64386
Ͳ0.72394
Ͳ0.61743
2.36574
Ͳ0.19961
1.960487
Ͳ1.47947
1.72529
1.755126
Ͳ1.64901
0.365322
Ͳ1.27459
Ͳ0.9579
1.588007
Ͳ2.25954
0.96465
1.684258
1.618101
Ͳ1.63264
0.106531
Ͳ1.11396
0.036112
Ͳ3.07968
Ͳ3.25157
Ͳ0.87808
Ͳ6.64386
Ͳ1.47991
Ͳ3.32459
Ͳ2.52405
1.341298
Ͳ0.00599
1.312989
Ͳ2.18169
0.844178
Ͳ1.04478
Ͳ0.67625
Ͳ1.54594
0.289098
Ͳ0.66277
Ͳ1.75284
0.005963
Ͳ2.39092
Ͳ2.99182
Ͳ1.13253
Ͳ6.64386
Ͳ6.64386
Ͳ1.95461
Ͳ1.07962
Ͳ1.72715
Ͳ2.38768
0.009632
1.179146
0.98088
80
hsaͲm
iRͲ4707Ͳ3p
2.78EͲ04
1.58EͲ05
2.890006
up
0.057047
0.06270809
Ͳ0.64187
1.980077
1.264575
2.122251
Ͳ0.66693
Ͳ0.2261
0.219235
0.017478
Ͳ0.51373
Ͳ0.99227
1.837112
0.019703
Ͳ6.64386
0.002276
0.334712
0.291085
Ͳ0.05519
Ͳ0.05116
0.572049
0.047387
0.687383
0.09714
Ͳ0.71536
0.973753
0.426647
Ͳ0.24854
0.857109
0.025935
0.002276
0.541163
0.989956
Ͳ6.64386
0.565129
0.215623
0.6841
1.119239
Ͳ0.84894
0.167954
0.922888
0.073681
Ͳ0.44531
0.249423
Ͳ0.14921
0.394008
0.569011
Ͳ0.43377
0.643756
2.01724
Ͳ0.21552
0.417667
Ͳ0.1424
0.291085
Ͳ0.54403
0.736652
0.384421
Ͳ0.19675
0.814347
0.462829
0.584217
0.217225
Ͳ0.46119
Ͳ0.04264
1.14321
0.761652
Ͳ0.04996
Ͳ6.64386
Ͳ0.1849
0.292075
Ͳ0.71011
0.240012
Ͳ6.64386
Ͳ6.64386
0.218506
Ͳ6.64386
Ͳ6.64386
Ͳ0.15944
Ͳ0.32161
Ͳ0.34953
Ͳ0.18676
Ͳ0.34314
Ͳ6.64386
Ͳ0.81824
Ͳ0.2225
Ͳ6.64386
Ͳ0.00228
Ͳ0.57316
Ͳ0.66362
Ͳ0.47382
Ͳ0.33178
Ͳ0.10614
Ͳ0.3107
Ͳ0.4922
0.696517
Ͳ6.64386
Ͳ0.63063
0.69023
Ͳ0.34044
0.084152
Ͳ0.66105
Ͳ0.18396
81
hsaͲm
iRͲ30bͲ3p
0.047798
0.009016
2.869683
up
Ͳ0.04508
Ͳ 6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.807344
Ͳ0.07629
0.877971
0.757829
0.148618
1.869096
Ͳ6.64386
1.130471
0.304738
1.175586
0.186093
0.787801
1.574181
1.060746
1.177883
0.124771
0.733581
0.4467
1.11691
0.335032
0.569194
0.513134
Ͳ0.08001
Ͳ0.11442
0.838551
1.733581
Ͳ6.64386
0.733581
0.002568
0.318544
Ͳ6.64386
Ͳ6.64386
0.485653
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.091812
Ͳ6.64386
0.137478
Ͳ0.09065
Ͳ6.64386
Ͳ6.64386
Ͳ0.14294
Ͳ6.64386
0.163544
0.968046
0.12668
Ͳ6.64386
1.762147
Ͳ0.16043
Ͳ6.64386
1.243339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.65419
1.89636
1.001796
0.256034
Ͳ6.64386
0.683125
0.843404
0.205627
Ͳ6.64386
Ͳ0.01902
Ͳ6.64386
Ͳ6.64386
0.34471
Ͳ 6.64386
0.631682
0.555187
0.468082
0.007097
0.271238
0.340154
Ͳ6.64386
Ͳ6.64386
Ͳ0.16716
Ͳ6.64386
Ͳ6.64386
0.438927
Ͳ0.05353
Ͳ6.64386
0.268711
Ͳ0.00257
Ͳ0.10108
Ͳ6.64386
Ͳ0.48881
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.179607
Ͳ6.64386
Ͳ6.64386
1.229819
82
hsaͲm
iRͲ 502Ͳ3p
2.08EͲ06
4.05EͲ08
2.867455
up
0.283712
0.27046216
Ͳ1.33104
Ͳ6.64386
Ͳ0.39933
Ͳ6.64386
1.071486
0.315516
1.859563
0.125623
1.704894
1.812647
0.967101
1.849503
0.747071
1.053277
1.147087
1.538006
2.07911
1.205742
0.890874
1.545846
Ͳ0.44504
Ͳ0.26912
0.744623
0.508179
0.691715
0.677179
0.803635
1.509393
0.691877
1.902503
Ͳ0.51158
0.132732
0.747123
1.569693
1.500736
2.014257
Ͳ1.20034
0.030986
0.0371
Ͳ0.18949
0.912288
Ͳ1.41732
Ͳ0.59208
0.078816
Ͳ0.44403
Ͳ0.65482
0.776165
0.080271
Ͳ0.63704
1.006892
1.485763
Ͳ0.96979
2.577021
Ͳ1.12158
0.297919
1.994436
Ͳ6.64386
Ͳ0.14534
2.07911
Ͳ0.8344
Ͳ0.03167
1.046697
Ͳ0.82453
Ͳ6.64386
1.173481
Ͳ1.23773
Ͳ0.15995
Ͳ1.31566
0.935112
Ͳ0.41736
Ͳ1.15011
Ͳ0.21219
Ͳ0.23005
Ͳ0.5179
0.109079
0.580601
Ͳ6.64386
Ͳ1.63243
Ͳ1.22986
Ͳ0.25462
Ͳ1.6096
Ͳ1.61
Ͳ0.54583
Ͳ0.82359
Ͳ0.53441
Ͳ0.59407
0.165959
Ͳ0.70484
Ͳ1.21991
Ͳ6.64386
Ͳ1.11631
Ͳ1.00016
0.268019
Ͳ1.42136
Ͳ0.55008
Ͳ0.60897
Ͳ1.13028
Ͳ0.93748
0.215801
Ͳ0.88186
83
hsaͲm
iRͲ4634
7.24EͲ08
5.72EͲ10
2.783406
up
1.454805
0.08024355
Ͳ1.43399
0.673245
Ͳ0.47631
0.015471
0.772598
0.217175
0.73494
1.237135
Ͳ0.0395
0.048417
0.00232
1.324248
Ͳ1.12054
2.602754
0.185442
0.346354
0.05897
Ͳ0.20702
0.577111
0.232894
0.924317
0.316796
0.970611
Ͳ0.37761
0.464919
0.17141
0.36489
0.489148
0.535823
1.478419
0.095955
Ͳ0.06428
0.17178
Ͳ0.3855
0.328132
0.720766
Ͳ1.01869
Ͳ0.87542
0.166601
Ͳ0.96482
Ͳ0.44246
Ͳ0.98053
0.166951
Ͳ0.04548
Ͳ0.37798
0.099334
0.053158
1.515279
1.439773
0.492933
Ͳ0.10087
0.032694
Ͳ0.24655
1.017947
Ͳ0.2083
0.48481
1.35985
Ͳ0.12104
1.313689
1.435741
0.560827
0.139216
0.686378
Ͳ0.00232
0.654644
Ͳ0.74597
Ͳ0.9935
Ͳ0.98303
Ͳ1.6555
Ͳ0.33679
Ͳ6.64386
Ͳ1.80318
Ͳ1.2013
Ͳ1.24469
Ͳ1.4275
0.182837
Ͳ0.74681
Ͳ0.19699
Ͳ0.60665
Ͳ0.99674
Ͳ6.64386
Ͳ1.48558
Ͳ0.80471
Ͳ0.8658
0.12403
Ͳ1.9053
Ͳ1.34206
Ͳ0.58419
Ͳ0.55197
0.715761
Ͳ0.35467
Ͳ1.542
Ͳ1.29075
Ͳ1.36422
Ͳ 0.86387
0.087595
Ͳ0.46166
Ͳ1.15394
Ͳ0.80208
Ͳ0.61632
84
hsaͲm
iRͲ4487
0.007933
0.001024
2.725489
up
Ͳ6.64386
Ͳ6.643856
Ͳ0.21612
0.890467
0.844308
1.785502
1.513682
0.102288
0.561316
0.354021
Ͳ0.04874
Ͳ6.64386
2.193337
0.121187
Ͳ0.34513
0.690947
Ͳ0.04874
0.303564
0.363278
0.002792
0.605487
Ͳ0.26523
0.095652
Ͳ0.10911
Ͳ0.36285
0.406164
0.241777
0.111419
1.72EͲ04
0.143907
Ͳ6.64386
0.431255
Ͳ6.64386
0.347191
0.06696
0.152896
Ͳ6.64386
0.586851
0.260283
Ͳ6.64386
0.851843
0.512765
Ͳ0.31066
Ͳ0.1204
0.268744
0.271509
0.163047
Ͳ6.64386
0.214296
1.359517
Ͳ0.24246
0.065433
Ͳ6.64386
0.214296
Ͳ6.64386
0.350034
0.160076
Ͳ0.0848
0.9142
0.137187
0.279214
Ͳ0.16728
Ͳ0.05419
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.134934
Ͳ0.10088
Ͳ0.40339
0.283458
Ͳ0.17522
0.270657
Ͳ0.09278
Ͳ6.64386
Ͳ0.39335
Ͳ0.26907
Ͳ0.34884
0.123365
Ͳ6.64386
Ͳ0.20852
Ͳ6.64386
0.130523
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ1.72EͲ04
0.285802
Ͳ0.70154
Ͳ6.64386
Ͳ0.50587
0.319552
0.479479
Ͳ0.10285
Ͳ6.64386
0.789179
0.230003
Ͳ6.64386
0.031752
Ͳ6.64386
Ͳ0.25877
Ͳ6.64386
Ͳ0.10602
85
hsaͲm
iRͲ636
0.032688
0.005821
2.65164
up
0.94097
Ͳ0.1102488
0.519727
2.349737
1.46631
Ͳ6.64386
Ͳ0.24464
0.254963
Ͳ0.0165
0.359051
0.508135
Ͳ6.64386
1.129623
0.561574
Ͳ6.64386
0.63161
0.687105
0.876677
Ͳ0.00431
0.490708
0.310957
0.614349
0.439178
0.004295
Ͳ0.21197
0.320977
0.497628
Ͳ6.64386
1.458481
Ͳ6.64386
0.168638
0.66157
1.049675
Ͳ6.64386
Ͳ0.03985
0.846304
0.573895
0.94584
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.159174
Ͳ6.64386
Ͳ0.01016
0.022289
0.795677
0.858394
0.180897
0.643478
Ͳ6.64386
0.129913
Ͳ0.05932
Ͳ6.64386
Ͳ0.18941
Ͳ6.64386
0.05613
Ͳ0.19924
0.244448
Ͳ6.64386
0.871044
0.693129
0.521154
0.038379
Ͳ6.64386
Ͳ0.03649
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.17398
0.237302
Ͳ0.00925
0.391846
0.049351
Ͳ6.64386
0.677706
Ͳ0.48888
Ͳ6.64386
0.087289
Ͳ6.64386
Ͳ0.01916
Ͳ6.64386
Ͳ6.64386
Ͳ0.43928
0.641169
Ͳ6.64386
0.084405
0.275224
Ͳ6.64386
Ͳ0.44501
0.050562
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.824609
Ͳ6.64386
0.610637
Ͳ0.24832
Ͳ0.07371
Ͳ6.64386
Ͳ6.64386
0.307567
Ͳ6.64386
86
hsaͲm
iRͲ3196
1.22EͲ08
7.09EͲ11
2.634303
up
2.413842
1.3972187
Ͳ1.12486
Ͳ0.34084
Ͳ1.16498
Ͳ0.65893
0.77429
0.114466
0.710776
1.097016
Ͳ0.31983
Ͳ0.02724
1.200211
2.335048
Ͳ1.39022
2.60197
0.121217
0.012623
Ͳ0.83604
Ͳ0.15564
1.422205
Ͳ0.11976
1.075859
1.017373
1.03431
0.649128
0.240534
0.489983
0.003937
0.56271
0.946671
1.096143
1.551362
Ͳ0.60535
1.036226
0.226218
0.520039
0.970715
Ͳ0.5582
Ͳ0.81041
0.409995
0.003589
Ͳ0.54592
0.10716
1.072002
Ͳ0.39897
0.19662
0.65266
Ͳ0.54894
0.425758
1.764868
0.930457
Ͳ0.06759
0.130025
Ͳ0.0036
0.591307
Ͳ0.3883
0.528303
1.538489
0.29549
1.445777
1.373349
1.373316
0.172536
0.482497
0.166359
0.711063
0.763373
Ͳ1.15412
Ͳ1.22386
Ͳ1.6111
Ͳ1.01378
Ͳ0.96976
Ͳ1.23483
Ͳ1.35452
Ͳ1.58938
Ͳ1.34172
Ͳ0.73188
Ͳ1.61978
Ͳ0.11603
Ͳ0.44785
Ͳ0.58016
Ͳ1.70399
Ͳ1.31249
Ͳ0.39773
Ͳ2.00637
Ͳ0.52165
Ͳ1.1641
Ͳ1.33072
Ͳ1.0531
0.223579
1.65095
Ͳ0.34906
Ͳ1.8701
Ͳ0.16932
Ͳ0.61299
Ͳ1.13706
Ͳ0.32598
Ͳ0.61192
Ͳ1.60672
Ͳ0.9952
Ͳ1.6962
87
hsaͲm
iRͲ500aͲ5p
1.92EͲ04
1.01EͲ05
2.592344
up
0.284614
0.0791602
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.840953
0.800457
2.171474
0.132369
1.834439
2.182363
1.181306
2.048564
0.84266
0.199628
1.709369
1.723457
2.28407
1.5974
0.488664
0.389129
Ͳ0.0227
Ͳ1.0963
0.587209
0.952211
0.428743
0.264584
1.219315
1.417875
0.447556
2.249477
Ͳ0.22773
0.75287
0.972726
1.190583
0.994044
1.901554
Ͳ6.64386
Ͳ0.69218
0.453778
Ͳ0.32621
0.864937
Ͳ0.6136
Ͳ1.05042
0.558185
0.602621
Ͳ0.69673
0.981769
Ͳ6.64386
Ͳ6.64386
0.80356
1.795811
Ͳ6.64386
2.669512
Ͳ6.64386
Ͳ0.2483
1.44327
Ͳ6.64386
Ͳ6.64386
2.054588
0.166396
Ͳ0.25599
0.720799
Ͳ6.64386
Ͳ6.64386
1.552299
Ͳ1.05107
0.026197
Ͳ0.5944
1.437715
Ͳ0.07409
Ͳ0.87114
Ͳ1.08417
0.022346
Ͳ0.48026
0.137775
0.748676
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.20953
Ͳ1.02935
Ͳ1.24238
Ͳ0.88471
Ͳ0.57797
Ͳ0.39763
Ͳ0.21711
0.70524
Ͳ0.22409
Ͳ0.9512
Ͳ6.64386
Ͳ0.72311
Ͳ0.70988
Ͳ0.16701
Ͳ6.64386
Ͳ0.80422
Ͳ0.79374
Ͳ0.81361
Ͳ6.64386
0.149883
Ͳ0.60776
88
hsaͲm
iRͲ185Ͳ5p
1.18EͲ05
3.55EͲ07
2.566472
up
0.277124
0.57841945
Ͳ0.8561
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.752601
Ͳ0.03987
2.128384
1.814216
1.074945
2.463237
Ͳ6.64386
0.887906
Ͳ0.06515
1.512153
2.442776
1.951466
1.761496
0.870586
Ͳ0.77528
1.496438
0.573028
0.127667
0.675905
1.602135
1.550467
Ͳ0.36852
1.377026
0.647807
2.175451
1.333249
0.676295
0.736929
Ͳ0.07484
1.137102
1.339063
1.828344
Ͳ1.23502
Ͳ0.60789
0.881563
Ͳ0.89866
0.489247
0.038801
Ͳ0.15702
0.746157
1.441417
Ͳ0.62435
1.100775
Ͳ6.64386
Ͳ0.22244
1.624912
1.327457
Ͳ0.74268
2.70039
Ͳ1.4785
Ͳ0.78605
1.193839
Ͳ1.34595
0.943392
0.15179
0.308169
0.468836
0.636885
Ͳ0.46016
Ͳ0.28306
1.562382
1.021931
0.381981
Ͳ0.83462
Ͳ0.62674
Ͳ0.33627
0.109568
Ͳ0.89801
Ͳ0.53971
0.707103
0.135346
Ͳ0.1488
Ͳ0.40877
Ͳ1.78274
Ͳ0.9419
Ͳ1.56247
1.470568
Ͳ1.20643
Ͳ1.27893
Ͳ0.99302
Ͳ0.78517
Ͳ0.55287
Ͳ0.62143
Ͳ0.19129
Ͳ2.52127
Ͳ2.16596
Ͳ0.5501
Ͳ1.07951
Ͳ6.64386
Ͳ1.49075
Ͳ0.43914
Ͳ2.21739
Ͳ0.91642
Ͳ1.43225
Ͳ0.19083
0.309533
89
hsaͲm
iRͲ4488
2.77EͲ07
2.77EͲ09
2.560814
up
2.393452
1.5051619
Ͳ1.08041
Ͳ0.15625
Ͳ2.07609
0.418929
1.081243
Ͳ0.11745
0.344768
0.974641
0.457912
Ͳ0.42343
1.223086
1.624118
Ͳ1.61789
2.330978
Ͳ0.25011
0.0473
Ͳ0.83661
Ͳ0.35612
1.728211
Ͳ0.1016
1.149925
0.847173
0.860823
0.451112
0.332759
0.406112
Ͳ0.00207
0.904473
0.645216
0.10914
1.850957
Ͳ1.12421
0.970531
0.69892
0.622669
0.685334
Ͳ0.43465
Ͳ0.44284
0.546511
0.365549
Ͳ0.61896
0.236912
0.914482
Ͳ0.39711
0.236728
1.020608
Ͳ0.74724
Ͳ0.09513
1.647884
0.881998
0.002065
0.265572
Ͳ0.09543
0.695902
Ͳ0.16252
0.440445
1.580442
0.403265
1.220822
1.493057
1.174728
Ͳ0.02748
0.356441
0.123605
0.516881
0.316202
Ͳ0.94695
Ͳ1.28209
Ͳ2.18004
Ͳ0.92258
Ͳ1.30146
Ͳ1.29053
Ͳ1.57157
Ͳ1.93634
Ͳ1.05704
Ͳ0.23727
Ͳ1.92096
Ͳ0.20752
Ͳ0.50971
0.01815
Ͳ1.82499
Ͳ1.6949
0.41415
Ͳ2.11453
Ͳ0.35188
Ͳ1.39011
Ͳ1.36905
Ͳ0.60694
0.156277
1.621327
Ͳ0.37311
Ͳ2.43281
Ͳ0.02214
Ͳ1.3062
Ͳ0.60412
Ͳ0.33147
Ͳ0.38757
Ͳ1.89646
Ͳ0.20894
Ͳ1.84728
90
hsaͲm
iRͲ513aͲ5p
1.57EͲ05
5.28EͲ07
2.5497
up
1.500692
1.4509012
Ͳ0.23456
Ͳ6.64386
Ͳ1.8535
Ͳ6.64386
0.899156
Ͳ1.8416
0.256918
Ͳ0.05587
2.618522
1.645461
1.358718
1.265019
Ͳ0.69434
1.561825
0.468127
Ͳ0.78671
2.71758
1.683958
0.159071
0.430744
0.473729
0.828179
0.026072
0.282901
1.200802
0.810549
Ͳ1.4965
0.997592
0.86668
1.493169
0.394928
Ͳ0.64268
Ͳ0.27042
1.673904
Ͳ0.87794
0.339786
Ͳ0.6757
Ͳ1.23894
1.217611
0.501067
Ͳ0.02098
Ͳ0.85873
1.000945
Ͳ0.48933
0.657626
Ͳ2.14474
0.802579
Ͳ1.49323
1.582476
1.43803
0.72606
0.301518
1.722394
Ͳ0.13919
0.467943
0.662824
Ͳ0.29399
0.855264
1.052737
Ͳ0.17417
Ͳ0.44451
1.079078
1.267366
0.227137
1.097019
0.237857
Ͳ1.298
0.23623
Ͳ1.82657
Ͳ0.04638
Ͳ0.14395
Ͳ0.90584
Ͳ1.41146
Ͳ0.91867
Ͳ0.47544
Ͳ0.8937
Ͳ1.99967
0.020676
Ͳ2.19532
Ͳ0.98627
Ͳ6.64386
Ͳ0.45258
Ͳ0.42398
Ͳ0.25178
0.140142
0.787359
Ͳ2.37657
Ͳ0.45742
1.497909
0.288645
Ͳ1.30714
Ͳ0.53011
Ͳ0.0991
Ͳ0.71963
Ͳ2.25441
Ͳ0.9211
Ͳ1.46772
Ͳ0.62188
Ͳ1.86966
Ͳ0.9051
91
hsaͲm
iRͲ 663a
1.75EͲ07
1.49EͲ09
2.543887
up
2.599052
1.2331554
Ͳ1.13597
Ͳ1.1136
Ͳ2.0175
Ͳ2.5288
0.965058
0.127544
0.548316
1.361637
0.092795
0.022953
Ͳ0.42805
2.07461
Ͳ1.98909
2.759127
0.111537
0.089652
Ͳ0.57624
Ͳ0.27193
2.106114
0.546609
1.609428
1.079452
1.2197
0.102009
0.995277
0.46032
0.564252
0.812011
1.31479
0.802073
1.056633
Ͳ1.02284
1.224852
0.488121
0.885553
0.985417
Ͳ0.56254
Ͳ0.36184
0.39227
Ͳ0.20376
Ͳ0.3398
Ͳ0.1685
1.412173
Ͳ0.48264
0.059245
0.914212
Ͳ0.24933
Ͳ6.64386
1.762184
0.765009
Ͳ0.51869
0.158866
0.300124
0.984902
Ͳ0.31923
0.927074
1.28806
0.530736
1.412895
1.581939
1.085043
Ͳ0.02332
0.233513
Ͳ0.17392
0.276887
0.108844
Ͳ0.82555
Ͳ1.23582
Ͳ1.78928
Ͳ0.66644
Ͳ1.70909
Ͳ0.97869
Ͳ1.02373
Ͳ1.52973
Ͳ1.32889
0.06412
Ͳ2.37377
0.188731
Ͳ0.63833
Ͳ0.54156
Ͳ1.64383
Ͳ1.20978
Ͳ1.01403
Ͳ2.62786
Ͳ0.23584
Ͳ1.25444
Ͳ1.38401
Ͳ0.67711
Ͳ0.33775
1.602202
Ͳ0.51656
Ͳ2.09096
Ͳ0.69871
Ͳ1.23708
Ͳ0.72743
0.225762
Ͳ0.20825
Ͳ2.58598
Ͳ0.45847
Ͳ1.24088
92
hsaͲm
iRͲ4783Ͳ5p
6.75EͲ04
4.59EͲ05
2.468174
up
0.529365
Ͳ0.7256264
Ͳ0.62046
Ͳ6.64386
Ͳ0.10972
Ͳ6.64386
Ͳ0.29899
0.183901
0.619154
0.913356
0.325841
0.565192
1.166642
0.409499
Ͳ6.64386
1.233138
0.600539
Ͳ0.00944
0.172666
0.385282
0.280299
0.04326
0.918715
0.213185
Ͳ6.64386
0.009101
0.71413
Ͳ0.35546
0.938018
Ͳ0.90375
0.608647
0.311032
0.136895
Ͳ6.64386
Ͳ0.12885
0.507679
0.166642
0.751605
Ͳ6.64386
Ͳ0.1102
0.638652
0.189726
Ͳ0.7627
0.510019
0.026917
0.381061
0.655486
Ͳ0.05874
0.612053
Ͳ6.64386
0.273807
0.149569
Ͳ6.64386
0.647677
Ͳ6.64386
0.950705
0.017264
0.255595
1.325384
Ͳ6.64386
0.623327
0.537437
0.345616
Ͳ6.64386
0.9445
0.026795
Ͳ0.30942
Ͳ6.64386
Ͳ0.20058
0.114175
Ͳ6.64386
0.77666
Ͳ6.64386
Ͳ0.68826
0.616522
Ͳ6.64386
Ͳ6.64386
Ͳ0.59687
Ͳ0.63426
0.341729
Ͳ6.64386
Ͳ0.78424
Ͳ0.92114
Ͳ1.33449
Ͳ0.32408
Ͳ0.55543
0.250549
Ͳ6.64386
Ͳ0.60678
Ͳ0.30766
Ͳ0.27924
0.212108
Ͳ0.00916
Ͳ0.96264
Ͳ6.64386
Ͳ0.67337
Ͳ6.64386
0.425729
Ͳ0.49131
Ͳ6.64386
Ͳ0.17971
Ͳ0.17991
93
hsaͲm
iRͲ514bͲ5p
4.14EͲ06
9.46EͲ08
2.451853
up
1.349805
1.387018
0.126258
Ͳ6.64386
0.158244
Ͳ6.64386
1.055025
Ͳ0.76227
0.12225
Ͳ0.16016
3.587739
0.575326
0.244432
0.885979
Ͳ1.11402
0.316487
0.815589
Ͳ1.08365
3.860532
0.233902
0.503237
0.887667
0.211518
0.96966
0.303254
1.222051
1.592503
Ͳ0.48173
Ͳ0.03116
0.64244
0.683858
1.898578
0.355697
Ͳ0.81763
Ͳ0.95699
2.418474
Ͳ0.23991
Ͳ0.21698
0.037147
0.293636
1.326161
1.41214
0.070244
Ͳ0.03368
0.821127
Ͳ0.23122
0.718994
Ͳ1.04402
1.101463
Ͳ6.64386
0.285014
1.270384
1.468472
0.430925
2.057369
Ͳ0.09657
Ͳ0.03833
0.818611
1.010544
Ͳ6.64386
Ͳ0.07405
0.16509
0.030505
0.833317
Ͳ0.12256
0.758359
1.018037
Ͳ1.83114
Ͳ0.77217
Ͳ6.64386
Ͳ1.29809
0.235338
Ͳ1.49102
Ͳ0.7669
Ͳ0.19894
Ͳ1.13629
Ͳ0.70995
Ͳ0.81838
Ͳ1.3658
0.512444
Ͳ0.72382
Ͳ0.19075
Ͳ 1.11644
Ͳ1.66246
Ͳ0.47966
Ͳ0.52113
Ͳ1.01818
Ͳ1.1294
Ͳ1.09158
Ͳ1.12316
Ͳ0.05613
0.373974
0.22671
Ͳ0.4808
0.601607
Ͳ6.64386
Ͳ1.25228
Ͳ0.94522
Ͳ0.56171
Ͳ0.92563
Ͳ0.37184
Ͳ0.65531
94
hsaͲm
iRͲ4497
3.24EͲ07
3.58EͲ09
2.42442
up
2.229457
1.6448939
Ͳ0.65078
Ͳ1.33664
Ͳ2.10265
Ͳ1.67429
1.309959
Ͳ0.47024
0.377411
0.890526
0.008392
Ͳ0.40453
1.918046
1.585322
Ͳ1.3649
1.679477
0.072383
0.706542
Ͳ0.63546
Ͳ0.00844
1.019483
0.01904
0.728604
0.613269
1.251857
0.700903
0.047952
0.083996
Ͳ0.8177
0.556427
0.570539
0.627826
1.78493
Ͳ0.57533
1.212248
0.181236
0.41273
0.565957
Ͳ0.82724
Ͳ1.66154
0.858549
0.040472
Ͳ0.51505
0.559905
1.24446
Ͳ0.03082
0.428984
1.007801
Ͳ0.75146
Ͳ1.71399
1.03529
0.862875
0.015557
0.089985
Ͳ0.13676
0.652966
Ͳ0.38556
0.700758
1.889005
0.661648
1.024356
1.659326
2.123896
Ͳ0.0716
0.891473
0.057145
0.567569
0.821313
Ͳ0.8483
Ͳ0.95509
Ͳ1.35051
Ͳ0.69294
Ͳ0.99608
Ͳ1.18358
Ͳ2.03207
Ͳ2.15313
Ͳ1.52347
Ͳ0.60208
Ͳ1.57049
Ͳ0.58916
Ͳ0.2501
0.267275
Ͳ1.7724
Ͳ1.66995
0.263759
Ͳ1.21467
Ͳ0.16577
Ͳ1.26797
Ͳ1.73125
Ͳ0.87832
Ͳ0.12986
1.138877
Ͳ1.04358
Ͳ2.20767
Ͳ0.18183
Ͳ1.43057
Ͳ0.65239
Ͳ0.5824
Ͳ0.74078
Ͳ1.16888
Ͳ0.02176
Ͳ1.32527
95
hsaͲm
iRͲ532Ͳ3p
8.07EͲ04
5.87EͲ05
2.41832
up
1.292311
0.7577972
Ͳ1.28794
Ͳ6.64386
Ͳ1.25121
Ͳ6.64386
0.973044
0.962392
1.225458
Ͳ0.05018
1.994217
1.643521
Ͳ6.64386
1.140965
0.780542
0.894328
0.608786
1.106729
2.000241
0.840889
0.864576
1.886365
Ͳ0.54322
Ͳ1.19955
1.079703
0.210783
0.466614
0.556045
0.661698
0.842908
1.09842
2.094213
Ͳ0.02103
0.420714
0.590343
1.878983
1.158541
0.962647
Ͳ1.53911
0.565
Ͳ0.52377
0.017995
0.432861
Ͳ1.04384
Ͳ0.84373
0.281932
0.38175
Ͳ0.16199
0.499571
Ͳ6.64386
Ͳ0.71207
0.844213
1.546897
Ͳ1.04405
2.409391
Ͳ6.64386
0.747006
1.495526
Ͳ6.64386
Ͳ6.64386
1.487748
Ͳ0.37182
Ͳ0.01822
1.177605
Ͳ0.96603
Ͳ1.25254
0.445149
Ͳ1.8663
Ͳ0.09999
Ͳ0.99955
1.144135
Ͳ0.37993
Ͳ0.75553
0.435821
Ͳ0.66212
Ͳ0.24206
1.144186
1.009277
Ͳ6.64386
Ͳ6.64386
Ͳ0.99965
Ͳ0.27952
0.02918
Ͳ1.01365
Ͳ0.73707
Ͳ1.04229
Ͳ1.02065
Ͳ0.53662
0.30581
Ͳ1.13817
Ͳ0.98168
Ͳ1.91645
Ͳ1.13507
0.105942
Ͳ6.64386
Ͳ6.64386
Ͳ0.26934
Ͳ0.14802
Ͳ0.64564
Ͳ6.64386
0.769307
Ͳ0.80919
96
hsaͲm
iRͲ4532
1.08EͲ08
5.66EͲ11
2.402943
up
2.225718
0.46836144
Ͳ1.36319
0.144695
1.741597
Ͳ1.02971
0.319954
Ͳ0.22615
0.115957
0.635791
0.789082
Ͳ0.67035
0.510308
1.055908
Ͳ1.49855
1.989158
Ͳ0.21172
0.733416
Ͳ0.27331
0.036849
2.023833
Ͳ0.02064
0.214473
1.154222
0.514246
0.281598
0.514836
Ͳ0.07004
0.020349
0.105358
0.741604
0.92404
1.008061
Ͳ0.19581
1.010169
Ͳ0.09708
0.26362
0.307447
Ͳ0.91056
Ͳ0.6653
0.497625
0.238009
Ͳ0.74094
0.707261
1.386374
0.383675
Ͳ0.30796
0.246059
Ͳ0.03615
0.119522
0.875251
0.171779
0.240129
Ͳ0.20505
Ͳ0.24425
0.693287
0.241958
0.786947
2.385365
Ͳ0.56503
2.015761
0.960547
1.156079
Ͳ0.17772
0.867865
0.076593
0.243614
0.367331
Ͳ1.20357
Ͳ1.22181
Ͳ1.69258
Ͳ0.47429
Ͳ1.69807
Ͳ0.38858
Ͳ0.60901
Ͳ1.79888
Ͳ1.6272
Ͳ0.94758
Ͳ1.05599
0.052116
Ͳ1.02022
Ͳ0.35771
Ͳ1.70305
Ͳ1.62323
Ͳ0.43766
Ͳ0.93793
Ͳ0.42736
Ͳ1.63311
Ͳ1.5798
Ͳ1.26134
Ͳ0.18958
0.780263
Ͳ0.41693
Ͳ1.5769
0.020954
Ͳ0.82066
Ͳ1.0384
Ͳ0.4755
Ͳ1.31185
Ͳ1.04603
Ͳ0.52812
Ͳ0.81017
97
hsaͲm
iRͲ140Ͳ3p
2.94EͲ04
1.69EͲ05
2.380397
up
0.33637
0.15502402
Ͳ0.02985
Ͳ1.7345
Ͳ2.26402
Ͳ6.64386
0.542884
0.99003
2.059311
0.520287
0.423783
Ͳ0.16554
Ͳ0.95038
1.153758
2.532876
Ͳ0.37562
1.048937
1.614851
0.598278
1.305331
0.029249
Ͳ0.80083
0.497783
Ͳ2.41616
Ͳ0.74766
0.330824
Ͳ0.17974
0.250024
0.641164
0.291045
0.535846
1.182378
Ͳ1.70053
0.590621
Ͳ1.00133
1.212967
Ͳ0.07445
3.20452
0.161366
3.115849
0.666345
0.185699
1.879816
0.596962
Ͳ1.58665
2.424559
0.577675
Ͳ0.05385
1.701855
Ͳ6.64386
Ͳ1.32279
0.042448
0.525235
0.38725
2.665917
0.969658
0.399936
0.972981
Ͳ2.48121
Ͳ1.43133
1.926398
Ͳ0.04487
0.476556
Ͳ0.6307
0.194152
0.973109
0.129864
Ͳ0.61279
Ͳ0.08076
0.557773
Ͳ0.87034
Ͳ1.52044
Ͳ0.36938
Ͳ2.27358
Ͳ0.38532
Ͳ0.90839
Ͳ0.71297
Ͳ0.86012
0.563027
Ͳ0.61917
0.245636
Ͳ0.92348
Ͳ0.99489
Ͳ2.42925
Ͳ2.1066
0.788367
Ͳ1.94783
Ͳ1.52646
Ͳ0.58489
Ͳ0.93328
Ͳ2.49893
Ͳ1.79031
Ͳ1.23592
Ͳ0.58433
Ͳ6.64386
Ͳ0.75535
Ͳ0.33395
Ͳ0.87272
Ͳ0.1349
Ͳ0.50069
1.143692
1.195903
98
hsaͲm
iRͲ4706
0.029612
0.005149
2.311177
up
0.029644
Ͳ6.643856
Ͳ0.68338
0.550556
0.86265
0.541445
Ͳ0.44778
Ͳ0.49601
0.98037
0.670554
Ͳ0.69354
0.099691
1.810588
0.061344
Ͳ6.64386
0.993221
1.200636
0.526655
Ͳ0.40212
1.01695
0.432357
Ͳ0.19383
0.570282
0.06397
Ͳ6.64386
0.027792
1.400433
Ͳ0.18043
0.188256
Ͳ0.71954
Ͳ6.64386
Ͳ0.09598
0.481281
Ͳ0.12769
1.127473
Ͳ0.13895
0.008989
0.975848
Ͳ0.64756
0.83598
1.151106
0.281519
Ͳ0.3772
0.087238
Ͳ0.59957
Ͳ0.31128
0.141367
0.870434
Ͳ0.57571
1.351396
Ͳ0.57262
0.051884
0.613299
0.729148
Ͳ0.81504
0.679234
0.391134
Ͳ0.40401
1.048555
Ͳ6.64386
0.266677
Ͳ0.12267
Ͳ6.64386
Ͳ0.59733
0.339564
0.668183
0.304568
Ͳ1.03729
Ͳ0.35586
Ͳ0.00905
0.766393
0.624409
Ͳ6.64386
Ͳ0.01279
0.226208
Ͳ0.55763
Ͳ0.68865
Ͳ0.15862
Ͳ6.64386
Ͳ0.01293
Ͳ0.52677
Ͳ0.32856
Ͳ6.64386
Ͳ1.15452
0.353146
Ͳ0.63766
0.153981
Ͳ1.02442
Ͳ0.45729
Ͳ6.64386
Ͳ0.23876
0.599125
0.321792
Ͳ6.64386
0.667437
Ͳ6.64386
Ͳ0.58641
0.037497
0.205595
0.312056
Ͳ6.64386
Ͳ0.28795
99
hsaͲm
iRͲ4306
9.11EͲ06
2.59EͲ07
2.30042
up
Ͳ0.1932
0.27637917
Ͳ0.69559
Ͳ2.39136
Ͳ1.98383
0.098957
1.709248
Ͳ0.23113
1.812654
1.727062
1.065929
2.287687
Ͳ1.62842
0.059816
Ͳ0.19354
1.306109
2.00494
1.384283
1.245601
0.732028
Ͳ0.64886
1.330063
0.499786
0.198045
0.554138
1.291188
1.286342
0.090041
0.8927
0.925226
1.802146
0.551149
0.757815
0.485454
Ͳ0.21457
0.896195
1.109072
1.389599
Ͳ1.14015
Ͳ0.74041
0.934946
Ͳ0.37923
0.106488
0.240714
Ͳ0.4354
0.098362
1.349944
Ͳ1.15887
1.005022
Ͳ1.72458
0.275159
1.292442
1.105779
Ͳ0.67565
2.356114
Ͳ1.21393
Ͳ0.53528
0.725637
Ͳ1.17716
1.182369
0.122894
Ͳ0.01912
Ͳ0.38494
0.636827
Ͳ0.49725
Ͳ0.23761
1.583859
0.190459
0.316662
Ͳ0.63277
Ͳ1.03335
Ͳ0.14952
Ͳ0.03799
Ͳ1.30952
Ͳ0.28197
0.592087
0.25515
Ͳ0.37762
Ͳ0.17811
Ͳ1.35928
Ͳ1.26042
Ͳ1.06377
0.889856
Ͳ1.37952
Ͳ1.03818
Ͳ0.86758
Ͳ1.05654
Ͳ0.47257
Ͳ0.57012
Ͳ0.41827
Ͳ1.71706
Ͳ1.83449
Ͳ0.45511
Ͳ1.07062
Ͳ1.90543
Ͳ1.89174
0.018872
Ͳ1.63416
Ͳ0.61717
Ͳ0.80432
Ͳ0.20641
0.053083
100
hsaͲm
iRͲ4440
0.013465
0.002015
2.267684
up
Ͳ0.58629
Ͳ0.6026661
0.339338
0.808667
1.502291
0.57298
Ͳ0.2898
Ͳ0.16115
0.333624
0.546905
Ͳ0.59282
0.32857
1.285008
0.070145
Ͳ6.64386
0.416225
Ͳ0.04489
Ͳ0.03193
Ͳ0.62744
0.40718
1.155923
0.190688
0.50108
0.588448
1.046849
Ͳ0.28757
0.443706
1.385603
0.067524
0.626298
Ͳ6.64386
0.218146
0.284323
Ͳ6.64386
0.535694
0.167993
Ͳ6.64386
1.051036
Ͳ0.4119
Ͳ6.64386
0.159205
Ͳ0.64013
0.081534
Ͳ0.36047
0.979759
Ͳ0.04986
Ͳ0.24669
Ͳ0.31242
0.244909
0.833404
2.149101
0.149792
Ͳ6.64386
Ͳ0.52292
Ͳ0.38551
0.610032
0.842765
0.07099
1.018627
1.581844
0.15017
0.041563
Ͳ0.44868
0.435408
Ͳ0.55186
Ͳ6.64386
Ͳ0.29755
Ͳ0.40758
Ͳ0.23627
Ͳ6.64386
0.701578
0.03124
Ͳ6.64386
Ͳ0.73038
Ͳ0.14736
Ͳ0.34633
0.555018
Ͳ0.37867
Ͳ6.64386
0.189949
Ͳ6.64386
Ͳ0.27827
Ͳ6.64386
Ͳ6.64386
Ͳ0.66957
Ͳ6.64386
0.167309
0.189312
Ͳ6.64386
Ͳ0.21176
0.621132
0.062657
0.399396
Ͳ0.73721
Ͳ0.43778
Ͳ0.70124
0.80228
Ͳ0.50119
0.069547
Ͳ0.28577
Ͳ0.10993
Ͳ0.05355
101
hsaͲm
iRͲ 1469
1.21EͲ05
3.71EͲ07
2.23717
up
3.588918
2.3715854
Ͳ1.23804
Ͳ0.80988
Ͳ1.50484
0.444918
1.887108
0.021453
0.220144
0.973932
Ͳ0.48701
Ͳ1.11178
Ͳ1.50193
1.214133
Ͳ1.74664
2.630956
Ͳ0.15304
Ͳ0.20823
Ͳ1.10319
Ͳ0.96262
1.768166
Ͳ0.04393
0.908915
0.961048
0.803002
0.68934
0.402097
Ͳ0.03195
0.20979
0.116643
0.654724
0.647718
1.728504
Ͳ0.67421
1.371313
0.003001
0.9423
0.33471
Ͳ0.76241
Ͳ0.51217
0.238952
0.363353
Ͳ0.26584
1.270251
1.721274
0.152422
0.25923
1.256393
Ͳ0.71784
Ͳ6.64386
1.513947
0.634729
0.458797
0.231733
Ͳ0.79419
0.968213
Ͳ0.81113
0.234045
2.686353
0.318314
1.565352
1.318278
2.61391
Ͳ0.00868
0.349485
0.228008
0.934862
2.064429
Ͳ1.04116
Ͳ1.37832
Ͳ1.82635
Ͳ0.49751
Ͳ1.59101
Ͳ0.6541
Ͳ0.68355
Ͳ1.73841
Ͳ1.71303
0.310105
Ͳ1.21271
Ͳ0.06076
0.049453
0.145832
Ͳ1.57435
Ͳ2.26398
0.159535
Ͳ2.13688
Ͳ0.36867
Ͳ1.44955
Ͳ1.46913
Ͳ0.80757
Ͳ0.50591
2.240648
Ͳ0.00301
Ͳ2.6821
Ͳ1.47943
Ͳ1.64762
Ͳ0.65325
Ͳ0.19815
Ͳ0.45883
Ͳ 1.76435
Ͳ0.24733
Ͳ1.7458
102
hsaͲm
iRͲ3180
1.03EͲ04
4.44EͲ06
2.207144
up
1.943047
Ͳ0.160598
Ͳ0.72607
0.32211
0.318373
1.857309
Ͳ0.04369
Ͳ0.40642
0.058455
1.82813
0.885677
Ͳ0.74866
0.246401
1.135397
0.388845
1.946327
1.533235
0.481954
Ͳ0.00952
Ͳ0.22259
1.480475
0.316089
1.310843
0.838929
Ͳ0.54975
0.852792
0.814938
0.347368
1.125811
Ͳ0.41851
Ͳ0.36945
1.274773
0.511101
Ͳ0.30109
1.433983
0.815855
1.607343
0.640384
Ͳ0.82256
0.036056
0.682609
0.059139
Ͳ0.00347
0.24412
Ͳ0.49056
0.176749
0.310475
Ͳ0.32293
Ͳ0.02824
0.705769
1.37588
Ͳ0.10301
Ͳ0.57483
0.556722
Ͳ0.29259
0.823162
Ͳ0.19612
Ͳ0.02307
1.866782
Ͳ6.64386
0.697432
1.033588
Ͳ0.06418
Ͳ0.65375
Ͳ0.98317
0.240032
0.784983
1.585713
Ͳ0.62436
Ͳ0.02619
0.14935
0.217234
Ͳ0.53954
Ͳ0.77421
0.550472
Ͳ0.79404
Ͳ0.60109
Ͳ0.78205
Ͳ0.29368
Ͳ0.08422
Ͳ0.18624
Ͳ0.41653
Ͳ0.89633
1.582175
Ͳ0.54691
Ͳ6.64386
Ͳ0.42442
Ͳ6.64386
Ͳ1.18704
Ͳ0.92519
Ͳ0.17071
0.599042
0.430047
Ͳ0.71069
Ͳ0.27917
Ͳ0.88056
Ͳ0.24858
0.364998
Ͳ0.45272
Ͳ0.54524
0.003464
Ͳ6.64386
103
hsaͲm
iRͲ4758Ͳ3p
0.007443
9.27EͲ04
2.140459
up
0.064995
0.28611553
Ͳ0.47256
1.603232
1.072183
2.029536
Ͳ0.01489
Ͳ5.30EͲ04
Ͳ0.23479
0.325508
Ͳ0.09729
Ͳ6.64386
1.524199
0.1712
Ͳ0.82492
Ͳ6.64386
Ͳ0.12517
0.473653
Ͳ0.05884
0.35017
Ͳ0.1543
Ͳ0.12114
0.539648
Ͳ0.29517
Ͳ0.33209
Ͳ0.04838
0.028242
0.045659
0.721007
Ͳ0.34171
0.236959
0.687205
1.449705
Ͳ0.02329
0.268562
Ͳ0.13046
0.688339
0.587209
Ͳ0.3128
0.180245
0.304254
0.123894
Ͳ0.66664
Ͳ0.15445
Ͳ0.6722
0.55333
0.300779
0.081566
0.740439
1.806836
Ͳ0.23989
Ͳ0.08959
0.680756
Ͳ0.03449
Ͳ6.64386
0.778089
0.609257
Ͳ0.18117
0.192252
0.657604
0.426583
0.425634
Ͳ0.27374
0.347755
0.228216
0.025386
0.676069
Ͳ0.41849
5.30EͲ04
0.066377
Ͳ0.42714
0.500959
Ͳ0.268
Ͳ6.64386
Ͳ0.22579
Ͳ0.40787
0.029524
Ͳ0.21524
0.238409
0.203328
Ͳ0.30738
Ͳ0.44104
Ͳ0.64982
Ͳ0.4613
Ͳ0.51962
Ͳ0.2805
0.310421
Ͳ6.64386
Ͳ0.32689
Ͳ0.2807
Ͳ0.05497
Ͳ6.64386
Ͳ0.31419
Ͳ0.73472
Ͳ6.64386
Ͳ6.64386
0.326495
0.506895
0.114238
0.066108
0.180485
Ͳ6.64386
104
hsaͲm
iRͲ211Ͳ3p
0.01656
0.002572
2.137208
up
2.790473
1.1317003
Ͳ0.58529
0.0342
2.748491
1.636873
0.511689
Ͳ0.06593
0.789211
0.184869
0.18299
0.193043
1.8482
2.446024
Ͳ0.89185
1.120952
0.592175
Ͳ0.48708
Ͳ0.05199
Ͳ0.62638
0.202864
1.019418
0.234622
0.403562
1.368379
0.231899
0.330547
Ͳ0.29589
Ͳ0.26691
Ͳ0.62437
1.209957
3.061171
2.173902
Ͳ0.12152
0.562701
0.915509
Ͳ0.16855
Ͳ0.15488
Ͳ0.35729
Ͳ0.07688
0.487143
Ͳ0.0287
Ͳ0.9493
0.430789
Ͳ0.82557
Ͳ0.00765
0.155379
Ͳ6.64386
Ͳ0.25442
1.08158
0.212
Ͳ0.28298
Ͳ0.51805
0.168275
Ͳ0.66316
Ͳ0.27396
Ͳ0.33966
0.657427
1.626371
Ͳ0.59028
0.049289
0.821927
1.654657
0.100522
0.007605
Ͳ6.64386
0.269219
0.809177
Ͳ0.41733
Ͳ0.01192
0.432488
0.592358
Ͳ0.22361
Ͳ0.37144
0.413309
Ͳ6.64386
Ͳ0.03872
Ͳ0.55975
0.02762
Ͳ0.07933
Ͳ0.56665
0.196364
Ͳ0.58909
Ͳ6.64386
Ͳ0.34549
Ͳ0.63527
Ͳ0.71481
Ͳ6.64386
Ͳ0.70185
Ͳ0.81351
0.352296
0.597815
0.506706
Ͳ0.56992
Ͳ0.09447
Ͳ6.64386
Ͳ0.84846
0.114055
Ͳ0.46005
0.293263
Ͳ0.0387
Ͳ0.63274
105
hsaͲm
iRͲ572
0.007836
9.83EͲ04
2.122475
up
1.915842
0.77388805
Ͳ0.63824
1.487843
Ͳ0.04712
1.465924
Ͳ0.04446
Ͳ0.00986
0.209586
0.676891
Ͳ0.02196
Ͳ6.64386
Ͳ0.19402
0.581385
Ͳ6.64386
1.675743
0.480888
0.395441
Ͳ0.13141
Ͳ0.64267
0.362282
0.231037
0.827338
0.482576
Ͳ0.56648
0.785946
0.537167
Ͳ0.80968
0.611916
Ͳ0.58333
0.339218
0.52153
0.500522
Ͳ0.7415
Ͳ6.64386
0.487058
0.704502
0.421534
Ͳ0.67641
0.31574
0.346122
0.534079
Ͳ0.87812
0.264837
Ͳ0.34602
0.531419
0.420183
0.13799
0.629906
0.233033
0.173537
Ͳ0.41754
Ͳ0.70749
0.477903
Ͳ0.63542
0.723445
Ͳ0.28681
0.002561
2.495055
Ͳ6.64386
2.35509
Ͳ0.00257
1.080286
0.127215
Ͳ0.06313
0.145139
Ͳ6.64386
Ͳ0.40675
Ͳ0.33816
0.184495
Ͳ0.6324
Ͳ0.00945
Ͳ0.07827
Ͳ0.786
0.474544
Ͳ6.64386
Ͳ6.64386
Ͳ0.57877
Ͳ0.23347
0.08828
0.385843
Ͳ6.64386
Ͳ0.7749
Ͳ0.9489
Ͳ0.30298
Ͳ0.63195
Ͳ0.57657
Ͳ0.96016
Ͳ0.55588
Ͳ0.72994
0.171972
0.572086
0.20837
0.514644
Ͳ0.17202
Ͳ6.64386
Ͳ6.64386
0.680022
Ͳ0.08133
Ͳ0.49207
0.022763
Ͳ6.64386
106
hsaͲm
iRͲ361Ͳ3p
0.004367
4.85EͲ04
2.0819
up
0.551142
Ͳ0.2528198
Ͳ0.25633
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.378973
1.023033
2.387514
0.573574
1.087747
1.902149
Ͳ6.64386
2.83179
1.657993
0.177282
Ͳ0.12513
0.172276
1.292316
1.228959
0.192056
1.177556
0.893975
Ͳ6.64386
0.550322
Ͳ0.02149
0.224754
Ͳ0.58679
0.013274
1.551506
1.258812
2.976964
Ͳ0.64392
1.576785
Ͳ0.00589
Ͳ0.25803
0.532377
1.26404
0.298755
0.432395
0.320256
Ͳ1.43087
1.250032
Ͳ 0.13816
Ͳ1.2215
0.101805
0.436836
Ͳ0.49966
1.485063
Ͳ6.64386
Ͳ0.98407
0.893975
0.504558
Ͳ1.22765
1.88751
Ͳ1.00003
0.777019
2.704204
Ͳ0.8033
Ͳ6.64386
2.275038
Ͳ0.25286
Ͳ1.21429
0.580085
Ͳ0.16134
0.015618
0.414976
Ͳ0.69321
0.005865
Ͳ0.57353
Ͳ1.01644
Ͳ1.18269
Ͳ1.27156
Ͳ0.56521
Ͳ6.64386
0.419287
0.52005
Ͳ0.18759
Ͳ0.5353
Ͳ0.47526
Ͳ0.6807
Ͳ6.64386
0.41243
Ͳ0.55013
Ͳ0.82439
Ͳ0.39219
0.698911
0.421742
Ͳ0.32032
0.837925
Ͳ0.42107
Ͳ0.686
Ͳ0.12525
0.232297
Ͳ6.64386
Ͳ0.89838
0.180341
Ͳ0.40741
Ͳ0.09192
Ͳ6.64386
Ͳ0.39308
1.426034
107
hsaͲm
iRͲ4466
4.49EͲ06
1.09EͲ07
2.079208
up
2.886106
1.2467649
Ͳ1.29142
0.159692
Ͳ0.7351
0.532511
0.77871
Ͳ0.19666
0.105518
0.769573
Ͳ0.47738
Ͳ0.59755
1.109929
1.71656
Ͳ1.88558
2.195091
0.018725
Ͳ0.08807
Ͳ1.29901
Ͳ0.24883
1.620442
Ͳ0.46252
0.928108
0.796972
0.070538
0.883839
Ͳ0.12434
0.305215
0.014625
0.722694
0.237795
Ͳ0.5549
1.693821
Ͳ1.51668
0.881676
0.292764
0.863261
0.688182
Ͳ0.38373
Ͳ0.54559
0.534356
0.358476
Ͳ0.65878
0.395926
0.248346
Ͳ0.01477
0.438973
0.970828
Ͳ0.59852
0.625758
1.529224
0.468549
Ͳ0.05475
0.562769
Ͳ0.62658
0.462496
Ͳ0.4269
0.288238
2.286104
0.37295
1.298788
1.436341
1.510461
Ͳ0.62007
0.52354
0.286023
0.977293
0.447245
Ͳ0.98252
Ͳ0.627
Ͳ1.49522
Ͳ0.44676
Ͳ0.97063
Ͳ1.17967
Ͳ0.74405
Ͳ1.59598
Ͳ1.41211
Ͳ0.88991
Ͳ1.10469
Ͳ0.27332
Ͳ0.19753
0.046348
Ͳ1.58383
Ͳ2.28276
Ͳ0.28574
Ͳ1.54025
Ͳ0.36928
Ͳ1.47112
Ͳ1.06183
Ͳ0.93616
0.114773
2.068698
0.278828
Ͳ2.33575
0.461615
Ͳ0.89246
Ͳ0.64897
Ͳ0.50341
Ͳ0.12355
Ͳ0.96608
Ͳ0.20333
Ͳ1.38171
108
hsaͲm
iRͲ3940Ͳ5p
7.03EͲ06
1.89EͲ07
2.071707
up
2.353066
1.0175661
Ͳ1.16204
0.074996
Ͳ0.59782
0.121696
0.554296
Ͳ0.55322
Ͳ0.18931
0.869781
Ͳ0.45567
Ͳ 0.77832
1.375087
1.789247
Ͳ2.31422
2.144612
Ͳ0.31466
Ͳ0.52222
Ͳ1.61159
Ͳ0.61204
1.941795
Ͳ0.18856
1.049003
1.074635
0.460108
0.606894
0.451538
0.919891
Ͳ0.15943
0.928168
Ͳ0.01595
Ͳ0.68599
1.199463
Ͳ1.9018
0.666696
0.480045
0.161586
0.393579
Ͳ0.39776
Ͳ0.17471
0.628386
0.674299
Ͳ0.92457
0.083065
0.681946
Ͳ0.51706
0.428425
0.432783
Ͳ0.52467
1.083648
2.013072
0.580588
0.015778
0.402491
Ͳ0.66448
0.889922
0.251033
0.103537
1.663821
0.615984
0.715445
1.163363
0.545768
Ͳ0.17914
0.105669
0.292087
0.594085
Ͳ0.04767
Ͳ0.95748
Ͳ0.72394
Ͳ2.30595
Ͳ0.63093
Ͳ0.68211
Ͳ1.38737
Ͳ0.84157
Ͳ1.51696
Ͳ0.75911
Ͳ1.40727
Ͳ0.9939
0.146814
Ͳ0.88822
0.100033
Ͳ1.85281
Ͳ1.76644
Ͳ0.54142
Ͳ1.67485
Ͳ0.71718
Ͳ1.10012
Ͳ1.09603
Ͳ1.15904
0.430867
1.602081
0.085165
Ͳ1.71746
0.379325
Ͳ1.1258
Ͳ0.3796
0.070737
Ͳ0.29309
Ͳ0.67475
Ͳ0.59181
Ͳ1.5935
109
hsaͲm
iRͲ4707Ͳ5p
7.75EͲ06
2.16EͲ07
2.062567
up
2.952557
0.97888535
Ͳ1.13176
Ͳ0.3288
Ͳ0.73293
0.081708
0.691793
Ͳ0.2749
0.084062
1.039967
Ͳ0.37783
Ͳ0.13597
1.157698
1.867163
Ͳ2.00418
2.497291
Ͳ0.15257
Ͳ0.35863
Ͳ1.40558
Ͳ0.24122
1.910572
Ͳ0.00813
1.364004
1.12655
0.127519
0.610481
0.440281
0.704984
0.018734
0.483426
0.008082
Ͳ0.39966
1.280827
Ͳ1.48961
0.85308
0.278283
0.68535
0.723555
Ͳ0.48766
Ͳ0.14496
0.817373
0.428615
Ͳ0.59153
0.050167
0.271569
Ͳ0.21441
0.566794
0.523464
Ͳ0.51646
0.572661
1.866187
0.37816
Ͳ0.01895
0.641371
Ͳ0.96053
0.930275
0.164618
0.050823
2.096807
0.174444
1.121279
1.449083
0.741169
Ͳ0.4822
0.091009
0.478205
0.707961
0.052992
Ͳ1.17359
Ͳ0.6921
Ͳ1.2953
Ͳ0.34743
Ͳ1.51744
Ͳ1.14406
Ͳ0.52021
Ͳ1.32409
Ͳ1.03425
Ͳ0.94942
Ͳ1.32826
0.204854
Ͳ0.60967
Ͳ0.1239
Ͳ1.70688
Ͳ1.89327
Ͳ0.42298
Ͳ1.85992
Ͳ0.30138
Ͳ1.28849
Ͳ0.71087
Ͳ1.09155
0.248643
2.204468
0.317059
Ͳ1.76091
0.784965
Ͳ0.94201
Ͳ0.4577
Ͳ0.02803
Ͳ0.17471
Ͳ1.11381
Ͳ0.38956
Ͳ1.43158
110
hsaͲm
iRͲ532Ͳ5p
0.001258
1.04EͲ04
2.049957
up
Ͳ0.04972
Ͳ0.870108
Ͳ1.39468
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.670829
1.305933
1.889785
0.309177
1.936202
2.008151
Ͳ6.64386
1.759569
1.148437
0.630871
1.521955
1.63546
2.332394
1.295352
0.967637
0.296059
Ͳ0.66787
Ͳ1.59579
Ͳ0.00804
1.194564
0.739587
0.560061
1.554967
1.381512
0.662066
2.15486
Ͳ1.34535
0.811102
0.707886
1.524916
1.115172
1.519553
Ͳ0.74772
0.141937
Ͳ0.2201
Ͳ0.01307
1.161674
Ͳ0.39849
Ͳ0.85735
0.443367
0.655353
0.344816
0.812065
Ͳ6.64386
Ͳ1.09352
0.802935
1.794972
Ͳ1.03343
2.6094
Ͳ1.60026
0.653822
1.358373
Ͳ6.64386
Ͳ6.64386
2.058569
0.008
0.507287
1.072984
Ͳ0.18589
Ͳ1.01373
1.17637
Ͳ0.18825
0.087424
Ͳ0.58922
1.600258
Ͳ0.16932
Ͳ0.23752
0.548992
0.870701
Ͳ0.01438
0.390967
1.031984
Ͳ6.64386
Ͳ6.64386
Ͳ0.69895
Ͳ0.13336
Ͳ0.44814
Ͳ0.85735
Ͳ0.364
Ͳ0.38281
Ͳ0.17143
Ͳ0.16201
1.148521
Ͳ0.94865
Ͳ1.20543
Ͳ1.64094
Ͳ0.82383
Ͳ0.03826
Ͳ6.64386
Ͳ1.23878
Ͳ0.89045
Ͳ0.91772
Ͳ1.13888
Ͳ1.38645
0.425579
Ͳ0.54864
111
hsaͲm
iRͲ187Ͳ5p
4.38EͲ05
1.62EͲ06
2.040338
up
1.897285
1.8021051
Ͳ0.55537
Ͳ6.64386
Ͳ0.32476
0.469506
1.046197
2.213342
Ͳ0.33586
1.374309
0.245925
0.563921
Ͳ1.09003
1.87903
Ͳ1.60528
1.484135
Ͳ0.25642
Ͳ0.53755
Ͳ1.10939
Ͳ0.72685
0.871797
0.89907
1.743577
1.829896
1.74805
0.639051
1.189687
0.221624
0.205752
0.506077
1.231016
1.513651
0.902595
Ͳ0.74185
0.367219
0.822223
0.775901
0.461603
Ͳ1.09179
0.104715
0.793085
0.429625
Ͳ1.05787
0.614988
0.665607
Ͳ0.12759
0.912937
0.704092
Ͳ0.05212
Ͳ1.11753
1.664579
0.489004
Ͳ0.4985
0.439489
Ͳ0.39354
1.018061
0.289585
1.866892
0.522474
Ͳ0.60348
1.028116
1.308845
Ͳ0.26669
Ͳ0.45744
Ͳ0.03612
0.870767
Ͳ1.50944
Ͳ1.25771
Ͳ0.04424
Ͳ0.73446
Ͳ0.73693
0.129581
Ͳ2.34621
Ͳ0.1878
Ͳ0.13781
Ͳ1.27965
Ͳ0.95478
Ͳ0.15567
Ͳ0.72454
0.282521
Ͳ0.53716
Ͳ0.80962
Ͳ0.65768
Ͳ1.66385
Ͳ0.68719
Ͳ1.61759
Ͳ0.33004
Ͳ1.88369
Ͳ1.03919
Ͳ0.56306
0.106331
1.662843
0.056341
Ͳ1.50219
Ͳ0.8403
Ͳ1.06863
Ͳ0.50203
0.708739
Ͳ 0.1229
Ͳ0.69916
0.035234
Ͳ0.72144
112
hsaͲm
iRͲ33bͲ3p
0.001779
1.60EͲ04
2.029654
up
1.518291
Ͳ0.3303604
0.328109
2.327134
1.399134
3.319998
0.037341
0.469445
Ͳ0.15268
Ͳ0.1029
Ͳ0.47945
Ͳ1.00161
1.541649
Ͳ0.39018
Ͳ0.797
Ͳ0.24036
Ͳ0.0293
0.472071
Ͳ0.00564
Ͳ0.20807
0.82476
Ͳ0.15099
Ͳ0.40545
Ͳ0.66557
0.13937
1.070156
Ͳ0.50566
0.172415
1.133815
0.0655
Ͳ0.10018
0.062333
0.280513
0.039965
Ͳ0.03277
0.175418
0.027578
0.665413
Ͳ0.16862
0.861359
0.299287
0.276211
0.3479
1.53816
0.757378
0.69457
1.129082
1.124009
0.737805
1.573873
Ͳ0.53882
0.711392
Ͳ0.12612
Ͳ0.30322
0.421144
0.531387
0.800098
Ͳ0.12524
Ͳ0.09345
0.101208
0.181441
2.162939
Ͳ0.76009
0.173388
1.085151
Ͳ0.145
0.019124
Ͳ0.22422
Ͳ0.43349
0.806967
Ͳ0.68737
Ͳ0.07568
1.343627
Ͳ0.82888
Ͳ0.03158
Ͳ1.20206
Ͳ0.42302
Ͳ0.14831
Ͳ0.02569
Ͳ0.3809
Ͳ0.6221
Ͳ0.37094
Ͳ0.7311
Ͳ0.09062
Ͳ0.84703
0.005622
0.189719
0.372053
Ͳ1.06088
Ͳ0.35568
Ͳ0.23178
0.389292
Ͳ6.64386
0.083422
Ͳ6.64386
Ͳ0.48515
Ͳ6.64386
0.642557
Ͳ0.80828
Ͳ0.88825
Ͳ0.39334
0.312803
113
hsaͲm
iRͲ718
0.001673
1.47EͲ04
2.019544
up
1.132979
Ͳ0.1240363
Ͳ0.45238
0.365855
0.093018
Ͳ0.24075
Ͳ0.46863
0.040215
0.259314
0.819615
Ͳ0.23479
Ͳ0.74069
0.576797
1.192887
Ͳ1.60693
1.051816
0.011387
0.528475
Ͳ0.57116
Ͳ0.03019
0.839539
0.568891
1.251701
1.271092
Ͳ0.47765
1.048072
0.991834
Ͳ0.40365
0.854192
Ͳ0.01199
0.079831
0.34767
0.753129
Ͳ0.98861
0.526352
0.77533
1.31799
1.166205
Ͳ0.59313
Ͳ0.43256
1.2946
0.46297
Ͳ1.24653
0.503155
0.05457
0.101844
0.693962
Ͳ0.01964
0.360077
Ͳ0.34026
0.479766
0.385976
Ͳ0.67703
0.775115
Ͳ0.34822
0.988236
Ͳ0.23846
0.330208
1.868939
Ͳ6.64386
0.859887
1.218526
0.499613
Ͳ0.59976
0.166633
0.585701
Ͳ6.64386
Ͳ1.2403
Ͳ0.12371
Ͳ0.03708
Ͳ0.15348
0.807705
Ͳ0.9264
Ͳ0.28724
0.933708
Ͳ0.82395
Ͳ1.52134
Ͳ 0.40459
Ͳ6.64386
0.168065
Ͳ0.2
Ͳ0.67688
Ͳ1.16814
Ͳ0.42518
0.026702
Ͳ0.82354
Ͳ0.08126
Ͳ1.57792
Ͳ0.88
Ͳ0.34547
Ͳ0.04814
0.604987
Ͳ0.01148
Ͳ0.23189
0.562561
Ͳ0.79693
Ͳ6.64386
0.235468
Ͳ0.19611
Ͳ0.76824
0.409041
Ͳ6.64386
114
hsaͲm
iRͲ1538
0.022286
0.003652
2.002481
up
Ͳ6.64386
Ͳ0.2691517
Ͳ0.19003
Ͳ6.64386
0.487509
2.162651
0.931877
Ͳ0.40675
0.448548
1.369251
Ͳ0.28032
Ͳ0.84313
0.459008
0.851595
Ͳ0.19932
0.533889
1.059274
0.462255
0.952478
0.845214
0.249772
Ͳ0.33519
0.542876
1.379652
Ͳ0.30862
Ͳ0.23141
0.722042
0.498657
0.403828
Ͳ0.35071
Ͳ0.04123
0.169832
Ͳ0.33327
1.398966
0.471719
0.047738
Ͳ6.64386
1.309024
Ͳ0.14846
Ͳ0.58337
0.518295
Ͳ0.2675
Ͳ0.08684
Ͳ0.19997
0.026897
0.281977
Ͳ0.08693
Ͳ6.64386
0.149664
Ͳ6.64386
0.142496
0.487022
Ͳ6.64386
0.587785
Ͳ0.27576
1.052445
0.27053
0.132755
0.702134
Ͳ0.55803
0.171118
Ͳ0.09618
Ͳ6.64386
Ͳ0.40361
0.598758
0.626706
Ͳ0.22323
Ͳ0.63742
Ͳ0.40258
0.309024
0.504543
0.27005
0.21993
Ͳ6.64386
Ͳ0.33249
Ͳ0.3768
0.01078
0.16583
0.022622
1.215821
Ͳ6.64386
0.043064
Ͳ0.79062
Ͳ0.55045
Ͳ0.78562
0.317574
0.373624
Ͳ0.82475
Ͳ0.6977
Ͳ0.62095
Ͳ0.1661
0.262222
0.464418
Ͳ0.0129
Ͳ6.64386
Ͳ0.60604
Ͳ0.12314
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.207937
Ͳ0.01086
115
hsaͲm
iRͲ27bͲ3p
0.001741
1.55EͲ04
2.012356
dow
n
Ͳ1.26981
0.79666317
1.57606
Ͳ3.02055
Ͳ6.64386
Ͳ4.72416
Ͳ1.56252
0.056054
0.107856
0.651323
Ͳ0.37351
Ͳ0.4993
Ͳ3.86202
Ͳ1.31133
0.474148
Ͳ0.79429
Ͳ0.2317
1.101021
Ͳ0.33952
Ͳ0.02593
Ͳ0.01595
Ͳ0.97411
0.085502
Ͳ1.01325
Ͳ0.87344
Ͳ0.29779
Ͳ0.58257
0.956899
Ͳ1.17284
Ͳ0.72351
0.60641
Ͳ1.80771
Ͳ3.12191
0.260126
Ͳ1.17652
Ͳ1.04267
0.313899
Ͳ0.17397
0.565463
0.658847
0.262749
Ͳ 0.59575
Ͳ0.00508
1.166903
0.421192
1.023712
Ͳ0.39344
0.57786
0.408345
Ͳ6.64386
Ͳ0.83045
Ͳ1.41466
0.411324
0.281288
0.238519
0.748278
0.186033
Ͳ1.04451
Ͳ6.64386
Ͳ2.03921
Ͳ0.04321
Ͳ1.30287
Ͳ2.10042
Ͳ1.33636
1.213793
1.584962
Ͳ1.78774
Ͳ3.08579
1.483213
1.078688
2.060654
1.513959
1.532379
2.205495
Ͳ0.26212
0.702888
Ͳ0.18423
Ͳ1.16312
1.084114
0.005063
0.985185
Ͳ1.72538
0.700753
0.865091
1.718491
1.167361
1.005149
0.984624
0.935707
0.959227
0.039455
Ͳ0.67916
Ͳ0.56536
Ͳ0.52585
Ͳ2.27816
Ͳ0.71513
0.599046
0.503399
0.725056
0.826108
Ͳ0.58245
0.715335
116
hsaͲm
iRͲ3149
1.18EͲ04
5.33EͲ06
2.016392
dow
n
0.30365
1.0570468
0.062376
4.539683
2.038397
3.156897
0.487923
0.906474
Ͳ0.91603
Ͳ1.81673
Ͳ0.06042
Ͳ1.1473
Ͳ0.95351
Ͳ0.6085
0.336097
Ͳ0.99393
Ͳ1.60791
Ͳ0.57813
Ͳ0.17245
Ͳ0.21868
Ͳ1.47208
0.687316
Ͳ1.22089
Ͳ0.98473
0.078304
Ͳ1.80988
Ͳ1.3394
Ͳ0.30934
Ͳ0.11565
Ͳ0.60904
0.568582
Ͳ0.01504
0.700529
0.67546
Ͳ0.37819
Ͳ0.56399
Ͳ0.45231
Ͳ2.50521
0.545253
0.130076
Ͳ 1.86839
Ͳ1.57167
0.374571
Ͳ0.53951
0.016747
Ͳ0.14443
Ͳ0.90193
0.941173
Ͳ0.11767
Ͳ3.49621
Ͳ1.18765
Ͳ0.14788
0.532692
Ͳ0.6555
Ͳ0.29022
Ͳ1.95443
Ͳ0.70972
0.258506
Ͳ6.64386
2.563517
Ͳ1.47632
Ͳ1.59172
1.034297
Ͳ0.01633
Ͳ0.35645
Ͳ0.57611
Ͳ0.50702
0.067418
0.761028
0.304295
1.401625
Ͳ0.86712
0.228128
0.811337
Ͳ2.10443
0.351839
0.311393
0.39324
1.060157
Ͳ0.51933
1.675566
0.731221
0.790689
Ͳ0.48548
1.026968
0.517566
0.181521
Ͳ0.20106
0.014886
0.441254
0.585039
Ͳ0.8723
Ͳ0.08876
0.401685
0.662751
2.392624
0.919332
0.378906
0.846154
0.736804
1.142166
0.224298
117
hsaͲm
iRͲ3126Ͳ3p
0.005012
5.70EͲ04
2.052046
dow
n
Ͳ0.88174
0.5461282
Ͳ0.7562
1.998511
1.241373
3.394584
Ͳ3.35EͲ05
0.078031
Ͳ6.64386
Ͳ0.43685
3.35EͲ05
Ͳ6.64386
2.870881
Ͳ6.64386
0.04972
Ͳ0.821
0.101001
Ͳ1.69751
Ͳ1.76767
Ͳ1.60236
Ͳ1.22817
Ͳ1.05129
Ͳ0.56642
Ͳ0.39418
Ͳ0.62574
Ͳ1.67898
Ͳ0.17094
Ͳ0.86247
0.286807
Ͳ0.68975
Ͳ0.93421
Ͳ1.40596
1.547287
Ͳ0.54536
Ͳ0.12381
Ͳ0.1733
0.393598
Ͳ1.07376
Ͳ1.37705
0.487126
0.558951
0.771702
Ͳ1.25284
0.185345
Ͳ0.88917
Ͳ0.49051
Ͳ0.12572
0.915815
Ͳ0.65312
6.13515
0.75319
Ͳ6.64386
0.866905
0.043953
Ͳ0.92285
0.947959
0.63197
Ͳ1.25988
1.27381
0.548564
Ͳ0.06365
Ͳ1.56997
0.286702
Ͳ0.82246
0.096992
0.008078
Ͳ0.6305
Ͳ1.39711
0.141382
0.139833
0.34903
0.825175
Ͳ1.96074
0.676594
1.309641
0.00189
1.920651
Ͳ0.38925
1.396427
Ͳ0.50841
1.556485
Ͳ0.3383
0.753905
1.521338
0.4542
Ͳ0.68605
Ͳ0.33189
Ͳ1.26522
0.12691
0.044901
1.180348
Ͳ0.30446
Ͳ0.07469
Ͳ0.80053
1.649003
1.617517
0.990667
1.325082
1.874664
1.238566
1.195859
Ͳ0.15975
118
hsaͲm
iRͲ454Ͳ3p
0.002884
2.92EͲ04
2.117273
dow
n
1.298576
0.94345605
Ͳ0.18786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.292698
1.002965
0.168303
Ͳ1.23934
0.577385
Ͳ0.30624
Ͳ0.90234
Ͳ2.06745
1.185068
Ͳ2.21653
Ͳ1.76757
Ͳ1.03708
0.885655
Ͳ0.71604
Ͳ0.99666
0.469005
Ͳ1.00573
Ͳ1.78411
0.848274
Ͳ1.69173
Ͳ1.39314
Ͳ0.34052
Ͳ1.69173
0.451194
0.373536
0.848422
0.15587
Ͳ0.40036
Ͳ0.11945
0.239733
0.211872
Ͳ1.19234
0.857054
0.806067
Ͳ1.58428
Ͳ0.49755
0.391202
Ͳ1.24039
Ͳ0.68186
Ͳ0.21067
Ͳ0.68095
Ͳ0.8891
0.551957
Ͳ0.06809
Ͳ1.66492
Ͳ0.53771
0.790771
Ͳ0.71027
0.107423
Ͳ1.38467
Ͳ1.51451
0.844353
Ͳ6.64386
Ͳ0.83912
Ͳ0.73461
Ͳ1.49607
2.697434
1.551265
Ͳ1.5192
Ͳ1.08534
Ͳ0.56609
0.848346
3.616093
1.143797
2.750768
2.413401
Ͳ1.36767
0.652893
0.474406
1.560831
0.472948
1.481219
1.560729
Ͳ1.76858
0.715824
0.572487
1.853831
0.141716
0.411521
0.731797
1.455712
Ͳ0.5585
Ͳ1.87813
Ͳ0.28195
0.065018
Ͳ1.37007
Ͳ0.12286
Ͳ0.08502
Ͳ1.6743
1.589802
1.813177
0.215886
1.031091
0.678421
0.069118
0.6927
119
hsaͲm
iRͲ595
0.001086
8.75EͲ 05
2.123006
dow
n
0.302087
1.3916117
Ͳ0.02039
2.946474
1.156945
Ͳ6.64386
0.938995
0.673524
Ͳ0.30499
Ͳ1.04662
0.62101
Ͳ0.07592
Ͳ0.59523
Ͳ0.54249
0.576156
Ͳ6.64386
Ͳ1.44938
Ͳ0.67484
Ͳ0.19543
Ͳ0.17004
Ͳ0.77279
0.323787
Ͳ1.17374
Ͳ0.70769
0.518912
Ͳ1.678
Ͳ1.42735
0.020106
Ͳ0.91504
0.135583
1.080088
Ͳ0.30499
0.608336
0.421634
Ͳ0.12531
Ͳ0.81711
Ͳ6.64386
Ͳ0.78913
0.764645
0.415691
Ͳ1.31798
Ͳ1.06373
0.385562
Ͳ6.64386
Ͳ0.67733
Ͳ0.78026
Ͳ1.36885
0.74051
Ͳ0.33154
Ͳ0.94975
Ͳ0.65197
Ͳ0.50122
0.580811
Ͳ0.38338
0.553706
Ͳ6.64386
Ͳ0.18044
0.511838
Ͳ6.64386
1.497381
Ͳ1.37297
Ͳ1.61987
1.108062
0.661251
Ͳ0.53064
Ͳ0.60621
Ͳ0.29225
Ͳ0.37703
1.044454
0.198593
1.301479
Ͳ1.45076
0.498598
1.096331
Ͳ6.64386
0.797799
1.22231
0.416341
0.562835
Ͳ0.40922
1.085649
0.58957
0.619119
Ͳ0.44938
0.897247
0.406725
0.374773
0.330775
0.508741
0.367366
1.079745
Ͳ0.75313
Ͳ0.21102
0.38134
Ͳ0.19156
1.737621
1.012179
Ͳ0.09471
1.219709
0.44741
0.827583
0.167349
120
hsaͲm
iRͲ5011Ͳ5p
2.97EͲ04
1.72EͲ05
2.12799
dow
n
Ͳ1.77005
Ͳ1.0371319
0.71404
Ͳ0.38095
Ͳ6.64386
Ͳ6.64386
Ͳ0.67594
Ͳ0.06976
Ͳ0.6616
Ͳ0.55188
0.167536
0.217659
Ͳ6.64386
Ͳ1.0955
Ͳ0.52434
Ͳ1.17956
Ͳ0.95111
Ͳ1.65009
Ͳ0.39645
Ͳ0.48454
Ͳ0.53438
0.183218
Ͳ0.81986
0.781119
Ͳ0.08508
Ͳ1.33877
Ͳ0.36298
1.13106
Ͳ1.39889
Ͳ0.62983
0.198949
Ͳ0.35853
Ͳ0.28394
Ͳ1.22795
Ͳ1.3981
Ͳ0.0137
0.210004
Ͳ0.16139
1.487516
Ͳ1.00669
0.073847
0.535268
0.245245
Ͳ0.36746
0.011417
0.720019
Ͳ0.01151
Ͳ0.09175
0.050352
Ͳ6.64386
0.492805
0.176935
Ͳ0.87386
0.470928
Ͳ1.71604
0.147996
0.728652
Ͳ0.21719
Ͳ6.64386
Ͳ6.64386
0.697122
Ͳ1.21369
Ͳ0.6204
Ͳ0.81547
0.529151
0.319416
0.17538
Ͳ6.64386
0.603152
0.489464
Ͳ0.90186
0.603174
Ͳ1.39494
Ͳ0.65067
0.395329
Ͳ0.44826
1.05988
Ͳ0.20106
0.585992
0.426039
0.89344
0.590098
Ͳ1.0934
1.443528
0.476874
1.600646
0.076954
0.684656
0.396194
0.828086
0.462463
0.999082
0.149881
0.404575
0.901337
0.312533
0.783295
Ͳ0.45638
0.269165
1.498936
0.429347
0.72442
121
hsaͲm
iRͲ134
0.010971
0.001605
2.169331
dow
n
0.20898
0.46790266
1.95676
Ͳ6.64386
1.527114
Ͳ6.64386
0.130431
0.695059
Ͳ0.80279
Ͳ0.1078
0.40561
Ͳ6.64386
Ͳ6.64386
Ͳ0.59439
1.100756
Ͳ0.48101
Ͳ0.61992
Ͳ0.19789
Ͳ0.52563
Ͳ0.87325
Ͳ0.52513
0.397705
Ͳ0.88296
Ͳ0.00157
0.171555
Ͳ0.22998
Ͳ0.77546
0.001564
Ͳ0.25597
0.286311
Ͳ0.62187
0.197211
0.205938
1.032152
Ͳ0.90626
0.586183
Ͳ6.64386
Ͳ6.64386
0.666696
Ͳ0.27399
Ͳ6.64386
Ͳ0.13355
Ͳ0.38881
0.533258
Ͳ0.0318
0.227998
Ͳ0.65781
1.223893
0.073414
Ͳ6.64386
Ͳ0.84952
Ͳ0.68185
1.491025
Ͳ0.35543
1.390713
Ͳ0.69485
Ͳ6.64386
0.285375
1.448736
Ͳ0.82325
Ͳ0.83229
Ͳ0.2954
1.865372
0.041272
Ͳ0.83317
Ͳ6.64386
Ͳ0.71381
0.76528
0.108841
0.353143
0.169129
0.49592
1.647619
0.482666
Ͳ0.44453
Ͳ0.17822
Ͳ 0.23229
0.23335
0.923869
1.08562
1.769383
0.747458
1.975044
2.027099
0.29505
0.684247
Ͳ0.72544
Ͳ0.02023
1.484143
Ͳ0.54402
Ͳ0.04921
0.154474
Ͳ0.04117
1.398724
Ͳ6.64386
1.979853
Ͳ0.67139
Ͳ1.2032
0.048237
0.431547
0.098174
0.42405
122
hsaͲm
iRͲ4701Ͳ3p
9.92EͲ05
4.18EͲ06
2.177509
dow
n
0.329428
1.3712337
Ͳ0.51478
3.538029
2.423956
Ͳ6.64386
0.359132
0.526141
Ͳ0.27013
Ͳ6.64386
0.104854
Ͳ0.52818
1.014323
Ͳ1.07348
0.37506
Ͳ1.01316
Ͳ1.03796
Ͳ0.48368
Ͳ1.06746
0.14397
Ͳ0.30086
Ͳ0.17533
Ͳ0.69282
Ͳ0.73055
Ͳ0.43558
Ͳ0.9871
Ͳ1.53
Ͳ0.19296
Ͳ1.18504
Ͳ0.1064
0.249877
Ͳ6.64386
1.150679
5.17EͲ04
0.763185
Ͳ0.54005
0.501415
Ͳ0.36389
0.544003
0.30864
Ͳ0.14151
Ͳ0.56136
0.487535
0.185196
Ͳ6.64386
Ͳ0.16077
Ͳ0.82952
0.600814
Ͳ0.26867
0.903963
Ͳ0.86099
Ͳ0.45468
0.39663
Ͳ0.26867
Ͳ0.01828
Ͳ0.28468
Ͳ0.67283
0.1941
Ͳ0.48006
1.118112
Ͳ0.85596
Ͳ0.72801
0.935768
Ͳ0.01981
Ͳ5.17EͲ04
0.384585
Ͳ0.37809
Ͳ0.37442
1.30246
0.708862
1.74943
Ͳ0.3826
0.082795
1.543776
Ͳ0.38271
0.80786
1.220762
0.633719
0.833532
Ͳ0.6408
1.529503
1.03224
0.539386
Ͳ0.76132
1.397365
0.599325
0.744094
Ͳ0.05138
0.082058
0.262263
1.118424
Ͳ0.0725
0.719702
Ͳ0.58961
1.102239
1.874217
0.874389
Ͳ0.48728
1.155195
0.958237
1.137908
Ͳ0.13568
123
hsaͲm
iRͲ331Ͳ3p
9.31EͲ04
6.97EͲ05
2.204815
dow
n
Ͳ0.09353
Ͳ0.1482702
Ͳ0.53206
Ͳ6.64386
Ͳ6.64386
Ͳ1.7983
0.595305
0.43311
0.12709
Ͳ0.09928
1.136705
Ͳ0.35102
Ͳ6.64386
0.231565
0.205092
Ͳ0.21702
Ͳ0.99037
0.00414
1.640112
0.248161
Ͳ0.04382
0.08171
0.445451
Ͳ2.19513
Ͳ0.6555
Ͳ0.09489
Ͳ1.05646
Ͳ1.53816
0.321844
Ͳ0.77219
0.969025
1.193799
Ͳ0.90712
0.805904
Ͳ0.85609
0.298202
Ͳ0.93787
0.3311
Ͳ1.6278
Ͳ1.26969
Ͳ0.22379
Ͳ1.28967
Ͳ0.82177
0.054109
Ͳ1.23231
Ͳ0.51164
0.134763
Ͳ0.71988
0.550968
Ͳ6.64386
Ͳ1.51958
8.16EͲ04
Ͳ0.40198
0.219346
0.364688
Ͳ1.3063
Ͳ1.1541
Ͳ0.02021
Ͳ6.64386
Ͳ6.64386
0.253241
Ͳ0.52075
0.573129
0.980541
Ͳ0.34778
0.454957
Ͳ0.23572
Ͳ0.81662
1.22571
0.790055
1.950619
1.041961
0.422772
0.356921
Ͳ0.19819
0.61113
0.606291
1.409773
0.337951
Ͳ1.69021
Ͳ0.57359
Ͳ0.46275
0.409861
0.989231
Ͳ0.04493
0.689569
1.046616
0.635343
0.972688
2.247124
Ͳ0.73744
Ͳ8.16EͲ04
1.231864
0.542509
Ͳ1.87499
0.753631
1.273035
Ͳ0.41984
0.512251
Ͳ0.36696
0.053157
1.091916
124
hsaͲm
iRͲ4489
0.008561
0.001149
2.226271
dow
n
Ͳ6.64386
Ͳ6.643856
0.658586
Ͳ6.64386
0.583419
0.637764
Ͳ0.7839
0.409971
Ͳ0.6995
Ͳ0.50824
Ͳ0.37495
Ͳ1.12251
0.655345
Ͳ6.64386
0.231178
0.28589
Ͳ0.911
Ͳ0.67899
Ͳ0.44555
Ͳ0.55281
Ͳ0.55634
0.923132
Ͳ0.25204
2.365275
Ͳ1.30528
Ͳ0.86209
0.685016
0.691378
Ͳ1.09656
0.204476
Ͳ6.64386
Ͳ0.66708
Ͳ6.64386
0.332924
Ͳ0.17693
0.38178
Ͳ6.64386
Ͳ0.089
0.944762
0.204476
0.065185
1.050681
0.04947
0.306844
1.728409
Ͳ0.14472
Ͳ0.49826
0.305639
Ͳ0.74312
0.426233
0.101737
0.019457
0.273831
Ͳ0.05281
Ͳ0.22582
0.815575
0.083073
Ͳ0.786
Ͳ6.64386
Ͳ0.47279
Ͳ0.27271
Ͳ6.64386
0.747945
Ͳ0.06569
Ͳ6.64386
Ͳ0.15963
Ͳ0.32547
Ͳ0.16006
Ͳ0.18031
0.481316
Ͳ0.26606
0.958738
Ͳ0.1207
Ͳ0.01972
0.461572
Ͳ0.17661
Ͳ0.12749
0.436717
1.43259
0.859316
0.741309
1.289265
0.604926
0.076615
1.256401
Ͳ0.33547
0.285796
Ͳ0.97884
Ͳ0.08068
Ͳ0.1908
0.249683
Ͳ0.23358
0.836243
0.610767
3.599657
2.767459
0.060743
1.625866
0.27868
2.204561
0.190607
Ͳ0.33245
125
hsaͲm
iRͲ98
9.47EͲ04
7.18EͲ05
2.361425
dow
n
0.614916
0.8835002
0.596174
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ1.41532
Ͳ0.17524
Ͳ0.21647
Ͳ2.13771
2.054571
1.005983
Ͳ6.64386
Ͳ6.64386
1.588764
0.096743
Ͳ1.13799
Ͳ0.59101
0.439921
Ͳ0.45146
Ͳ1.1695
0.136127
1.243778
Ͳ0.83788
Ͳ1.34729
Ͳ0.12953
Ͳ0.71449
0.977383
Ͳ1.23263
Ͳ1.56249
1.27183
Ͳ0.32822
Ͳ0.6427
0.400982
Ͳ6.64386
1.279481
0.434102
Ͳ2.23645
0.491956
0.421967
Ͳ1.73915
Ͳ0.27637
0.050057
0.246859
Ͳ1.9555
0.58191
Ͳ0.9971
Ͳ1.9617
Ͳ0.9911
Ͳ6.64386
Ͳ6.64386
0.622069
0.007987
Ͳ1.86309
1.04816
Ͳ0.53811
0.14267
Ͳ0.08423
Ͳ6.64386
0.544672
Ͳ0.00803
Ͳ6.64386
2.149321
Ͳ2.51502
Ͳ1.96106
Ͳ0.95973
Ͳ2.24315
Ͳ6.64386
2.330163
2.06499
Ͳ6.64386
1.043729
0.395784
1.427217
Ͳ0.10191
2.236234
1.359935
1.305928
Ͳ1.7053
Ͳ0.21748
0.692517
Ͳ6.64386
0.881884
0.938702
0.840987
1.616075
1.366715
0.562912
Ͳ0.62218
1.140002
0.606352
Ͳ1.33685
0.50082
1.45543
1.366793
0.808173
0.690479
Ͳ0.0379
Ͳ0.1499
0.332261
0.745143
1.052152
126
hsaͲm
iRͲ196bͲ3p
0.035312
0.006363
2.420995
dow
n
Ͳ0.02615
0.8544895
Ͳ0.17564
Ͳ6.64386
0.551105
2.03445
0.588173
0.067795
Ͳ0.27891
0.354865
0.460679
0.614941
Ͳ6.64386
Ͳ6.64386
0.402673
Ͳ0.31144
Ͳ6.64386
0.305497
Ͳ0.10588
Ͳ6.64386
Ͳ6.64386
0.102413
0.069016
0.163813
0.509588
Ͳ6.64386
Ͳ0.05335
0.342581
Ͳ0.06299
Ͳ0.00826
0.482107
0.069016
Ͳ6.64386
0.980479
Ͳ6.64386
Ͳ0.00498
0.273521
Ͳ0.01236
Ͳ0.39438
Ͳ0.29777
Ͳ6.64386
Ͳ0.31533
Ͳ0.37794
0.004968
Ͳ0.30333
0.14758
0.446736
0.336718
Ͳ0.197
Ͳ6.64386
Ͳ0.34987
0.007088
Ͳ0.06434
0.092503
Ͳ6.64386
0.200541
0.005115
0.574505
Ͳ6.64386
0.122491
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.340083
0.223549
Ͳ0.16848
Ͳ6.64386
Ͳ0.02186
Ͳ6.64386
0.697369
Ͳ0.15187
1.041123
3.515998
0.214858
0.293326
Ͳ0.15921
2.293079
0.349145
0.825958
4.064089
0.325304
Ͳ0.47197
Ͳ0.32969
Ͳ0.08048
0.512219
0.372882
0.642544
Ͳ0.33368
Ͳ6.64386
Ͳ0.19343
Ͳ6.64386
0.992159
1.057265
0.070704
1.340709
0.606313
0.494929
1.366293
127
hsaͲm
iRͲ505Ͳ3p
0.030783
0.005417
2.509697
dow
n
0.419352
0.4337105
0.763693
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.495971
0.410624
Ͳ0.15549
Ͳ1.05324
1.543095
0.701482
Ͳ6.64386
Ͳ0.18997
0.691071
Ͳ1.31356
0.100846
0.596739
0.525468
0.480999
Ͳ6.64386
0.277174
0.640366
Ͳ6.64386
Ͳ6.64386
Ͳ0.7358
Ͳ1.15734
Ͳ0.33237
Ͳ6.64386
0.188403
0.437762
Ͳ0.07749
Ͳ6.64386
0.941368
Ͳ0.47274
0.092434
0.451976
0.428037
Ͳ0.63354
Ͳ0.01038
Ͳ1.41496
Ͳ0.07169
0.12002
Ͳ6.64386
Ͳ6.64386
Ͳ0.11138
0.088746
1.195044
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.3576
Ͳ0.02909
1.023272
1.057094
Ͳ6.64386
Ͳ0.61591
Ͳ0.1387
Ͳ6.64386
Ͳ6.64386
0.066036
0.56938
1.03822
0.52234
0.010303
Ͳ6.64386
0.610051
Ͳ6.64386
2.017436
0.545607
Ͳ0.58788
Ͳ6.64386
Ͳ6.64386
0.28705
Ͳ6.64386
0.2664
1.621009
1.339393
Ͳ0.03525
Ͳ1.31744
1.046977
0.817164
0.731123
Ͳ0.26136
1.421164
0.311408
1.002782
1.55757
1.228122
1.375825
Ͳ0.50117
Ͳ6.64386
Ͳ0.36818
0.955617
Ͳ0.33715
Ͳ0.68074
0.849161
Ͳ0.10134
1.009612
Ͳ0.05183
1.470129
0.876756
128
hsaͲm
iRͲ4639Ͳ3p
0.046873
0.008718
2.577534
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
2.177031
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.529056
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.494563
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.437827
2.337277
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.633474
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.246667
Ͳ6.64386
2.101275
Ͳ6.64386
129
hsaͲm
iRͲ4753Ͳ5p
0.004079
4.41EͲ04
2.579822
dow
n
Ͳ0.56765
0.25857008
Ͳ0.2822
2.301876
0.197485
0.168165
0.285776
Ͳ0.01412
Ͳ6.64386
Ͳ0.68761
0.429495
0.21292
Ͳ6.64386
Ͳ0.5514
0.563247
Ͳ6.64386
Ͳ0.77113
Ͳ0.37663
0.014055
Ͳ6.64386
Ͳ6.64386
Ͳ0.15075
Ͳ0.20176
Ͳ0.43085
Ͳ0.1936
Ͳ0.70602
Ͳ6.64386
0.568591
Ͳ0.84352
0.084484
Ͳ0.00564
Ͳ0.20176
0.814785
1.15732
Ͳ0.11333
Ͳ0.79932
Ͳ6.64386
Ͳ6.64386
0.666994
0.174681
0.051268
0.420157
Ͳ0.38568
Ͳ0.32666
Ͳ6.64386
Ͳ0.42265
Ͳ0.31002
0.571426
Ͳ0.24539
1.101417
0.110561
Ͳ0.10543
0.438342
0.400975
Ͳ0.11212
Ͳ0.73914
0.424757
Ͳ0.05339
Ͳ0.05435
Ͳ0.35379
Ͳ0.40098
Ͳ0.14948
0.467774
0.22975
0.12449
0.659587
0.291973
Ͳ0.49321
0.005622
0.408737
Ͳ0.03919
Ͳ0.37032
Ͳ0.79175
Ͳ0.03258
Ͳ0.48487
0.458149
0.591548
0.404344
0.477253
0.596314
0.835179
0.307228
0.29951
Ͳ1.02583
1.016064
0.702413
Ͳ0.3826
0.112656
0.090268
Ͳ0.01995
0.868196
Ͳ0.00632
0.366145
Ͳ0.21436
0.214712
0.379079
0.812319
Ͳ0.06828
0.96326
1.470555
0.679243
0.241637
130
hsaͲm
iRͲ568
6.07EͲ04
4.06EͲ05
2.588553
dow
n
0.554108
1.8036497
0.412796
4.938838
0.428726
Ͳ0.5793
1.466576
1.921755
Ͳ1.3056
Ͳ2.18317
0.635562
Ͳ1.63343
Ͳ2.82039
Ͳ1.33952
1.107797
Ͳ1.78052
Ͳ2.64799
Ͳ0.61633
0.149104
Ͳ1.15589
Ͳ1.96823
1.26539
Ͳ1.87038
Ͳ0.83895
0.794542
Ͳ1.51465
Ͳ1.86346
0.119176
Ͳ0.19503
0.107624
0.747657
Ͳ0.02908
1.15944
1.146426
Ͳ1.08107
Ͳ0.49043
Ͳ0.47386
Ͳ3.14441
0.857538
Ͳ0.07226
Ͳ1.34844
Ͳ1.06095
Ͳ0.22564
Ͳ0.24933
0.374768
0.168588
Ͳ0.91422
2.006103
0.028505
Ͳ6.64386
Ͳ0.77127
Ͳ0.84202
1.752981
Ͳ0.59208
Ͳ0.09935
Ͳ2.56537
Ͳ0.66445
Ͳ0.31472
Ͳ6.64386
3.007619
Ͳ1.74196
Ͳ2.97984
2.075717
Ͳ0.26476
Ͳ0.71572
Ͳ0.44899
Ͳ0.28038
0.194699
1.030174
0.412541
1.466475
Ͳ0.95566
Ͳ0.24312
1.544893
Ͳ2.09201
0.427763
1.143428
0.249842
1.782257
Ͳ0.84194
2.36313
1.256324
1.686301
0.943198
1.86839
0.489212
Ͳ0.15016
Ͳ0.64299
1.008923
0.184994
1.268817
Ͳ0.81407
Ͳ0.09271
0.118627
1.674655
3.242322
1.333897
0.528957
1.827516
1.19115
1.973541
Ͳ0.09699
131
hsaͲm
iRͲ889
0.022175
0.003622
2.626288
dow
n
Ͳ6.64386
Ͳ6.643856
1.993608
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.601054
3.749028
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.241535
3.157415
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.394487
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
132
hsaͲm
iRͲ3664Ͳ3p
0.046873
0.008718
2.658377
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
3.668351
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.475301
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.316792
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.405497
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.686996
Ͳ6.64386
1.943202
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.939427
Ͳ6.64386
2.810619
Ͳ6.64386
Ͳ6.64386
1.905164
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.06545
Ͳ6.64386
Ͳ6.64386
133
hsaͲm
iRͲ1273f
0.0043
4.76EͲ04
2.661917
dow
n
Ͳ6.64386
Ͳ0.4418034
Ͳ0.20407
1.490435
5.290788
2.635978
Ͳ0.47696
Ͳ0.41966
0.677556
Ͳ0.62012
Ͳ0.9663
0.929619
Ͳ6.64386
0.525553
0.078094
Ͳ0.23274
Ͳ6.64386
Ͳ0.00519
0.039723
0.744193
Ͳ0.05941
Ͳ0.15726
Ͳ0.46604
Ͳ0.01287
Ͳ0.03865
Ͳ0.18947
Ͳ0.79638
0.121506
Ͳ6.64386
0.071835
0.926915
0.355628
Ͳ6.64386
Ͳ0.19186
Ͳ0.31288
Ͳ1.0121
Ͳ6.64386
Ͳ0.58136
0.332073
Ͳ6.64386
Ͳ6.64386
Ͳ0.58734
0.538492
Ͳ6.64386
0.632468
Ͳ0.64281
Ͳ6.64386
Ͳ0.56474
Ͳ0.766
0.304189
Ͳ0.45315
Ͳ0.07648
0.206388
Ͳ0.10304
0.194952
Ͳ0.53838
Ͳ0.34629
Ͳ0.14568
Ͳ6.64386
0.87459
Ͳ0.96028
0.457307
Ͳ0.20946
0.467167
0.688882
0.178953
0.878638
0.070072
0.157228
Ͳ0.0854
Ͳ0.05194
Ͳ0.23584
0.265223
Ͳ0.29625
Ͳ0.33004
0.436928
0.054421
0.678778
0.444511
Ͳ0.45902
0.044235
0.264381
Ͳ0.95299
0.039852
0.286364
0.249109
0.323528
0.081334
Ͳ0.7468
0.358428
0.98935
0.393936
0.379474
0.078094
0.342238
0.611837
Ͳ0.03279
0.179778
0.234882
0.358276
0.005171
0.308824
134
hsaͲm
iRͲ631
0.047798
0.008991
2.766758
dow
n
1.120461
1.9307773
0.443042
0.648471
Ͳ6.64386
Ͳ6.64386
1.65284
1.076123
Ͳ6.64386
Ͳ0.00766
0.752363
Ͳ0.33934
Ͳ6.64386
0.00762
0.099336
Ͳ6.64386
Ͳ6.64386
0.320393
Ͳ0.24161
Ͳ6.64386
Ͳ6.64386
0.728516
0.264485
Ͳ0.31879
0.84446
0.095004
Ͳ6.64386
Ͳ0.19892
0.461786
Ͳ6.64386
1.484932
0.426756
Ͳ6.64386
0.15757
Ͳ6.64386
0.224432
Ͳ6.64386
Ͳ6.64386
0.45713
0.560668
Ͳ6.64386
Ͳ0.07921
Ͳ0.31175
Ͳ6.64386
Ͳ0.03191
0.245097
0.426432
1.346649
0.583428
Ͳ6.64386
0.046407
Ͳ0.38241
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.31879
0.009921
Ͳ6.64386
0.461299
Ͳ0.06653
Ͳ6.64386
1.489813
Ͳ0.14756
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.41944
0.389556
Ͳ0.21617
Ͳ6.64386
Ͳ0.27891
0.893774
Ͳ0.29809
0.610602
0.517062
0.86426
Ͳ6.64386
Ͳ0.07921
Ͳ6.64386
0.487804
1.425227
0.535132
Ͳ0.18937
0.18738
0.324745
0.232824
1.012053
0.893342
0.834789
Ͳ0.15188
Ͳ6.64386
0.705057
Ͳ6.64386
1.089798
1.28231
0.131872
0.9201
Ͳ6.64386
1.156179
0.3917
135
hsaͲ m
iRͲ135bͲ3p
0.021434
0.00349
2.782404
dow
n
Ͳ0.70375
Ͳ0.3724423
Ͳ0.24864
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.172457
0.628039
Ͳ0.13327
1.186215
Ͳ0.03734
Ͳ6.64386
Ͳ6.64386
Ͳ0.66295
Ͳ0.80517
Ͳ0.0897
0.164415
0.120788
0.02115
Ͳ0.08174
0.016815
1.041906
Ͳ0.5483
1.659658
Ͳ0.50201
0.064036
0.792734
0.720884
0.210877
1.39477
Ͳ6.64386
Ͳ0.22637
0.143808
Ͳ0.3963
Ͳ0.29002
Ͳ0.39991
Ͳ6.64386
Ͳ6.64386
0.642028
Ͳ6.64386
Ͳ0.30401
0.482394
0.637012
Ͳ0.18832
Ͳ0.04972
0.170059
Ͳ0.05362
Ͳ0.12607
0.145036
Ͳ6.64386
1.490888
0.643871
Ͳ0.3295
Ͳ0.06142
0.150998
0.171743
Ͳ6.64386
Ͳ6.64386
1.189115
Ͳ6.64386
Ͳ6.64386
Ͳ0.33914
Ͳ0.13465
Ͳ0.35591
0.282368
1.534585
0.76526
Ͳ0.26515
0.219868
0.43659
Ͳ0.29968
1.949963
1.768565
Ͳ0.20374
1.252532
Ͳ0.50108
Ͳ0.73114
0.576391
1.232097
0.289749
Ͳ6.64386
1.057492
Ͳ0.17528
0.37358
0.917779
0.418998
0.375473
0.078528
1.765101
Ͳ0.21275
0.518976
1.023826
0.342367
1.685819
0.751371
1.227993
Ͳ0.37187
Ͳ0.00872
Ͳ0.0584
1.541012
Ͳ0.16404
0.008668
136
hsaͲm
iRͲ3156Ͳ5p
0.029612
0.005149
2.818424
dow
n
Ͳ6.64386
Ͳ0.6178877
0.549098
Ͳ6.64386
3.267388
0.490581
Ͳ0.27249
Ͳ0.05106
0.045898
Ͳ0.29931
Ͳ0.42544
Ͳ0.22005
Ͳ6.64386
Ͳ6.64386
Ͳ0.61306
Ͳ0.14459
Ͳ0.09428
Ͳ6.64386
Ͳ6.64386
0.014966
0.100054
Ͳ0.28327
Ͳ0.12403
1.013342
Ͳ0.20326
Ͳ0.37653
0.527798
0.058177
Ͳ0.48615
Ͳ0.12546
Ͳ6.64386
Ͳ6.64386
Ͳ0.13326
Ͳ0.1544
0.426461
0.406835
Ͳ6.64386
0.123901
0.699096
Ͳ6.64386
Ͳ0.14337
0.856205
0.173182
0.637202
1.230816
0.407188
0.364849
Ͳ0.59119
Ͳ0.54316
Ͳ6.64386
0.275798
0.173942
Ͳ0.66688
0.51417
Ͳ6.64386
0.644929
0.515092
Ͳ0.301
Ͳ6.64386
1.383757
Ͳ0.10454
Ͳ6.64386
0.558966
Ͳ0.718
Ͳ0.11298
0.746442
0.169095
0.145242
Ͳ0.02525
0.445829
0.419729
1.260697
Ͳ0.92188
0.172272
0.501976
Ͳ0.0892
Ͳ0.02804
Ͳ0.09913
0.863687
1.24652
Ͳ0.01512
0.814365
Ͳ0.31231
Ͳ0.93911
0.603852
0.280763
0.23709
Ͳ0.77283
Ͳ0.75302
0.767213
0.18731
0.745802
1.557267
0.316546
0.019118
0.40411
0.188911
Ͳ0.59738
Ͳ0.18227
1.308428
0.193323
0.467864
137
hsaͲm
iRͲ4689
0.002805
2.80EͲ04
2.843713
dow
n
Ͳ0.51064
0.25561225
0.076989
Ͳ0.01025
Ͳ0.00963
0.155118
Ͳ0.40597
Ͳ0.39323
Ͳ0.56445
Ͳ6.64386
Ͳ0.70118
Ͳ0.65812
Ͳ0.61735
Ͳ6.64386
Ͳ0.32797
Ͳ6.64386
Ͳ0.39112
Ͳ1.20847
Ͳ6.64386
Ͳ0.23462
Ͳ0.28615
0.665758
Ͳ0.11904
1.816538
Ͳ0.96841
0.141274
0.36391
0.241219
Ͳ1.09973
0.111612
Ͳ0.88478
Ͳ6.64386
0.944633
Ͳ6.64386
Ͳ1.11195
0.035781
0.0083
Ͳ6.64386
1.40211
Ͳ0.24106
Ͳ6.64386
0.888939
0.752327
0.410866
0.746767
Ͳ6.64386
Ͳ0.3858
Ͳ0.29031
Ͳ0.3813
1.435215
0.459363
0.487684
0.111833
0.02716
Ͳ0.54851
Ͳ0.76512
0.538003
Ͳ0.58877
0.357921
1.092818
Ͳ1.09955
Ͳ6.64386
0.345688
Ͳ0.70434
Ͳ0.10201
1.52004
Ͳ0.67463
Ͳ0.87071
0.776658
Ͳ1.13931
0.476449
1.709565
0.359617
0.515262
1.685324
0.246371
Ͳ0.00835
0.144442
0.416685
0.605146
0.690533
1.372305
Ͳ0.21337
Ͳ0.28204
1.187515
0.579988
0.00869
Ͳ0.40844
Ͳ0.03738
Ͳ0.29537
0.654512
0.152421
0.804116
0.650659
1.408037
Ͳ0.52433
0.678594
Ͳ0.19452
0.660619
1.317558
0.637468
Ͳ1.09721
138
hsaͲm
iRͲ26bͲ5p
2.04EͲ06
3.86EͲ08
2.913235
dow
n
1.092519
0.3195488
0.816256
Ͳ1.25043
Ͳ6.64386
Ͳ6.64386
0.571934
0.385677
Ͳ0.6222
Ͳ1.26805
0.84113
Ͳ0.65313
Ͳ6.64386
Ͳ2.2055
0.342902
Ͳ0.48431
Ͳ1.56419
Ͳ1.37229
0.022167
Ͳ0.40981
Ͳ0.46939
1.127952
Ͳ0.02251
Ͳ1.03736
0.127833
Ͳ3.16716
Ͳ1.76795
Ͳ0.11139
Ͳ2.08469
Ͳ0.0565
1.413631
Ͳ0.29879
Ͳ0.05715
Ͳ0.06714
Ͳ0.31054
Ͳ1.20024
1.080013
Ͳ2.60408
Ͳ0.1066
1.179712
Ͳ1.23641
Ͳ0.21384
Ͳ0.10511
Ͳ0.30432
Ͳ0.92315
0.142209
Ͳ1.34941
Ͳ0.16933
0.328616
Ͳ6.64386
Ͳ0.63045
Ͳ0.25913
Ͳ0.50719
Ͳ0.16202
0.898506
0.036082
0.475141
0.52227
Ͳ6.64386
0.550403
Ͳ0.31737
Ͳ3.19683
0.283981
0.666139
Ͳ 1.41825
Ͳ0.10255
Ͳ0.21049
Ͳ2.19871
2.227731
0.520521
0.753314
1.004015
0.836324
0.943876
1.061722
1.843601
2.508872
1.640628
1.088483
Ͳ0.40539
0.835993
Ͳ0.16829
1.113881
Ͳ0.39253
0.747031
1.574105
1.218045
0.830481
Ͳ0.52582
1.013336
1.181109
Ͳ0.86903
1.73611
1.026748
0.578322
0.660607
0.61205
0.041131
1.159809
0.436653
1.059665
1.062601
139
hsaͲm
iRͲ670
1.31EͲ04
6.20EͲ06
2.954435
dow
n
0.091411
1.4729269
0.101864
2.613373
0.736341
Ͳ6.64386
0.647181
0.777144
Ͳ0.39372
Ͳ0.73298
0.222593
Ͳ0.70711
Ͳ6.64386
Ͳ0.37257
0.631813
Ͳ6.64386
Ͳ6.64386
Ͳ0.98989
Ͳ0.79185
Ͳ0.84743
Ͳ0.62907
0.136462
Ͳ0.68323
Ͳ0.52474
0.156614
Ͳ0.63032
Ͳ6.64386
0.423686
Ͳ6.64386
0.411847
Ͳ0.07576
Ͳ6.64386
0.452489
Ͳ0.76569
Ͳ0.35944
Ͳ6.64386
Ͳ6.64386
Ͳ0.4353
0.997153
Ͳ0.50569
Ͳ6.64386
Ͳ6.64386
0.562841
Ͳ6.64386
0.044831
Ͳ0.89523
Ͳ6.64386
0.459777
Ͳ0.57485
0.134297
Ͳ0.06822
Ͳ0.37076
0.544344
Ͳ0.50446
0.225795
Ͳ6.64386
Ͳ0.55868
Ͳ 0.026
Ͳ6.64386
2.190013
Ͳ0.79185
Ͳ6.64386
1.205258
0.694975
Ͳ6.64386
Ͳ6.64386
Ͳ0.21544
Ͳ0.13986
1.055552
0.030362
0.798683
Ͳ6.64386
Ͳ0.60339
1.383743
Ͳ6.64386
0.665842
0.96741
0.396292
0.800891
0.02554
1.329889
0.988677
Ͳ0.18958
0.168265
0.929533
0.541657
0.51139
0.464435
0.671772
0.62575
1.185536
Ͳ6.64386
0.505641
0.098381
0.553016
1.575514
1.312616
Ͳ6.64386
1.109047
0.75684
1.1495
Ͳ0.20119
140
hsaͲm
iRͲ4700Ͳ5p
1.30EͲ04
5.95EͲ06
3.067645
dow
n
0.106693
1.363932
Ͳ0.60272
2.31994
0.785361
Ͳ6.64386
0.617802
0.563932
Ͳ0.41927
Ͳ6.64386
0.230209
0.132783
0.48331
Ͳ0.87514
0.250386
Ͳ6.64386
Ͳ6.64386
Ͳ0.98227
Ͳ0.62811
0.205992
Ͳ0.69546
Ͳ0.3888
Ͳ0.63608
Ͳ0.55107
Ͳ0.19043
Ͳ6.64386
Ͳ6.64386
0.168268
Ͳ6.64386
0.179997
Ͳ0.34825
Ͳ0.67561
0.782033
0.512014
0.281546
Ͳ0.67161
Ͳ6.64386
0.06264
0.820345
0.349922
Ͳ0.18344
Ͳ0.10886
0.140469
0.370257
Ͳ6.64386
Ͳ0.36073
Ͳ0.74038
0.401838
Ͳ0.93497
1.239115
Ͳ0.69954
Ͳ0.48344
0.62568
0.017726
Ͳ0.18246
Ͳ0.64362
Ͳ0.65798
Ͳ0.17958
Ͳ6.64386
0.139477
Ͳ0.74359
Ͳ6.64386
1.011399
0.984605
Ͳ0.28974
0.173419
Ͳ0.4172
Ͳ0.51445
0.377079
0.749853
1.176029
Ͳ0.01795
Ͳ0.0819
0.913617
Ͳ0.38562
0.275485
0.657713
0.600556
0.600604
Ͳ0.47499
1.005933
1.053122
Ͳ0.0469
Ͳ0.91339
1.417601
0.507619
Ͳ0.20704
Ͳ0.15731
0.430823
Ͳ0.01871
0.828993
Ͳ0.43349
0.875023
Ͳ0.25929
1.15199
1.049496
1.001955
0.246439
1.075378
1.307461
1.163222
Ͳ0.174
141
hsaͲm
iRͲ16Ͳ2Ͳ3p
0.005456
6.27EͲ04
3.170327
dow
n
0.251575
0.25509527
0.293632
Ͳ1.17954
Ͳ6.64386
Ͳ6.64386
0.799226
Ͳ0.46306
0.989006
Ͳ1.05441
0.042653
Ͳ0.94052
Ͳ6.64386
0.514721
1.21036
Ͳ0.17798
1.302009
0.867023
Ͳ0.06003
0.648616
Ͳ6.64386
0.340734
0.447859
Ͳ6.64386
0.115641
Ͳ6.64386
Ͳ1.09628
Ͳ0.86556
Ͳ0.59585
Ͳ0.14904
1.71037
0.876703
Ͳ0.44944
1.201376
Ͳ1.48649
Ͳ6.64386
Ͳ6.64386
Ͳ0.95403
0.712316
1.966435
Ͳ6.64386
Ͳ1.95885
1.375144
Ͳ0.50927
Ͳ1.77909
Ͳ0.45282
Ͳ1.42595
Ͳ0.1467
Ͳ1.02319
Ͳ 6.64386
Ͳ6.64386
Ͳ1.09212
0.200234
Ͳ1.02319
0.562132
Ͳ0.65581
0.524041
2.145913
Ͳ6.64386
Ͳ6.64386
Ͳ0.99863
Ͳ6.64386
0.803223
0.169061
0.076312
Ͳ6.64386
Ͳ0.04395
Ͳ0.52479
1.127891
Ͳ0.1973
1.579195
Ͳ0.95917
Ͳ0.41376
1.281975
Ͳ0.87683
0.999388
0.876745
1.321242
0.28512
0.677775
0.518351
Ͳ0.79576
1.35494
0.949411
0.052531
1.62109
0.760696
0.435651
Ͳ0.17805
0.913085
0.860311
Ͳ0.1519
Ͳ0.31401
0.178947
Ͳ6.64386
0.322743
1.398095
Ͳ0.29153
0.720601
0.044529
2.159905
1.303076
142
hsaͲm
iRͲ1224Ͳ3p
0.02713
0.004603
3.188798
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.182935
Ͳ6.64386
Ͳ6.64386
1.620418
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.886011
1.690851
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.92238
2.142371
Ͳ6.64386
1.487998
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.576763
1.829647
Ͳ6.64386
1.760899
Ͳ6.64386
143
hsaͲm
iRͲ4675
0.011764
0.001742
3.270106
dow
n
0.944268
1.2048725
Ͳ0.14999
0.120628
0.879051
1.678512
0.809787
1.251128
Ͳ0.68149
Ͳ0.91182
Ͳ0.3511
Ͳ6.64386
0.100459
Ͳ6.64386
0.93465
Ͳ6.64386
Ͳ6.64386
Ͳ0.11214
0.448468
Ͳ0.5475
Ͳ0.8668
Ͳ0.50925
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.4365
Ͳ6.64386
0.203029
0.335235
0.276478
0.795444
Ͳ6.64386
0.034186
Ͳ0.2454
Ͳ6.64386
Ͳ0.28837
Ͳ0.14043
Ͳ0.31716
0.715479
Ͳ6.64386
Ͳ0.49951
Ͳ6.64386
0.570687
1.005569
0.308352
0.760678
0.109005
1.394563
0.509344
Ͳ6.64386
Ͳ1.00932
Ͳ0.93042
0.614817
Ͳ0.16873
Ͳ0.22452
Ͳ0.45156
Ͳ6.64386
0.276748
Ͳ6.64386
1.339033
Ͳ6.64386
Ͳ0.21356
2.221177
Ͳ6.64386
0.289618
Ͳ6.64386
Ͳ0.1185
0.59752
0.44862
0.984498
0.346425
Ͳ0.76854
Ͳ0.55042
1.182797
Ͳ6.64386
Ͳ0.21897
Ͳ0.4454
1.132275
1.481269
Ͳ0.89026
1.334299
1.015629
0.952813
Ͳ6.64386
1.604152
1.442585
Ͳ0.06641
Ͳ0.10345
0.15868
0.208502
0.224279
Ͳ0.03502
0.797762
Ͳ6.64386
0.251228
1.787259
0.324779
Ͳ0.65735
0.34882
1.029588
1.461899
0.088151
144
hsaͲm
iRͲ23c
4.38EͲ05
1.61EͲ06
3.371118
dow
n
Ͳ1.87844
1.4308528
2.866311
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ2.19246
0.038905
0.426437
0.190047
0.289485
Ͳ0.20335
Ͳ6.64386
Ͳ2.86026
1.562403
0.172537
Ͳ1.05834
0.476932
Ͳ0.45621
Ͳ1.37718
Ͳ0.21168
Ͳ0.38161
0.39696
Ͳ0.61732
0.547898
Ͳ1.6019
Ͳ1.31277
1.377485
Ͳ6.64386
Ͳ1.16689
0.868172
Ͳ2.87937
Ͳ6.64386
0.620298
Ͳ3.16838
Ͳ1.78701
0.444552
Ͳ2.13624
0.254765
0.828682
Ͳ0.67376
Ͳ0.74434
Ͳ1.31674
0.342476
Ͳ0.49461
0.752127
Ͳ1.40755
Ͳ1.18191
Ͳ0.38143
Ͳ6.64386
Ͳ0.15992
Ͳ2.7778
0.586187
Ͳ0.19085
0.544847
1.072277
0.807053
Ͳ1.89942
Ͳ6.64386
Ͳ6.64386
Ͳ0.95539
Ͳ2.35978
Ͳ6.64386
Ͳ1.40463
0.788872
1.979042
Ͳ3.08313
Ͳ6.64386
2.145837
1.715007
1.930693
1.379194
1.512329
2.40334
Ͳ1.10914
1.234193
1.451531
Ͳ0.66058
1.684249
0.18695
1.787844
Ͳ1.79422
0.701542
1.46577
1.630865
2.21239
1.097505
2.216364
0.807595
0.860691
0.347376
Ͳ1.00174
Ͳ0.03998
0.271962
Ͳ6.64386
Ͳ2.77426
0.962273
0.660211
1.511328
1.594092
Ͳ0.05198
1.057133
145
hsaͲm
iRͲ4468
0.007443
9.29EͲ04
3.498524
dow
n
Ͳ0.09636
1.1750661
Ͳ0.15561
0.743168
0.390384
1.237826
0.190653
Ͳ0.07383
Ͳ0.00985
Ͳ6.64386
0.580963
0.006054
0.961443
Ͳ6.64386
0.117562
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.319506
Ͳ0.40898
Ͳ6.64386
Ͳ0.21732
Ͳ0.41321
0.235188
0.029387
Ͳ6.64386
Ͳ6.64386
0.272006
Ͳ6.64386
Ͳ0.26387
0.54492
Ͳ6.64386
1.293719
0.490577
0.495479
Ͳ6.64386
Ͳ6.64386
0.015683
0.298478
0.488206
Ͳ0.2748
Ͳ0.44432
Ͳ0.59713
Ͳ0.36106
Ͳ6.64386
Ͳ0.51396
Ͳ0.40737
0.831337
Ͳ0.32357
1.754387
Ͳ6.64386
Ͳ0.20694
1.225722
0.203679
Ͳ0.2823
Ͳ6.64386
0.089337
Ͳ0.48854
Ͳ6.64386
0.919233
Ͳ0.52849
Ͳ6.64386
0.65712
0.185585
Ͳ6.64386
0.469235
Ͳ6.64386
Ͳ6.64386
0.126609
Ͳ0.38767
1.006795
Ͳ0.09338
Ͳ0.36904
0.39686
Ͳ0.16608
0.564542
0.71386
0.195195
Ͳ6.64386
Ͳ0.31879
1.303549
0.921634
0.868078
Ͳ6.64386
0.596001
Ͳ0.04014
Ͳ0.13801
0.568755
0.100004
Ͳ0.00608
0.497136
Ͳ0.18928
0.159367
0.09109
1.491499
1.699857
0.765057
0.089337
0.887282
0.949527
0.194281
Ͳ0.04487
146
hsaͲm
iRͲ182Ͳ3p
0.004453
4.97EͲ04
3.530612
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.329762
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.341248
Ͳ6.64386
2.122248
2.133746
2.089637
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.384565
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.51717
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.781573
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
147
hsaͲm
iRͲ136Ͳ3p
0.009735
0.001349
3.622702
dow
n
Ͳ6.64386
Ͳ6.643856
4.088126
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.255418
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.327028
Ͳ6.64386
Ͳ6.64386
3.251814
5.707155
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.639216
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.096446
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
148
hsaͲm
iRͲ3667Ͳ5p
2.33EͲ04
1.30EͲ05
3.667121
dow
n
0.302482
1.0626261
0.457855
Ͳ0.38692
0.031605
Ͳ6.64386
0.853568
0.776616
Ͳ1.13416
Ͳ1.18391
0.407497
0.003919
Ͳ6.64386
Ͳ1.03308
0.73419
Ͳ0.81346
Ͳ6.64386
Ͳ0.92253
Ͳ0.48391
Ͳ6.64386
Ͳ0.93828
Ͳ0.07768
Ͳ1.13416
Ͳ0.14181
Ͳ0.21425
Ͳ6.64386
Ͳ6.64386
0.773445
Ͳ0.82805
0.600142
0.899255
Ͳ0.69604
0.084018
0.15957
Ͳ6.64386
Ͳ0.27972
Ͳ0.28295
Ͳ6.64386
1.311865
Ͳ0.00393
Ͳ0.75726
Ͳ0.53724
0.102763
0.127437
Ͳ0.72325
0.009661
Ͳ0.583
1.228174
Ͳ0.48813
0.200613
0.043172
Ͳ0.39184
0.581094
Ͳ0.17779
Ͳ0.09246
Ͳ6.64386
Ͳ1.23201
0.134094
Ͳ6.64386
0.564346
Ͳ6.64386
Ͳ6.64386
1.299059
0.270745
Ͳ0.16666
Ͳ0.08133
0.118286
0.114002
0.44224
0.692065
Ͳ0.03939
Ͳ0.57837
Ͳ0.11623
0.693068
Ͳ1.02602
0.5617
0.165316
1.073747
1.637658
Ͳ0.16527
1.608408
0.995741
1.152912
Ͳ0.7566
1.477609
1.153761
Ͳ0.80156
0.749621
1.011223
Ͳ0.09271
0.999771
Ͳ0.39739
0.401341
Ͳ0.29729
0.42971
1.729331
1.728266
Ͳ0.54235
1.578443
2.169561
1.39156
0.202767
149
hsaͲm
iRͲ4435
0.001689
1.49EͲ04
3.713703
dow
n
Ͳ0.35166
0.9739261
Ͳ0.3018
2.73261
1.605603
1.851293
0.578539
0.64305
Ͳ6.64386
Ͳ6.64386
Ͳ0.00854
Ͳ6.64386
0.37688
Ͳ6.64386
0.548941
Ͳ6.64386
Ͳ6.64386
Ͳ0.21423
0.335651
Ͳ0.70404
Ͳ0.26846
Ͳ0.05987
Ͳ6.64386
Ͳ6.64386
0.436944
Ͳ6.64386
Ͳ0.72266
0.080043
0.356842
0.075792
0.782359
Ͳ0.34053
0.4137
0.268276
Ͳ0.6291
Ͳ0.2129
Ͳ6.64386
0.144434
Ͳ0.60801
Ͳ0.10641
Ͳ0.7016
Ͳ6.64386
Ͳ0.63693
Ͳ6.64386
0.256586
Ͳ0.22233
0.07832
1.05189
0.293912
1.895248
Ͳ0.31241
Ͳ6.64386
0.874655
Ͳ0.34854
Ͳ0.58367
Ͳ0.13862
0.193888
Ͳ0.49762
Ͳ6.64386
1.553483
Ͳ0.11573
Ͳ6.64386
0.794025
Ͳ6.64386
0.032845
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.538122
Ͳ0.17749
0.546743
Ͳ0.56668
Ͳ6.64386
1.352763
Ͳ0.69441
0.401389
1.892349
0.47885
0.820383
Ͳ0.32434
1.627124
0.115179
1.161249
1.351726
0.695971
Ͳ0.21043
0.020904
Ͳ0.38927
0.463287
0.229624
1.015531
Ͳ0.36531
0.008491
Ͳ0.20397
0.369771
1.073828
0.910987
0.506478
1.349464
0.844526
1.071447
Ͳ0.05925
150
hsaͲm
iRͲ3148
2.36EͲ04
1.33EͲ05
3.753175
dow
n
0.524538
1.8629395
Ͳ0.0154
3.316778
3.189443
Ͳ6.64386
1.178163
1.201314
Ͳ0.90067
Ͳ6.64386
0.621973
Ͳ0.49245
Ͳ6.64386
Ͳ0.37803
0.91299
Ͳ1.06579
Ͳ6.64386
Ͳ0.9443
Ͳ0.3262
Ͳ0.2525
Ͳ6.64386
Ͳ0.74136
Ͳ1.35133
Ͳ1.26861
0.234327
Ͳ1.32912
Ͳ6.64386
0.367767
Ͳ0.92576
0.297827
1.094674
Ͳ1.12894
0.435691
0.414202
Ͳ0.40064
Ͳ0.71751
Ͳ1.10886
Ͳ6.64386
1.102033
Ͳ0.25287
Ͳ6.64386
Ͳ6.64386
0.523643
Ͳ0.89433
Ͳ1.02144
Ͳ0.03553
Ͳ6.64386
0.993562
Ͳ0.1521
Ͳ6.64386
Ͳ0.78114
Ͳ0.5868
0.78226
Ͳ0.84242
0.285845
Ͳ6.64386
Ͳ6.64386
0.488907
Ͳ6.64386
1.338097
Ͳ6.64386
Ͳ1.20258
1.791555
0.458678
Ͳ0.24342
Ͳ6.64386
Ͳ0.9691
0.144391
1.294646
0.612802
1.100983
Ͳ6.64386
0.069377
1.668484
Ͳ6.64386
0.807679
1.016404
0.456074
1.345738
Ͳ0.95326
1.839737
1.044138
0.956215
Ͳ1.12577
1.531645
1.040799
0.309334
0.430009
0.76073
0.607575
1.361622
Ͳ0.86026
Ͳ0.09544
0.01524
0.777342
2.416637
1.33818
Ͳ6.64386
1.456933
1.119287
1.397708
0.089701
151
hsaͲm
iRͲ26bͲ3p
0.007891
9.94EͲ04
3.759939
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.995308
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.320714
1.804336
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.023609
Ͳ6.64386
2.191947
2.095408
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.87339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
2.190005
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.32873
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.646386
152
hsaͲm
iRͲ601
1.18EͲ05
3.53EͲ07
3.796099
dow
n
0.578421
1.1489502
0.705389
Ͳ6.64386
Ͳ0.27896
Ͳ6.64386
0.817242
0.966437
Ͳ1.01485
Ͳ2.14056
0.043596
Ͳ1.78384
Ͳ6.64386
Ͳ6.64386
0.71169
Ͳ6.64386
Ͳ6.64386
Ͳ1.05848
Ͳ0.32384
Ͳ2.16126
Ͳ1.26882
0.171753
Ͳ1.8084
Ͳ0.69766
Ͳ0.69325
Ͳ1.1756
Ͳ2.58284
0.448453
Ͳ1.1756
0.943372
Ͳ0.2295
Ͳ1.59982
0.788289
0.117597
Ͳ0.44079
Ͳ0.8044
Ͳ0.33731
Ͳ2.18726
1.325734
Ͳ0.01002
Ͳ6.64386
Ͳ1.11778
0.619114
0.221786
Ͳ0.83152
0.55554
Ͳ1.88005
2.20729
Ͳ0.51099
Ͳ0.31225
Ͳ0.70246
Ͳ0.93816
1.11369
Ͳ0.27779
0.568018
Ͳ1.51338
Ͳ0.62992
Ͳ0.20591
Ͳ6.64386
1.134157
Ͳ1.36823
Ͳ6.64386
1.857712
Ͳ0.26693
Ͳ0.75214
0.260718
Ͳ0.13845
0.229842
0.665121
1.535851
1.228335
Ͳ0.86151
0.009948
1.243151
Ͳ1.29298
0.587952
0.259555
1.291611
2.401164
Ͳ0.60138
2.187287
1.035472
1.078064
Ͳ0.50484
1.668769
0.976811
Ͳ0.21513
0.532634
0.99247
0.652511
0.639319
Ͳ0.76628
0.669327
0.248841
1.07584
3.168791
1.830258
0.343364
1.510759
2.229849
1.844212
0.126166
153
hsaͲm
iRͲ3616Ͳ3p
0.01974
0.00312
3.940568
dow
n
Ͳ0.48616
Ͳ6.643856
0.539189
0.251132
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.24271
Ͳ6.64386
0.020986
Ͳ0.48243
Ͳ6.64386
0.586518
Ͳ6.64386
Ͳ0.0213
Ͳ0.39366
Ͳ0.2829
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.42139
0.806882
Ͳ6.64386
2.510026
Ͳ6.64386
Ͳ6.64386
0.750017
0.735481
Ͳ6.64386
0.356983
Ͳ6.64386
Ͳ6.64386
0.050759
0.219602
0.492643
0.380067
Ͳ6.64386
Ͳ6.64386
0.874643
0.53207
Ͳ0.46957
0.933665
Ͳ0.02203
0.360873
1.537608
Ͳ0.52523
Ͳ6.64386
Ͳ0.51502
Ͳ6.64386
0.796227
0.594221
0.33991
0.909196
Ͳ0.45206
0.078336
0.954207
Ͳ0.34122
Ͳ6.64386
0.52939
Ͳ6.64386
Ͳ0.12848
Ͳ6.64386
0.170599
Ͳ6.64386
Ͳ0.34626
0.428365
0.486511
Ͳ0.72019
0.162193
0.59508
0.021827
0.718241
Ͳ6.64386
0.191729
0.44543
Ͳ0.70599
0.067251
Ͳ0.22518
2.615177
0.949433
0.797682
1.443383
0.833746
Ͳ0.2939
1.502653
Ͳ0.07962
Ͳ0.08027
Ͳ6.64386
Ͳ0.10835
Ͳ6.64386
0.38133
Ͳ0.42151
1.185544
0.295178
2.893411
2.922836
0.900906
2.019185
0.73136
2.715569
0.164045
Ͳ6.64386
154
hsaͲm
iRͲ3064Ͳ5p
0.03839
0.006966
4.001939
dow
n
Ͳ6.64386
2.6062727
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.03873
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.026057
1.67461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.734219
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.96276
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.857535
Ͳ6.64386
1.654248
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.809129
2.077799
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.425656
2.821568
2.076391
Ͳ6.64386
2.228177
Ͳ6.64386
Ͳ6.64386
2.673761
Ͳ6.64386
Ͳ6.64386
2.45874
Ͳ6.64386
1.956482
Ͳ6.64386
2.527175
Ͳ6.64386
1.444551
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.537929
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.859189
Ͳ6.64386
Ͳ6.64386
2.423176
Ͳ6.64386
Ͳ6.64386
1.816707
Ͳ6.64386
2.049244
Ͳ6.64386
155
hsaͲm
iRͲ3127Ͳ5p
0.021434
0.003479
4.025753
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
2.093345
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.68749
Ͳ 6.64386
Ͳ0.01572
Ͳ 0.44333
Ͳ0.62814
1.433419
Ͳ0.39752
0.772403
Ͳ6.64386
Ͳ 6.64386
0.741376
0.83732
0.535363
0.882411
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
0.015554
Ͳ6.64386
Ͳ 6.64386
Ͳ0.19107
Ͳ0.44172
Ͳ6.64386
0.910731
0.168331
Ͳ6.64386
1.404399
0.788356
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.329185
Ͳ0.46791
Ͳ0.3541
0.199028
2.00826
Ͳ0.27279
0.772403
0.154792
Ͳ0.25893
0.718317
2.880779
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.33036
0.092283
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.307322
1.754519
Ͳ6.64386
Ͳ6.64386
0.032041
Ͳ6.64386
Ͳ0.21014
Ͳ6.64386
Ͳ6.64386
0.257866
3.297328
0.128278
1.810618
0.174698
0.162255
1.264854
0.229317
0.701914
0.286629
0.609766
2.790717
Ͳ6.64386
1.208967
0.795248
1.754003
2.77514
0.750634
0.592028
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.643275
0.168541
Ͳ6.64386
0.38284
0.080525
Ͳ6.64386
2.260591
1.508859
Ͳ6.64386
0.690829
Ͳ0.12411
4.79292
0.367623
156
hsaͲm
iRͲ4750
0.007443
9.29EͲ04
4.045383
dow
n
0.225464
0.5334388
Ͳ6.64386
0.38717
0.202502
0.787863
0.161028
Ͳ6.64386
Ͳ6.64386
Ͳ0.1924
Ͳ0.46457
Ͳ0.24453
1.514466
Ͳ0.33529
Ͳ0.2607
Ͳ0.11568
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.01712
0.266466
Ͳ0.0961
Ͳ0.43638
0.318933
Ͳ0.17436
Ͳ0.41567
Ͳ0.62586
0.221869
Ͳ6.64386
Ͳ6.64386
Ͳ0.2856
Ͳ 6.64386
1.094393
0.164015
0.862497
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.424686
0.768817
0.115486
Ͳ0.11956
0.097933
0.042032
Ͳ0.18773
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.691878
0.266611
Ͳ0.12577
0.323926
Ͳ0.1488
Ͳ6.64386
0.164978
Ͳ0.16649
Ͳ0.16249
0.975631
Ͳ6.64386
Ͳ0.21062
0.016915
0.415332
0.453132
Ͳ0.0378
0.652311
0.370997
Ͳ0.4607
0.644045
0.126814
1.00547
Ͳ0.22087
Ͳ0.35072
0.465596
Ͳ0.4211
0.286709
1.067826
0.379335
0.039724
0.48812
0.740197
0.729439
0.039661
Ͳ0.36916
0.595918
Ͳ0.56196
Ͳ0.10357
Ͳ0.08763
Ͳ0.33076
0.045426
0.968997
0.361384
0.683448
Ͳ0.32942
Ͳ6.64386
0.663629
0.276336
0.292938
0.41525
0.297578
0.272706
Ͳ0.45397
157
hsaͲm
iRͲ4303
7.50EͲ 04
5.18E Ͳ05
4.217161
dow
n
Ͳ 0.3464
0.61768067
Ͳ 0.29746
Ͳ6.64386
1.416423
1.165586
0.08756
0.780675
Ͳ 0.40073
Ͳ0.03544
Ͳ 6.64386
0.235767
Ͳ 6.64386
Ͳ0.33722
0.838933
Ͳ6.64386
Ͳ0.30762
Ͳ0.39705
Ͳ6.64386
0.101465
Ͳ6.64386
0.477179
Ͳ0.35342
Ͳ0.318
Ͳ0.41333
Ͳ0.37851
Ͳ6.64386
0.459549
Ͳ0.01078
Ͳ0.1666
0.04528
Ͳ6.64386
0.638484
0.184236
Ͳ6.64386
0.0107
Ͳ6.64386
Ͳ6.64386
0.969223
Ͳ0.40761
Ͳ0.33962
0.185786
0.391108
0.124989
Ͳ6.64386
Ͳ0.0462
Ͳ0.06482
1.115358
Ͳ0.18132
Ͳ6.64386
0.216551
Ͳ6.64386
0.06994
0.714845
0.187252
Ͳ6.64386
Ͳ6.64386
0.561945
0.716506
Ͳ6.64386
Ͳ6.64386
Ͳ0.27053
1.819939
0.752698
Ͳ6.64386
0.760238
Ͳ6.64386
0.543359
0.443151
0.672114
0.376405
0.867913
Ͳ0.28374
0.533507
0.292516
0.566245
Ͳ0.09847
0.898314
0.916969
Ͳ0.14352
1.67065
1.05975
0.887949
Ͳ0.14869
1.623026
0.662492
Ͳ0.0601
Ͳ0.03442
1.379816
Ͳ0.01148
0.759279
Ͳ0.15
0.17164
Ͳ0.14458
Ͳ6.64386
0.562717
0.966186
Ͳ6.64386
0.71331
1.375846
1.173489
Ͳ0.37507
158
hsaͲm
iRͲ4277
0.019562
0.003082
4.243334
dow
n
0.541376
2.0092998
Ͳ0.35022
2.361591
Ͳ6.64386
Ͳ6.64386
1.250381
1.081073
Ͳ6.64386
Ͳ6.64386
0.075175
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.582693
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.10643
Ͳ6.64386
Ͳ6.64386
0.120041
Ͳ6.64386
Ͳ6.64386
0.446726
0.15885
Ͳ6.64386
0.102411
0.258385
0.170795
Ͳ0.14921
Ͳ6.64386
0.564392
Ͳ0.07909
Ͳ6.64386
Ͳ6.64386
Ͳ0.14921
Ͳ6.64386
0.348571
0.170795
Ͳ6.64386
Ͳ0.42279
Ͳ0.3479
0.289818
Ͳ6.64386
0.216079
0.426032
1.746856
0.420422
1.801096
Ͳ6.64386
Ͳ0.16039
1.284843
0.448436
0.027877
Ͳ6.64386
0.366201
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.02843
1.113393
1.413806
Ͳ6.64386
0.184201
Ͳ6.64386
0.18104
Ͳ6.64386
0.68363
Ͳ0.05356
0.565526
Ͳ6.64386
Ͳ6.64386
1.825693
Ͳ6.64386
0.907392
3.559931
Ͳ0.04555
1.083471
Ͳ6.64386
3.054707
0.398631
1.219852
4.085065
0.62383
Ͳ6.64386
0.353878
0.094565
0.76952
0.261794
1.453173
Ͳ0.30158
Ͳ6.64386
Ͳ6.64386
0.06165
1.712024
1.003231
Ͳ0.21876
1.624988
Ͳ0.20632
1.293484
Ͳ0.23007
159
hsaͲm
iRͲ 200bͲ5p
9.31EͲ04
6.99EͲ05
4.466938
dow
n
2.06311
Ͳ0.4000202
0.190519
1.166663
0.54475
3.24449
0.106813
0.361832
0.694932
Ͳ0.73033
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.20914
Ͳ0.57171
Ͳ0.42751
Ͳ0.18959
Ͳ0.47423
Ͳ6.64386
Ͳ0.48095
0.76701
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.38431
1.161694
Ͳ1.17262
0.184317
0.370281
Ͳ0.54257
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.5681
Ͳ0.45056
Ͳ0.13114
Ͳ6.64386
0.018148
Ͳ0.45092
0.550542
Ͳ0.04444
Ͳ0.61902
1.034576
1.904214
1.029016
Ͳ0.48506
0.065996
1.564538
0.088711
Ͳ6.64386
Ͳ6.64386
1.014596
Ͳ6.64386
Ͳ0.84619
0.482547
Ͳ0.90384
0.566711
Ͳ6.64386
Ͳ6.64386
0.253942
Ͳ0.49858
2.775184
Ͳ6.64386
Ͳ1.00253
1.199397
Ͳ0.69514
Ͳ0.0368
0.059598
1.308721
0.578448
1.177426
0.368443
0.235659
1.220375
Ͳ0.46802
3.133529
3.083151
0.433215
Ͳ6.64386
Ͳ6.64386
0.001122
Ͳ0.00112
0.783186
0.87985
0.349657
0.654887
1.842629
1.858897
Ͳ0.88729
2.203689
0.849356
0.924354
Ͳ0.49707
Ͳ0.79411
Ͳ0.34674
0.72408
0.116559
0.612035
Ͳ0.10085
1.13699
Ͳ0.47463
1.344069
160
hsaͲletͲ7aͲ3p
0.031593
0.005576
4.507036
dow
n
Ͳ6.64386
Ͳ6.643856
2.157339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.0015
Ͳ6.64386
1.305282
0.41118
0.834391
2.70886
Ͳ6.64386
2.578553
1.348965
0.498788
2.120442
1.778053
0.359789
0.637994
Ͳ6.64386
Ͳ6.64386
2.001501
Ͳ6.64386
0.81333
Ͳ6.64386
Ͳ6.64386
0.973487
Ͳ6.64386
0.901506
0.150865
0.001501
Ͳ6.64386
0.210955
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.908392
1.426967
Ͳ6.64386
Ͳ6.64386
1.417496
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.543313
Ͳ6.64386
1.822517
0.105402
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.744727
Ͳ6.64386
0.159062
1.899055
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.925437
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.13055
1.0051
Ͳ6.64386
1.776549
2.534915
1.73584
0.219407
1.635083
Ͳ6.64386
Ͳ6.64386
1.692982
1.498005
Ͳ6.64386
2.79
1.248977
2.390173
0.494798
0.791773
1.63515
0.789978
1.057728
1.749502
Ͳ6.64386
Ͳ6.64386
1.858674
Ͳ6.64386
1.292396
1.386479
0.48116
2.204706
161
hsaͲm
iRͲ29cͲ5p
0.018817
0.002954
4.759145
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.096446
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.83202
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.807877
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.482914
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.513147
Ͳ6.64386
Ͳ6.64386
2.014949
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.438412
4.235473
Ͳ6.64386
2.496888
1.862073
1.745949
4.023752
1.635291
3.373026
1.971312
Ͳ6.64386
2.198127
2.31047
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.937852
Ͳ6.64386
2.408645
Ͳ6.64386
1.818009
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.799522
162
hsaͲm
iRͲ15bͲ3p
3.97EͲ05
1.40EͲ06
4.796393
dow
n
0.326097
Ͳ0.2453425
Ͳ0.07594
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.407101
0.841483
0.195183
Ͳ1.61462
0.710718
Ͳ0.27114
Ͳ6.64386
Ͳ6.64386
1.593935
Ͳ0.98783
Ͳ0.58833
Ͳ0.07084
Ͳ0.32025
Ͳ6.64386
Ͳ6.64386
Ͳ0.17397
0.525331
Ͳ6.64386
1.050793
Ͳ6.64386
Ͳ1.62108
Ͳ0.01983
Ͳ0.87173
0.336547
0.597134
1.153363
Ͳ0.74629
1.838489
Ͳ6.64386
Ͳ1.34514
Ͳ1.28481
Ͳ6.64386
0.463492
1.506472
Ͳ6.64386
Ͳ1.43092
1.078379
Ͳ0.95813
Ͳ1.21669
0.471432
Ͳ1.02242
Ͳ0.51619
Ͳ1.43341
Ͳ6.64386
Ͳ1.55312
Ͳ1.25426
0.713429
Ͳ1.31476
0.800948
Ͳ1.44268
0.313827
0.618606
Ͳ6.64386
Ͳ1.00478
Ͳ6.64386
Ͳ6.64386
1.428831
0.81969
Ͳ0.44556
Ͳ6.64386
Ͳ0.24032
0.165565
1.69692
0.376837
2.642351
Ͳ0.49327
0.019561
0.569415
Ͳ0.32702
1.686026
1.356512
1.964584
1.149198
Ͳ0.45054
0.713149
Ͳ0.23626
1.304089
1.646403
1.10219
1.911115
1.5633
1.277694
0.263258
1.507233
0.405554
Ͳ0.94267
0.112415
1.384217
Ͳ6.64386
1.121966
1.845437
0.313827
1.613596
0.291136
1.839247
0.804968
163
hsaͲm
iRͲ4712Ͳ3p
0.008318
0.001099
4.874474
dow
n
Ͳ6.64386
Ͳ6.643856
1.289105
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.076081
Ͳ6.64386
Ͳ0.54142
Ͳ0.59117
0.216852
0.657708
Ͳ6.64386
Ͳ0.32912
Ͳ0.36248
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.92256
0.561949
Ͳ0.04262
1.933918
0.348955
1.68266
0.825393
Ͳ6.64386
0.196952
1.135298
Ͳ6.64386
0.399581
Ͳ6.64386
Ͳ0.54142
Ͳ6.64386
Ͳ6.64386
0.626254
Ͳ6.64386
Ͳ6.64386
Ͳ0.11855
0.614907
0.5416
0.03867
0.149646
0.531819
Ͳ6.64386
0.178336
Ͳ6.64386
0.114479
Ͳ6.64386
Ͳ6.64386
0.229006
0.501874
0.554274
Ͳ6.64386
0.305328
Ͳ0.94797
0.436799
1.260568
Ͳ0.68709
Ͳ6.64386
Ͳ6.64386
Ͳ0.01275
Ͳ6.64386
Ͳ6.64386
Ͳ0.00719
Ͳ0.33849
1.082483
Ͳ0.44787
Ͳ0.63626
0.007158
Ͳ0.28847
0.393403
0.163575
Ͳ1.18008
Ͳ0.59029
1.616098
0.601527
1.751886
0.604536
Ͳ0.09928
1.372039
Ͳ0.82262
0.280899
Ͳ6.64386
0.587115
0.325912
1.183004
0.162222
1.336154
0.975435
Ͳ0.09844
2.062547
Ͳ0.01978
0.113224
1.411965
1.715116
0.427292
2.215043
1.395498
Ͳ6.64386
1.028854
Ͳ0.1806
0.077115
164
hsaͲm
iRͲ374bͲ5p
7.74EͲ04
5.45EͲ05
4.971394
dow
n
2.361097
2.0258822
0.538847
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.198434
0.374784
Ͳ0.75672
Ͳ6.64386
2.277809
0.424098
Ͳ6.64386
Ͳ6.64386
1.565277
Ͳ0.69755
Ͳ6.64386
Ͳ6.64386
0.752737
Ͳ1.5759
Ͳ6.64386
2.947954
Ͳ0.45293
Ͳ1.2696
2.414734
Ͳ6.64386
Ͳ0.8801
0.385196
Ͳ6.64386
0.508286
0.414344
Ͳ0.38168
0.527554
1.243285
Ͳ0.87974
0.256747
Ͳ0.58566
Ͳ6.64386
0.172202
1.963081
Ͳ6.64386
Ͳ0.40229
Ͳ0.0099
Ͳ6.64386
Ͳ0.34628
Ͳ1.1869
Ͳ6.64386
0.344225
Ͳ0.75595
Ͳ6.64386
Ͳ0.56799
Ͳ1.11082
0.54105
Ͳ0.59089
1.687447
Ͳ6.64386
Ͳ0.331
Ͳ0.62239
Ͳ6.64386
1.184031
Ͳ0.50276
Ͳ6.64386
1.595456
1.156157
Ͳ6.64386
Ͳ0.84785
Ͳ0.05911
Ͳ1.48379
2.328858
Ͳ0.10182
1.633712
0.233514
Ͳ0.21012
0.66234
Ͳ1.19993
2.320422
2.890542
Ͳ0.30439
1.407638
Ͳ1.29306
1.724609
0.595102
2.448154
Ͳ0.79419
0.968687
1.770808
0.597065
0.618017
1.085615
0.31717
1.183114
Ͳ6.64386
Ͳ0.54708
1.018354
0.009829
1.278512
2.128583
0.803649
2.076469
0.628354
1.716454
0.82254
165
hsaͲm
iRͲ23bͲ5p
0.010427
0.001494
5.084345
dow
n
Ͳ6.64386
Ͳ6.643856
2.712426
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.627304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.781573
Ͳ6.64386
Ͳ6.64386
1.583677
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.663487
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.806512
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.683726
Ͳ6.64386
1.875405
Ͳ6.64386
2.750764
3.13466
Ͳ6.64386
1.387378
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.558255
Ͳ6.64386
1.573303
1.185439
Ͳ6.64386
2.613519
Ͳ6.64386
2.818036
Ͳ6.64386
2.253937
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.972322
166
hsaͲm
iRͲ192Ͳ5p
0.008451
0.001122
5.301906
dow
n
1.798755
0.03289726
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.573027
1.263815
Ͳ6.64386
Ͳ0.49519
1.299992
1.577526
Ͳ6.64386
0.563027
2.528261
Ͳ0.38353
Ͳ6.64386
Ͳ0.3286
0.608579
0.325987
Ͳ6.64386
2.612429
Ͳ0.5787
Ͳ6.64386
Ͳ0.59908
Ͳ0.09856
Ͳ6.64386
Ͳ0.03367
Ͳ6.64386
Ͳ0.1227
4.731943
0.554565
Ͳ0.36052
0.733889
Ͳ6.64386
Ͳ0.21458
Ͳ6.64386
Ͳ6.64386
0.599553
0.662562
Ͳ6.64386
Ͳ6.64386
1.23738
0.201364
Ͳ6.64386
Ͳ0.04693
Ͳ0.56274
0.896216
0.832866
Ͳ6.64386
Ͳ6.64386
1.112994
Ͳ6.64386
2.158185
1.565649
Ͳ6.64386
Ͳ6.64386
3.415572
Ͳ6.64386
Ͳ6.64386
Ͳ0.27895
Ͳ6.64386
0.102597
0.643577
0.827941
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.249095
1.54792
2.323438
2.250693
Ͳ0.39002
1.775598
1.946897
7.049262
8.122993
1.887004
0.271643
Ͳ6.64386
Ͳ6.64386
1.280146
2.438423
1.444578
0.04679
1.321196
2.954734
1.63915
Ͳ0.38175
5.555607
0.621485
Ͳ0.48492
Ͳ6.64386
1.501626
Ͳ6.64386
0.459438
1.394496
Ͳ6.64386
3.660407
Ͳ6.64386
Ͳ0.06466
3.782035
167
hsaͲm
iRͲ374aͲ5p
0.005488
6.33EͲ04
5.316285
dow
n
1.021758
0.421046
1.970136
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.260433
1.737187
Ͳ6.64386
Ͳ6.64386
3.138069
0.123321
Ͳ6.64386
Ͳ6.64386
2.394193
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ1.48651
Ͳ1.367
Ͳ1.47574
2.089044
Ͳ0.79293
0.135694
1.999915
Ͳ6.64386
Ͳ1.00938
1.94773
Ͳ6.64386
2.131159
Ͳ1.27292
Ͳ0.22589
Ͳ6.64386
1.452182
Ͳ6.64386
0.476213
Ͳ0.88826
Ͳ6.64386
0.118064
1.870035
Ͳ6.64386
0.237766
Ͳ0.10238
Ͳ6.64386
0.738437
Ͳ1.63846
Ͳ6.64386
0.095593
Ͳ6.64386
Ͳ6.64386
0.291914
Ͳ0.60076
Ͳ0.26223
0.202971
0.799949
Ͳ6.64386
1.325878
Ͳ0.38293
Ͳ6.64386
0.318633
Ͳ0.52833
Ͳ6.64386
Ͳ6.64386
1.902343
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ2.001
1.859345
Ͳ0.545
0.423244
Ͳ0.43243
0.198426
Ͳ0.18829
0.610007
2.193544
3.096263
0.612806
1.723741
Ͳ0.88776
Ͳ6.64386
1.223138
1.467604
0.353307
0.169452
1.221213
0.25901
0.895301
2.301505
Ͳ0.5344
2.050403
Ͳ6.64386
Ͳ1.3184
0.930576
0.701377
Ͳ0.54871
1.953801
0.813766
2.04609
1.412145
0.465778
0.624027
168
hsaͲm
iRͲ625Ͳ3p
6.00EͲ04
3.98EͲ05
5.362473
dow
n
0.486391
0.67629135
0.151398
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.249191
0.278293
0.065831
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.300161
Ͳ0.36572
1.411886
Ͳ6.64386
Ͳ6.64386
0.124084
Ͳ6.64386
Ͳ0.24019
Ͳ6.64386
0.800256
Ͳ6.64386
0.564628
0.290626
0.268151
Ͳ6.64386
Ͳ6.64386
0.411109
Ͳ6.64386
1.061176
Ͳ6.64386
0.174387
Ͳ0.00632
Ͳ6.64386
Ͳ6.64386
0.305102
Ͳ6.64386
Ͳ0.27792
Ͳ0.22666
Ͳ6.64386
0.314893
0.305721
Ͳ6.64386
Ͳ0.35192
0.205278
Ͳ6.64386
1.223704
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.25313
Ͳ0.12589
Ͳ0.05977
Ͳ6.64386
Ͳ6.64386
0.460154
Ͳ6.64386
0.163441
Ͳ6.64386
Ͳ6.64386
0.495027
0.934587
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.307066
Ͳ6.64386
Ͳ6.64386
0.133232
0.872706
0.790244
0.26732
0.924665
1.590979
2.603513
1.313076
Ͳ6.64386
0.315373
0.200864
1.858665
1.648084
Ͳ0.01828
1.100687
Ͳ6.64386
0.93567
0.026504
2.021555
0.487591
0.61134
Ͳ6.64386
1.055742
Ͳ6.64386
1.800249
1.788654
0.967984
0.006291
Ͳ6.64386
0.190166
0.671569
169
hsaͲm
iRͲ654Ͳ3p
0.040924
0.007482
5.409095
dow
n
2.455466
2.8837745
5.195929
4.043083
2.418164
Ͳ6.64386
2.295139
2.102373
Ͳ6.64386
Ͳ6.64386
1.350828
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.66045
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.817968
Ͳ6.64386
Ͳ6.64386
1.822384
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.594548
1.812198
1.122266
1.562839
2.02273
Ͳ6.64386
1.048266
Ͳ6.64386
1.450364
1.099898
1.025182
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.776306
1.61086
1.215514
Ͳ6.64386
3.601564
Ͳ6.64386
1.871998
Ͳ6.64386
Ͳ6.64386
2.515205
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.545759
1.147399
Ͳ6.64386
3.005166
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.6106
Ͳ6.64386
2.138309
Ͳ6.64386
Ͳ6.64386
3.065861
Ͳ6.64386
1.547131
1.857868
1.558567
Ͳ 6.64386
3.82199
2.501044
1.641567
4.773651
5.836112
1.930169
Ͳ6.64386
0.999016
Ͳ6.64386
5.657347
1.314777
1.788812
Ͳ6.64386
Ͳ6.64386
1.503945
Ͳ6.64386
3.664637
2.818127
Ͳ6.64386
2.877577
Ͳ6.64386
2.691745
1.51116
170
hsaͲm
iRͲ3609
0.00615
7.19EͲ04
5.480611
dow
n
2.640783
2.0142174
0.246379
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.918386
1.53858
Ͳ0.25965
Ͳ6.64386
1.978464
Ͳ0.18387
Ͳ6.64386
Ͳ6.64386
2.495005
Ͳ0.48273
Ͳ6.64386
Ͳ0.54206
1.138458
Ͳ0.84284
Ͳ6.64386
1.964431
Ͳ6.64386
Ͳ6.64386
1.452438
Ͳ6.64386
Ͳ1.16185
Ͳ0.17031
Ͳ1.0381
0.017098
2.306973
1.770597
Ͳ0.19619
2.206435
Ͳ0.01264
Ͳ0.10777
0.663116
Ͳ6.64386
Ͳ0.10802
2.399818
Ͳ6.64386
Ͳ6.64386
1.100054
Ͳ0.9265
Ͳ0.71706
Ͳ0.29809
Ͳ6.64386
2.554539
Ͳ0.01599
Ͳ6.64386
Ͳ6.64386
Ͳ0.63133
2.696127
Ͳ6.64386
2.479901
Ͳ6.64386
Ͳ1.03069
1.335982
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.344473
1.897708
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.888016
2.419423
0.012525
1.49236
Ͳ6.64386
Ͳ0.11671
3.821995
Ͳ0.70924
2.247189
1.826658
2.302515
1.452677
Ͳ0.24123
3.561262
1.02901
3.26905
0.727123
0.591786
0.373057
0.42301
Ͳ0.0278
0.976227
1.564318
0.869304
Ͳ6.64386
0.212984
1.35573
Ͳ6.64386
1.944151
2.197089
1.474105
1.990227
0.379168
1.174651
1.149182
171
hsaͲm
iRͲ1306Ͳ3p
4.41EͲ04
2.74EͲ05
5.499783
dow
n
0.077389
1.3577682
Ͳ6.64386
1.144733
1.172045
Ͳ6.64386
0.498475
0.539473
0.345333
Ͳ6.64386
Ͳ0.0738
0.461883
Ͳ6.64386
Ͳ6.64386
0.623634
Ͳ6.64386
Ͳ6.64386
0.361827
0.60541
0.301706
Ͳ0.05918
Ͳ6.64386
Ͳ6.64386
Ͳ0.3071
0.158966
Ͳ0.32746
Ͳ6.64386
Ͳ0.11528
Ͳ0.23435
0.346794
Ͳ6.64386
Ͳ0.07997
Ͳ6.64386
0.250176
0.267373
Ͳ6.64386
Ͳ6.64386
0.064207
0.347692
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.414181
Ͳ6.64386
Ͳ6.64386
Ͳ0.31127
Ͳ6.64386
0.753494
Ͳ0.04343
Ͳ6.64386
Ͳ6.64386
Ͳ0.46383
0.705459
Ͳ6.64386
0.350428
Ͳ6.64386
Ͳ 6.64386
0.154437
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.920489
0.482586
0.539615
Ͳ0.11021
1.087619
0.026143
1.795747
0.025733
2.023031
Ͳ6.64386
1.218605
1.914208
Ͳ6.64386
1.195879
0.863563
0.949251
0.380028
Ͳ6.64386
1.007718
0.522138
1.106768
0.64404
0.801289
Ͳ0.0262
1.489812
0.456256
Ͳ0.32842
0.814662
1.084393
0.263151
Ͳ0.04752
Ͳ0.46126
Ͳ6.64386
0.899446
Ͳ0.19111
Ͳ6.64386
0.511587
Ͳ6.64386
1.116186
0.089789
172
hsaͲm
iRͲ4644
7.74EͲ04
5.47EͲ05
5.508903
dow
n
Ͳ0.74194
0.39489216
0.027415
5.939665
2.384125
2.189621
0.185036
0.084279
Ͳ6.64386
Ͳ6.64386
0.304176
1.087601
Ͳ6.64386
Ͳ0.92464
0.771829
0.424253
Ͳ6.64386
Ͳ0.98738
Ͳ0.13726
Ͳ6.64386
Ͳ6.64386
Ͳ0.70056
Ͳ6.64386
Ͳ1.0416
1.023471
Ͳ6.64386
Ͳ6.64386
0.841236
Ͳ6.64386
Ͳ0.08814
0.341791
0.149358
Ͳ0.46254
2.252646
Ͳ6.64386
Ͳ1.01775
Ͳ6.64386
Ͳ6.64386
0.476825
0.004968
Ͳ6.64386
Ͳ6.64386
0.424871
Ͳ6.64386
1.119752
Ͳ6.64386
Ͳ 6.64386
0.063575
Ͳ0.72434
Ͳ6.64386
Ͳ0.5124
0.216714
0.15978
Ͳ0.53672
0.356552
Ͳ6.64386
Ͳ0.33378
0.011919
Ͳ6.64386
Ͳ0.4618
Ͳ6.64386
Ͳ6.64386
1.082988
0.522363
Ͳ0.68613
0.011565
Ͳ0.75714
Ͳ0.51488
0.712235
0.081784
0.105886
Ͳ6.64386
Ͳ0.24794
0.808423
Ͳ6.64386
1.146488
0.654829
0.261319
0.849526
Ͳ0.32809
1.150576
0.215806
1.235991
Ͳ0.30315
1.800124
0.820817
Ͳ6.64386
0.657769
0.430449
Ͳ0.00499
0.921216
Ͳ0.48525
Ͳ0.68925
0.344818
Ͳ0.43091
0.727906
0.638131
Ͳ0.33378
1.361667
1.61257
0.730857
0.295432
173
hsaͲm
iRͲ103b
0.013613
0.002044
5.532397
dow
n
1.122968
1.4088964
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.224263
1.605174
0.087213
0.331191
0.228941
Ͳ6.64386
Ͳ6.64386
0.013213
0.813904
Ͳ6.64386
Ͳ6.64386
0.411318
0.491304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.01333
1.707838
Ͳ6.64386
Ͳ6.64386
0.15232
0.448058
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.380944
Ͳ6.64386
0.613605
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.589184
Ͳ6.64386
1.189717
0.176852
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.275757
Ͳ6.64386
1.465936
Ͳ6.64386
Ͳ6.64386
0.918317
Ͳ6.64386
Ͳ6.64386
0.312967
Ͳ6.64386
0.295763
1.224327
0.850974
Ͳ6.64386
1.507901
Ͳ0.05896
2.202786
0.287835
2.465806
0.128845
1.442148
2.044409
Ͳ6.64386
1.252575
Ͳ6.64386
1.825619
1.588562
Ͳ6.64386
1.007299
0.602139
0.296371
0.125289
1.014471
1.757601
0.332147
0.465105
0.43591
2.257441
0.056537
Ͳ6.64386
Ͳ6.64386
0.046077
Ͳ6.64386
Ͳ6.64386
0.57075
Ͳ6.64386
1.129991
Ͳ6.64386
Ͳ6.64386
1.012172
174
hsaͲm
iRͲ4311
0.010702
0.001551
5.535323
dow
n
1.856663
3.287876
Ͳ6.64386
2.75503
Ͳ6.64386
Ͳ6.64386
2.255714
2.163827
Ͳ6.64386
Ͳ6.64386
1.733876
2.263797
Ͳ6.64386
Ͳ6.64386
2.378217
1.995308
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.654233
Ͳ6.64386
Ͳ6.64386
2.559133
Ͳ6.64386
1.933576
2.440093
Ͳ6.64386
Ͳ6.64386
1.67461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.437827
Ͳ6.64386
1.774348
Ͳ6.64386
2.091084
1.771149
1.530936
Ͳ6.64386
Ͳ6.64386
1.787242
Ͳ6.64386
Ͳ6.64386
1.898256
1.55895
Ͳ6.64386
Ͳ6.64386
1.816881
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.913369
Ͳ6.64386
Ͳ6.64386
2.593048
1.81904
Ͳ6.64386
2.475936
Ͳ6.64386
Ͳ6.64386
2.106811
Ͳ6.64386
1.915858
Ͳ6.64386
Ͳ6.64386
2.856288
Ͳ6.64386
1.735601
1.994376
2.004497
2.58359
1.769032
2.707242
2.309031
2.546985
Ͳ6.64386
2.602433
2.215211
Ͳ6.64386
1.656573
1.805601
1.872594
2.728327
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.573446
2.104994
Ͳ6.64386
2.446906
2.810275
2.409905
Ͳ6.64386
175
hsaͲm
iRͲ92aͲ1Ͳ5p
0.032566
0.005782
5.652854
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.522339
Ͳ6.64386
1.849697
Ͳ6.64386
Ͳ6.64386
2.830838
2.437827
Ͳ6.64386
1.633474
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.057346
Ͳ6.64386
Ͳ6.64386
1.67461
Ͳ6.64386
2.398976
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.739717
1.745949
Ͳ6.64386
2.475301
Ͳ6.64386
Ͳ6.64386
2.084161
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.128498
1.968341
Ͳ6.64386
Ͳ6.64386
2.236935
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.962189
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.65062
Ͳ6.64386
Ͳ6.64386
2.630413
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.173206
2.316315
2.897028
1.932462
Ͳ6.64386
Ͳ6.64386
2.094094
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.802997
3.378551
2.355891
4.017071
2.86829
3.181061
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.468565
Ͳ6.64386
2.437827
Ͳ6.64386
2.178114
1.630929
3.190005
1.477135
1.853933
1.62915
Ͳ6.64386
Ͳ6.64386
2.915874
2.350972
Ͳ6.64386
1.654496
1.529457
Ͳ6.64386
Ͳ6.64386
2.955801
2.647757
176
hsaͲm
iRͲ934
0.004177
4.58EͲ04
5.713632
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.720414
Ͳ6.64386
Ͳ6.64386
1.463106
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.867803
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.79373
1.656737
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.981079
1.431994
2.770402
Ͳ6.64386
Ͳ6.64386
3.312089
2.241535
Ͳ6.64386
2.83126
2.976537
2.059006
Ͳ6.64386
Ͳ6.64386
2.796974
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
177
hsaͲm
iRͲ374cͲ5p
0.002805
2.80EͲ04
6.082301
dow
n
1.859147
1.8171436
1.080469
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.477413
0.412481
Ͳ0.64624
Ͳ6.64386
2.828533
1.171211
Ͳ6.64386
Ͳ6.64386
1.892311
Ͳ0.39317
Ͳ6.64386
Ͳ6.64386
0.734545
Ͳ6.64386
Ͳ6.64386
3.162806
Ͳ0.04834
Ͳ0.90914
2.956138
Ͳ6.64386
Ͳ0.87524
0.92365
Ͳ6.64386
0.906811
0.180017
Ͳ0.1008
Ͳ0.17808
1.466238
Ͳ0.8076
0.279763
Ͳ6.64386
Ͳ6.64386
0.218657
2.164827
Ͳ6.64386
Ͳ6.64386
0.28232
Ͳ6.64386
0.183651
Ͳ6.64386
Ͳ6.64386
0.149808
Ͳ6.64386
Ͳ6.64386
Ͳ0.13921
Ͳ0.97276
Ͳ0.00274
Ͳ0.40746
1.763905
Ͳ6.64386
0.313249
Ͳ0.8505
Ͳ6.64386
1.621398
Ͳ0.53135
Ͳ6.64386
0.028428
1.725454
Ͳ6.64386
Ͳ0.76637
Ͳ0.06754
Ͳ6.64386
2.364561
0.002735
1.145268
Ͳ0.27867
Ͳ0.49549
0.778953
Ͳ6.64386
2.626906
3.376529
Ͳ0.25046
1.5089
Ͳ0.58468
1.185049
0.637564
2.501167
Ͳ0.52393
0.654881
1.913162
0.54027
1.300147
1.488944
0.372734
1.616506
Ͳ6.64386
Ͳ0.51087
1.410159
Ͳ0.33435
0.343144
2.544057
0.814647
2.291188
0.551697
1.752286
0.84531
178
hsaͲm
iRͲ622
5.67EͲ06
1.46EͲ07
6.138279
dow
n
Ͳ0.37129
Ͳ6.643856
0.242127
1.496646
0.960614
0.730393
Ͳ6.64386
Ͳ0.2458
Ͳ6.64386
0.138493
Ͳ6.64386
Ͳ6.64386
1.880784
Ͳ6.64386
Ͳ0.48666
Ͳ0.40722
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.55377
0.090398
Ͳ0.70315
Ͳ6.64386
Ͳ0.08648
1.552022
0.393452
Ͳ0.20982
Ͳ0.34227
0.135141
Ͳ0.65658
Ͳ0.2373
Ͳ6.64386
0.953914
Ͳ0.558
0.011586
Ͳ0.37674
Ͳ6.64386
Ͳ6.64386
Ͳ0.27012
0.250307
Ͳ6.64386
0.595319
Ͳ0.74192
Ͳ0.014
Ͳ0.45374
Ͳ0.63912
0.082394
Ͳ6.64386
Ͳ6.64386
1.744839
0.297537
Ͳ6.64386
Ͳ0.18715
Ͳ6.64386
Ͳ0.01168
Ͳ0.15828
0.367239
Ͳ6.64386
0.895756
Ͳ0.22688
Ͳ0.33224
Ͳ6.64386
0.086676
0.631369
Ͳ6.64386
0.229831
Ͳ6.64386
Ͳ6.64386
0.891945
0.579431
0.872106
0.024806
1.879913
0.331535
0.695332
0.605279
0.122413
0.157151
0.400875
Ͳ0.42405
0.649116
0.321424
0.960657
1.308313
0.33147
Ͳ0.45937
Ͳ0.1149
0.442824
0.414604
0.083872
1.384818
0.257073
Ͳ0.19751
0.919334
Ͳ0.24226
0.136073
0.472779
0.729809
0.326519
0.721144
1.304422
0.112681
179
hsaͲm
iRͲ610
0.006736
8.06EͲ04
6.325314
dow
n
Ͳ6.64386
2.8077621
Ͳ6.64386
Ͳ6.64386
5.868232
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.850285
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.574062
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.734219
1.705307
Ͳ6.64386
Ͳ6.64386
1.490692
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.080222
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.870206
1.678614
Ͳ6.64386
1.864195
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.031351
2.199493
Ͳ6.64386
4.105862
2.077554
Ͳ6.64386
Ͳ6.64386
1.854677
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.053631
1.504433
Ͳ6.64386
1.94772
Ͳ6.64386
Ͳ6.64386
1.496108
1.693319
Ͳ6.64386
1.989184
Ͳ6.64386
Ͳ6.64386
2.690807
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.864085
Ͳ6.64386
1.667859
Ͳ6.64386
180
hsaͲm
iRͲ224Ͳ3p
8.00EͲ04
5.69EͲ05
6.372761
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.718526
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.03669
2.379218
1.897643
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.647741
Ͳ6.64386
3.024101
2.416665
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.379522
1.097976
Ͳ6.64386
3.810237
1.839642
3.163533
Ͳ6.64386
1.605548
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.576763
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.988674
181
hsaͲm
iRͲ181cͲ3p
0.003249
3.41EͲ04
6.808747
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.676787
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.782786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.630983
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.787627
2.148546
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.048043
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.117231
Ͳ6.64386
2.208153
Ͳ6.64386
1.829379
2.718638
1.817717
Ͳ6.64386
Ͳ6.64386
1.625578
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.651046
1.589829
1.958053
Ͳ6.64386
Ͳ6.64386
1.618099
1.631359
1.532428
1.726006
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.1694
Ͳ6.64386
182
hsaͲm
iRͲ4520aͲ3p
0.022563
0.003721
6.89
dow
n
2.053243
2.5661304
Ͳ6.64386
3.202604
Ͳ6.64386
3.614553
1.85489
1.6038
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.178908
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.602213
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.026057
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.035456
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.936209
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.191433
Ͳ6.64386
3.996568
Ͳ6.64386
Ͳ6.64386
1.784427
1.721181
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.373255
Ͳ6.64386
1.7399
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
2.171747
Ͳ6.64386
Ͳ6.64386
1.72461
1.700145
Ͳ6.64386
Ͳ6.64386
1.386777
1.717715
Ͳ6.64386
Ͳ6.64386
3.246389
Ͳ6.64386
1.918816
Ͳ6.64386
1.84061
Ͳ6.64386
2.077028
Ͳ6.64386
1.821091
Ͳ6.64386
3.168732
Ͳ6.64386
1.393437
Ͳ6.64386
2.523175
1.65926
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.980388
2.261028
2.114419
2.430308
1.931079
1.655536
Ͳ6.64386
183
hsaͲm
iRͲ194Ͳ5p
0.010414
0.001487
6.899473
dow
n
2.039175
Ͳ0.1923784
Ͳ0.51649
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.201835
1.537543
Ͳ6.64386
Ͳ0.34758
1.850561
1.15363
Ͳ6.64386
1.306241
2.816298
Ͳ6.64386
Ͳ6.64386
0.143969
1.468769
0.519234
Ͳ6.64386
2.369856
Ͳ0.11726
Ͳ6.64386
Ͳ0.2709
Ͳ6.64386
Ͳ0.22427
Ͳ0.41331
Ͳ6.64386
Ͳ0.34911
4.693038
1.334437
Ͳ6.64386
1.850561
Ͳ6.64386
0.043206
Ͳ6.64386
Ͳ 6.64386
0.264764
0.11032
Ͳ6.64386
Ͳ 6.64386
1.39272
Ͳ 6.64386
Ͳ6.64386
Ͳ 0.15075
Ͳ6.64386
0.877049
0.901399
Ͳ 6.64386
Ͳ0.10691
0.82364
Ͳ6.64386
2.283033
2.201949
Ͳ6.64386
Ͳ6.64386
2.988014
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.014425
0.89778
0.59083
Ͳ6.64386
Ͳ0.05468
2.248845
1.142742
2.584638
1.692041
Ͳ0.55607
1.979197
1.799548
6.823635
7.719881
2.17676
0.221425
Ͳ6.64386
Ͳ6.64386
0.785412
2.185077
2.067659
Ͳ0.04454
1.01004
3.292496
1.712329
2.15188
5.715419
0.487314
Ͳ0.26748
Ͳ0.26848
1.022448
Ͳ6.64386
0.360147
1.190616
Ͳ6.64386
3.183478
Ͳ6.64386
Ͳ6.64386
3.492302
184
hsaͲm
iRͲ7Ͳ1Ͳ3p
0.013779
0.002091
7.00258
dow
n
0.109394
Ͳ0.0969015
0.02762
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.42398
Ͳ0.11329
0.194998
Ͳ6.64386
0.497561
1.81594
Ͳ6.64386
0.218845
1.163747
Ͳ6.64386
Ͳ6.64386
0.85764
Ͳ6.64386
0.680425
Ͳ6.64386
0.834116
0.005964
Ͳ6.64386
0.478791
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.240086
1.467078
0.339388
Ͳ6.64386
1.062548
Ͳ6.64386
Ͳ6.64386
0.248437
Ͳ6.64386
0.223911
1.557568
Ͳ6.64386
Ͳ6.64386
0.637621
Ͳ0.38362
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.849739
0.761425
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.046402
1.134985
Ͳ6.64386
Ͳ0.27631
0.838553
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.229335
0.183986
0.338754
Ͳ6.64386
0.658356
Ͳ0.32897
1.053579
Ͳ0.65816
0.209581
0.026731
Ͳ0.65358
2.346782
0.905116
3.011919
3.480595
2.70126
0.481163
Ͳ6.64386
0.434209
Ͳ0.01626
2.510812
0.55985
0.733126
0.415407
Ͳ6.64386
1.932983
Ͳ1.06673
0.435395
Ͳ0.67733
Ͳ6.64386
0.812144
0.23564
0.538646
Ͳ6.64386
1.647729
Ͳ0.21218
0.451813
Ͳ6.64386
1.301179
Ͳ0.00599
185
hsaͲm
iRͲ31Ͳ5p
0.003738
4.00EͲ04
7.086216
dow
n
2.606509
1.0443804
3.802274
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.89647
Ͳ0.66743
Ͳ0.69267
Ͳ1.50976
Ͳ6.64386
Ͳ6.64386
Ͳ1.33783
Ͳ0.06623
2.905756
Ͳ 2.00274
Ͳ0.9702
0.480935
0.401242
2.880854
Ͳ0.37098
Ͳ 6.64386
3.355001
Ͳ 6.64386
0.004389
Ͳ 0.91041
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
0.652615
Ͳ 0.69267
Ͳ6.64386
4.459109
Ͳ6.64386
Ͳ1.15786
Ͳ1.26577
2.818293
3.890906
Ͳ6.64386
Ͳ6.64386
0.529433
1.223549
3.030664
Ͳ0.0044
1.954172
2.08476
4.422665
Ͳ0.13936
Ͳ6.64386
Ͳ2.21014
Ͳ6.64386
Ͳ6.64386
3.765939
Ͳ6.64386
2.632103
Ͳ6.64386
2.096123
Ͳ6.64386
0.03182
0.087351
Ͳ1.27194
Ͳ6.64386
Ͳ2.08558
6.225945
6.296974
0.695955
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ1.91595
2.01603
6.691265
5.156364
5.22871
3.420003
6.345237
Ͳ6.64386
2.948905
4.507284
0.455922
3.987699
1.121189
5.189586
4.88536
Ͳ6.64386
Ͳ6.64386
5.210703
Ͳ6.64386
4.56983
4.832521
Ͳ0.79387
4.248865
Ͳ6.64386
5.127465
5.544663
3.372379
3.365554
2.903546
1.459037
3.206612
186
hsaͲm
iRͲ4474Ͳ5p
0.004085
4.46EͲ04
7.169808
dow
n
Ͳ6.64386
3.451515
Ͳ6.64386
2.727507
Ͳ6.64386
Ͳ6.64386
2.190213
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.613845
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.359824
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.649331
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.55145
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.952106
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.790343
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.275979
Ͳ6.64386
Ͳ6.64386
1.813013
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.396334
1.84082
1.911163
Ͳ6.64386
1.865087
Ͳ6.64386
Ͳ6.64386
1.578571
1.925953
Ͳ6.64386
2.663302
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.84257
2.438099
1.790808
Ͳ6.64386
3.040648
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
187
hsaͲm
iRͲ149Ͳ5p
1.47EͲ04
7.24EͲ06
7.747861
dow
n
Ͳ0.33207
1.1644148
0.509382
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.09681
Ͳ6.64386
0.005863
0.623161
Ͳ0.44219
Ͳ6.64386
Ͳ6.64386
0.960857
Ͳ6.64386
1.330623
2.557957
2.596448
Ͳ6.64386
Ͳ6.64386
0.014352
1.25725
Ͳ0.59862
Ͳ0.54195
Ͳ0.08977
Ͳ0.35145
0.103637
0.141556
Ͳ6.64386
Ͳ0.31335
Ͳ0.41832
Ͳ6.64386
1.846388
Ͳ6.64386
Ͳ0.41431
0.992463
0.192182
Ͳ0.27745
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.25997
Ͳ6.64386
1.150667
Ͳ 6.64386
Ͳ0.5711
Ͳ0.58747
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.631777
0.577586
Ͳ6.64386
0.27664
Ͳ6.64386
Ͳ6.64386
0.159668
Ͳ6.64386
Ͳ6.64386
0.309997
Ͳ0.00589
1.034794
1.614685
0.336724
Ͳ6.64386
0.151176
3.25865
0.10972
2.961028
1.447955
1.684604
0.839246
0.803035
Ͳ0.39091
0.499439
0.544191
0.881885
0.148434
2.13767
Ͳ0.03214
2.305105
1.903065
0.37906
1.164916
3.441813
2.352657
1.906011
0.977319
Ͳ6.64386
Ͳ0.15578
0.505487
1.069563
Ͳ6.64386
Ͳ0.15379
1.110828
Ͳ6.64386
0.417061
Ͳ6.64386
1.919202
0.862448
188
hsaͲm
iRͲ16Ͳ1Ͳ3p
0.010709
0.001557
7.805436
dow
n
2.179667
1.8127222
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.367125
1.871406
3.335123
1.992589
2.03873
Ͳ6.64386
Ͳ6.64386
2.374334
2.446389
Ͳ6.64386
2.042342
1.583677
Ͳ6.64386
2.057346
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.57533
Ͳ6.64386
Ͳ6.64386
1.482914
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.042342
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.180352
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.852816
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.355071
Ͳ6.64386
2.071335
Ͳ6.64386
1.576763
2.282282
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.809479
1.730568
2.108166
Ͳ6.64386
Ͳ6.64386
2.450975
2.784997
Ͳ6.64386
2.852843
Ͳ6.64386
Ͳ6.64386
3.325012
Ͳ6.64386
1.770322
1.521116
2.247746
2.579866
Ͳ6.64386
1.901456
Ͳ6.64386
2.395138
Ͳ6.64386
1.789757
2.385062
1.684392
1.496108
2.523952
2.598076
2.057712
Ͳ6.64386
1.743972
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.30406
1.529457
2.529138
1.909494
2.251484
2.273157
189
hsaͲm
iRͲ7Ͳ5p
5.58EͲ08
4.12EͲ10
8.046594
dow
n
Ͳ0.63
Ͳ1.6485517
0.816993
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.27626
2.601965
Ͳ1.37578
0.130162
Ͳ0.75873
0.6413
Ͳ0.1053
Ͳ1.12438
0.034934
Ͳ6.64386
Ͳ1.522
Ͳ0.00655
Ͳ1.88806
Ͳ0.59077
Ͳ6.64386
Ͳ 0.4224
0.168041
Ͳ2.89447
Ͳ0.04346
Ͳ6.64386
Ͳ6.64386
Ͳ1.19387
Ͳ2.64663
0.444638
0.693998
Ͳ1.70643
0.006517
2.474386
Ͳ0.73678
Ͳ6.64386
0.767776
Ͳ0.69186
0.629556
0.712118
Ͳ2.41694
Ͳ2.7022
Ͳ0.20682
Ͳ0.16705
Ͳ1.91793
Ͳ0.91243
Ͳ1.29106
1.628931
Ͳ0.05974
Ͳ1.64374
Ͳ0.90167
Ͳ1.76254
Ͳ0.74154
0.019332
0.502929
Ͳ0.71883
Ͳ0.14131
Ͳ0.53463
Ͳ6.64386
2.078277
Ͳ2.23384
Ͳ6.64386
Ͳ0.06612
0.172849
1.162329
Ͳ1.76404
1.666734
Ͳ0.45434
2.975302
1.359522
0.332055
0.173939
1.434083
3.081241
4.60415
4.605849
4.808523
3.815133
3.110069
Ͳ1.03924
1.339864
2.421348
2.935575
1.351255
2.57953
1.28519
0.40403
2.865188
Ͳ1.42484
1.945308
0.726911
0.266518
2.254752
0.964012
1.795653
Ͳ0.30643
4.012891
1.911219
1.763585
2.202329
1.672685
1.319723
190
hsaͲm
iRͲ3170
5.75EͲ04
3.75EͲ05
8.304263
dow
n
Ͳ6.64386
0.38874757
Ͳ6.64386
6.977388
3.693345
1.590369
0.38187
0.682224
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.711709
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.014126
0.47467
Ͳ6.64386
Ͳ0.01574
Ͳ6.64386
Ͳ6.64386
Ͳ0.14623
Ͳ6.64386
Ͳ0.01427
Ͳ6.64386
Ͳ6.64386
0.240276
Ͳ6.64386
0.345137
Ͳ6.64386
3.19758
0.305658
Ͳ6.64386
Ͳ6.64386
0.627012
0.307663
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.013662
Ͳ6.64386
0.767094
Ͳ6.64386
Ͳ6.64386
0.524879
Ͳ6.64386
0.985829
Ͳ6.64386
0.598711
0.617344
Ͳ6.64386
0.217701
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.763504
Ͳ6.64386
Ͳ6.64386
1.932853
0.089557
Ͳ6.64386
Ͳ6.64386
0.646074
0.952416
1.001374
Ͳ6.64386
0.931371
Ͳ6.64386
Ͳ6.64386
1.509308
Ͳ6.64386
1.488268
0.583346
0.727822
0.862003
Ͳ6.64386
1.609638
0.626885
1.215468
0.2252
1.471852
1.182831
0.513207
Ͳ0.22967
Ͳ0.13348
0.563335
0.504417
Ͳ6.64386
0.543673
Ͳ0.03372
0.804989
1.184305
0.674445
Ͳ6.64386
1.192834
2.246168
1.572305
0.372594
191
hsaͲm
iRͲ3131
0.002805
2.81EͲ04
8.680573
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
2.256387
3.336063
Ͳ6.64386
1.821208
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.267901
Ͳ6.64386
1.633474
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.529457
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.739717
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.335124
1.986809
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.684738
Ͳ6.64386
Ͳ6.64386
1.726755
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.700145
2.222124
Ͳ6.64386
Ͳ6.64386
1.706045
1.690337
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.999675
2.381614
2.344619
Ͳ6.64386
1.563883
1.523571
Ͳ6.64386
1.362842
Ͳ 6.64386
1.686596
2.040205
Ͳ6.64386
1.865847
Ͳ6.64386
Ͳ6.64386
2.088916
Ͳ6.64386
Ͳ6.64386
1.740668
1.976758
2.000199
1.824543
192
hsaͲm
iRͲ2278
0.001325
1.12EͲ04
8.703324
dow
n
1.802125
3.1461701
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.436693
1.633882
Ͳ6.64386
Ͳ6.64386
2.065538
1.877408
Ͳ6.64386
Ͳ6.64386
1.985164
Ͳ6.64386
Ͳ6.64386
1.407856
Ͳ6.64386
1.333088
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.863904
Ͳ6.64386
0.99897
1.894001
Ͳ6.64386
1.970058
2.058952
Ͳ6.64386
Ͳ6.64386
1.805119
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.166081
1.224631
Ͳ6.64386
Ͳ6.64386
1.741496
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.741859
1.485858
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.412829
Ͳ6.64386
Ͳ6.64386
1.593953
Ͳ6.64386
1.677061
Ͳ6.64386
Ͳ6.64386
2.033443
1.950832
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.759362
2.177094
1.477018
Ͳ6.64386
Ͳ6.64386
2.06781
2.436899
Ͳ6.64386
2.13781
2.216776
1.977307
1.811187
Ͳ6.64386
1.569702
1.925486
2.087412
1.085385
1.946317
1.971392
Ͳ6.64386
1.969789
2.095067
1.503593
2.367323
Ͳ6.64386
Ͳ6.64386
1.477018
Ͳ6.64386
2.004742
2.296296
Ͳ6.64386
2.57508
1.794844
2.341644
1.459134
193
hsaͲm
iRͲ1305
1.48EͲ05
4.76EͲ07
8.817349
dow
n
Ͳ0.05392
0.2911118
Ͳ0.31813
3.147101
1.828015
Ͳ6.64386
Ͳ0.06561
0.494649
0.026804
Ͳ0.39492
Ͳ0.29717
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.3367
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.37132
0.01122
Ͳ0.24507
Ͳ0.32102
0.425353
0.97732
Ͳ0.6208
Ͳ0.20979
Ͳ0.37418
0.334538
Ͳ6.64386
0.977571
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.127188
Ͳ6.64386
Ͳ6.64386
Ͳ0.04954
1.346713
Ͳ6.64386
0.213351
1.316431
Ͳ0.12469
Ͳ6.64386
1.248259
Ͳ0.07247
Ͳ6.64386
0.106187
Ͳ6.64386
Ͳ6.64386
0.599998
Ͳ0.16783
0.474505
1.318161
Ͳ6.64386
Ͳ0.04309
Ͳ0.32102
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.730551
Ͳ0.01131
Ͳ0.08881
1.579177
1.561056
0.460362
0.292661
1.052339
0.521721
0.760654
0.655925
0.338785
0.025912
0.635198
Ͳ0.38433
0.124144
1.033562
1.846946
0.339426
1.352803
0.566948
Ͳ0.19708
2.877851
0.927422
Ͳ0.04708
0.277972
0.884922
0.493784
0.499197
1.327915
2.57843
0.025867
0.646373
Ͳ0.11758
Ͳ0.39133
Ͳ6.64386
1.279204
1.609427
0.394351
0.418273
194
hsaͲm
iRͲ3146
0.001636
1.43EͲ04
9.022174
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.709423
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.794761
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.060057
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.905605
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.760424
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.997475
2.675849
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.176678
Ͳ6.64386
1.651177
Ͳ6.64386
Ͳ6.64386
2.257288
Ͳ6.64386
Ͳ6.64386
1.758747
2.302558
2.490294
Ͳ6.64386
5.362976
Ͳ6.64386
1.315536
Ͳ6.64386
3.483781
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.138691
1.917761
Ͳ6.64386
1.911721
Ͳ6.64386
5.723573
Ͳ6.64386
195
hsaͲm
iRͲ27bͲ5p
0.002927
2.98EͲ04
9.261446
dow
n
Ͳ6.64386
2.4386322
4.066857
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.005816
1.715055
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.457444
Ͳ6.64386
Ͳ6.64386
2.607524
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.511827
Ͳ6.64386
Ͳ6.64386
2.632738
Ͳ6.64386
Ͳ6.64386
1.890339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.263148
1.745949
Ͳ6.64386
Ͳ6.64386
2.686242
2.454675
2.022789
2.156613
Ͳ6.64386
2.37396
2.458146
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.716448
Ͳ6.64386
Ͳ6.64386
1.730921
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.687984
3.235098
Ͳ6.64386
Ͳ6.64386
3.23005
2.473869
2.826667
2.213773
4.060155
3.956826
Ͳ6.64386
3.131321
Ͳ6.64386
Ͳ6.64386
2.633876
Ͳ6.64386
2.590073
Ͳ6.64386
3.434176
3.507367
2.756324
4.521228
3.047589
4.170197
3.002121
3.717723
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.813938
Ͳ6.64386
1.717346
1.882997
Ͳ6.64386
3.169
196
hsaͲm
iRͲ3713
0.006907
8.44EͲ04
9.587804
dow
n
Ͳ6.64386
3.579584
1.578571
Ͳ6.64386
8.886287
Ͳ6.64386
1.996426
2.095881
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.553304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.294992
Ͳ6.64386
Ͳ6.64386
2.350487
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.692399
Ͳ6.64386
1.745949
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
2.370747
Ͳ6.64386
Ͳ6.64386
1.652839
2.248792
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.995927
Ͳ6.64386
3.006669
Ͳ6.64386
Ͳ6.64386
2.367342
1.721181
Ͳ6.64386
Ͳ6.64386
1.880878
2.221898
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.597522
2.368003
3.496071
Ͳ6.64386
Ͳ6.64386
3.591678
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.138298
Ͳ6.64386
2.533964
Ͳ6.64386
2.936627
1.660408
Ͳ6.64386
3.331266
Ͳ6.64386
2.264149
2.169837
1.675574
2.024855
Ͳ6.64386
3.000579
2.683266
Ͳ6.64386
Ͳ6.64386
2.3324
1.850196
1.690188
Ͳ6.64386
1.329455
1.846348
2.573445
1.679923
3.098117
Ͳ6.64386
1.943721
2.929984
2.041359
Ͳ6.64386
2.745544
2.217496
2.038223
Ͳ6.64386
197
hsaͲm
iRͲ297
0.010271
0.001461
9.661793
dow
n
1.62404
3.2727983
1.496108
2.654046
Ͳ6.64386
Ͳ6.64386
2.254688
1.674634
Ͳ6.64386
Ͳ6.64386
2.290269
2.463106
Ͳ6.64386
2.003965
2.633474
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.654233
Ͳ6.64386
Ͳ6.64386
2.031201
Ͳ6.64386
1.785477
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.890339
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.833755
2.553304
Ͳ6.64386
Ͳ6.64386
2.58089
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.999074
Ͳ6.64386
2.263391
Ͳ6.64386
Ͳ6.64386
1.977751
2.386139
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.358678
2.374137
2.016461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.334363
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.349749
2.580146
Ͳ6.64386
2.737703
3.192593
1.813224
2.197504
1.68657
2.449144
2.110457
2.256251
1.345904
1.869759
1.918543
Ͳ6.64386
2.900498
1.914777
1.796679
2.674466
Ͳ6.64386
Ͳ6.64386
1.947583
Ͳ6.64386
2.27338
2.727771
Ͳ6.64386
2.703888
Ͳ6.64386
2.150422
Ͳ6.64386
198
hsaͲm
iRͲ617
1.49EͲ05
4.87EͲ07
10.12681
dow
n
0.866089
1.8715293
Ͳ0.35085
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.669351
1.274259
Ͳ6.64386
Ͳ0.5151
0.318632
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.168996
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.545329
Ͳ6.64386
1.15105
1.027202
Ͳ0.44604
Ͳ6.64386
1.160642
Ͳ0.58355
0.197617
0.163184
Ͳ6.64386
0.797226
Ͳ0.25589
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.419175
Ͳ0.40028
Ͳ6.64386
Ͳ6.64386
0.672662
Ͳ0.50481
0.389568
Ͳ0.15485
Ͳ6.64386
1.248307
Ͳ0.22357
Ͳ6.64386
0.023055
Ͳ0.41736
1.280387
Ͳ0.08271
Ͳ0.24693
Ͳ6.64386
Ͳ6.64386
Ͳ0.09992
Ͳ6.64386
0.952995
Ͳ6.64386
Ͳ6.64386
2.590314
0.231691
Ͳ6.64386
Ͳ6.64386
Ͳ0.02343
0.835593
1.628633
0.900037
1.401683
Ͳ6.64386
2.29596
2.06441
Ͳ0.59271
0.831726
0.069851
0.982684
1.947986
Ͳ6.64386
2.015002
2.749249
1.359686
0.179001
2.463919
1.202064
0.626901
1.004244
0.954892
0.365213
1.842247
Ͳ0.47408
0.218052
1.215539
1.728248
2.468187
1.324452
Ͳ6.64386
1.641007
1.952464
1.994414
Ͳ0.41677
199
hsaͲm
iRͲ299Ͳ3p
0.001145
9.29EͲ05
10.29763
dow
n
Ͳ6.64386
Ͳ6.643856
0.015134
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.263997
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.251423
Ͳ6.64386
0.694129
Ͳ6.64386
0.603743
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.9374
Ͳ6.64386
1.426226
Ͳ6.64386
0.7538
Ͳ6.64386
0.459353
Ͳ6.64386
Ͳ6.64386
0.760185
1.000965
0.240134
Ͳ6.64386
Ͳ6.64386
0.964485
Ͳ6.64386
0.327669
Ͳ6.64386
0.592607
0.487367
0.642976
Ͳ6.64386
1.404109
Ͳ6.64386
Ͳ6.64386
0.611054
1.156698
Ͳ6.64386
Ͳ6.64386
0.59654
Ͳ6.64386
1.464595
0.415493
0.59201
Ͳ6.64386
1.028083
0.899497
0.259328
0.840595
0.408889
1.083634
0.901427
1.400698
1.155918
0.623675
1.440847
1.718301
1.038486
0.434473
0.941901
1.193961
0.348321
0.655032
0.252262
Ͳ6.64386
0.407451
1.22685
0.867243
0.297033
Ͳ6.64386
1.04119
Ͳ0.01529
Ͳ6.64386
Ͳ6.64386
0.218076
Ͳ6.64386
Ͳ6.64386
1.315351
Ͳ6.64386
1.091995
200
hsaͲm
iRͲ3125
1.56EͲ05
5.17EͲ07
10.45982
dow
n
Ͳ0.05449
0.5209886
Ͳ0.00651
Ͳ6.64386
Ͳ6.64386
2.094955
0.403678
0.249612
Ͳ6.64386
Ͳ6.64386
0.287839
0.332539
Ͳ6.64386
Ͳ6.64386
0.342286
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.118141
4.75EͲ04
Ͳ6.64386
Ͳ6.64386
0.590317
Ͳ0.19377
Ͳ0.16106
Ͳ6.64386
Ͳ6.64386
0.49429
0.361839
0.739021
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.47666
0.040572
Ͳ6.64386
Ͳ4.75EͲ04
0.335462
Ͳ0.08433
Ͳ6.64386
0.242669
Ͳ6.64386
Ͳ0.06108
Ͳ6.64386
1.097886
0.012274
Ͳ6.64386
0.051703
Ͳ0.33783
Ͳ0.22253
Ͳ6.64386
Ͳ6.64386
Ͳ0.11762
Ͳ6.64386
0.754722
Ͳ6.64386
Ͳ6.64386
0.49767
0.144095
Ͳ6.64386
0.053308
0.075569
Ͳ0.03813
0.348044
0.468294
1.422355
0.155954
0.451442
0.372965
0.535932
0.085801
0.707341
0.330278
1.102969
Ͳ6.64386
1.08567
1.035971
0.748606
Ͳ0.83175
0.74572
0.636719
Ͳ6.64386
Ͳ0.00651
0.333108
0.322683
1.199933
Ͳ0.19248
0.271988
Ͳ0.54753
Ͳ0.04547
1.07372
1.425929
Ͳ0.04413
1.39653
1.123079
1.09166
0.191027
201
hsaͲm
iRͲ4768Ͳ3p
3.71EͲ04
2.23EͲ05
11.11902
dow
n
Ͳ6.64386
1.577872
Ͳ6.64386
4.331938
2.38232
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.678835
Ͳ6.64386
Ͳ6.64386
1.330911
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.145219
Ͳ6.64386
Ͳ6.64386
1.511827
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.005816
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.649331
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.252812
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.857377
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.785609
1.980832
Ͳ6.64386
2.202605
Ͳ6.64386
Ͳ6.64386
1.873628
Ͳ6.64386
2.540364
1.990994
3.229013
1.345904
3.305186
Ͳ6.64386
Ͳ6.64386
1.83491
1.582138
Ͳ6.64386
1.756746
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.986455
Ͳ6.64386
2.242366
2.940017
2.390491
Ͳ6.64386
202
hsaͲm
iRͲ4719
0.007075
8.69EͲ04
11.2437
dow
n
Ͳ6.64386
Ͳ6.643856
2.694048
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.553304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.947583
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.962416
Ͳ6.64386
4.98451
Ͳ6.64386
Ͳ6.64386
2.115898
2.604936
Ͳ6.64386
2.506761
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.105845
Ͳ6.64386
Ͳ6.64386
2.944786
2.620418
Ͳ6.64386
2.643502
1.784423
1.974683
3.070095
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.241806
2.018382
2.463269
Ͳ6.64386
1.712858
1.839867
1.980118
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.623901
1.645786
Ͳ6.64386
2.253624
Ͳ6.64386
2.214072
Ͳ6.64386
2.300538
Ͳ6.64386
2.408824
1.817329
2.459166
1.733138
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.774064
2.68657
Ͳ6.64386
3.680322
3.403603
1.682939
4.071057
1.530495
Ͳ6.64386
1.537929
2.306247
Ͳ6.64386
2.246686
Ͳ6.64386
2.603777
3.008983
6.353902
5.403158
1.811231
4.122412
3.053942
5.203001
1.90521
Ͳ6.64386
203
hsaͲm
iRͲ3682Ͳ3p
8.17EͲ05
3.31EͲ06
13.37263
dow
n
1.183652
1.9550555
0.074497
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.408979
1.63161
Ͳ6.64386
Ͳ6.64386
0.883422
0.132941
Ͳ6.64386
Ͳ6.64386
1.130515
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.368589
0.788703
Ͳ6.64386
Ͳ6.64386
0.785362
Ͳ6.64386
0.434521
0.406346
Ͳ6.64386
Ͳ6.64386
0.344445
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.426908
0.282518
Ͳ6.64386
Ͳ6.64386
0.596626
Ͳ6.64386
0.154968
Ͳ6.64386
Ͳ6.64386
1.237155
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.182982
Ͳ6.64386
Ͳ6.64386
0.002427
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.108174
Ͳ6.64386
Ͳ6.64386
1.705668
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.149808
0.622684
0.189408
0.536687
Ͳ6.64386
Ͳ0.00243
1.592877
Ͳ6.64386
0.435832
0.867218
0.967055
1.623775
Ͳ6.64386
2.015618
1.705948
1.176137
Ͳ6.64386
1.235052
0.920644
0.286933
0.589071
1.178911
0.600104
1.196631
0.368739
Ͳ6.64386
0.089873
0.441966
1.597709
2.125108
Ͳ6.64386
1.616736
1.720587
1.571806
0.163855
204
hsaͲm
iRͲ1183
4.14EͲ06
9.60EͲ08
13.50259
dow
n
Ͳ6.64386
1.2184236
Ͳ6.64386
1.830135
0.346827
Ͳ6.64386
0.085354
0.600568
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.282899
Ͳ6.64386
Ͳ6.64386
Ͳ0.35068
Ͳ0.2495
Ͳ6.64386
0.251147
Ͳ0.32001
Ͳ6.64386
0.04256
Ͳ0.41763
Ͳ6.64386
Ͳ6.64386
0.781005
Ͳ6.64386
0.770951
Ͳ6.64386
Ͳ6.64386
Ͳ0.08887
Ͳ6.64386
0.481942
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.487274
Ͳ6.64386
Ͳ6.64386
0.019101
0.654461
Ͳ6.64386
Ͳ0.58673
Ͳ6.64386
Ͳ6.64386
0.482315
Ͳ6.64386
Ͳ6.64386
1.397837
Ͳ0.05348
0.643013
0.412282
Ͳ0.0478
Ͳ0.23199
Ͳ6.64386
Ͳ0.31077
Ͳ6.64386
0.921681
Ͳ6.64386
Ͳ6.64386
0.438894
0.272656
0.387555
0.396787
1.241854
Ͳ0.43303
0.880579
0.228679
0.931114
Ͳ 0.26358
0.396129
1.39893
0.071195
0.917487
0.841443
0.577231
0.900773
0.527248
1.214669
0.630651
0.723167
0.365967
0.191023
Ͳ0.07576
1.285069
Ͳ0.01936
0.104184
1.018129
1.255652
0.805208
1.897316
Ͳ0.47791
Ͳ6.64386
1.194965
Ͳ0.27306
Ͳ0.5424
0.392544
0.436377
0.781254
0.395295
205
hsaͲm
iRͲ200cͲ5p
2.14EͲ04
1.17EͲ05
13.61658
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.66417
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.721181
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.623958
Ͳ6.64386
2.363826
Ͳ6.64386
Ͳ6.64386
2.008805
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.628072
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.956759
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.711329
3.723585
Ͳ6.64386
3.486183
2.709221
3.45182
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.376096
2.227259
Ͳ6.64386
Ͳ6.64386
3.597163
3.694048
Ͳ6.64386
3.16346
1.708104
1.926096
2.733171
Ͳ6.64386
Ͳ6.64386
1.764648
1.73368
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.246747
206
hsaͲm
iRͲ2115Ͳ3p
1.64EͲ04
8.45EͲ06
13.62161
dow
n
Ͳ6.64386
2.62955
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.830511
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.593946
Ͳ6.64386
1.627304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.870494
Ͳ6.64386
2.014884
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.67461
1.729495
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.692399
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.485072
1.646413
Ͳ6.64386
Ͳ6.64386
1.648011
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.325085
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.661207
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.014873
1.795519
Ͳ6.64386
1.861184
1.764044
1.414997
2.802075
Ͳ6.64386
Ͳ6.64386
1.566621
Ͳ6.64386
1.950177
Ͳ6.64386
2.136902
2.844026
1.710107
2.968341
1.730384
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.956586
Ͳ6.64386
1.765037
1.649598
Ͳ6.64386
1.816338
2.068079
2.153004
1.813959
Ͳ6.64386
1.88048
2.478255
2.168061
Ͳ6.64386
207
hsaͲm
iRͲ1244
1.30EͲ05
4.04EͲ07
13.87607
dow
n
Ͳ1.17784
0.45319122
1.185614
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.018604
1.841017
Ͳ6.64386
Ͳ6.64386
0.020897
Ͳ0.3825
Ͳ6.64386
Ͳ6.64386
1.924928
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ1.30936
Ͳ6.64386
Ͳ6.64386
0.457779
Ͳ6.64386
Ͳ6.64386
1.279992
Ͳ6.64386
Ͳ6.64386
Ͳ0.412
Ͳ6.64386
Ͳ0.47889
1.442522
1.665505
2.047183
1.48108
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.578596
Ͳ0.0212
Ͳ6.64386
Ͳ6.64386
0.528892
Ͳ6.64386
Ͳ1.05235
Ͳ0.47881
Ͳ6.64386
1.742239
Ͳ0.51948
Ͳ6.64386
Ͳ6.64386
Ͳ1.23292
0.053485
Ͳ6.64386
Ͳ1.61333
Ͳ6.64386
Ͳ1.66116
0.256286
Ͳ6.64386
4.134129
Ͳ6.64386
Ͳ 6.64386
0.965265
0.879787
Ͳ6.64386
Ͳ6.64386
Ͳ1.16636
1.129898
1.53226
0.269576
1.566097
Ͳ6.64386
0.128173
2.722334
1.094314
2.252738
2.249179
2.86814
2.000881
Ͳ6.64386
2.2658
1.786254
2.782764
0.257192
1.898753
2.930369
1.401092
0.957808
0.40144
1.186396
1.265948
Ͳ6.64386
0.464933
2.620073
Ͳ6.64386
1.354936
1.571996
0.642619
1.508699
1.713129
2.955161
0.933477
208
hsaͲm
iRͲ10aͲ3p
0.001258
1.04EͲ04
15.86066
dow
n
2.130308
2.45289
Ͳ6.64386
Ͳ6.64386
9.730393
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.072678
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.089357
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.207026
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.1727
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.785477
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.305376
Ͳ6.64386
3.03873
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.482914
Ͳ6.64386
Ͳ6.64386
2.317855
Ͳ6.64386
1.816338
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.735724
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.720469
1.500101
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.916878
Ͳ6.64386
6.159987
6.330161
4.272388
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.099307
Ͳ6.64386
3.086661
Ͳ6.64386
5.408282
5.33283
2.385925
4.085471
3.705755
2.157878
1.947215
1.858597
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.97453
Ͳ6.64386
2.171114
1.937805
5.533538
4.239199
209
hsaͲm
iRͲ182Ͳ5p
1.59EͲ10
1.67EͲ13
16.29153
dow
n
Ͳ2.39413
Ͳ1.3608972
Ͳ6.64386
0.458665
Ͳ0.54648
1.731219
Ͳ2.14087
0.379067
Ͳ6.64386
Ͳ1.87957
Ͳ2.477
Ͳ6.64386
Ͳ0.77012
Ͳ6.64386
Ͳ1.31548
Ͳ2.40766
Ͳ2.20597
Ͳ1.78181
Ͳ 2.24357
Ͳ6.64386
0.759984
Ͳ6.64386
Ͳ0.1907
Ͳ2.36655
Ͳ1.6268
Ͳ1.85491
Ͳ1.59248
Ͳ0.64721
Ͳ1.6359
Ͳ2.29023
Ͳ2.16373
Ͳ2.85366
Ͳ0.13298
0.316261
0.614767
Ͳ1.53077
0.925616
Ͳ1.98013
0.390755
Ͳ1.58302
Ͳ1.23901
Ͳ0.39001
Ͳ2.51821
0.659415
Ͳ2.7021
Ͳ0.72269
Ͳ0.90568
1.863248
Ͳ2.51878
2.951473
Ͳ1.25622
Ͳ6.64386
Ͳ0.29057
1.945688
2.240499
Ͳ1.55864
Ͳ1.24369
Ͳ2.53421
Ͳ0.60851
Ͳ0.31223
Ͳ1.94589
Ͳ0.11595
0.107323
1.942737
Ͳ0.34475
1.31057
0.429375
Ͳ0.92802
4.226424
1.279001
2.868915
4.160359
2.684435
3.603123
2.996245
3.101135
3.876514
3.461414
2.085054
1.298048
0.966914
1.402365
3.312961
1.954631
2.78522
1.342767
2.877373
2.770814
1.351255
2.10913
2.061064
1.580144
2.578555
2.852946
0.819637
3.639093
3.550882
0.408385
2.505319
2.341479
0.978574
3.129126
210
hsaͲm
iRͲ206
3.85EͲ04
2.35EͲ05
18.04436
dow
n
2.482465
3.8463438
Ͳ6.64386
3.505062
Ͳ6.64386
Ͳ6.64386
2.642643
2.604895
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.671948
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.576024
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.09679
2.408914
Ͳ6.64386
Ͳ6.64386
2.58089
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.039655
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.456808
Ͳ6.64386
Ͳ6.64386
1.64366
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.579031
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.280787
2.576147
Ͳ6.64386
2.127694
Ͳ6.64386
1.62337
3.656008
Ͳ6.64386
1.975337
1.915572
1.736504
Ͳ6.64386
Ͳ6.64386
2.545847
2.57931
2.692561
1.345904
2.626003
1.837118
Ͳ6.64386
2.109085
2.251618
1.867179
2.281539
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.489209
2.026071
Ͳ6.64386
2.814846
2.229295
3.544617
Ͳ6.64386
211
hsaͲm
iRͲ205Ͳ5p
0.001084
8.52EͲ05
19.47374
dow
n
Ͳ6.64386
Ͳ6.643856
2.543556
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.302733
Ͳ6.64386
1.545704
Ͳ6.64386
Ͳ6.64386
3.38687
Ͳ6.64386
Ͳ6.64386
2.067209
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.675947
Ͳ6.64386
2.102417
1.535084
Ͳ6.64386
Ͳ6.64386
1.367505
Ͳ6.64386
1.276635
1.332422
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.483893
Ͳ6.64386
Ͳ6.64386
2.180419
1.138943
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.763262
2.405979
1.379899
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
4.371404
1.994102
Ͳ6.64386
1.736766
Ͳ6.64386
Ͳ 6.64386
1.871373
1.709114
1.242374
Ͳ 6.64386
3.784923
1.894262
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
1.550092
Ͳ6.64386
Ͳ6.64386
0.998922
4.997757
Ͳ6.64386
8.650956
3.999262
3.702507
Ͳ6.64386
2.186637
3.669132
Ͳ6.64386
8.408801
2.400521
1.355506
1.770257
Ͳ6.64386
9.035079
6.368046
5.311546
Ͳ6.64386
9.017161
10.15843
Ͳ6.64386
5.671045
Ͳ6.64386
8.17779
2.218376
Ͳ6.64386
1.903229
6.868095
1.901233
2.249682
1.244075
Ͳ6.64386
Ͳ6.64386
2.884594
212
hsaͲm
iRͲ4672
1.31EͲ04
6.27EͲ06
22.65654
dow
n
Ͳ6.64386
1.984375
1.694048
4.605628
2.266473
Ͳ6.64386
1.535663
1.94296
Ͳ6.64386
Ͳ6.64386
1.855866
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.931815
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.53022
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.290269
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.159525
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.665778
Ͳ6.64386
2.413579
Ͳ6.64386
Ͳ6.64386
2.393255
Ͳ 6.64386
3.161374
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.583677
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.39119
Ͳ6.64386
Ͳ6.64386
3.343539
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.527687
2.55554
2.389805
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.737369
Ͳ6.64386
1.914986
3.340124
2.168564
2.450371
Ͳ6.64386
2.871958
2.042605
2.449426
3.131399
2.801703
2.544203
Ͳ6.64386
Ͳ6.64386
1.666293
Ͳ6.64386
2.12616
1.711961
1.800944
Ͳ6.64386
1.814988
2.891103
1.97231
1.529457
2.379075
3.452785
2.303614
1.768247
213
hsaͲm
iRͲ31Ͳ3p
0.001084
8.62EͲ05
22.97718
dow
n
3.298647
Ͳ6.643856
4.583571
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.457444
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.559328
4.102861
Ͳ6.64386
Ͳ6.64386
4.033297
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.998863
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.955402
5.112731
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.394476
3.384967
Ͳ6.64386
1.984672
2.209584
5.074743
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.451574
Ͳ6.64386
1.922329
Ͳ6.64386
1.824113
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.951115
7.631747
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.357228
8.953256
5.251068
5.925877
4.146474
7.961279
Ͳ6.64386
2.808561
4.379732
Ͳ6.64386
5.136356
Ͳ6.64386
5.853822
6.457269
Ͳ6.64386
Ͳ6.64386
7.155984
Ͳ6.64386
5.129321
5.049271
Ͳ6.64386
4.568679
Ͳ6.64386
5.189562
6.621948
2.889353
4.168341
3.230947
Ͳ6.64386
3.801113
214
hsaͲm
iRͲ196bͲ5p
1.03EͲ04
4.44EͲ06
23.30624
dow
n
2.455547
2.4258037
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.747193
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.81269
Ͳ6.64386
Ͳ6.64386
2.532545
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.267147
Ͳ6.64386
1.751849
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.398976
Ͳ6.64386
Ͳ6.64386
2.031201
Ͳ6.64386
3.190734
2.182935
Ͳ6.64386
Ͳ6.64386
2.67461
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.437827
Ͳ6.64386
Ͳ6.64386
3.024346
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.646413
2.550228
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.515572
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.18927
Ͳ6.64386
Ͳ6.64386
3.891116
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.983416
3.423932
5.198485
5.066869
3.01391
2.144915
1.68657
2.230907
3.835825
3.722601
3.621538
2.598254
1.684066
Ͳ6.64386
3.339383
2.404085
3.060201
2.115131
Ͳ6.64386
Ͳ6.64386
3.008983
Ͳ6.64386
3.77383
3.354509
2.772313
3.83651
4.278963
Ͳ6.64386
5.1758
215
hsaͲm
iRͲ29bͲ2Ͳ5p
4.74EͲ06
1.17EͲ07
24.81251
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.067877
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.822362
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.627304
Ͳ6.64386
1.627304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.479246
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.791229
2.450923
Ͳ6.64386
Ͳ6.64386
2.409374
Ͳ6.64386
2.728728
2.365332
1.790343
3.998252
1.748003
3.022802
2.459844
Ͳ6.64386
1.847348
2.383618
2.034188
1.878883
Ͳ6.64386
2.270693
1.60958
1.754677
1.097976
Ͳ6.64386
1.760101
Ͳ6.64386
1.932207
Ͳ6.64386
2.378338
Ͳ6.64386
Ͳ6.64386
2.27971
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.034008
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.724771
2.115117
216
hsaͲm
iRͲ3120Ͳ3p
9.80EͲ07
1.50EͲ08
25.58355
dow
n
Ͳ 6.64386
Ͳ6.643856
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
2.808945
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
1.633474
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.94325
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.627304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.742302
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.99982
1.857609
1.934512
2.18027
2.02612
Ͳ6.64386
1.903325
Ͳ6.64386
2.232426
Ͳ6.64386
2.396425
1.694062
2.643437
2.075256
2.363392
1.612208
Ͳ6.64386
1.45304
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.867369
Ͳ6.64386
Ͳ6.64386
1.776257
Ͳ6.64386
1.66696
2.236681
2.692858
2.072051
Ͳ6.64386
217
hsaͲm
iRͲ452Ͳ5p
3.02EͲ06
6.36EͲ08
28.70594
dow
n
Ͳ6.64386
Ͳ6.643856
2.163533
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.424021
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.852864
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.993542
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.157395
Ͳ6.64386
1.43542
Ͳ6.64386
2.553304
Ͳ6.64386
Ͳ6.64386
2.875973
Ͳ6.64386
Ͳ6.64386
4.898855
4.165499
Ͳ6.64386
Ͳ6.64386
2.153696
2.179412
Ͳ6.64386
4.052115
1.185439
1.774915
4.41984
3.425241
4.122891
Ͳ6.64386
3.16633
1.8167
Ͳ6.64386
1.949772
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.599846
1.907665
Ͳ6.64386
2.273435
3.114737
218
hsaͲm
iRͲ215
3.54EͲ04
2.11EͲ05
30.10806
dow
n
Ͳ6.64386
1.791288
Ͳ6.64386
3.516109
Ͳ6.64386
Ͳ6.64386
2.695824
1.710519
Ͳ6.64386
Ͳ6.64386
2.623693
2.866462
Ͳ6.64386
Ͳ6.64386
3.833412
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.611251
Ͳ6.64386
Ͳ6.64386
1.871044
Ͳ6.64386
Ͳ6.64386
1.734219
Ͳ6.64386
1.785477
4.606743
Ͳ6.64386
Ͳ6.64386
3.434659
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.649331
2.067877
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.837862
2.998715
2.539684
Ͳ6.64386
Ͳ6.64386
3.240342
Ͳ 6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
2.634834
2.14768
Ͳ 6.64386
2.011205
Ͳ 6.64386
Ͳ6.64386
2.994101
2.031351
1.865094
2.349119
Ͳ 6.64386
2.131167
2.339902
8.051354
9.874141
2.332071
1.748907
Ͳ6.64386
Ͳ6.64386
2.732009
2.427342
2.326795
2.462767
2.70173
2.946894
2.851589
1.540263
5.855945
2.723157
Ͳ6.64386
Ͳ6.64386
2.915874
Ͳ6.64386
1.734613
3.015701
Ͳ6.64386
4.934322
3.236831
1.656272
3.552462
219
hsaͲm
iRͲ200aͲ5p
4.47EͲ06
1.06EͲ07
31.4116
dow
n
Ͳ6.64386
Ͳ6.643856
1.537929
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.574409
Ͳ6.64386
Ͳ6.64386
1.577551
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.875232
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.536495
Ͳ6.64386
2.231376
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.676787
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.922329
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
2.724386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.485429
Ͳ6.64386
2.796342
2.197499
Ͳ6.64386
3.652993
Ͳ6.64386
5.156231
4.398421
2.710615
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.212055
3.428893
1.736605
1.524229
3.56941
4.015976
Ͳ6.64386
4.346792
2.323832
1.964022
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.794441
2.258928
1.83202
1.844451
3.069983
Ͳ6.64386
2.808512
220
hsaͲm
iRͲ375
1.84EͲ05
6.29EͲ07
34.56165
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.147311
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.732574
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.801626
Ͳ6.64386
2.841957
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.618293
Ͳ6.64386
6.499745
6.743495
4.014879
5.8937
2.072454
6.341023
8.287909
5.053287
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.901217
4.758795
Ͳ6.64386
Ͳ6.64386
3.027064
Ͳ6.64386
1.45304
Ͳ6.64386
7.435738
Ͳ6.64386
Ͳ6.64386
6.464828
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.141037
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
221
hsaͲm
iRͲ335Ͳ3p
9.59EͲ07
1.36EͲ08
40.52689
dow
n
Ͳ6.64386
1.9473028
2.51717
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.025668
Ͳ6.64386
1.968341
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.096446
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.505209
Ͳ6.64386
2.529457
1.802331
Ͳ6.64386
Ͳ6.64386
1.926865
Ͳ6.64386
2.705307
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.448334
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.559133
Ͳ6.64386
1.819636
1.88451
Ͳ6.64386
Ͳ6.64386
2.680683
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.551571
1.806878
1.81054
Ͳ6.64386
2.22328
2.275966
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.942748
Ͳ6.64386
Ͳ6.64386
2.780321
Ͳ6.64386
3.144674
2.773043
2.418374
Ͳ6.64386
2.371807
4.509064
4.708716
2.903948
5.465372
5.303201
5.112988
2.538584
Ͳ6.64386
2.98775
Ͳ6.64386
3.172565
4.01684
3.830475
1.864945
7.846808
4.783685
2.532842
2.655378
4.53279
2.591036
2.926926
3.891626
Ͳ6.64386
2.201055
5.217361
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.407255
2.441137
222
hsaͲm
iRͲ539Ͳ5p
1.20EͲ06
2.03EͲ08
43.96934
dow
n
2.190137
3.3347106
2.993608
3.356413
Ͳ6.64386
Ͳ6.64386
2.303154
2.217319
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.468415
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.823951
2.110786
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.649331
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.645844
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.954144
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.181104
1.993876
2.652874
Ͳ6.64386
2.022868
3.814069
Ͳ6.64386
1.55312
1.725232
Ͳ6.64386
2.958761
Ͳ6.64386
2.61824
3.070195
3.500971
4.424406
2.984013
2.962968
Ͳ6.64386
1.963234
4.042819
Ͳ6.64386
2.343497
Ͳ6.64386
1.813432
Ͳ6.64386
1.821169
2.963802
2.586379
Ͳ6.64386
3.204887
3.168765
2.539138
Ͳ6.64386
223
hsaͲm
iRͲ224Ͳ5p
1.05EͲ06
1.66EͲ08
93.71726
dow
n
Ͳ6.64386
Ͳ6.643856
4.847437
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.652839
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.237399
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.146678
2.666961
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.386296
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.849697
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.174792
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.208921
4.787451
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.813504
5.007939
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.90582
Ͳ6.64386
Ͳ6.64386
4.815803
4.046845
Ͳ6.64386
7.984912
7.251938
4.029405
Ͳ6.64386
4.879878
5.468244
3.108067
6.301655
4.589829
4.643017
6.597619
5.713559
7.227228
Ͳ6.64386
5.688231
5.010399
3.847826
5.532823
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.110406
4.858077
Ͳ6.64386
5.197605
5.813853
224
hsaͲm
iRͲ183Ͳ3p
4.11EͲ09
1.73EͲ11
101.0339
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.583677
3.05377
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.144083
Ͳ6.64386
Ͳ6.64386
2.217608
1.906083
2.032985
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.425625
Ͳ6.64386
3.401002
3.342296
2.816768
4.927058
2.053547
3.964409
4.10996
4.272332
1.796847
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.012541
2.589829
2.642444
Ͳ6.64386
2.913539
3.739562
2.419608
1.945243
Ͳ6.64386
Ͳ6.64386
1.929603
3.424021
Ͳ6.64386
3.086237
3.646633
Ͳ6.64386
2.309555
2.249044
1.803736
2.991254
225
hsaͲm
iRͲ96Ͳ5p
1.73EͲ08
1.10EͲ10
120.4834
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.792491
Ͳ6.64386
1.720414
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.146678
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.437827
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.546238
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.607524
4.241425
Ͳ6.64386
1.66696
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.426354
Ͳ6.64386
2.807014
Ͳ6.64386
2.833385
Ͳ6.64386
Ͳ6.64386
5.565236
1.955402
Ͳ6.64386
4.256535
4.232493
4.675314
2.857361
4.20588
5.261838
4.147274
Ͳ6.64386
2.213817
Ͳ6.64386
1.864022
4.415655
4.222098
2.681299
2.013496
4.248974
5.333458
6.020633
3.372524
3.127603
3.080836
Ͳ6.64386
3.446389
3.012178
2.50429
4.881888
Ͳ6.64386
3.333087
Ͳ6.64386
Ͳ6.64386
4.036845
226
hsaͲm
iRͲ335Ͳ5p
2.00EͲ07
1.89EͲ09
138.4271
dow
n
Ͳ6.64386
Ͳ6.643856
2.136566
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.399878
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.899078
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.662425
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.614704
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.938594
4.228208
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.675923
Ͳ6.64386
2.048683
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.424829
Ͳ6.64386
3.076114
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.200717
Ͳ6.64386
Ͳ6.64386
4.92613
Ͳ6.64386
5.089027
4.656276
2.628592
Ͳ6.64386
4.407883
5.362462
5.43689
3.573526
6.576824
6.276807
6.401944
2.651433
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
4.925941
5.96371
5.504751
1.859107
8.859451
6.027031
4.783433
4.107597
4.964871
2.634991
4.218923
2.553304
2.508047
2.75743
4.87672
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
5.864027
3.526846
227
hsaͲm
iRͲ141Ͳ3p
1.08EͲ08
5.70EͲ11
206.6276
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.996565
Ͳ6.64386
5.690934
4.716564
6.100595
7.096242
4.643966
7.012046
6.440188
6.14308
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
8.024351
4.532605
5.388854
Ͳ6.64386
6.665632
6.486796
Ͳ6.64386
6.195076
5.821557
4.624888
5.564531
Ͳ6.64386
5.435197
Ͳ6.64386
5.615339
Ͳ6.64386
Ͳ6.64386
2.774148
Ͳ6.64386
Ͳ6.64386
228
hsaͲm
iRͲ183Ͳ5p
3.29EͲ11
1.73EͲ14
220.7499
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.499997
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.606842
Ͳ6.64386
1.06726
Ͳ6.64386
Ͳ0.79334
Ͳ0.12776
Ͳ6.64386
Ͳ0.11381
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.145262
1.457373
Ͳ6.64386
1.037928
Ͳ6.64386
0.886194
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
0.991139
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.035598
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ0.2991
2.491782
3.593911
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.090938
1.956955
3.49981
0.105481
2.405292
1.49048
1.586915
5.603319
2.124504
4.59957
5.098662
4.070099
5.30181
2.425333
4.480907
4.87867
4.886312
2.765623
0.43138
0.91664
2.412575
4.186466
3.532285
3.848818
2.059882
4.356683
4.484016
3.067942
3.340379
2.339276
1.801685
3.60959
4.100788
0.184588
4.43499
4.239808
Ͳ0.39316
2.290528
2.91702
1.077474
3.925004
229
hsaͲm
iRͲ200cͲ3p
1.29EͲ06
2.24EͲ08
250.7467
dow
n
Ͳ6.64386
1.6647556
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.146678
Ͳ6.64386
1.690807
2.209349
Ͳ6.64386
1.646413
2.067877
Ͳ6.64386
Ͳ6.64386
1.583677
1.822362
Ͳ6.64386
2.731091
Ͳ6.64386
Ͳ6.64386
1.792491
Ͳ6.64386
Ͳ6.64386
1.923253
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.869777
2.179845
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.759422
Ͳ6.64386
1.821898
Ͳ6.64386
2.990368
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.202807
Ͳ6.64386
2.291497
3.291671
Ͳ6.64386
Ͳ6.64386
2.853971
Ͳ6.64386
4.063372
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
9.625264
Ͳ6.64386
8.428825
9.15929
9.101168
9.525241
8.307747
9.549577
9.980152
9.575782
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
9.591814
7.911758
8.48603
1.814146
9.729015
9.240942
1.509767
9.089896
8.777734
8.307912
9.558488
Ͳ6.64386
8.268933
2.707257
8.228431
2.772313
3.602228
5.281549
Ͳ6.64386
3.390024
230
hsaͲm
iRͲ203
2.10EͲ08
1.44EͲ10
273.6629
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.869777
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.022789
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
3.044015
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.717753
8.240705
Ͳ6.64386
8.593708
8.169198
4.057256
9.515739
6.508771
7.7847
8.597561
6.500341
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
8.599569
7.193373
6.38941
3.585008
7.174556
6.838052
Ͳ6.64386
6.406392
5.675826
1.899844
2.892465
Ͳ6.64386
5.054634
4.777253
1.957669
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.661317
231
hsaͲm
iRͲ429
3.83EͲ10
9.84EͲ13
515.7665
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.420277
Ͳ6.64386
7.613358
5.770904
Ͳ6.64386
6.967307
4.746356
9.079278
7.742215
5.645379
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
6.887367
6.882612
5.761467
4.553696
7.70415
7.797739
Ͳ6.64386
7.893101
5.880541
2.900603
Ͳ6.64386
Ͳ6.64386
4.283564
5.515992
5.658337
4.336812
4.94549
5.935157
Ͳ6.64386
4.985175
232
hsaͲm
iRͲ200aͲ3p
6.01EͲ10
1.90EͲ12
680.575
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ 6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.507057
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.287948
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.218887
8.158494
2.723229
7.526166
6.018402
Ͳ6.64386
8.018527
5.70135
9.273381
8.438392
6.371428
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
7.645335
6.560478
6.271986
5.426714
7.447526
7.822802
Ͳ6.64386
8.500496
6.339582
4.523888
Ͳ6.64386
Ͳ6.64386
5.743196
6.376397
6.57624
5.196213
5.587393
6.525964
Ͳ6.64386
5.650887
233
hsaͲm
iRͲ200bͲ3p
3.83EͲ10
1.01EͲ12
1717.021
dow
n
Ͳ6.64386
Ͳ6.643856
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.073311
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.740389
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.362675
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.291462
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
2.82428
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
1.468495
9.002238
4.670761
8.308356
7.606107
6.264066
8.759889
7.135377
10.38666
10.29634
8.254377
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
Ͳ6.64386
8.849936
8.08524
7.420899
6.55574
8.970141
9.275731
Ͳ6.64386
9.262872
8.580368
6.422963
6.676389
Ͳ6.64386
7.172816
7.947908
8.199331
6.696708
7.327133
8.068628
Ͳ6.64386
7.288504
GLIO
M
A
O
VARIAN
PAN
CREATIC
PRO
STATE
REN
AL
BREAST
CO
LO
RECTAL
M
elanocytesand
M
elanoblasts
N
evus
Serum
/PLASM
AͲM
elanom
a
Patient
M
ELAN
O
M
A
U
VEALM
ELAN
O
M
A
72
GeneName p (Corr)  p  FC (abs) Regulation Relevance to Melanoma REFERENCES
hsa‐miR‐211‐5p 3.43E‐07 3.97E‐09 276.84088 up Known Pigment Cell Melanoma Res. 2011 Jun;24(3):525‐37
hsa‐miR‐514a‐3p 2.96E‐07 3.12E‐09 204.08942 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐509‐3p 5.15E‐07 6.24E‐09 139.35081 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐204‐5p 5.50E‐06 1.39E‐07 93.670715 up Known
hsa‐miR‐509‐5p 2.29E‐06 4.59E‐08 65.2407 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐513b 1.08E‐05 3.13E‐07 61.259735 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐509‐3‐5p 3.46E‐06 7.48E‐08 55.923203 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐145‐5p 1.31E‐04 6.27E‐06 54.31673 up Known Int J Oncol. 2013 Apr;42(4):1443‐51
hsa‐miR‐146a‐5p 3.50E‐10 5.54E‐13 36.32244 up Known Cancer Res. 2010 May 15;70(10):4163‐73.
hsa‐miR‐508‐3p 7.57E‐05 3.03E‐06 31.908644 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐506‐3p 1.47E‐04 7.38E‐06 27.691364 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐513c‐5p 1.56E‐04 7.97E‐06 26.930325 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐4731‐5p 1.47E‐04 7.29E‐06 24.178703 up NOVEL
hsa‐miR‐508‐5p 6.88E‐07 9.42E‐09 21.59629 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐363‐3p 0.001080965 8.32E‐05 17.002277 up Known Cancer Res. 2010 May 15;70(10):4163‐73.
hsa‐miR‐551b‐3p 0.002793076 2.75E‐04 13.102462 up NOVEL
hsa‐miR‐4708‐3p 0.001086084 8.76E‐05 12.242638 up NOVEL
hsa‐miR‐510 0.00186919 1.69E‐04 11.336461 up Known Oncogene. 2012 Mar 22;31(12):1558‐70.
hsa‐miR‐584‐3p 9.67E‐05 4.02E‐06 10.361748 up NOVEL
hsa‐miR‐5701 0.008838477 0.00119678 10.0155525 up NOVEL
GeneName p (Corr)  p  FC (abs) Regulation Relevance to Melanoma REFERENCES
hsa‐miR‐617 1.49E‐05 4.87E‐07 10.126807 down NOVEL
hsa‐miR‐299‐3p 0.001144688 9.29E‐05 10.297629 down NOVEL
hsa‐miR‐3125 1.56E‐05 5.17E‐07 10.459817 down NOVEL
hsa‐miR‐4768‐3p 3.71E‐04 2.23E‐05 11.119021 down NOVEL
hsa‐miR‐4719 0.00707513 8.69E‐04 11.243696 down NOVEL
hsa‐miR‐3682‐3p 8.17E‐05 3.31E‐06 13.372626 down NOVEL
hsa‐miR‐1183 4.14E‐06 9.60E‐08 13.502589 down NOVEL
hsa‐miR‐200c‐5p 2.14E‐04 1.17E‐05 13.616578 down Known Virchows Arch. 2012 Oct;461(4):441‐12
hsa‐miR‐2115‐3p 1.64E‐04 8.45E‐06 13.621608 down NOVEL
hsa‐miR‐1244 1.30E‐05 4.04E‐07 13.876072 down NOVEL
hsa‐miR‐10a‐3p 0.001257804 1.04E‐04 15.860663 down NOVEL
hsa‐miR‐182‐5p 1.59E‐10 1.67E‐13 16.291529 down Known Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814‐9.
hsa‐miR‐206 3.85E‐04 2.35E‐05 18.044355 down NOVEL
hsa‐miR‐205‐5p 0.001083732 8.52E‐05 19.473736 down Known http://www.ncbi.nlm.nih.gov/pubmed/?term=miR‐205+and+melanoma
hsa‐miR‐4672 1.31E‐04 6.27E‐06 22.656536 down NOVEL
hsa‐miR‐31‐3p 0.001083732 8.62E‐05 22.977182 down Known Oncotarget. 2012 Sep;3(9):1011‐25.
hsa‐miR‐196b‐5p 1.03E‐04 4.44E‐06 23.306242 down NOVEL
hsa‐miR‐29b‐2‐5p 4.74E‐06 1.17E‐07 24.812508 down Known Cell Commun Signal. 2012 Dec 17;10(1):41.
hsa‐miR‐3120‐3p 9.80E‐07 1.50E‐08 25.58355 down NOVEL
hsa‐miR‐452‐5p 3.02E‐06 6.36E‐08 28.705942 down NOVEL
hsa‐miR‐215 3.54E‐04 2.11E‐05 30.10806 down NOVEL
hsa‐miR‐200a‐5p 4.47E‐06 1.06E‐07 31.411602 down Known Virchows Arch. 2012 Oct;461(4):441‐9
hsa‐miR‐375 1.84E‐05 6.29E‐07 34.56165 down Known FEBS Lett. 2011 Aug 4;585(15):2467‐76.
hsa‐miR‐335‐3p 9.59E‐07 1.36E‐08 40.526886 down NOVEL
hsa‐miR‐539‐5p 1.20E‐06 2.03E‐08 43.96934 down NOVEL
hsa‐miR‐224‐5p 1.05E‐06 1.66E‐08 93.71726 down NOVEL
hsa‐miR‐183‐3p 4.11E‐09 1.73E‐11 101.033875 down Known Cancer Res. 2010 May 15;70(10):4163‐73.
hsa‐miR‐96‐5p 1.73E‐08 1.10E‐10 120.48337 down Known PLoS One. 2012;7(8):e43569
hsa‐miR‐335‐5p 2.00E‐07 1.89E‐09 138.42706 down NOVEL
hsa‐miR‐141‐3p 1.08E‐08 5.70E‐11 206.62756 down Known PLoS One. 2012;7(8):e43569
hsa‐miR‐183‐5p 3.29E‐11 1.73E‐14 220.74986 down Known Cancer Res. 2010 May 15;70(10):4163‐73.
hsa‐miR‐200c‐3p 1.29E‐06 2.24E‐08 250.74672 down Known Virchows Arch. 2012 Oct;461(4):441‐13
hsa‐miR‐203 2.10E‐08 1.44E‐10 273.66293 down Known Virchows Arch. 2012 Oct;461(4):441‐13
hsa‐miR‐429 3.83E‐10 9.84E‐13 515.76654 down NOVEL
hsa‐miR‐200a‐3p 6.01E‐10 1.90E‐12 680.57495 down Known Virchows Arch. 2012 Oct;461(4):441‐10
hsa‐miR‐200b‐3p 3.83E‐10 1.01E‐12 1717.0214 down Known Virchows Arch. 2012 Oct;461(4):441‐10
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Sample ID Type Cohort qRT PCR validation Sample ID Type Cohort qRT PCR validation Sample ID Type Cohort T PCR validation
QF1160MB Melanoblast Discovery Yes C045 STAGE_III_ Discovery Yes MM370 STAGE_IV_ Validation Yes
MELA Melanocyte Discovery Yes C050 STAGE_III_ Discovery Yes MM386 STAGE_IV_ Validation Yes
MM653 Nevus Discovery Yes C052 STAGE_III_ Discovery Yes MM415 STAGE_IV_ Validation Yes
22rV‐1 Other Discovery Yes C054 STAGE_III_ Discovery Yes MM426 STAGE_IV_ Validation Yes
786‐O Other Discovery Yes C057 STAGE_III_ Discovery Yes MM466 STAGE_IV_ Validation Yes
ALVA‐1 Other Discovery Yes C058 STAGE_III_ Discovery Yes MM473 STAGE_IV_ Validation Yes
BT474 Other Discovery Yes C060 STAGE_III_ Discovery Yes MM485 STAGE_IV_ Validation Yes
BxPC‐3 Other Discovery Yes C062 STAGE_III_ Discovery Yes MM537 STAGE_IV_ Validation Yes
CAKI‐1 Other Discovery Yes C065 STAGE_III_ Discovery Yes MM548 STAGE_IV_ Validation Yes
CAKI‐2 Other Discovery Yes C067 STAGE_III_ Discovery Yes MM649 STAGE_IV_ Validation Yes
CaOV‐3 Other Discovery Yes C071 STAGE_III_ Discovery Yes MM96L STAGE_IV_ Validation Yes
CAPAN‐1 Other Discovery Yes C074 STAGE_III_ Discovery Yes SKMEL28 STAGE_IV_ Validation Yes
CAPAN‐2 Other Discovery Yes C076 STAGE_III_ Discovery Yes SKMEL5 STAGE_IV_ Validation Yes
Co115 Other Discovery Yes C077 STAGE_III_ Discovery Yes 92_1 Uveal MM Discovery Yes
Du145 Other Discovery Yes C078 STAGE_III_ Discovery Yes MEL202 Uveal MM Discovery Yes
HT29 Other Discovery Yes C079 STAGE_III_ Discovery Yes MEL270 Uveal MM Discovery Yes
LIM1899 Other Discovery Yes C080 STAGE_III_ Discovery Yes MEL285 Uveal MM Discovery Yes
LIM2405 Other Discovery Yes C081 STAGE_III_ Discovery Yes MEL290 Uveal MM Discovery Yes
LN‐18 Other Discovery Yes C083 STAGE_III_ Discovery Yes OCM8 Uveal MM Discovery Yes
LNCAP Other Discovery Yes C084 STAGE_III_ Discovery Yes OMM1 Uveal MM Discovery Yes
MCF‐7 Other Discovery Yes C086 STAGE_III_ Discovery Yes
MDAMB231 Other Discovery Yes C088 STAGE_III_ Discovery Yes
OAW28 Other Discovery Yes C089 STAGE_III_ Discovery Yes
OVCAR‐3 Other Discovery Yes C091 STAGE_III_ Discovery Yes
PANC‐1 Other Discovery Yes C092 STAGE_III_ Discovery Yes
PC‐3 Other Discovery Yes C094 STAGE_III_ Discovery Yes
PE04 Other Discovery Yes C096 STAGE_III_ Discovery Yes
PL45 Other Discovery Yes C097 STAGE_III_ Discovery Yes
SKBR3 Other Discovery Yes C100 STAGE_III_ Discovery Yes
SK‐OV‐3 Other Discovery Yes C106 STAGE_III_ Discovery Yes
SN12K‐1 Other Discovery Yes C108 STAGE_III_ Discovery Yes
SW48 Other Discovery Yes A02 STAGE_IV_ Discovery Yes
SW839 Other Discovery Yes A04 STAGE_IV_ Discovery Yes
T46 Other Discovery Yes A06 STAGE_IV_ Validation Yes
T47D Other Discovery Yes A13 STAGE_IV_ Validation Yes
T50 Other Discovery Yes A15 STAGE_IV_ Validation Yes
U118 Other Discovery Yes AF6 STAGE_IV_ Validation Yes
MM200 STAGE I/II Validation Yes C‐32 STAGE_IV_ Validation Yes
MM229 STAGE I/II Validation Yes CJM STAGE_IV_ Validation Yes
MM329 STAGE I/II Validation Yes D01 STAGE_IV_ Validation Yes
MM540 STAGE I/II Validation Yes D04 STAGE_IV_ Validation Yes
C001 STAGE_III_MM Discovery Yes D05 STAGE_IV_ Validation Yes
C002 STAGE_III_MM Discovery Yes D08 STAGE_IV_ Validation Yes
C003 STAGE_III_MM Discovery Yes D10 STAGE_IV_ Validation Yes
C004 STAGE_III_MM Discovery Yes D11 STAGE_IV_ Validation Yes
C006 STAGE_III_MM Discovery Yes D14 STAGE_IV_ Validation Yes
C008 STAGE_III_MM Discovery Yes D17 STAGE_IV_ Validation Yes
C011 STAGE_III_MM Discovery Yes D20 STAGE_IV_ Validation Yes
C012 STAGE_III_MM Discovery Yes D22 STAGE_IV_ Validation Yes
C013 STAGE_III_MM Discovery Yes D24 STAGE_IV_ Validation Yes
C016 STAGE_III_MM Discovery Yes D25 STAGE_IV_ Validation Yes
C017 STAGE_III_MM Discovery Yes D28 STAGE_IV_ Validation Yes
C021 STAGE_III_MM Discovery Yes D29 STAGE_IV_ Validation Yes
C022 STAGE_III_MM Discovery Yes D32 STAGE_IV_ Validation Yes
C025 STAGE_III_MM Discovery Yes D35 STAGE_IV_ Validation Yes
C027 STAGE_III_MM Discovery Yes D36 STAGE_IV_ Validation Yes
C028 STAGE_III_MM Discovery Yes D40 STAGE_IV_ Validation Yes
C037 STAGE_III_MM Discovery Yes D41 STAGE_IV_ Validation Yes
C038 STAGE_III_MM Discovery Yes D59 STAGE_IV_ Discovery Yes
C042 STAGE_III_MM Discovery Yes HT144 STAGE_IV_ Validation Yes
C043 STAGE_III_MM Discovery Yes MM127 STAGE_IV_ Validation Yes
C044 STAGE_III_MM Discovery Yes MM253 STAGE_IV_ Validation Yes
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NF1 Accession 
Number
Miranda Alignment 
Score
Location
Start 
Position
End 
Position
Comments
NM_000267.3 146 CODING 3413 3435 Exon 23 binding site
NM_000267.3 140 CODING 1341 1361 Exon 9 binding site
NM_000267.3 139 CODING 2546 2566 Below default threshold
NM_000267.3 133 3'UTR 11833 11854 Below default threshold
NM_000267.3 133 5'UTR 48 70 Below default threshold
NM_000267.3 133 CODING 5754 5775 Below default threshold
NM_000267.3 128 CODING 6165 6184 Below default threshold
NM_000267.3 126 CODING 7581 7604 Below default threshold
NM_000267.3 125 3'UTR 9231 9254 Below default threshold
NM_000267.3 124 3'UTR 9762 9781 Below default threshold
NM_000267.3 122 CODING 3813 3835 Below default threshold
NM_000267.3 121 CODING 4630 4651 Below default threshold
NM_000267.3 120 CODING 2612 2632 Below default threshold
NM_000267.3 119 CODING 7643 7660 Below default threshold
NM_000267.3 118 CODING 7080 7102 Below default threshold
NM_000267.3 118 CODING 8792 8813 Below default threshold
NM_000267.3 117 CODING 4013 4038 Below default threshold
NM_000267.3 116 3'UTR 10945 10965 Below default threshold
NM_000267.3 115 CODING 3753 3773 Below default threshold
NM_000267.3 114 CODING 4232 4253 Below default threshold
NM_000267.3 113 3'UTR 10773 10793 Below default threshold
NM_000267.3 113 CODING 8092 8113 Below default threshold
NM_000267.3 113 CODING 8820 8842 Below default threshold
NM_000267.3 112 CODING 6443 6463 Below default threshold
NM_000267.3 111 3'UTR 11259 11281 Below default threshold
NM_000267.3 111 3'UTR 12016 12036 Below default threshold
NM_000267.3 111 CODING 561 581 Below default threshold
NM_000267.3 111 CODING 2802 2825 Below default threshold
NM_000267.3 110 3'UTR 11885 11906 Below default threshold
NM_000267.3 110 CODING 1352 1371 Below default threshold
NM_000267.3 109 3'UTR 10871 10892 Below default threshold
NM_000267.3 109 CODING 1199 1218 Below default threshold
NM_000267.3 109 CODING 5802 5824 Below default threshold
NM_000267.3 109 CODING 8242 8267 Below default threshold
NM_000267.3 109 CODING 8321 8340 Below default threshold
NM_000267.3 108 3'UTR 11669 11688 Below default threshold
NM_000267.3 107 3'UTR 9063 9083 Below default threshold
NM_000267.3 106 3'UTR 11143 11164 Below default threshold
NM_000267.3 106 CODING 3115 3137 Below default threshold
NM_000267.3 106 CODING 3599 3619 Below default threshold
NM_000267.3 106 CODING 3849 3869 Below default threshold
NM_000267.3 106 CODING 4652 4673 Below default threshold
NM_000267.3 106 CODING 7411 7431 Below default threshold
NM_000267.3 105 3'UTR 10993 11018 Below default threshold
NM_000267.3 105 3'UTR 11366 11389 Below default threshold
NM_000267.3 105 CODING 6592 6613 Below default threshold
NM_000267.3 104 3'UTR 9864 9884 Below default threshold
NM_000267.3 104 3'UTR 10277 10297 Below default threshold
NM_000267.3 104 3'UTR 10466 10486 Below default threshold
NM_000267.3 104 3'UTR 11422 11442 Below default threshold
NM_000267.3 104 3'UTR 12158 12178 Below default threshold
NM_000267.3 104 CODING 2598 2618 Below default threshold
NM_000267.3 104 CODING 3039 3059 Below default threshold
NM_000267.3 104 CODING 3344 3364 Below default threshold
NM_000267.3 104 CODING 4527 4547 Below default threshold
NM_000267.3 104 CODING 6342 6365 Below default threshold
NM_000267.3 104 CODING 8336 8356 Below default threshold
NM_000267.3 104 CODING 8499 8519 Below default threshold
NM_000267.3 103 3'UTR 9255 9275 Below default threshold
NM_000267.3 103 3'UTR 10838 10858 Below default threshold
NM_000267.3 103 CODING 3079 3099 Below default threshold
NM_000267.3 103 CODING 7703 7723 Below default threshold
NM_000267.3 102 CODING 2156 2177 Below default threshold
NM_000267.3 102 CODING 5379 5400 Below default threshold
NM_000267.3 102 CODING 6432 6452 Below default threshold
NM_000267.3 101 CODING 2918 2938 Below default threshold
NM_000267.3 100 3'UTR 9361 9381 Below default threshold
NM_000267.3 100 3'UTR 10745 10767 Below default threshold
NM_000267.3 100 3'UTR 11646 11666 Below default threshold
NM_000267.3 100 CODING 696 716 Below default threshold
NM_000267.3 100 CODING 1389 1409 Below default threshold
NM_000267.3 100 CODING 1669 1689 Below default threshold
NM_000267.3 100 CODING 2233 2253 Below default threshold
NM_000267.3 100 CODING 2290 2310 Below default threshold
NM_000267.3 100 CODING 5152 5172 Below default threshold
NM_000267.3 100 CODING 6813 6833 Below default threshold
NM_000267.3 100 CODING 6828 6848 Below default threshold
NM_000267.3 100 CODING 7165 7185 Below default threshold
NM_000267.3 100 CODING 7287 7307 Below default threshold
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Chapter 3 
The prognostic and predictive value of melanoma-related microRNAs 
using tissue and serum: a microRNA expression analysis. 
Mitchell S. Stark, Kerenaftali Klein, Benjamin Weide, Lauren E. Haydu, Annette 
Pflugfelder, Yue Hang Tang, Jane M. Palmer, David C. Whiteman, Richard A. Scolyer, 
Graham J. Mann, John F. Thompson, Georgina V. Long, Andrew P. Barbour, H. Peter 
Soyer, Claus Garbe, Adrian Herington, Pamela M. Pollock, Nicholas K. Hayward. The 
prognostic and predictive value of melanoma-related microRNAs using tissue and serum: 
a microRNA expression analysis. EBioMedicine. (2015) May 23. 
http://dx.doi.org/10.1016/j.ebiom.2015.05.011. 
3.1. Relevance to thesis aims 
This chapter specifically addresses Aims 2 and 3 of the thesis. Using a panel of 
melanoma-related miRNAs identified in Chapter 2 (Aim 1), these were measured in 
cohorts of serum and tissue from melanoma patients (Aim 2) and was correlated with 
disease progression (Aim3). Specifically, in a minimally-invasive blood test, a seven-
miRNA panel (‘MELmiR-7’) detected the presence of melanoma (relative to controls) with 
high sensitivity (93%) and specificity (≥82%) when ≥4 miRNAs were expressed (Aim 2). In 
serially collected samples from stage IV patients, members of the ‘MELmir-7’ panel 
confirmed tumour progression in 100% of cases (Aims 2 and 3).  Additionally, in 
melanoma tissues, members of the melanoma-related panel were found to be predictors of 
stage, recurrence, and survival (Aim 3). 
3.2. Contribution of candidate 
I developed the concept and initial study design which was agreed upon and refined by my 
supervisors. I performed the majority of the experimental work, data analysis and 
interpretation, and writing of the manuscript. 
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5. they agree to the use of the publication in the student’s thesis and its publication on the
QUT ePrints database consistent with any limitations set by publisher requirements.
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detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥82%)
when ≥4 miRNAs were expressed. Moreover, the ‘MELmiR-7’ panel characterised overall survival of melanoma
patients better than both serum LDH and S100B (delta log likelihood = 11, p b 0.001). This panel was found to
be superior to currently used serological markers for melanoma progression, recurrence, and survival; and
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Table 1
Descriptive statistics for tissue cohorts.
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Melanomas are among themost commonly occurring cancers. Crude
incidence rates in Australia (AIHW, 2014) and the USA (SEER, 2014)
were approximately 50 cases (in 2010) and 20 cases (in 2011) per
100,000 respectively. With the number of new cases rising each year,
melanoma is currently is listed as the 4th and 6thmost common cancer
in Australia and the USA respectively (AIHW, 2014; SEER, 2014).
Current clinical staging criteria classify melanoma progression from
a pre-invasive lesion, confined to the epidermis (stage 0), a series
of early stages of local invasion (I and II), a stage involving regional
lymph nodes (stage III) and finally metastasis to distant sites (stage
IV). The overall 5-year survival for melanoma is 91%, which is largely
due to curative surgery for early stage disease. However, cure rates
are b15% (Balch et al., 2009) if distant metastasis occurs (stage IV;
AJCC 7th edition). We now have evidence that current therapeutic
options for late stage disease aremore effective if the disease is treat-
ed with a lower disease burden (Sosman et al., 2012; Hodi et al.,
2010). Hence, melanoma must be treated in earlier stages to maxi-
mise the chances of patient survival. Therefore, the ability to identify
signs of melanoma progression sooner would be a valuable clinical
tool.
Melanoma progression biomarkers have been studied intensively
with varying levels of success. Serum lactate dehydrogenase (LDH)
levels have been integrated into current staging regimens (Balch
et al., 2009) and elevation of LDH levels increases in specificity as dis-
ease progresses (stages II (83%), III (87%), and IV (92%)). However
the sensitivity of this marker is reduced during progression (stages
II (95%), III (57%), and IV (79%)) (Brochez and Naeyaert, 2000;
Finck et al., 1983; Karakousis et al., 1996; Sirott et al., 1993; Weide
et al., 2012; Deichmann et al., 1999). S100B, a calcium binding pro-
tein, is raised in serum of stages III and IV melanoma patients (Guo
et al., 1995; Smit et al., 2005). However, the proportion of patients
with elevated S100B levels varies by stage: 0–9% in stages I/II, 5–
98% in stage III, and 40–100% in stage IV (reviewed in Kruijff
et al., 2009). As such, serum S100B is not routinely used in the
clinic (Leiter et al., 2014), highlighting the fact that the current
serological methods of progression detection, whilst relatively
specific, are inadequate due to variability in sensitivity across all
stages of disease. To date, there are no biomarkers that are sensi-
tive or specific enough to be beneficial for early detection of
melanoma (all stages). A blood test (‘circulating’ biomarkers)
that detected melanoma with regional spread, prior to clinically
evident distant metastasis, could improve treatment and out-
comes for melanoma patients.
For a circulating biomarker to be effective, not only must it be
sufficiently sensitive and specific, but it must also be highly stable and
resistant to degradation. In recent years, circulating microRNAs
(miRNAs) have been studied for their utility as biomarkers in a
wide range of malignancies and disorders (Allegra et al., 2012;
De Guire et al., 2013). miRNAs are small (20–22 nt) non-coding
RNAs which function to regulate gene expression in the cell. Re-
cently, tumour cells have been shown to release miRNAs into the
circulation (Mitchell et al., 2008), contained primarily in micro-
vesicles or exosomes (extracellular vesicles), or bound to AGO2 — a
part of the miRNA-mediated silencing complex (Allegra et al., 2012;
De Guire et al., 2013). Due to the ‘encapsulation’ of these miRNAs in
serum or plasma they are highly resistant to degradation by RNases
(highly concentrated in the blood), thus their potential usefulness as a
‘biomarker’ is relatively high. To date, circulating melanoma-related
miRNAs have been rarely studied (Fleming et al., 2015; Friedman
et al., 2012).
Hereinwe report amulti-centre study that identifies a panel of ‘mel-
anoma-related’miRNAs that offer superior sensitivity to currently used
serological markers for melanoma progression, recurrence, and
survival.2. Materials and Methods
2.1. Patient Specimen Details
Formalin-fixed paraffin-embedded (FFPE) melanoma tissues and
serum (melanoma and control patients) were obtained from prospec-
tively collected biobanks in Australia and Germany.2.2. Tissue Validation Cohort
FFPE melanoma tissues, collected at diagnosis of stage III (PAH-
tissue)were obtained via a database of prospective stage IIIA–C cutaneous
melanoma cases, presenting to the Princess Alexandra Hospital (PAH)
Melanoma Unit and affiliated private hospitals, which has been main-
tained since 1997. Permission to collect and use informationwas approved
by the hospital ethics committee (HREC Reference number: HREC/11/
QPAH/650; SSA reference number: SSA/11/QPAH/694). Inclusion criteria
were the same as those previously presented (Tembe et al., 2015). An addi-
tional collection (collected at diagnosis) of stages III and IV melanoma tis-
sues (MIA-tissue) were obtained via a database of prospectively recruited
melanoma cases, presenting to the Melanoma Institute Australia (MIA)
and affiliated private hospitals, which has been maintained since 1967. In-
formedwritten consentwas obtained for each patient under approved pro-
tocols (Protocol No. X10-0305 &HREC/10/RPAH/539 and Protocol No. X10-
0300 HREC/10/RPAH/530) governed by the Human Research Ethics
Committee of the Royal Prince AlfredHospital (SydneyNSW, Australia). In-
clusion criteria were the same as those previously presented (Tembe et al.,
2015). See Table 1 for participant descriptive statistics. Supplementary
Table 2 shows the mean, median, and range of follow-up times.83
Table 2
Descriptive statistics for serum cohorts.
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Sera from ‘healthy co7ntrols’ were ascertained from a cohort of
participants collected as part of the Australian Cancer Study (ACS)
(QIMR Berghofer HREC approved project no. P399). As part of the
ACS, potential controls were randomly selected from the Australian
Electoral Roll (enrolment is compulsory). Controls were prospec-
tively sampled from within strata of age (in 5 year age-groups) and
state of residence. Of the 3258 potentially eligible control partici-
pants, 41 could not be contacted and 175 were excluded because
they were deceased (16), too ill (61), or unable to read or write in
English (98). Of 3042 controls meeting the inclusion criteria, 1680
(55%) gave their consent to take part. Completed questionnaires
were returned by 1580 controls (48% of all potentially eligible con-
trols selected from the roll). See Table 2 for participant descriptive
statistics.
Sera from ‘high naevus count’ and ‘history of melanoma, disease-
free’ participants were prospectively collected from cohorts who were
enrolled in the study: ‘Pigmentation genotypes and phenotypic correla-
tions with dermoscopic naevus types and distribution’. These samples
were included as ‘controls’ to determine the level of expressionmeasur-
able in sera derived from patients with a high melanocyte burden. All
study participants were enrolled in the following human ethics
approved projects: QIMR HREC/P1237, The Metro South Health District
HREC/09/QPAH/162, and UQ HREC approval number is 2009001590.
Participants with a history of melanoma (clinically free of disease at
time of blood draw) were recruited through the Melanoma Unit and
Dermatology Department of the Princess Alexandra Hospital, Brisbane,
Queensland, Australia, betweenMay 2012 and November 2012. Control
participants, with no personal history of melanoma, were recruited
from the Brisbane Twin Naevus Study between August 2012 andNovember 2012. All participants had 16-panel full-body images and
dermoscopic images of significant naevi recorded. Significant naevi
were defined as naevi greater than or equal to 5mmon all body sites ex-
cept the scalp, buttocks, mucosal surfaces and genitals, and greater than
or equal to 2mmon the back of bothmales and females and on the legs
of females. All significant naevi were classified by the predominant
dermoscopic pattern (reticular, globular, or non-specific), colour, and
profile (flat, raised, domed or papillomatous). See Table 2 for participant
descriptive statistics.
The description of ‘controls’ used in the analyses refers to a
combined cohort of ‘healthy controls’, ‘high naevus count’, and ‘history
of melanoma, disease-free’ participants.
2.4. Serum Validation Cohorts: Melanoma Patient Sera
Sera from stages I–IV melanoma patients (at time of blood draw
and staged according to the current AJCC staging manual 3 (Balch
et al., 2009)) had blood drawn and serum stored as part of a large
prospectively collected cohorts from the university department of
dermatology in Tubingen, Germany (‘Tubingen’ cohort) andMelano-
ma Institute of Australia, Sydney (‘MIA’ cohort). Usage of the ‘Tubingen’
bio-bank with corresponding patient data was approved by the Ethics
Committee, University of Tübingen (approvals 657/2012BO2). Serially-
collected stage IV patients (‘MIA’ cohort only) had blood drawn at time
of diagnosis or at lower disease burden and then at higher disease bur-
den (determined by routine diagnostic tests). All samples from the
‘MIA’ cohort had informed written consent obtained from each patient
under approved protocols (Protocol No. X10-0305 &HREC/10/RPAH/
539 and Protocol No. X10-0300 HREC/10/RPAH/530) governed by the
Human Research Ethics Committee of the Royal Prince Alfred Hospital
(SydneyNSW,Australia). See Table 2 for participant descriptive statistics.84
Fig. 1. Study summary.
674 M.S. Stark et al. / EBioMedicine 2 (2015) 671–680Supplementary Table 2 shows themean,median, and range of follow-up
times.
All serum samples were collected in 10-mL BD serum tubes then
centrifuged for 10 min at 1500 ×g. The supernatant serum was then
aliquoted into 1.5-mL cryovials and stored at −80 °C until further
use.
2.5. Total RNA Extraction From Validation Cohorts
A sterile disposable biopsy punch (Kai Medical, Japan) was used to
retrieve tumour content from blocks that had been scored and marked
for content via H&E histological staining. The extraction of total RNA
from FFPE tissue and serum was performed respectively using
miRNeasy FFPE Kits (Qiagen) as per manufacturer's instructions or as
previously described (Tembe et al., 2015).
2.6. Selection Criteria for ‘Melanoma-related’ miRNAs
In our previously published miRNA microarray dataset (Stark et al.,
2015) we found a total of 233/1898 miRNAs (‘Discovery’ set) (Fig. 1)
thatwere differentially expressed (DE; correctedp ≤0.05 and ≥2-fold) be-
tween the melanoma cell lines (n = 55) and the ‘other’ solid cancers
(n = 34). We applied filtering criteria to the 233 DE miRNAs to identifywhich miRNAs would be suitable to measure in patient derived serum.
The following strict criteria were used to filter the ‘Discovery’ set:
≥15-fold higher expression in cutaneous melanoma vs. ‘other’ solid
malignancies (n = 14/14), or ≥2-fold higher expression in cutaneous
melanoma vs ‘other’ solid malignancies with no detectable expression
in melanocytes or melanoblasts (n = 3/6). In addition, miR-16, which
is known to be highly expressed in blood, was assessed for its suitability
as an endogenous control. The 18 miRNA panel (MELmiR-18) compris-
ing: miR-211-5p, miR-514a-3p, miR-509-3p, miR-204-5p, miR-509-5p,
miR-513b, miR-145-5p, miR-146a-5p, miR-508-3p, miR-506-3p, miR-
513c-5p, miR-4731-5p, miR-508-5p, miR-363-3p, miR-4487, miR-
4469, miR-4706, andmiR-16. This panel was carried forward for testing
in independent cohorts of FFPEmelanoma tumours and patient derived
sera.
2.7. Reverse Transcription, Pre-amplification, Taqman Assays and Fluidigm
Real-time PCR
We performed a custom Taqman assay combined with a sensitive
method of detection (Fluidigm, HD Biomark) as previously described
(Tembe et al., 2015). Briefly, a custom reverse transcription (RT) primer
pool consisting of equal amounts ofmiRNA-specific RTprimers contained
within each TaqMan®Assay (Life Technologies, Carlsbad, USA;miR-211-85
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675M.S. Stark et al. / EBioMedicine 2 (2015) 671–6805p (000514), miR-514a-3p (001147), miR-509-3p (002236), miR-204-
5p (000508), miR-509-5p (002235), miR-513b (002757), miR-145-5p
(002278), miR-146a-5p (000468), miR-508-3p (001052), miR-506-3p
(001050), miR-513c-5p (002756), miR-4731-5p (464084_mat), miR-
508-5p (002092), miR-363-3p (001271), miR-4487 (462492_mat),
miR-4469 (465059_mat), miR-4706 (464518_mat), and miR-161
(000391) along with cel-miR-39 (000200; serum spiked-in control) and
RNU-6 (001973; FFPE endogenous control)) plus an additional pool of
the corresponding TaqMan® MicroRNA Assay (Pre-Amp Primer Pool)
were used to pre-amplify the RT reaction. Each assay had a serial dilution
of a positive control sample (known expression for all miRNAs in panel)
that had a total input of 1, 3, 15, and 45 ng in the original cDNA reaction.
2.8. qRT-PCR Analysis
The expression of the ‘MELmiR-18’panel (Fig. 1)was assayed in each
sample with at least 4 technical replicate Taqman assays to determine
their expression. Real-time expression data was extracted and analysed
as previously described (Tembe et al., 2015).
2.9. Statistical Methods
Themarker level differences (e.g., univariate analysis of eachmiRNA
in each cohort comparison represented in Table 3) were assessed using
theMann–Whitney U-test and adjusted for multiple comparisons using
the Benjamini & Hochberg method. Significantmarkers' predictive abil-
ity was evaluated using receiver operating characteristic (ROC curve)
and area under the curve (AUC) or AUROC. Univariate and multivariate
logistic regressions with backward covariate search based on AIC
(Sakamoto et al., 1986; Vermont et al., 1991)were performed to identify
significant markers which were associated with melanoma status/
disease stages, when time to event information was missing. For
survival and recurrence analyses, univariate and multivariate Cox
proportional hazard model with backward covariate search based on
AIC (Sakamoto et al., 1986; Vermont et al., 1991) was performed.
Time to follow-up was measured from date of blood collection which
was ≤1 month of staging. The proportional hazards assumption was
also evaluated for each Cox regression (Grambsch and Therneau,
1994). The model fits were compared using likelihood ratio test. The
predictive abilities of the selected significant markers were evaluated
using AUROC. The selected markers were then used to classify patients
using conditional inference tree analysis (Hothorn et al., 2006). For
serum markers, the cutoff point of each marker that characterised the
melanoma status was determined to maximise AUROC statistics.
5000 nonparametric bootstrapswere performed, per cohort (e.g., con-
trols versus stage IV) andmiRNA analysis pairs, to obtain robust effect size
estimates, p values (for univariate analysis) and AUROC. To reflect the un-
certainties of the values greater than Ct 36, the values above 36 were re-
placed by random values from 37 to 40 during the bootstrap. The original
data was analysed without this consideration and the final models were
rerun using 5000 bootstrap runs to generate robust outcomes.
For the analyses, OptimalCutpoints (v1.1–3), boot, and party
packages onRversion3.0.2were used tofind cutpoints in univariate anal-
yses (cohort vs. markers), bootstrapping and tree analyses respectively.
ROC curves and scatter plots were drawn using GraphPad Prism 6.
Survival analysis was performed using R version 3.0.2.
2.10. Diagnostic Inclusion Criteria, Score Assignment, and Test Evaluation
To maximise the chances of having a positive signal in the patients
serum, a combined stage IV cohort (n = 119; ‘Tubingen’ and ‘MIA’)1 The miR-16 Taqman primer assay (00039) is specifically designed to bind to mature
miRNA sequence of miR-16-5p which is derived from hsa-miR-16-1 and hsa-miR-16-2
stem–loop sequences. The alias formiR-16-5p ismiR-16 hence the reasoning for the short-
ened name. Ta
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676 M.S. Stark et al. / EBioMedicine 2 (2015) 671–680was compared with disease-free ‘controls’ (n = 130; no history of
melanoma or nevi, prior history of melanoma but disease-free, high
nevus count with no melanoma). Initially, all members of the
‘MELmiR-17’ (miR-4469 was excluded due to assay failure) panel
underwent a simple Mann–Whitney U test to identify the highly signif-
icant (p b 0.0001)miRNAs to be included in the next step (Fig. 1). Those
miRNAs that met these criteria then underwent AUROC analysis to
determine their area under the curve (AUC) (Figs. 1 and 2). AUC scores
of ≥0.70 were deemed to be diagnostically useful (Wians, 2009).
The miRNAs that had an AUC of ≥0.70 were interrogated further to
classify themedian-normalised Ct values as ‘high’ or ‘low’ expression (in-
terpretation of themedian normalised Ct expression values used to deter-
mine ROC curves were evaluated with the Optimal Cutoff algorithm
(‘OptimalCutpoints’ R package v1.1–3)). For those miRNAs that met the
criteria for inclusion in the diagnostic panel, the patient was given a diag-
nostic score (ranging from 0 to 7) determined by the number of miRNAs
that were present as ‘high’ and ‘low’ or ‘normal’ (most like the ‘control’
cohort). To be deemed positive for melanoma, the patients sample must
have had a score of ≥4 (max 7). A negative test was a score of 0–3.
The following formulaswere used to determine diagnostic test ability:
Positive Predictive Value (PPV) or Precision = True Positive (TP) /
(TP+ False Positive (FP)); Negative Predictive Value (NPV)= True Neg-
ative (TN) / (False Negative (FN) + TN); Sensitivity = TP / (TP + FN);
Specificity = TN / (FP + TN) False Positive Rate = 1− Specificity; False
Negative Rate= 1− Sensitivity; Likelihood Ratio Positive= Sensitivity /
1− Specificity; Likelihood Ratio Negative=1− Sensitivity / Specificity;
Diagnostic Odds Ratio (DOR) = (TP / FN) / (FP / TN).
2.11. Funding
This project was funded by the National Health and Medical Re-
search Council (NHMRC) of Australia.
3. Results
3.1. Members of the ‘MELmiR-17’ Panel are Predictors of Stage, Recurrence,
and Survival in Patient Tissue
To confirm that miRNA expression was detectable in melanoma tis-
sues prior to the serum assessment, we first measured an 18-miRNA
panel (MELmiR-18) in a prospective collection (Tissue ValidationFig. 2. Expression of MELmiR-7 inCohort, see Materials and Methods) of melanoma tissues derived from
stage III (n = 76) and stage IV (n = 10) melanoma patients (Table 1
and Fig. 1). Expression was detected in all dilutions of a positive control
(except miR-4469 which had assay failure thus the panel herein will be
referred to as ‘MELmiR-17’) and in tissue samples (Fig. 1), which indi-
cated that even at low input levels, the assay and detection method
was adequate (data not shown). We observed that thirteen miRNAs
were differentially expressed when stage III tissues were compared
with stage IV tissues (logistic regression, p b 0.05; Supplementary
Table 1 and Supplementary Fig. 1). All but one of these miRNAs (miR-
204) showed higher levels in stage III compared with stage IV tissues
(Supplementary Table 1 and Supplementary Fig. 1). Of these miRNAs,
seven (miR-506-3p, miR-508-3p, miR-508-5p, miR-509-3p, miR-509-
5p,miR-513c, andmiR-514a)weremembers of themiR-506–514a clus-
ter (Streicher et al., 2012). Supplementary Table 1 summarises the as-
sociated AUROC analyses. Members of the miR-506–514 cluster, had
AUC scores ranging from 0.65 to 0.79 with the highest scores being
shared by miR-506-3p and miR-509-5p. To determine the minimum
number of miRNAs required to discriminate stage III from stage IV,
we next performed a multivariate logistic regression and illustrated
this using a conditional inference tree (Supplementary Fig. 2).
These analyses revealed that only miR-4731 (p = 0.003, OR = 3.0,
CI 1.45–6.2) and miR-204 (p = 0.015, OR = 0.63, CI 0.43–0.92)
were required to discriminate the tissue stage (in general, higher
Ct values = lower expression). Subsequent AUROC analysis
(AUC = 0.89) showed an improved score than individual miRNAs
(Supplementary Table 1).
We next used multivariate Cox regression modelling using the
‘MELmiR-17’ panel together with available records of pathology of the
primary melanoma (SMM, NM) and number of involved nodes (N
stage) to determine its value as a prognostic marker at stage III in the
PAH tissue cohort (Table 1). These analyses showed that only nodular
histotype (NM; p = 0.002; HR = 3.5; CI 1.57–7.81) and expression of
miR-509-5p (p = 0.015; HR = 0.85; CI 0.75–0.97) were associated
with overall survival. Expression levels of the ‘MELmiR-17’ panel were
not significantly different between the two largest pathology classes
(SMM and NM) (data not shown). Furthermore, using the same multi-
variate analysis, N-stage (p = 0.014; HR = 1.52; CI 1.09–2.12) and
lower expression of miR-513b (p = 0.038; HR = 1.08; CI 1.00–1.17)
and higher miR-513c expression (p = 0.020; HR = 0.92; CI 0.86–
0.99) were related to recurrence.stage IV progression patients.
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Table 4
Sensitivity and specificity summary.
MELmiR-7-panel Melanoma
vs.
controls
Stages I/II
vs.
controls
Stage III
vs.
controls
Stage IV
vs.
controls
Sensitivity 93% 93% 86% 95%
Specificity ≥82% ≥82% ≥82% ≥82%
False Positive Rate 18% 18% 18% 18%
False Negative Rate 7% 7% 14% 5%
Positive Predictive Value (PPV) 91% 77% 64% 82%
Negative Predictive Value (PPV) 85% 95% 94% 95%
Likelihood Ratio Positive 5.01 5.04 4.66 5.14
Likelihood Ratio Negative 0.09 0.09 0.17 0.06
Diagnostic Odds Ratio (DOR) 54.86 58.89 27.13 83.18
Table 5
Multivariate survival analysis of serummiRNAs and melanoma stage.
Covariate HR Lower 95% CI Upper 95% CI p value
Stage III 6.03 2.33 15.56 0.0002
Stage IV 8.48 3.12 23.01 b0.0001
hsa-miR-16 1.04 0.88 1.23 ns
hsa-miR-211 0.87 0.82 0.91 b0.0001
hsa-miR-4487 0.88 0.79 0.98 0.02
hsa-miR-4706 0.45 0.29 0.69 0.0002
hsa-miR-4731 0.98 0.90 1.06 ns
hsa-miR-509-3p 1.04 1.00 1.09 ns
hsa-miR-514a 0.92 0.85 0.99 0.02
677M.S. Stark et al. / EBioMedicine 2 (2015) 671–6803.2. A Seven-miRNA Panel Identifies Melanoma with High Sensitivity and
Specificity Using Patient Sera
The ‘MELmiR-17’ panel was next assessed in independent cohorts of
patient sera (serum validation cohorts, see Materials and Methods)
with different stages of disease at time of blood collection (fromnomel-
anoma to stages I–IV) (Table 2 and Fig. 1). All expression values (Ct)
were normalised to cel-miR-39 (synthetic ‘spike-in’ control) according
to previously publishedmethods (Tembe et al., 2015) prior to statistical
analysis. In miRNA derived from serum, expression of 13 miRNAs was
detected (Fig. 1 and Table 3). Notably, the expression of the miR-506–
514a cluster was generally quite low (miR-506-3p and miR-514a) or
not detected (miR-508-3p, miR-508-5p, miR-513b, and miR-513c
(data not shown)). In the 13 detected miRNAs, seven (miR-16, miR-
211-5p, miR-4487, miR-4706, miR-4731, miR-509-3p, and miR-509-
5p) showed highly significant differences (Mann–Whitney; corrected
p b 0.0001) between ‘controls’ (no melanoma) and patients with stage
IV disease (Table 3 and Supplementary Figs. 3 and 4). The samemiRNAs
were also differentially detectable in stages I/II and stage III, compared
with ‘controls’, with the exception of miR-211 (Table 3 and Supplemen-
tary Figs. 3 and 4). Whilst miR-16 was originally included as a blood
control, our data show that it is significantly associated with disease in
both tissue and serum, as observed previously in a study of colorectal
cancer (Ristau et al., 2014). Intriguingly, levels of expression of most
of these differentially expressed miRNAs were lower in melanoma pa-
tients compared to patients without disease (controls). The miRNAs
−4487,−4706,−4731, 509-3p, and 509-5p all showed lower expres-
sion (on average) and miRNAs −16 and −211 (stage IV only) had
higher expression (on average) in melanoma patients (Supplementary
Fig. 3). The observed lower serum expression of miR-4487, miR-4706,
miR-4731,miR-509-3p, andmiR-509-5p in themelanoma caseswas as-
sociated with melanoma (presence of or recently removed tumour; see
Discussion), and in the case of miR-509-3p, has been noted previously
by Leidinger et al. (2010).
AUROC analysis revealed which of the differentially detected
miRNAs (Table 3 and Supplementary Fig. 5) have the potential to be
used for diagnostic purposes. Particular attention is paid to those
miRNAs that were able to discriminate stage IV disease (i.e., distal
metastatic deposits) from disease-free controls (Table 3). These were:
miR-16, miR-211-5p, miR-4487, miR-4706, miR-4731, miR-509-3p,
and miR-509-5p (herein referred to as ‘MELmiR-7’). Multivariate
logistic regression identified the five most robust markers of the
‘MELmiR-7’ panel (miR-211, p b 0.0001; miR-509-3p, p = 0.0014;
miR-509-5p, p b 0.0001; miR-4706, p = 0.028; and miR-4731,
p b 0.0001). Subsequent AUROC analysis revealed these five markers
produced a near perfect AUC score of 0.9907 (cf. ‘MELmiR-7’ =
0.9911). Furthermore, a conditional inference tree analysis highlighted
that patients could be discriminated into categories based on combina-
tions of expression levels by members of the MELmiR-7 panel. Supple-
mentary Fig. 6 illustrates that only four miRNAs (miR-509-5p, miR-
miR-4731, miR-211, and miR-509-3p) were required to discriminate
the stage IV samples (AUC = 0.9738) from controls. Further compari-
sons showed that ‘MELmiR-7’ panel members can also discriminate
stages I/II (AUC = 0.991) and stage III (AUC = 0.9722) from ‘controls’
(Supplementary Figs. 7 and 8).
The sensitivity and specificity of the ‘MELmiR-7’ was then assessed
by assigning a diagnostic score to the data. The expression values
graphed in the Supplementary Fig. 3 were used to observe the direction
of the data (i.e., higher or lower expression in ‘controls’ vs. all stages).
The optimal cut points (Vermont et al., 1991) in the AUROC datasets
were identified which allowed the expression values to be categorised
as positive or negative for melanoma (see Materials and Methods). A
diagnostic score (see Materials and Methods) was then applied to
each sample which ranged from 0 to 3 (low likelihood of melanoma)
and 4 to 7 (high likelihood of melanoma). Upon applying the derived
diagnostic score, the ‘MELmiR-7’ panel was evaluated as a group. Wefound that it had the ability to identify melanoma (independent of
stage), when ≥4 miRNAs (93% sensitivity and ≥82% specificity) reached
or exceeded their optimal cut point (Table 4). The sensitivity of the
‘MELmiR-7’ panel increased to 95% in the stage IV cohort. Table 4 pro-
vides a summary of the effectiveness of the ‘MELmiR-7’ panel in relation
to other stages. The diagnostic odds ratio (DOR) was used to determine
the lowest diagnostic score possible for the ‘MELmiR-7’ panelwhilst still
maintaining very high sensitivity and specificity. Moreover, upon com-
parison with currently used serological tests (LDH and S100B), we
found that the ‘MELmiR-7’ panel wasmore sensitive than the combined
power of both tests. Using the available data (Tubingen cohort), elevat-
ed levels of LDH and S100Bwere found in 40% (27/67) and 63% (42/67)
of these patients (Table 2). In the same patients, the ‘MELmiR-7’ panel
achieved 91% (63/67) (when ≥4 miRNAs reached or exceeded their op-
timal cut-points) sensitivity and ≥82% specificity (specificity could not
be determined for serum LDH and S100B as ‘controls’ were not
assayed). The sensitivity of the ‘MELmiR-7’ panel was confirmed in an
independent serial collection of stage IV patients (initial blood draw at
lower disease burden and one at a higher disease burden) (Fig. 2).
Fig. 2 highlights that the ‘MELmiR-7’ panel can be used to monitor tu-
mour progression in 100% of the patients assessed (≥2 miRNAs with
≥1.5-fold relative expression). Subsequent AUROC analysis (Fig. 2)
highlights that if measured in isolation, the most informative markers
would be miR-509-5p and miR-4731 (AUC= 0.84) respectively.
3.3. Members of the ‘MELmiR-17’ Differentiate Stage and are Associated
With Survival in Patient Sera
To discern whether significant differences in stage could be
found, we first assessed the ‘MELmiR-17’ panel using Mann–Whit-
ney tests (with corrected p values) combined with AUROC analysis
for stages I/II vs. IV and stages III vs. IV. Table 3 summarises the asso-
ciated corrected p values and AUROC scores. Next, multivariate logis-
tic regression was used to identify the minimummiRNAs required to
predict differences in the melanoma stages which was illustrated
using conditional inference trees (Supplementary Figs. 9 and 10)
and AUROC analysis (AUC scores for stages I/II vs. IV and stages III
vs. IV were 0.989 and 0.9945 respectively). There were no markers,88
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when Cox regression was performed.
The ‘MELmiR-17’panelwas next assessed to identifymiRNAs related
to OS in the serum cohorts from Tubingen (n = 131) and Melanoma
Institute of Australia (MIA; n = 124) first separately and then jointly
(n = 255) (Table 2). The predictive performance of the joint model on
each cohort was statistically equivalent to that of the best separate
analysis on each cohort (likelihood ratio test; p = 0.34 for MIA co-
hort; p = 0.22 for Tubingen cohort), hence the joint model was
used to analyse the combined Tubingen and MIA cohorts. Further-
more, the miR-4706 marker was dichotomised at Ct 37 to meet the
proportionality assumption. The outcome from the combined
analysis is summarised in Table 5.
A conditional inference tree analysis for the survival data was then
performed which showed that stage at blood draw together with miR-
211 expression could be used to triage patients based on overall survival
(OS) status (Fig. 3 with Kaplan–Meier plots per each classification).
Importantly, upon diagnosis with stage IV, miR-211 expression was
able to discern survival based on high (Ct ≤ 24; median survival =
4.8 months, CI 4.5–5.9) and low expression (Ct ≥ 24.01; median
survival = 2.7 years, CI 1.7–NA).
Finally, the MELmiR-7 panel was further assessed for its utility in
terms of predicting OS in serum cohorts having LDH and S100B status
available (Tubingen) (Table 2). The ‘MELmiR-7’ panel performed signif-
icantly better than both serum LDH and S100B (delta log likelihood =
11, p b 0.001).
4. Discussion
Five-year survival proportions for melanoma are poor for patients
with metastatic disease, however if disease is detected in its early
stages, then survival is one of the highest for all cancers. Even for
those with metastases, survival differs depending on the extent ofFig. 3. Conditional inference tree pdisease spread. Patients with metastases confined to regional lymph
nodes (stage III disease) have 5-year survival of ~50%, whereas patients
with widely disseminated metastases (stage IV disease) have 5-year
survival of b15%. Thus better monitoring of a patient's tumour burden
may improve survival by precipitating earlier therapeutic interventions.
In support of this, clinical trials in stage III unresectable and stage IV
melanoma patients, treated with ipilimumab (Hodi et al., 2010),
vemurafenib (Sosman et al., 2012), combined dabrafenib and
trametinib (Flaherty et al., 2014) or anti-PD1 pembrolizumab (Joseph
et al., 2014), have observed improved overall survival and response
rate in patients with lower disease volume (M1a/M1b) as compared
to those with distal disease (M1c). Moreover, it is believed that there
is potential for long-term survival if relapses are identified promptly
with treatment initiated without delay (Davidson et al., 2014). In clini-
cal practice, there is currently a lack of reliable, sensitive and specific
predictive biomarkers for detecting early melanoma progression. This
study aimed to identify a more effective biomarker that was sensitive
and specific enough to identify early metastatic disease. Since com-
mencement of this study there have been a number of studies investi-
gating the utility of miRNAs to serve as melanoma blood and tissue
biomarkers (Fleming et al., 2015; Friedman et al., 2012; Tembe et al.,
2015; Leidinger et al., 2010; Greenberg et al., 2013; Margue et al.,
2015; Bonazzi et al., 2012). For example, a study by Friedman et al.
(2012) screened 355 miRNAs in sera from 80 melanoma patients
using a previously characterised panel of serum-expressed miRNAs.
The authors found detectable expression for 170 miRNAs and a panel
of five miRNAs (miR-150, miR-15b, miR-199a-5p, miR-33a, and miR-
424) showed a significant association with recurrence-free survival.
This five-miRNA signature was able to classify the patients into high
and low recurrence risk. Our approach was to identify a panel of
melanoma-related miRNAs that involved first screening a panel of
melanoma cell lines (n = 55) in comparison with a group of other
solid malignancies (cell lines were derived from breast, ovarian,redicting survival outcomes.
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miRNA panel indentified by Friedman et al. (2012) was not present in
our dataset which may indicate that this panel is not specifically
melanoma-related but instead related to the tumourigenic process.
We focused on miRNAs that were highly expressed or more predomi-
nantly expressed in melanoma with the premise that these may be
both ‘diagnostic’ for melanoma and/or more easily detectable in patient
serum. Our current approach differed from the aforementioned studies
as: 1) this study harnessed the power of our previous comprehensive
analysis of known miRNAs (n = 1898) in relation to melanoma (Stark
et al., 2015); 2) this study validated the cell-line derived miRNA panel
(MELmiR-17) in a large of panel of stage III and IV melanoma tissues
prior to serum analysis to confirm they were expressed; and 3) this
study used an ultra-sensitive method of detection (see Materials and
Methods) to ensure that lowly expressed miRNAs could be detected.
We have successfully used these approaches in a previous study
where a panel of miRNAs were identified that was related to good and
poor prognosis in stage III melanoma patients (Tembe et al., 2015).
However, our current study was limited by the lack of available serially
collected specimens (to detect recurrence as in Friedman et al., 2012) at
time of study design. To address this limitation, further studies in larger,
independent, prospectively collected melanoma cohorts will be
required to strengthen these data.
In sum, we found that a ‘melanoma-related’ panel of miRNAs was
expressed in metastatic melanoma in a stage-specific manner and, to-
getherwith the tissue pathology andnodal status,wasprognostic for re-
currence and OS. These markers may therefore also be useful to support
histopathologic diagnosis ofmetastatic deposits suspected of beingmel-
anoma. We further observed that expression of the various miRNAs
from the MELmiR-17 panel in stage IV tissues was often lower than in
stage III tissue, which is in keeping with previous studies. For example,
miR-211 expression is commonly lost in subsets of melanoma cell
lines (Stark et al., 2015; Boyle et al., 2011), and miR-506, a member of
the miR-506–514 cluster, has been shown to be lost during metastatic
colonisation despite being up-regulated in early melanoma progression
(Streicher et al., 2012; Mueller et al., 2009). We have also recently re-
ported that inhibition of miR-514a leads to increased cell proliferation
(Stark et al., 2015). These data indicate that expression of this cluster
reduces during melanoma progression.
Currently there is an unmet need for aminimally invasive, highly spe-
cific, and predictive serum biomarker of melanoma burden. For many
years the use of the seroproteinmarkers S100B and LDH has been disput-
ed, due to reported inconsistencies in sensitivity and specificity (Brochez
and Naeyaert, 2000; Finck et al., 1983; Karakousis et al., 1996; Sirott et al.,
1993; Weide et al., 2012; Guo et al., 1995; Smit et al., 2005; Kruijff et al.,
2009). Despite this lack of consensus, a recent study didfind that elevated
levels of S100B were prognostic of survival times in patients with
unresectable melanoma (Weide et al., 2013).
Here, we present data that shows that our ‘MELmiR-7’ panel has the
potential to be used as a primary screening tool for clinically undetected
metastatic melanoma due to its high sensitivity (93%) and specificity
(≥82%). However, detection of early melanoma lesions (in situ and stages
I/IImelanoma) is currently being adequately achieved (as evident by high
survival rates) via clinical strategies. The ‘MELmiR-7’ panel could be
utilised during routine follow-up (i.e., post-primary excision ofmelanoma
and later in advanced disease) of melanoma patients. In comparisonwith
serum LDH and S100B, expression levels of the ‘MELmiR-7’ panel per-
formed better than both markers in predicting overall survival. We have
shown that the ‘MELmiR-7’ panel was measurable at time of progression
in 100% of stage IVmelanoma patients. These data suggest that this panel
would therefore be suited to monitor tumour burden.
According to the AJCC Staging committee, stage III melanoma
patients have a 50% chance of survival beyond 5 years (Balch et al.,
2009); these patients also remain themost difficult forwhom to provide
effective treatments/surveillance regimens and accurate survival esti-
mates. Following treatment, stage III patients are subjected to a seriesof physical examinations, scans and serology at regular intervals. The fre-
quency of these tests is deemed necessary for early detection of
recurrence; however this causes a burden to both the patient and the
healthcare system. It is important to note that these guidelines are not uni-
versally accepted and differ from centre to centre (Leiter et al., 2014). We
foresee that the ‘MELmiR-7’ panel could be offered to patients to comple-
ment physical examination. If the diagnostic score for melanoma positivity
has changed from earlier measurements, then this may indicate the pres-
ence of disease recurrence and as such, these patients may qualify earlier
for adjuvant, systemic, or targeted therapies that would otherwise be only
offered to stage IV patients. As previously discussed, due to the panel's
high sensitivity and specificity, the use of this miRNA panel in this manner
has the potential to increase the chances of survival, by earlier and more
precise detection of the presence of metastases.
In terms of prognosis, elevatedmiR-211 expression levelswere asso-
ciated with poorer survival in stage IV patients. Therefore, miR-211
measurement might allow better triaging of patients diagnosed with
stage IV disease, into good and poor prognosis which would be highly
informative for not only the treating clinician but also for the quality
of life of the patients.
The original premise of this study was that the melanoma-enriched
miRNAs identified in our previous study (Stark et al., 2015) would be
translated directly to the expression observed in melanoma patient-
derived serum. Evidence for this notion is apparent in the serially collect-
ed stage IVmelanomapatients,when, at progression (or recurrence), the
MELmiR-7 panel increases, which is reflective of increased tumour
burden (i.e., the detectable miRNA expression was from the presence
of tumour cells and/or tumour derived extracellular vesicles (e.g.,
exosomes) in the circulation). These data strongly suggest that the
expression is tumour derived and as such this panel could be considered
melanoma-related. However, aswehave noted,we observe a paradoxical
decrease in the expression of the significantly expressed (miR-509-5p,
miR-509-3p, miR-4731-5p, miR-4487, miR-4706) miRNAs when mela-
noma serum cohorts were compared with control cohorts. These data
thus provide evidence that the assessed miRNAs (detectable in serum)
are not restricted to the melanocytic lineage as initially thought. The
source of this miRNA expression is currently unknown but could include
cells of the haematopoietic lineage including T-cells, B-cells and NK cells.
This loss of expression from a ‘non-tumour’ source has not been eluci-
dated butwarrants further investigation. An observed loss of expression
of serum-derived miRNAs has been noted previously by Friedman et al.
(2012) in post-operative specimens as compared to specimens collect-
ed at disease relapse. A plausible reason for a loss of expression observed
in the serummay be due to a cytokine-driven systemic response. For ex-
ample, pro-inflammatory cytokines have been shown to down-regulate
miRNAs present in the circulation (Noren Hooten et al., 2013). Specifical-
ly, in a study by Noren Hooten et al. (2013) the serum expression of miR-
181a was found to be negatively correlated with pro-inflammatory cyto-
kines IL-6 and TNFα and positively correlatedwith the anti-inflammatory
cytokines TGFβ and IL-10 (Noren Hooten et al., 2013). Recently, it has
been confirmed that IL-6 expression is induced in melanoma cells with
mutant BRAF (V600E). Therefore a possible explanation for what we
have observed is that the miRNAs of interest could be expressed by
non-melanocyte derived cells where expression is down-regulated in pa-
tients with melanoma due to melanoma-related cytokines (e.g. IL-6)
(Whipple and Brinckerhoff, 2014).
In conclusion, we envisage that as a growing number of miRNA-
panels have been identified as potential prognostic indicators for mela-
noma (Fleming et al., 2015; Friedman et al., 2012; Tembe et al., 2015), it
will eminently feasible to quantify circulating cell-free miRNAs directly
(Ono et al., 2015), paving the way for rapid measurements to occur in a
diagnostic laboratory. Given these advances, combined with the data
presented herein, future melanoma treatment regimens should consid-
er the utility of miRNAs as a prognostic aid in the clinical setting.
Our sensitive and specific miRNA panel, in combination with newly
identified panels, may enable more precise measurement of disease90
680 M.S. Stark et al. / EBioMedicine 2 (2015) 671–680progression, and in conjunction with current therapy options, may
herald an increase in overall survival.
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SUPPLEMENTARY TABLES 
Supplementary Table 1 
Univariate Logistic Regression analysis (stage III vs. IV tissues) and associated p values and Odds Ratios (OR) 
along with AUC scores for 17 detectable miRNAs in FFPE tissue derived from melanoma patients. 
miRNA Names OR Lower 95%CI 
Upper 
95%CI p Value 
AUC 
Scores 
hsa-miR-211 1·1 1·04 1·17 0·0017 0·78 
hsa-miR-508-3p 1·12 1·04 1·21 0·0025 0·78 
hsa-miR-514a 1·12 1·04 1·21 0·0032 0·73 
hsa-miR-4731 1·78 1·2 2·64 0·004 0·84 
hsa-miR-146a 1·6 1·15 2·23 0·0056 0·75 
hsa-miR-509-3p 1·18 1·05 1·34 0·0063 0·77 
hsa-miR-506-3p 1·12 1·03 1·22 0·0083 0·79 
hsa-miR-509-5p 1·17 1·04 1·31 0·0087 0·79 
hsa-miR-508-5p 1·12 1·02 1·24 0·0143 0·65 
hsa-miR-4487 2·15 1·16 3·98 0·0148 0·8 
hsa-miR-16 2·07 1·07 3·97 0·0297 0·73 
hsa-miR-204 0·85 0·73 0·99 0·0361 0·66 
hsa-miR-513c 1·09 1.00 1·18 0·0445 0·69 
hsa-miR-513b 1·1 0·98 1·24 ns 0·65 
hsa-miR-145 1·21 0·84 1·73 ns 0·61 
hsa-miR-363-3p 1·04 0·94 1·15 ns 0·63 
hsa-miR-4706 1·01 0·89 1·14 ns 0·5 
93
  
Supplementary Table 2 
Follow-up (FU) times of cohorts used in recurrence and survival analysis. Yrs = years. SEM = standard error of 
the mean. CI = confidence interval. NA = not available 
Centre Type Stage Totals Deaths 
Restricted 
mean 
survival Yrs 
±SEM 
Median Survival 
Yrs 
(95% CI) 
Range FU 
Yrs 
Median 
FU 
Yrs 
PAH Tissue IIIB IIIC 
25 
41 
13 
29 
5.77 ± 1.01 
3.81 ± 0.73 
2.22 (1.24, NA) 
0.95 (0.70, 1.98) 
0.49 - 11.68 
0.29 - 10.43 
1.81 
0.95 
Tubingen Serum 
I/II 
IV 
52 
79 
2 
62 
6.68 ± 0.16 
1.88 ± 0.29 
NA 
0.48 (0.44, 1.72) 
0.0 - 3.9 
0.03 - 9.94 
2.05 
0.48 
MIA Serum 
I/II 
III 
IV 
34 
50 
40 
4 
16 
20 
5.14 ± 0.21 
3.86 ± 0.33 
3.03 ± 0.40 
NA 
NA (2.99, NA) 
0.96 (0.66, NA) 
1.03 - 5.86 
0.01 - 5.57 
0.13 - 4.58 
4.86 
1.61 
1.50 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1 
Graphical representation of the data presented in Supplementary Table 1 for stage III and IV FFPE tissues. P 
values represent the output from a univariate logistic regression analysis. ns = no significance. Error bars 
represent the mean with SD. 
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Supplementary Figure 1 (cont.) 
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Supplementary Figure 2 
A conditional inference tree (CI tree) illustrates that stage III tissues (0) can be discriminated from stage IV 
tissues (1) by significant (p value as indicated) differential expression of miR-4731 and miR-204. Dark shading 
relates to the ratio of stage IV tissues present in each class (node). 
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Supplementary Figure 3 
Graphical representation of the data presented in Table 3 for the ‘MELmir-7’ panel which were those that 
showed high significance (Mann-Whitney U test, corrected P <0·0001) between stage IV versus ‘controls’. ns = 
no significance. Error bars represent the mean with SD. 
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Supplementary Figure 3 (cont) 
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Supplementary Figure 4 
Graphical representation of the data presented in Table 3 for the miRNAs that had significance ranging from 
non-significance to p<0.0001. Refer 3 for associated P values.  
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Supplementary Figure 5 
ROC curves derived from the data presented in Table 2 for the ‘MELmir-7’ panel which were those that showed 
high significance (Mann-Whitney U test, corrected P <0·0001) between stage IV versus ‘controls’. All members 
of the ‘MELmir-7’ panel have AUC scores >0·7. 
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Supplementary Figure 6 
A conditional inference tree illustrates that serum collected from stage IV patients can be discriminated from 
‘control’ patients by significant (p value as indicated) differential expression of miR-509-5p, miR-4731, miR-
211, and miR-509-3p. Dark shading relates to the ratio of stage IV sera present in each class (node). 
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Supplementary Figure 7 
A conditional inference tree illustrates that serum collected from stage I/II patients can be discriminated from 
‘control’ patients by significant (p value as indicated) differential expression of miR-509-5p, miR-16, miR-
4487, and miR-509-3p. Dark shading relates to the ratio of stage I/II sera present in each class (node). 
103
Supplementary Figure 8 
A conditional inference tree illustrates that serum collected from stage III patients can be discriminated from 
‘control’ patients by significant (p value as indicated) differential expression of miR-4487 and miR-16. Dark 
shading relates to the ratio of stage III sera present in each class (node). 
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Supplementary Figure 9 
A conditional inference tree illustrates that serum collected from stage I/II patients can be discriminated from IV 
patients by significant (p value as indicated) differential expression of miR-509-3p, miR-miR-211, miR-16, and 
miR-4487. Dark shading relates to the ratio of stage IV sera present in each class (node). 
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Supplementary Figure 10 
A conditional inference tree illustrates that serum collected from stage III patients can be discriminated from IV 
patients by significant (p value as indicated) differential expression of miR-509-3p, miR-16, miR-204, and miR-
4487. Dark shading relates to the ratio of stage IV sera present in each class (node). 
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Chapter 4 
MicroRNA and mRNA expression profiling in metastatic melanoma 
reveal associations with BRAF mutation and patient prognosis 
Varsha Tembe*, Sarah-Jane Schramm*, Mitchell S. Stark*, Ellis Patrick, Vivek Jayaswal, 
Yue Hang Tang, Andrew Barbour, Nicholas K. Hayward, John F. Thompson, Richard A. 
Scolyer, Yee Hwa Yang, Graham J. Mann. MicroRNA and mRNA expression profiling in 
metastatic melanoma reveal associations with BRAF mutation and patient prognosis. 
Pigment Cell and Melanoma Research. 2015 May;28(3):254-66. doi: 10.1111/pcmr.12343. 
Epub 2015 Jan 5. 
* These authors contributed equally to this work.
4.1. Relevance to thesis aims 
The data presented in this chapter is related to Aims 2-4 and represents an alternative 
method (compared with the data presented in Chapters 2 and 3) for identifying miRNAs 
relevant to patient prognosis and target gene identification. Global miRNA and mRNA 
expression profiles in fresh-frozen metastatic melanomas were analysed in relation to 
clinical outcome and BRAF mutation. This cohort of patients from the Melanoma Institute 
of Australia (MIA) has some of the best clinically annotated data available and thus the 
patients, at time of last follow-up (FU; 4 years) were classified as having good (GP; >4 yr 
survival after resection of lymph metastatic disease with no sign of relapse) or poor 
prognosis (PP; died within 1 yr of resection). The differentially expressed miRNAs (GP vs. 
PP) were then validated in independent cohorts of tissue and serum (Aims 2 and 3). 
Target genes were identified following integration of the matched miRNA and mRNA data 
in relation to prognosis and BRAF mutation (Aim 4). 
4.2. Contribution of candidate 
This collaborative study was developed independent of my supervisors. The initial study 
concept was conducted with my collaborators at the MIA. My contribution entailed; editing 
and rewriting of the original manuscript which was drafted by Sarah-Jane Schramm and 
Varsha Tembe. Following this, I put forward that there was a great need for further 
validation of the identified miRNA panel. The study was extended to include the serum and 
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tissue validation cohorts. Overall, my contribution was significant and as such I was 
included as a co-lead author. In summary, I performed ~1/3 of the experimental work, data 
analysis and interpretation, and writing of the manuscript. 
4.3 Statement of Contribution of Co-Authors 
The authors listed below have certified* that: 
1. they meet the criteria for authorship in that they have participated in the conception,
execution, or interpretation, of at least that part of the publication in their field of
expertise;
2. they take public responsibility for their part of the publication, except for the responsible
author who accepts overall responsibility for the publication;
3. there are no other authors of the publication according to these criteria;
4. potential conflicts of interest have been disclosed to (a) granting bodies, (b) the editor
or publisher of journals or other publications, and (c) the head of the responsible
academic unit, and
5. they agree to the use of the publication in the student’s thesis and its publication on the
QUT ePrints database consistent with any limitations set by publisher requirements.
In the case of this chapter: 
Publication title and date of publication or status: MicroRNA and mRNA expression 
profiling in metastatic melanoma reveal associations with BRAF mutation and patient 
prognosis. 2015 May;28(3):254-66. Published in Pigment Cell and Melanoma 
Research. 
Contributor Statement of contribution* 
Mitchell S. Stark Mitchell edited and rewrote 
the original manuscript which 
was drafted by Sarah-Jane 
Schramm and Varsha 
Tembe. Following this, 
Mitchell proposed that there June 15
th , 2015 
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was a great need for further 
validation of the identified 
miRNA panel. The study was 
extended to include the 
serum and tissue validation 
cohorts. Overall, Mitchell’s 
contribution was significant 
and as such he was included 
as a co-lead author. In 
summary, Mitchell performed 
~1/3 of the experimental 
work, data analysis and 
interpretation, and writing of 
the manuscript. 
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SUPPLEMENTARY METHODS 
 
RNA extractions 
 
Discovery cohort 
 
Total RNA was extracted from fresh frozen tissues using the Roche High Pure 
miRNA Isolation kit (Cat No 05080576001, Roche Diagnostic, Indiana, IN, USA) in 
accordance with the manufacturer’s protocol. The quality and quantity of small RNAs 
present in the total RNA extract was assessed using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). 
 
FFPE validation cohort 
 
The extraction of total RNA from FFPE tissue was performed using miRNeasy FFPE 
Kits (QIAGEN, Hilden, Germany) as per manufacturer’s instructions.  
 
Serum validation cohort  
 
Total RNA was extracted from serum following the manufacturer’s protocol using the 
miRNeasy Serum/Plasma Kits (QIAGEN, Hilden, Germany). As there is currently no 
consensus as to which miRNA should be used as an endogenous control, a 
synthetic miRNA mimic (miRNeasy Serum/Plasma Spike-In Control: C. elegans miR-
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39 miRNA mimic, Cat No 219610, QIAGEN, Hilden, Germany)) was spiked into each 
sample to allow for normalisation of expression data. 
 
miRNA expression microarray profiling, pre-processing, and statistical 
evaluation of differential expression 
 
Discovery cohort 
 
Profiling was performed in accordance with the manufacturer’s protocol using the 
Agilent Human miRNA Microarray Release 16.0, 8x60K (G4872A-031181, Agilent 
Technologies, Santa Clara, CA, USA). Expression data are deposited in the Gene 
Expression Omnibus (GEO) database repository: GSE59334. We used a mixed 
effects model for analysing microarray data. Given that every miRNA on the chip 
corresponded to at least one probe and each probe had technical replicates, we 
modelled the expression of a miRNA as: 
 
ijklijkkiijkl εγηαμy ++++=   (1), 
 
where yijkl denotes the normalized log2 expression for the ith condition, jth sample, kth 
probe and lth replicate,  µ denotes the baseline expression, αi denotes the effect of 
the ith condition, ηk denotes the effect of the kth probe, γ ijk denotes the variability in 
the ith condition for jth sample and kth probe, and εijkl denotes the measurement error. 
This linear mixed effects model takes into account three sources of variability - 
condition (PP vs GP), probe (incorporating typically two or more probes per 
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microRNA), and sample. The model had two fixed effect coefficients, namely µ and 
α, and three random terms, namely η, γ, and ε. We assumed the random terms to be 
normally distributed with zero means and variances σ12, σ22, and σ32 for η, γ, and ε, 
respectively. We implemented the model in R (R_Core_Team, 2014) using the 
library nlme. 
 
We identified DE miRNAs among stage III patients with better and worse prognosis. 
For patient outcome-related analyses: 1) i = 1, 2 (corresponding to the two 
conditions); 2) j = 1,…, 23 for GP and 1,…, 22 for PP, 3) k ≥ 1 (the actual number of 
probes varies from one miRNA to another); and, 4) l > 1 (the actual number of 
technical replicates varies from one probe to another). For every miRNA, we used 
the mixed effect model (refer Equation 1) to test the null hypothesis that the average 
expression values in the two conditions were the same. We considered a miRNA to 
be DE by controlling the 5% false discovery rate (FDR). Similarly, we obtained the 
DE miRNAs for BRAF mutant vs. wild type. 
 
Validation of DE miRNAs via quantitative reverse transcription-
PCR  
 
Discovery cohort 
 
The expression of selected miRNAs was assessed using qRT-PCR. cDNA was 
prepared from total RNA using the Taqman® miRNA Reverse Transcription kit 
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(Applied Biosystems, Foster City, CA, USA). Predesigned TaqMan® miRNA Assays 
for miR-150-5p (002637), miR-142-3p (000464), miR-142-5p (002248), miR-146b-5p 
(001097) were also purchased from Applied Biosystems (Foster City, CA, USA) and 
qRT-PCR was performed using StepOnePlus™ Real-Time PCR Systems, (Applied 
Biosystems, Foster City, CA, USA). RNU44 (001094) small nuclear RNA was used 
for normalization of input RNA/cDNA levels. All reactions were run in duplicate and 
no-template controls were included for each assay.  
 
We used a mixed effects model for analysis of qRT-PCR data. We observed that the 
normalization of qRT-PCR data using RNU-44 resulted in higher coefficient of 
variation values compared to un-normalized data. This suggested that RNU-44 was 
inappropriate for data normalization and we used the un-normalized data for 
downstream analysis. We considered a mixed effects model for testing the null 
hypothesis that the average expression in the two conditions of interest (GP vs. PP 
or BRAF mutant vs. wild type) was the same. Specifically, we considered the model: 
 
ijmmiijm εηαμy +++=   (2), 
 
where yikm denotes the Ct-value for the ith condition, jth sample (or patient) and mth 
low density array,  µ denotes the baseline expression, αi denotes effect of the ith 
condition, ηm denotes the effect of the mth array, and εijm denotes the measurement 
error. This model had two fixed effect coefficients, namely µ and α, and two random 
terms, namely η and ε. We assumed the random terms to be normally distributed 
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with zero means and variances σa2 and σb2, for η and ε, respectively. We considered 
a miRNA to be DE by controlling the 5% FDR. 
 
FFPE and serum validation cohorts 
 
The standard TaqMan® MicroRNA Assay protocol calls for an individual gene 
specific reverse transcription (RT) reaction for each assay, however, in order to 
maximize the full capability of the Biomark™ HD (Fluidigm®, South San Francisco, 
USA) system, we developed a modified protocol (User bulletin publication part 
number 4465407, revision date January 2013 (Rev. C)). Briefly, a custom RT primer 
pool consisting of equal amounts of miRNA-specific RT primers contained within 
each TaqMan® Assay (Life Technologies, Carlsbad, USA; miR-629-3p (001562), 
miR-150-3p (002637), miR-150-5p (000473), miR-146b-5p (001097), miR-142-5p 
(002248), miR-142-3p (000464), miR-767-5p (001993), miR-29b-1-5p (002165), 
miR-21-3p (002438), miR-187-5p (002740), miR-141-3p (000463), miR-124-3p 
(001182), along with cel-miR-39 (000200; serum spiked-in control) and RNU-6 
(001973; FFPE endogenous control)) plus an additional pool of the corresponding 
TaqMan® MicroRNA Assay (PreAmp Primer Pool) were used to preamplify the RT 
reaction. The TaqMan® PreAmp Master Mix (Life Technologies, Carlsbad, USA) was 
used to amplify small amounts of cDNA reactions (this is specifically designed to not 
introduce amplification bias). The RT protocol was as per manufacturers guidelines 
and the PreAmplification protocol was modified in the following way: total reaction 
volume was scaled down to 10µL (2.5µL of RT-product, 5µL of TaqMan® PreAmp 
Master Mix (2X), and 1.5µL of PreAmp Primer Pool, with the final volume adjusted 
with H2O) and with a total of 14 cycles used in the PreAmplification.  
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 The 96.96 Dynamic™ Array (Fluidigm®, South San Francisco, USA) allows 
simultaneous measurement of 96 assays with 96 samples totaling 9216 reactions 
with minimal cDNA and (2.7ul) assay (2.5ul) input. The Dynamic™ Array has an on-
chip network of microfluidic channels, chambers and valves that automatically 
assemble individual PCR reactions. The BioMark™ (Fluidigm®, South San 
Francisco, USA) system has the ability to detect a single copy in a 6.75nl reaction 
volume, a feat not possible with conventional real-time PCR instruments (5ul 
minimum volume). In this way, it is possible to combine up to 96 primer assays to 
create a high throughput, specific and highly sensitive custom miRNA expression 
panel, which maximizes the information that can be obtained from each RNA 
sample. This ultra-sensitivity allows for absolute confidence in its ability to detect 
subtle changes in gene expression – a requirement for serum miRNA detection. 
Guidelines for loading and additional reagents required for the 96.96 Dynamic™ 
Array were as per the manufactures instructions (PN 68000130, Rev. C.). 
 
The expression of each sample was assayed with at least 4 replicate Taqman 
assays to determine its median normalized Ct expression value. Firstly, real-time 
expression data was analyzed and extracted using Fluidigm’s Real-Time PCR 
Analysis software using default parameters (Quality Threshold = 0.65, Baseline 
Correction Method = Linear, and Ct Threshold Method = Auto (Global)). The 
combined data from all 96.96 Dynamic Array runs were then combined in Microsoft 
Excel so as to perform global normalization (median normalized Ct value method) 
(Kroh EM et al., 2010). 
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 For the serum samples, firstly, the average Ct value was determined for each 
sample-assay combination (including cel-miR-39). The normalization factor was then 
derived by subtracting the mean cel-miR-39 Ct value of each sample from median 
cel-miR-39 Ct value of all samples. The median normalized Ct value was then 
calculated by adding the normalization factor to the averaged Ct value of each 
sample-assay combination. 
 
For the FFPE samples, again, the average Ct value was determined for each 
sample-assay combination (including RNU-6). The normalization factor was then 
derived by subtracting the mean RNU-6 Ct value of a positive control sample with 
known quantity (15ng) of total RNA (added to the initial cDNA reaction) from each 
RNU-6 assay-sample combination. The median normalized Ct value was then 
calculated by adding the normalization factor to the averaged Ct value of each 
sample-assay combination. 
 
All data analysis was performed in Graph Pad Prism 6 or SPSS for Windows, 
version 21.0 (Statistical Package for the Social Sciences, SPSS, Inc., Chicago, IL) 
using default parameters using median-normalized Ct expression values. To classify 
‘high’ and ‘low’ expression for survival analysis of the 66 stage III patients with 
known prognosis (Barbour et al., 2014), interpretation of Ct expression values used 
to determine ROC curves were evaluated with an arbitrary cut-off of 80% sensitivity. 
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Those that were greater than this cut-off were classed as ‘high’ and those that were 
below were ‘low’. 
 
Integration of mRNA and miRNA information from the same samples 
 
Multivariate random forest-based integration of microRNA and mRNA expression 
profiling information (unsupervised integration) 
 
The multivariate random forest (MRF)-based analysis is used to identify microRNA 
(miRNA) clusters (single miRNAs or groups of them) that are enriched in terms of 
potential co-targets, and vice versa (Jayaswal et al., 2011). First enriched miRNA 
clusters are identified using miRNA expression data and miRNA-mRNA prediction 
algorithms. Here, "an enriched miRNA cluster" implies that the miRNAs share a 
larger number of genes as targets than expected by chance. Similarly, enriched 
gene clusters are identified using gene expression data and miRNA-mRNA 
prediction algorithms. This is achieved as per the following example:  
 
Let the total number of miRNAs and genes equal 10 and 100, respectively. 
Now, the miRNA-mRNA prediction algorithms are used to generate a 10x100 
binary matrix comprising 10 miRNAs as rows and 100 mRNAs as columns. 
Now assume that one of the miRNA clusters obtained using MRF has two 
miRs. This allows us to filter the miRNA-mRNA matrix from 10x100 to 2x100. 
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Now using the 2x100 matrix we obtain the average distance between the 
genes. Next we use a permutation test to determine whether randomly 
chosen 2x100 matrices have the same (or smaller) average distance between 
genes. If no, then the miRNA cluster is considered as enriched. Therefore, 
enrichment implies that the miRNAs in the cluster share a larger than 
expected number of predicted targets. Note that if a miRNA cluster has just 
one miRNA, then we can't test this. However, such miRNA clusters are 
always included in the downstream analysis for the identification of miRNA-
mRNA cliques. The "enriched" gene clusters are obtained in a similar manner. 
 
The next step determines whether the enrichment translates into expression-level 
associations between "enriched" miRNA clusters and "enriched" gene clusters. Here, 
a combination of miRNA cluster and gene cluster is a clique. So, if a clique has 2 
miRNAs and 30 genes, then the total number of miRNA-gene pairs is 60. Given 
these pairs, we next perform the following steps: 
i. Determine whether the pair is computationally predicted by at least one of 
the following algorithms: TargetScan (Version 6.2) (Grimson et al., 2007), 
PicTar (Krek et al., 2005), and MicroCosm (Version 5.0) (Griffiths-Jones et 
al., 2008).; and, 
ii.  Use a linear model to determine whether the change in miRNA expression 
produces a change in gene expression. 
Once (i) and (ii) have been performed for each of the 60 pairs, we obtain "X", the 
number of pairs with statistically significant association. Next we test whether a 
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randomly selected set of 30 genes would result in "X" or more pairs with significant 
associations. If not, then the clique is considered to be statistically significant. Note 
that for the enriched modules, not every possible microRNA-gene pair is required to 
have a significant association. Therefore, the actual microRNA-gene pairs that have 
a significant association (within an enriched clique) are provided in Supplementary 
Table 1 (for poor prognosis, the column headed ‘Statistically associated miRNA-
mRNA pairs’) and Supplementary Table 2 (for BRAF mutation). All p-values are 
unadjusted except for the identification of enriched modules. The choice of 
unadjusted p-values ensured that, in the first step, we included miRNAs and genes 
with a weak change in expression across biological states. So, the enriched gene 
clusters and microRNA clusters have unadjusted p-values less than 0.05. However, 
the enriched microRNA-gene modules correspond to FDR adjusted p-values less 
than 0.05.  
 
Pathway-supervised integration of microRNA and mRNA expression profiling 
information (supervised integration) 
 
In the pathway-supervised analysis of miRNA and mRNA expression from the same 
samples, we examined whether a set of genes was potentially co-regulated by a 
miRNA, while also belonging to the same biologic pathway. To do this we used the 
method described in (E. Patrick et al., unpublished data) which took as input two 
experimental datasets and two external databases. The specific data used were: 
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i. mRNA data (Jayawardana et al., 2014; Mann et al., 2013) comprising 
10,292 genes and 45 samples;  
ii. miRNA data (refer MATERIALS AND METHODS, main manuscript) 
comprising 603 miRNAs and 45 samples matching those from which 
the mRNA information above were derived; 
iii. miRNA-mRNA binding site targets using the TargetScan database 
(Grimson et al., 2007), version 6.2 (accessed using R package version 
2.14.0 (R_Core_Team, 2014)), compiled on Bioconductor in the 
package targetscan.Hs.eg.db v0.6.0; and, 
iv. Pathway information from KEGG (Kanehisa et al., 2012), downloaded 
on the 15th of March (accessed using R package version 0.6.1 
(R_Core_Team, 2014)), 2011 and compiled on Bioconductor in the 
package goseq v1.10.0). 
 
After matching of identifiers, and considering only genes that present in both KEGG 
and TargetScan, the analysis was left with a subset of 190 miRNAs and 2,183 
mRNA target genes. In the 3-step algorithm described next we considered only 
miRNA-pathway intersections greater than 4, leaving a total of 5,847 miRNA-
pathways pairs. 
 
From the two experimental datasets considered, two statistics are calculated for use 
in the supervised analysis. The first of these is used to determine if a miRNA’s 
expression is associated with a comparison of interest. This is determined by one-
sided p-values from two sample t-tests measuring differential expression between 
patient groups (clinical outcome or BRAF mutation status) in the miRNA expression 
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data. The second statistic is used to determine if an mRNA is negatively correlated 
with a miRNA. For this empirical p-values are determined from the miRNA-mRNA 
correlations. These p-values are estimated using a rank transform of the miRNA-
mRNA correlations defined as: 
 (rank�rij� −  0.5)/(number of miRNA × number of genes) (3) 
 
where rij is the correlation between the ith miRNA and jth gene; 
 
The procedure outlined in (E. Patrick et al., unpublished data) uses a 3-step 
algorithm to generate an integrative score (IS) for ranking each miRNA that may be 
regulating a set of genes that lie in the same pathway. For a particular miRNA these 
three steps are: 
 
i. The intersecting genes between miRNA-mRNA binding site targets and 
KEGG pathways are identified (referred to as miR-pathways); 
ii. The p-values associated with the observed correlations between a miRNA 
and its targets are combined for those genes that lay in the miR-pathways 
found in (1) using (Stouffer et al., 1949); and,  
iii. After an FDR-correction, the combined p-values from (2) are combined with 
the corresponding miRNA DE p-value using (Pearson, 1934).  
 
The two combination approaches used above are further described as follows: for n 
tests with n corresponding p-values, the combination approach outlined in (Pearson, 
1934) for determining if all n tests show deviation from the null is: 
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 P(χ2n2 < −2∑ log(1 − pi)ni=1 ) (4) 
 
and approach described in (Stouffer et al., 1949) for determining if any of the tests 
have deviated from the null is defined as: 
 
Φ((∑ Φ−1(pi))/√n)ni=1  (5) 
 
Here, Φ() is the cumulative distribution function for a standard normal. 
 
Literature review protocol  
 
For all miRNA-mRNA pairs with an IS<0.05 (Supplementary Table 3), we examined 
the peer-reviewed literature for primary research articles that evaluated the role of 
the mRNA (gene) in relation to any cancer. The search was conducted on May 31st 
2014 using the PubMed medical literature database using each gene symbol ID in 
turn together with the search term “cancer”. The title and abstract of each citation 
was inspected to identify those manuscripts reporting on the role of the queried gene 
in relation to cancer progression, invasion, migration, proliferation, and/or prognosis. 
In each case, the direction of differential expression observed in the present study 
for each gene was compared with the findings of prior reports of its expression 
change(s) in relation to cancer(s). Each gene was then classified as ‘according’ if 
observations of its behaviour were concordant between our findings and those 
previously reported in the literature, or ‘did not accord’ if the opposite was true 
(Supplementary Table 4). Where accordance or otherwise could not be ascertained 
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the gene was assigned as ‘uninformative’. Two examples of the classification 
approach are given below. The review process was repeated for all genes for which 
relevant literature was available. 
 
Example 1 – gene behaviour ‘accorded’ with prior literature reports 
 
The ITGB3 gene was identified via the IS (<0.05) as a putative, pathway-associated 
target of miR-let-7d, miR-30c, and miR- 98 (Supplementary Table 3). PubMed 
literature was examined for previous reports of ITGB3 in relation to any cancer 
(Supplementary Table 4). The direction of expression change observed in the 
present study (up-regulation in association with poor prognosis) was qualitatively 
assessed in relation to prior reports of the gene’s behaviour which were: up-
regulation of ITGB3 in association with poor prognosis and tumour 
progression/invasion in cancer especially with BRAF mutation (Muller and 
Bosserhoff, 2008; Zhao et al., 2014). In this example, the behaviour of ITGB3 
observed in the present study shows accord with respect to prior reports. Thus, it 
was designated as ‘consistent’.  
 
Example 2 – gene behaviour ‘did not accord’ with prior literature reports 
 
The CCND2 gene was identified via the IS (<0.05) as a putative, pathway-associated 
target of miR-211, miR-506, let-7a, and let-7c (Supplementary Table 3). PubMed 
literature was therefore examined for previous reports of CCND2 in relation to any 
cancer (Supplementary Table 4). The observed direction of expression change 
(down-regulation in association with poor prognosis) was qualitatively assessed in 
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relation to the prior reports of gene behaviour: down-regulation of CCND2 in 
association with inhibition of tumor formation of gastric and prostate cancers, 
respectively (Gong et al., 2014; Zhang et al., 2013). In this case, the behaviour of 
CCND2 observed in the present study appears at odds with respect to prior reports. 
Thus, the direction of gene expression reported in the present study was classified 
as ‘not consistent’ with those reports. This process of analysis was repeated for all 
genes for which the relevant literature was available. 
 
Network figures were modelled using CytoScape v3.0.2 (Smoot et al., 2011). 
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SUPPLEMENTARY RESULTS 
 
Integrated analysis of mRNA and miRNA expression 
 
Unsupervised integration analysis identified groups of negatively correlated miRNAs 
and their predicted targets, in relation to patient clinical outcome and mutation status 
 
In the first analysis (unsupervised integration), we used the miRNA and gene 
expression data and miRNA-target gene prediction algorithms to identify 
associations between groups (clusters) of miRNAs and groups (clusters) of mRNAs. 
Associated miRNA-mRNA clusters (cliques) contain miRNAs and mRNAs, based on 
their differential miRNA and mRNA expression, as previously described (Jayaswal et 
al., 2011) and summarised in the SUPPLEMENTARY METHODS.  
 
We identified 9 cliques, containing 57 significantly (adjusted P<0.05) associated 
miRNA-target gene pairs, that were related to poor prognosis in stage III melanoma 
(Supplementary Table 1). With respect to BRAF mutation status, 1 clique with 
significant (adjusted P<0.05) associations observed for 47 miRNA-target gene pairs 
was identified (Supplementary Table 2). 
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SUPPLEMENTARY DISCUSSION 
 
Serum samples (serum validation cohort) 
The serum cohorts for the stage IV patients (≤1 year or ≥2 years) had differing 
survival cut-offs compared to the discovery stage III cohorts (≤4 or ≥4 years), 
because the vast majority of stage IV patients do not survive beyond one year. 
Within the stage IV cohort, the survival could be considered ≤2 years (short) or ≥2 
years (long), however patients with >1 year but <2 were not sampled in this instance. 
This was to maximise the chance of finding any differences between 2 largely similar 
cohorts (5 yr survival is <15%). 
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SUPPLEMENTARY TABLES 
 
Supplementary Table 1: Unsupervised bioinformatics analysis in relation to 
patient clinical outcome 
 
Multivariate random forest (MRF)-based integration of miRNA and mRNA expression 
profiling information revealed the subset of genes (within a cluster) that were 
observed to have a significant association to one or more of the miRNAs in a clique. 
For example, in the first row of the table, a cluster of 7 miRNAs (potential co-
regulators) has been identified in association with 32 genes (potential targets) (refer 
METHODS AND MATERIALS, SUPPLEMENTARY METHODS). However, of these 
32 genes, only 6 were observed to have a statistically significant association with 
one or more of the miRNAs in the clique namely: hsa-miR-548b-5p:CCL23, hsa-miR-
32x:CD58, hsa-miR-553:HLA-DOB, hsa-miR-548b-5p:IL18BP, hsa-miR-553:NFS1, 
and hsa-miR-32x:PSMA4.  
 
Supplementary Table 2: Unsupervised bioinformatics analysis in relation to 
BRAF mutation status 
 
Multivariate random forest (MRF)-based integration of miRNA and mRNA expression 
profiling information revealed a subset of significantly associated miRNA-mRNA 
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pairs, with respect to tumor BRAF mutation status (see Supplementary Table 1 for 
more details). 
 
Supplementary Table 3: microRNAs and their negatively correlated potential 
gene targets, deregulated in relation to poor prognosis and BRAF mutation 
 
To identify putative miRNA-target gene pairs and gain insights into global regulatory 
patterns in relation to patient outcome and BRAF mutation status, we integrated 
miRNA and mRNA expression profiling information in the same samples. We 
determined the Integrative Score: a p-value associated with this particular method 
(E. Patrick et al., unpublished data) for identifying regulatory miRNAs that may be 
targeting a group of genes, that share a common biologic function. Prior knowledge 
from TargetScan (Grimson et al., 2007) and KEGG (Kanehisa et al., 2012) pathways 
was combined with the expression data during the analysis (MATERIALS AND 
METHODS, SUPPLEMENTARY METHODS). 
 
Supplementary Table 4: Shortlist of miRNA/mRNA pairs identified via the 
pathway-supervised analysis, for which prior literature describing the mRNA in 
relation to cancer(s) was available  
 
For all miRNA-mRNA pairs with an IS<0.05 (Supplementary Table 3), we examined 
the peer-reviewed literature for primary research articles that evaluated the role of 
the mRNA (gene) in relation to any cancer. Via systematic review of prior reports 
using the PubMed search engine, each gene was classified as either ‘consistent’ 
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with previous literature (if observations of its behaviour in cancer were concordant 
between our findings and those previously reported) or ‘inconsistent’ if the opposite 
was true (MATERIALS AND METHODS, SUPPLEMENTARY METHODS). 
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Supplementary Figure Legend 
 
Survival analysis (Kaplan-Meier) for hsa-miR-150-5p expression did not confirm an 
association with survival in stage III patients in the formalin-fixed paraffin-embedded 
(FFPE) validation cohort (Hazard Ratio 1.346, 95% confidence interval 0.735-2.465, 
P=0.35). Median survival was 9-10 months for low expression cf. 25 months for high 
expression. 
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Supplementary Figure 1 
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miRNAs in the cluster # mRNAs (genes) 
in cluster cont.
hsa-miR-548b-5p CCL23 hsa-miR-33a BATF
hsa-miR-32x CD58 hsa-miR-33a C1orf162
hsa-miR-553 HLA-DOB hsa-miR-33a C1QB
hsa-miR-548b-5p IL18BP hsa-miR-33a CCL7
hsa-miR-553 NFS1 hsa-miR-33a CD96
hsa-miR-32x PSMA4 hsa-miR-33a IL2RB
hsa-miR-597 GNA15 hsa-miR-33a WNT10A
hsa-miR-592 HCST hsa-miR-33a XBP1
hsa-miR-597 CCNG2 hsa-miR-590-3p AQP9
hsa-miR-597 PTGS1 hsa-miR-590-3p C12orf56
hsa-miR-597 PTOV1 hsa-miR-590-3p FAM105A
hsa-miR-597 THAP11 hsa-miR-590-3p HVCN1
hsa-miR-650 THAP11 hsa-miR-590-3p MS4A6A
hsa-miR-342-5p DIS3L2
hsa-miR-342-5p DLL3
hsa-miR-342-5p MEA1
hsa-miR-342-5p PDZD4
hsa-miR-342-5p SF3B4
hsa-miR-124 ADI1
hsa-miR-124 ARHGDIA
hsa-miR-124 C17orf101
hsa-miR-124 GCDH
hsa-miR-124 PDCD6
hsa-miR-124 PEX19
hsa-miR-124 PPP2R5D
hsa-miR-124 QPCT
hsa-miR-124 SAMD4B
hsa-miR-124 TMEM117
hsa-miR-124 USP21
hsa-miR-141 EXOC7
hsa-miR-141 KIF1C
hsa-miR-141 MKS1
hsa-miR-141 TUSC1
hsa-miR-141 ZNF416
hsa-miR-155 CIAPIN1
hsa-miR-155 RPTOR
hsa-miR-155 PIGV
hsa-miR-205 ELF1
hsa-miR-205 ERRFI1
hsa-miR-205 IFI44L
hsa-miR-205 PTP4A2
hsa-miR-205 RASA2
hsa-miR-205 SRSF5
43hsa-miR-205
hsa-miR-141 28
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hsa-miR-33a 48
hsa-miR-590-3p 43
28
hsa-miR-155 15
24
110
Statistically associated miRNA-
mRNA pairs
hsa-miR-192, hsa-miR-215, hsa-
miR-342-5p
hsa-miR-124
hsa-miR-144*, hsa-miR-32*, hsa-
miR-330-3p, hsa-miR-454*, hsa-
miR-548b-5p, hsa-miR-553, hsa-
miR-577, hsa-miR-645
32
hsa-miR-16-2*, hsa-miR-187*, 
hsa-miR-21*, hsa-miR-592, hsa-
miR-597, hsa-miR-602, hsa-miR-
610, hsa-miR-629*, hsa-miR-650
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miRNAs in the cluster # mRNAs (genes) in cluster Correlation p-value
hsa-miR-20a SMOC1 -0.12 3.3E-05
hsa-miR-93 M6PR -0.29 1.5E-04
hsa-miR-93 DIRC2 -0.28 1.5E-04
hsa-miR-106b M6PR -0.25 5.0E-04
hsa-miR-93 ACOT9 -0.14 9.3E-04
hsa-miR-93 EGLN1 -0.14 1.0E-03
hsa-miR-106b ACOT9 -0.13 1.2E-03
hsa-miR-106b EGLN1 -0.11 3.7E-03
hsa-miR-93 RUNX3 -0.50 4.8E-03
hsa-miR-106b DIRC2 -0.19 5.4E-03
hsa-miR-106b CNNM2 -0.05 5.6E-03
hsa-miR-106b SMOC1 -0.10 5.7E-03
hsa-miR-20a SLC11A1 -0.27 5.9E-03
hsa-miR-93 MKNK2 -0.17 7.3E-03
hsa-miR-20a SLC2A4RG -0.11 8.6E-03
hsa-miR-93 FPR1 -0.30 9.2E-03
hsa-miR-93 SMOC1 -0.10 1.0E-02
hsa-miR-20a DIRC2 -0.14 1.3E-02
hsa-miR-20a CATSPER2P1 -0.08 1.4E-02
hsa-miR-106b ESRP1 -0.04 1.4E-02
hsa-miR-93 ST6GALNAC6 -0.17 1.4E-02
hsa-miR-93 SLC11A1 -0.31 1.4E-02
hsa-miR-93 CNNM2 -0.04 1.5E-02
hsa-miR-20a ORMDL3 -0.08 1.8E-02
hsa-miR-20a ST6GALNAC6 -0.12 1.8E-02
hsa-miR-93 ABHD5 -0.12 1.9E-02
hsa-miR-106b BCR -0.09 2.0E-02
hsa-miR-93 TNFSF13 -0.08 2.0E-02
hsa-miR-106b MKNK2 -0.13 2.1E-02
hsa-miR-93 TLN1 -0.15 2.1E-02
hsa-miR-20a TLN1 -0.11 2.1E-02
hsa-miR-93 ADTRP -0.10 2.1E-02
hsa-miR-20a SFXN5 -0.08 2.5E-02
hsa-miR-93 CCS -0.14 2.7E-02
hsa-miR-106b SFXN5 -0.09 2.8E-02
hsa-miR-93 OTUD1 -0.10 2.8E-02
hsa-miR-93 CATSPER2P1 -0.09 3.5E-02
hsa-miR-106b CCS -0.13 3.8E-02
hsa-miR-20a PSAT1 -0.11 4.1E-02
hsa-miR-20a GINM1 -0.05 4.1E-02
hsa-miR-20a CCS -0.10 4.1E-02
hsa-miR-20a LAMA3 -0.02 4.3E-02
hsa-miR-106b SLC11A1 -0.23 4.5E-02
hsa-miR-20a F2RL1 -0.08 4.5E-02
hsa-miR-20a M6PR -0.11 4.6E-02
hsa-miR-106b POLH -0.03 4.7E-02
hsa-miR-93 POLH -0.03 4.9E-02
Statistically associated 
miRNA-mRNA pairs
hsa-miR-106b, hsa-miR-20a, 
hsa-miR-302c, hsa-miR-93 128
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Supplementary Table 3A
Gene Symbol ID miRNA Integrative Score Probability of miRNA DE Probability of correlation Probability of gene DE miRNA-gene correlation KEGG Pathway
ACSL4 hsa-miR-211 0.019 0.120 0.033 0.049 -0.300 Metabolic pathways
ACTN1 hsa-miR-30b 0.016 0.170 0.140 0.029 -0.190 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ACTN1 hsa-miR-30b 0.021 0.170 0.140 0.029 -0.190 Regulation of actin cytoskeleton
ACTN1 hsa-miR-30b 0.022 0.170 0.140 0.029 -0.190 Tight junction
ACTN1 hsa-miR-30b 0.029 0.170 0.140 0.029 -0.190 Focal adhesion
ADPGK hsa-miR-9 0.026 0.150 0.130 0.014 -0.190 Metabolic pathways
ATXN3 hsa-miR-125b 0.010 0.053 0.220 0.047 -0.140 Protein processing in endoplasmic reticulum
CAMK2D hsa-miR-211 0.023 0.120 0.220 0.005 -0.130 Long-term potentiation
CAMK2D hsa-miR-211 0.024 0.120 0.220 0.005 -0.130 Calcium signaling pathway
CAMK2D hsa-miR-211 0.024 0.120 0.220 0.005 -0.130 Oocyte meiosis
CAMK2D hsa-miR-30b 0.016 0.170 0.210 0.005 -0.140 Wnt signaling pathway
CAMK2D hsa-miR-30b 0.017 0.170 0.210 0.005 -0.140 Calcium signaling pathway
CAMK2D hsa-miR-30b 0.018 0.170 0.210 0.005 -0.140 Long-term potentiation
CAMK2D hsa-miR-30b 0.021 0.170 0.210 0.005 -0.140 Melanogenesis
CAMK2D hsa-miR-30b 0.025 0.170 0.210 0.005 -0.140 Oocyte meiosis
CAMK2D hsa-miR-30b 0.041 0.170 0.210 0.005 -0.140 Neurotrophin signaling pathway
CASK hsa-miR-363 0.047 0.270 0.021 0.044 -0.330 Tight junction
CASK hsa-miR-506 0.011 0.130 0.260 0.044 -0.120 Tight junction
CBLB hsa-miR-30b 0.016 0.170 0.140 0.049 -0.190 Pathways in cancer
CBLB hsa-miR-30b 0.023 0.170 0.140 0.049 -0.190 Bacterial invasion of epithelial cells
CBLB hsa-miR-30b 0.023 0.170 0.140 0.049 -0.190 Endocytosis
CBLB hsa-miR-30b 0.023 0.170 0.140 0.049 -0.190 Chronic myeloid leukemia
CBLB hsa-miR-30b 0.028 0.170 0.140 0.049 -0.190 Jak-STAT signaling pathway
CBLB hsa-miR-30b 0.029 0.170 0.140 0.049 -0.190 Ubiquitin mediated proteolysis
CBLB hsa-miR-30b 0.048 0.170 0.140 0.049 -0.190 T cell receptor signaling pathway
CCL3 hsa-let-7a 0.009 0.120 0.004 0.009 -0.430 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7a 0.009 0.120 0.004 0.009 -0.430 Toll-like receptor signaling pathway
CCL3 hsa-let-7a 0.020 0.120 0.004 0.009 -0.430 Chemokine signaling pathway
CCL3 hsa-let-7a 0.020 0.120 0.004 0.009 -0.430 Chagas disease (American trypanosomiasis)
CCL3 hsa-let-7c 0.040 0.260 0.001 0.009 -0.490 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7c 0.049 0.260 0.001 0.009 -0.490 Chemokine signaling pathway
CCL3 hsa-let-7c 0.049 0.260 0.001 0.009 -0.490 Toll-like receptor signaling pathway
CCL8 hsa-miR-181a 0.036 0.130 0.006 1.7E-04 -0.400 Chemokine signaling pathway
CCL8 hsa-miR-181b 0.017 0.110 0.004 1.7E-04 -0.430 Chemokine signaling pathway
CCND2 hsa-let-7a 0.019 0.120 0.130 0.049 -0.190 Jak-STAT signaling pathway
CCND2 hsa-let-7a 0.029 0.120 0.130 0.049 -0.190 Cell cycle
CCND2 hsa-let-7a 0.029 0.120 0.130 0.049 -0.190 p53 signaling pathway
CCND2 hsa-let-7c 0.048 0.260 0.260 0.049 -0.110 Cell cycle
CCND2 hsa-miR-211 0.011 0.120 0.005 0.049 -0.420 Jak-STAT signaling pathway
CCND2 hsa-miR-211 0.019 0.120 0.005 0.049 -0.420 Cell cycle
CCND2 hsa-miR-211 0.031 0.120 0.005 0.049 -0.420 Focal adhesion
CCND2 hsa-miR-506 0.011 0.130 0.017 0.049 -0.350 Focal adhesion
CCR2 hsa-miR-125b 0.010 0.053 0.068 0.011 -0.250 Cytokine-cytokine receptor interaction
CCR2 hsa-miR-125b 0.011 0.053 0.068 0.011 -0.250 Chemokine signaling pathway
CCR7 hsa-let-7a 0.009 0.120 0.270 0.012 -0.110 Cytokine-cytokine receptor interaction
CCR7 hsa-let-7a 0.020 0.120 0.270 0.012 -0.110 Chemokine signaling pathway
CCR7 hsa-let-7c 0.040 0.260 0.320 0.012 -0.086 Cytokine-cytokine receptor interaction
CCR7 hsa-let-7c 0.049 0.260 0.320 0.012 -0.086 Chemokine signaling pathway
CD4 hsa-miR-181b 0.035 0.110 0.035 0.005 -0.300 T cell receptor signaling pathway
CD86 hsa-let-7a 0.010 0.120 0.018 3.6E-04 -0.350 Toll-like receptor signaling pathway
CD86 hsa-let-7c 0.049 0.260 0.100 3.6E-04 -0.210 Toll-like receptor signaling pathway
CEBPA hsa-miR-181b 0.017 0.110 0.095 0.032 -0.220 Pathways in cancer
CEBPA hsa-miR-181b 0.017 0.110 0.095 0.032 -0.220 Acute myeloid leukemia
CEBPA hsa-miR-506 0.039 0.130 0.360 0.032 -0.065 Pathways in cancer
CHMP2B hsa-miR-135b 0.038 0.160 0.400 0.036 -0.050 Endocytosis
CHMP2B hsa-miR-30b 0.023 0.170 0.260 0.036 -0.110 Endocytosis
CHST15 hsa-miR-9 0.023 0.150 0.012 0.027 -0.370 Glycosaminoglycan biosynthesis - chondroitin sulfate
CHUK hsa-let-7a 0.010 0.120 0.095 0.022 -0.220 Toll-like receptor signaling pathway
CHUK hsa-let-7a 0.010 0.120 0.095 0.022 -0.220 Prostate cancer
CHUK hsa-let-7a 0.012 0.120 0.095 0.022 -0.220 Pathways in cancer
CHUK hsa-let-7a 0.019 0.120 0.095 0.022 -0.220 Chronic myeloid leukemia
CHUK hsa-let-7a 0.020 0.120 0.095 0.022 -0.220 Chemokine signaling pathway
CHUK hsa-let-7a 0.020 0.120 0.095 0.022 -0.220 Chagas disease (American trypanosomiasis)
CHUK hsa-let-7a 0.025 0.120 0.095 0.022 -0.220 T cell receptor signaling pathway
CHUK hsa-let-7a 0.029 0.120 0.095 0.022 -0.220 Hepatitis C
CHUK hsa-let-7a 0.044 0.120 0.095 0.022 -0.220 Small cell lung cancer
CHUK hsa-let-7c 0.040 0.260 0.460 0.022 -0.023 Prostate cancer
CHUK hsa-let-7c 0.048 0.260 0.460 0.022 -0.023 Pathways in cancer
CHUK hsa-let-7c 0.049 0.260 0.460 0.022 -0.023 Chemokine signaling pathway
CHUK hsa-let-7c 0.049 0.260 0.460 0.022 -0.023 Toll-like receptor signaling pathway
CHUK hsa-let-7c 0.049 0.260 0.460 0.022 -0.023 Chronic myeloid leukemia
CTSC hsa-let-7a 0.025 0.120 0.022 0.004 -0.330 Lysosome
CYBB hsa-miR-520c-3p 0.048 0.230 0.500 0.001 -0.006 Osteoclast differentiation
CYLD hsa-miR-30b 0.033 0.170 0.280 0.030 -0.100 RIG-I-like receptor signaling pathway
DPYD hsa-miR-92b 0.044 0.180 0.360 0.040 -0.067 Metabolic pathways
DSE hsa-miR-9 0.023 0.150 0.020 0.015 -0.340 Glycosaminoglycan biosynthesis - chondroitin sulfate
DUSP5 hsa-miR-181b 0.044 0.110 0.230 0.044 -0.130 MAPK signaling pathway
EDEM1 hsa-miR-125b 0.010 0.053 0.230 0.031 -0.130 Protein processing in endoplasmic reticulum
EDEM1 hsa-miR-211 0.034 0.120 0.068 0.031 -0.250 Protein processing in endoplasmic reticulum
EHD4 hsa-miR-9 0.047 0.150 0.031 0.039 -0.310 Endocytosis
ETV6 hsa-miR-181b 0.019 0.110 0.510 0.007 -3.7E-04 Dorso-ventral axis formation
GALC hsa-let-7a 0.025 0.120 0.260 0.050 -0.110 Lysosome
GCH1 hsa-miR-9 0.026 0.150 0.180 0.001 -0.160 Metabolic pathways
GCNT1 hsa-miR-125b 0.010 0.053 0.099 0.036 -0.220 Metabolic pathways
GLUD1 hsa-miR-9 0.026 0.150 0.240 0.012 -0.130 Metabolic pathways
GNAI2 hsa-miR-30b 0.017 0.170 0.150 0.013 -0.180 Gap junction
GNAI2 hsa-miR-30b 0.020 0.170 0.150 0.013 -0.180 Axon guidance
GNAI2 hsa-miR-30b 0.021 0.170 0.150 0.013 -0.180 Melanogenesis
GNAI2 hsa-miR-30b 0.022 0.170 0.150 0.013 -0.180 Tight junction
GNAI2 hsa-miR-30b 0.034 0.170 0.150 0.013 -0.180 Chemokine signaling pathway
GNAI2 hsa-miR-30b 0.043 0.170 0.150 0.013 -0.180 Long-term depression
GNAI2 hsa-miR-30b 0.043 0.170 0.150 0.013 -0.180 Chagas disease (American trypanosomiasis)
GNAI2 hsa-miR-506 0.011 0.130 0.089 0.013 -0.230 Tight junction
GNAI2 hsa-miR-506 0.011 0.130 0.089 0.013 -0.230 Leukocyte transendothelial migration
GRB2 hsa-miR-506 0.011 0.130 0.360 0.022 -0.069 Focal adhesion
GRB2 hsa-miR-506 0.039 0.130 0.360 0.022 -0.069 Pathways in cancer
ICOS hsa-let-7a 0.025 0.120 0.260 0.012 -0.120 T cell receptor signaling pathway
IDE hsa-miR-30b 0.022 0.170 0.140 0.015 -0.190 Alzheimer's disease
IFNAR2 hsa-miR-30b 0.025 0.170 0.073 0.025 -0.250 Cytokine-cytokine receptor interaction
IFNAR2 hsa-miR-30b 0.028 0.170 0.073 0.025 -0.250 Jak-STAT signaling pathway
IFNAR2 hsa-miR-30b 0.028 0.170 0.073 0.025 -0.250 Hepatitis C
IFNAR2 hsa-miR-30b 0.042 0.170 0.073 0.025 -0.250 Natural killer cell mediated cytotoxicity
IL2RA hsa-miR-30b 0.016 0.170 0.014 5.4E-05 -0.360 Hematopoietic cell lineage
IL2RA hsa-miR-30b 0.023 0.170 0.014 5.4E-05 -0.360 Endocytosis
IL2RA hsa-miR-30b 0.025 0.170 0.014 5.4E-05 -0.360 Cytokine-cytokine receptor interaction
IL2RA hsa-miR-30b 0.028 0.170 0.014 5.4E-05 -0.360 Jak-STAT signaling pathway
ITPR1 hsa-miR-211 0.023 0.120 0.029 0.010 -0.310 Long-term potentiation
ITPR1 hsa-miR-211 0.023 0.120 0.029 0.010 -0.310 Huntington's disease
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ITPR1 hsa-miR-211 0.024 0.120 0.029 0.010 -0.310 Calcium signaling pathway
ITPR1 hsa-miR-211 0.024 0.120 0.029 0.010 -0.310 Oocyte meiosis
JAK1 hsa-miR-30b 0.016 0.170 0.480 0.028 -0.011 Pathways in cancer
JAK1 hsa-miR-30b 0.028 0.170 0.480 0.028 -0.011 Jak-STAT signaling pathway
JAK1 hsa-miR-30b 0.028 0.170 0.480 0.028 -0.011 Hepatitis C
JAK1 hsa-miR-30b 0.039 0.170 0.480 0.028 -0.011 Pancreatic cancer
LIPA hsa-miR-125b 0.002 0.053 0.001 0.011 -0.490 Lysosome
LYN hsa-miR-30b 0.024 0.170 0.110 0.001 -0.210 B cell receptor signaling pathway
LYN hsa-miR-30b 0.034 0.170 0.110 0.001 -0.210 Chemokine signaling pathway
LYN hsa-miR-30b 0.043 0.170 0.110 0.001 -0.210 Long-term depression
M6PR hsa-miR-125b 0.002 0.053 0.008 0.041 -0.390 Lysosome
M6PR hsa-miR-9 0.026 0.150 0.240 0.041 -0.130 Phagosome
MAP3K5 hsa-miR-30b 0.017 0.170 0.330 0.007 -0.079 MAPK signaling pathway
MAP3K5 hsa-miR-30b 0.034 0.170 0.330 0.007 -0.079 Protein processing in endoplasmic reticulum
MAP3K5 hsa-miR-30b 0.041 0.170 0.330 0.007 -0.079 Neurotrophin signaling pathway
MGAT4A hsa-miR-125b 0.010 0.053 0.025 0.048 -0.320 Metabolic pathways
MTHFD2 hsa-miR-9 0.026 0.150 0.150 0.010 -0.180 Metabolic pathways
NCOA4 hsa-miR-506 0.039 0.130 0.340 0.039 -0.076 Pathways in cancer
PI4K2B hsa-miR-125b 0.006 0.053 0.098 0.029 -0.220 Phosphatidylinositol signaling system
PI4K2B hsa-miR-125b 0.010 0.053 0.098 0.029 -0.220 Metabolic pathways
PI4K2B hsa-miR-125b 0.010 0.053 0.098 0.029 -0.220 Inositol phosphate metabolism
PI4K2B hsa-miR-181b 0.035 0.110 0.330 0.029 -0.082 Phosphatidylinositol signaling system
PI4K2B hsa-miR-181b 0.041 0.110 0.330 0.029 -0.082 Inositol phosphate metabolism
PPP2R5C hsa-miR-125b 0.016 0.053 0.210 0.005 -0.140 mRNA surveillance pathway
PPP2R5C hsa-miR-125b 0.025 0.053 0.210 0.005 -0.140 Oocyte meiosis
PPP3CB hsa-miR-30b 0.016 0.170 0.020 0.035 -0.340 Wnt signaling pathway
PPP3CB hsa-miR-30b 0.017 0.170 0.020 0.035 -0.340 MAPK signaling pathway
PPP3CB hsa-miR-30b 0.017 0.170 0.020 0.035 -0.340 Calcium signaling pathway
PPP3CB hsa-miR-30b 0.018 0.170 0.020 0.035 -0.340 Long-term potentiation
PPP3CB hsa-miR-30b 0.020 0.170 0.020 0.035 -0.340 Axon guidance
PPP3CB hsa-miR-30b 0.022 0.170 0.020 0.035 -0.340 Alzheimer's disease
PPP3CB hsa-miR-30b 0.024 0.170 0.020 0.035 -0.340 B cell receptor signaling pathway
PPP3CB hsa-miR-30b 0.025 0.170 0.020 0.035 -0.340 Oocyte meiosis
PPP3CB hsa-miR-30b 0.041 0.170 0.020 0.035 -0.340 VEGF signaling pathway
PPP3CB hsa-miR-30b 0.042 0.170 0.020 0.035 -0.340 Natural killer cell mediated cytotoxicity
PPP3CB hsa-miR-30b 0.048 0.170 0.020 0.035 -0.340 T cell receptor signaling pathway
PRKCD hsa-miR-181a 0.036 0.130 0.110 0.045 -0.210 Chemokine signaling pathway
PRKCD hsa-miR-181a 0.036 0.130 0.110 0.045 -0.210 GnRH signaling pathway
PRKCD hsa-miR-181b 0.017 0.110 0.130 0.045 -0.190 Chemokine signaling pathway
PRKCD hsa-miR-181b 0.017 0.110 0.130 0.045 -0.190 GnRH signaling pathway
PRKCD hsa-miR-181b 0.041 0.110 0.130 0.045 -0.190 Fc epsilon RI signaling pathway
PTEN hsa-miR-363 0.041 0.270 0.006 0.013 -0.400 Small cell lung cancer
PTEN hsa-miR-363 0.042 0.270 0.006 0.013 -0.400 Focal adhesion
PTEN hsa-miR-363 0.043 0.270 0.006 0.013 -0.400 Prostate cancer
PTEN hsa-miR-363 0.045 0.270 0.006 0.013 -0.400 Pathways in cancer
PTEN hsa-miR-363 0.047 0.270 0.006 0.013 -0.400 Tight junction
PTEN hsa-miR-92b 0.044 0.180 0.290 0.013 -0.099 Focal adhesion
RAB8A hsa-miR-30b 0.028 0.170 0.087 1.3E-04 -0.230 Pancreatic secretion
RASGRP3 hsa-miR-30b 0.017 0.170 0.110 0.022 -0.210 MAPK signaling pathway
RASGRP3 hsa-miR-30b 0.024 0.170 0.110 0.022 -0.210 B cell receptor signaling pathway
RASSF5 hsa-miR-371-5p 0.024 0.079 0.033 0.004 -0.300 Pathways in cancer
RASSF5 hsa-miR-506 0.011 0.130 0.130 0.004 -0.190 Leukocyte transendothelial migration
RASSF5 hsa-miR-506 0.039 0.130 0.130 0.004 -0.190 Pathways in cancer
RPS6KA1 hsa-miR-125b 0.004 0.053 0.001 0.042 -0.490 Progesterone-mediated oocyte maturation
RPS6KA1 hsa-miR-125b 0.006 0.053 0.001 0.042 -0.490 mTOR signaling pathway
RPS6KA1 hsa-miR-125b 0.016 0.053 0.001 0.042 -0.490 Neurotrophin signaling pathway
RPS6KA1 hsa-miR-125b 0.025 0.053 0.001 0.042 -0.490 Oocyte meiosis
RPS6KA3 hsa-miR-211 0.023 0.120 0.044 0.039 -0.280 Long-term potentiation
RPS6KA3 hsa-miR-211 0.024 0.120 0.044 0.039 -0.280 Oocyte meiosis
RUNX1 hsa-miR-181b 0.017 0.110 0.250 0.037 -0.120 Pathways in cancer
RUNX1 hsa-miR-181b 0.017 0.110 0.250 0.037 -0.120 Acute myeloid leukemia
RUNX1 hsa-miR-181b 0.036 0.110 0.250 0.037 -0.120 Chronic myeloid leukemia
RUNX1 hsa-miR-30b 0.016 0.170 0.018 0.037 -0.340 Pathways in cancer
RUNX1 hsa-miR-30b 0.023 0.170 0.018 0.037 -0.340 Chronic myeloid leukemia
RUNX1 hsa-miR-9 0.019 0.150 0.140 0.037 -0.180 Pathways in cancer
RUNX1 hsa-miR-9 0.048 0.150 0.140 0.037 -0.180 Chronic myeloid leukemia
SGPL1 hsa-miR-125b 0.010 0.053 0.170 0.014 -0.170 Metabolic pathways
SGPL1 hsa-miR-211 0.019 0.120 0.170 0.014 -0.170 Metabolic pathways
SH2B3 hsa-miR-125b 0.016 0.053 0.380 0.036 -0.057 Neurotrophin signaling pathway
SH2B3 hsa-miR-30b 0.041 0.170 0.033 0.036 -0.310 Neurotrophin signaling pathway
SH3GLB1 hsa-miR-9 0.047 0.150 0.150 0.004 -0.180 Endocytosis
SH3KBP1 hsa-miR-30b 0.023 0.170 0.210 0.017 -0.140 Endocytosis
SOCS1 hsa-miR-30b 0.028 0.170 0.190 0.009 -0.150 Jak-STAT signaling pathway
SOCS1 hsa-miR-30b 0.029 0.170 0.190 0.009 -0.150 Ubiquitin mediated proteolysis
TFRC hsa-miR-9 0.026 0.150 0.210 0.019 -0.140 Phagosome
TFRC hsa-miR-9 0.047 0.150 0.210 0.019 -0.140 Endocytosis
THBS1 hsa-let-7a 0.010 0.120 0.150 0.011 -0.180 Bladder cancer
THBS1 hsa-let-7a 0.029 0.120 0.150 0.011 -0.180 p53 signaling pathway
THBS1 hsa-let-7c 0.040 0.260 0.210 0.011 -0.140 Bladder cancer
TNC hsa-miR-9 0.017 0.150 0.130 0.005 -0.200 Focal adhesion
TNC hsa-miR-9 0.017 0.150 0.130 0.005 -0.200 ECM-receptor interaction
TNFRSF1B hsa-let-7a 0.009 0.120 0.009 0.034 -0.380 Cytokine-cytokine receptor interaction
TNFRSF1B hsa-let-7c 0.040 0.260 0.011 0.034 -0.370 Cytokine-cytokine receptor interaction
TNFRSF1B hsa-miR-125b 0.010 0.053 0.033 0.034 -0.300 Cytokine-cytokine receptor interaction
TPM4 hsa-miR-30b 0.016 0.170 0.003 0.004 -0.440 Hypertrophic cardiomyopathy (HCM)
TPM4 hsa-miR-30b 0.016 0.170 0.003 0.004 -0.440 Dilated cardiomyopathy
TPM4 hsa-miR-363 0.047 0.270 0.130 0.004 -0.190 Hypertrophic cardiomyopathy (HCM)
TRAF3 hsa-miR-30b 0.016 0.170 0.011 0.007 -0.370 Pathways in cancer
TRAF3 hsa-miR-30b 0.028 0.170 0.011 0.007 -0.370 Hepatitis C
TRAF3 hsa-miR-30b 0.033 0.170 0.011 0.007 -0.370 RIG-I-like receptor signaling pathway
TRAF3 hsa-miR-30b 0.050 0.170 0.011 0.007 -0.370 Small cell lung cancer
TRAF3 hsa-miR-363 0.041 0.270 0.013 0.007 -0.360 Small cell lung cancer
TRAF3 hsa-miR-363 0.045 0.270 0.013 0.007 -0.360 Pathways in cancer
TRAF3 hsa-miR-506 0.039 0.130 0.080 0.007 -0.240 Pathways in cancer
TRAF3 hsa-miR-9 0.019 0.150 0.110 0.007 -0.210 Pathways in cancer
TRAF3 hsa-miR-9 0.019 0.150 0.110 0.007 -0.210 Small cell lung cancer
UBE2I hsa-miR-30b 0.029 0.170 0.100 0.045 -0.210 Ubiquitin mediated proteolysis
UBE2J1 hsa-miR-125b 0.010 0.053 0.008 0.003 -0.390 Protein processing in endoplasmic reticulum
UBE2J1 hsa-miR-125b 0.013 0.053 0.008 0.003 -0.390 Ubiquitin mediated proteolysis
UBE2J1 hsa-miR-211 0.008 0.120 0.019 0.003 -0.340 Ubiquitin mediated proteolysis
UBE2J1 hsa-miR-211 0.034 0.120 0.019 0.003 -0.340 Protein processing in endoplasmic reticulum
UBE2J1 hsa-miR-30b 0.029 0.170 0.059 0.003 -0.260 Ubiquitin mediated proteolysis
UBE2J1 hsa-miR-30b 0.034 0.170 0.059 0.003 -0.260 Protein processing in endoplasmic reticulum
UGP2 hsa-miR-92b 0.044 0.180 0.490 0.027 -0.010 Metabolic pathways
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Supplementary Table 3B
Gene Symbol ID miRNA Integrative Score Probability of miRNA DE Probability of correlation Probability of gene DE miRNA-gene correlation KEGG Pathway
ALDH5A1 hsa-miR-133a 0.034 0.170 0.250 0.036 -0.120 Metabolic pathways
B3GALNT1 hsa-miR-133a 0.034 0.170 0.250 0.018 -0.120 Metabolic pathways
CANT1 hsa-let-7g 0.014 0.160 0.080 0.035 -0.240 Pyrimidine metabolism
CANT1 hsa-let-7g 0.017 0.160 0.080 0.035 -0.240 Purine metabolism
CDS2 hsa-miR-141 2.60E-05 0.006 0.014 0.040 -0.360 Metabolic pathways
NME1 hsa-miR-141 2.60E-05 0.006 0.005 0.007 -0.420 Metabolic pathways
PIP4K2C hsa-miR-25 0.044 0.230 0.340 0.050 -0.078 Regulation of actin cytoskeleton
PPP2CB hsa-miR-133a 0.028 0.170 0.430 0.048 -0.034 Tight junction
PPP2CB hsa-miR-133a 0.031 0.170 0.430 0.048 -0.034 Wnt signaling pathway
PPP2CB hsa-miR-133a 0.034 0.170 0.430 0.048 -0.034 mRNA surveillance pathway
PPP2CB hsa-miR-133a 0.043 0.170 0.430 0.048 -0.034 Oocyte meiosis
PPT2 hsa-miR-141 2.60E-05 0.006 0.002 0.038 -0.450 Metabolic pathways
SF3B3 hsa-miR-1 0.007 0.080 0.270 0.016 -0.110 Spliceosome
XPO5 hsa-miR-29a 0.014 0.150 0.081 0.019 -0.240 RNA transport
XPO5 hsa-miR-29b 0.002 0.054 0.005 0.019 -0.420 RNA transport
XPO5 hsa-miR-29c 0.007 0.025 0.014 0.019 -0.360 RNA transport
XYLT1 hsa-miR-133a 0.034 0.170 0.050 0.005 -0.270 Metabolic pathways
XYLT2 hsa-miR-25 0.035 0.230 0.310 0.008 -0.091 Metabolic pathways
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Supplementary Table 3C
Gene Symbol ID miRNA Integrative Score Probability of miRNA DE Probability of correlation Probability of gene DE miRNA-gene correlation KEGG Pathway
ACAP2 hsa-miR-30b 0.043 0.250 0.460 0.049 -0.023 Endocytosis
ACAP2 hsa-miR-30d 0.014 0.076 0.290 0.049 -0.098 Endocytosis
ACOX1 hsa-miR-25 0.002 0.031 0.140 0.012 -0.180 Metabolic pathways
ACOX1 hsa-miR-370 0.037 0.110 0.073 0.012 -0.250 Metabolic pathways
ADO hsa-miR-181d 0.022 0.099 0.043 0.003 -0.290 Metabolic pathways
ADO hsa-miR-25 0.002 0.031 0.048 0.003 -0.280 Metabolic pathways
ARAP2 hsa-miR-130a 0.024 0.069 0.015 0.002 -0.360 Endocytosis
ARAP2 hsa-miR-30b 0.043 0.250 0.120 0.002 -0.200 Endocytosis
ARAP2 hsa-miR-30d 0.014 0.076 0.034 0.002 -0.300 Endocytosis
C1GALT1 hsa-miR-181d 0.022 0.099 0.330 0.008 -0.081 Metabolic pathways
CAT hsa-miR-30d 0.033 0.076 0.330 0.000 -0.082 Amyotrophic lateral sclerosis (ALS)
CDC42 hsa-miR-25 0.003 0.031 0.110 0.038 -0.210 MAPK signaling pathway
CDC42 hsa-miR-25 0.005 0.031 0.110 0.038 -0.210 Regulation of actin cytoskeleton
CDC42 hsa-miR-25 0.005 0.031 0.110 0.038 -0.210 Focal adhesion
CDC42 hsa-miR-25 0.026 0.031 0.110 0.038 -0.210 Endocytosis
CDK2 hsa-miR-520d-3p 0.050 0.190 0.170 0.023 -0.170 Small cell lung cancer
CHMP2B hsa-miR-30b 0.043 0.250 0.260 0.030 -0.110 Endocytosis
CHMP2B hsa-miR-30d 0.014 0.076 0.290 0.030 -0.099 Endocytosis
CMPK1 hsa-miR-130a 0.010 0.069 0.021 0.011 -0.330 Metabolic pathways
CPEB1 hsa-miR-130a 0.043 0.069 0.230 0.016 -0.130 Oocyte meiosis
CPEB1 hsa-miR-19b 0.049 0.130 0.053 0.016 -0.270 Progesterone-mediated oocyte maturation
CSNK1A1 hsa-miR-30d 0.004 0.076 0.380 0.033 -0.059 Wnt signaling pathway
DUSP10 hsa-miR-181d 0.021 0.099 0.002 0.001 -0.470 MAPK signaling pathway
DUSP10 hsa-miR-25 0.003 0.031 0.019 0.001 -0.340 MAPK signaling pathway
FOS hsa-miR-181b 0.047 0.240 0.075 0.002 -0.240 Chagas disease (American trypanosomiasis)
FOS hsa-miR-181b 0.048 0.240 0.075 0.002 -0.240 Osteoclast differentiation
FOS hsa-miR-181b 0.048 0.240 0.075 0.002 -0.240 Pathways in cancer
FOS hsa-miR-181b 0.048 0.240 0.075 0.002 -0.240 Colorectal cancer
FOS hsa-miR-181d 0.021 0.099 0.250 0.002 -0.120 MAPK signaling pathway
FOS hsa-miR-181d 0.022 0.099 0.250 0.002 -0.120 Osteoclast differentiation
FOS hsa-miR-181d 0.022 0.099 0.250 0.002 -0.120 Chagas disease (American trypanosomiasis)
FOS hsa-miR-181d 0.024 0.099 0.250 0.002 -0.120 Colorectal cancer
FOS hsa-miR-181d 0.033 0.099 0.250 0.002 -0.120 B cell receptor signaling pathway
FOS hsa-miR-181d 0.033 0.099 0.250 0.002 -0.120 Pathways in cancer
FOS hsa-miR-181d 0.036 0.099 0.250 0.002 -0.120 T cell receptor signaling pathway
GCNT2 hsa-miR-181d 0.022 0.099 0.350 0.033 -0.072 Metabolic pathways
GEMIN2 hsa-miR-29a 0.007 0.096 0.080 0.021 -0.240 RNA transport
GNA13 hsa-miR-30d 0.004 0.076 0.390 0.022 -0.052 Vascular smooth muscle contraction
GNA13 hsa-miR-30d 0.004 0.076 0.390 0.022 -0.052 Regulation of actin cytoskeleton
GNA13 hsa-miR-30d 0.028 0.076 0.390 0.022 -0.052 Long-term depression
IGF2R hsa-miR-30d 0.014 0.076 0.056 0.013 -0.270 Lysosome
JAK1 hsa-miR-30b 0.034 0.250 0.480 0.046 -0.011 Pathways in cancer
JAK1 hsa-miR-30b 0.049 0.250 0.480 0.046 -0.011 Jak-STAT signaling pathway
JAK1 hsa-miR-30b 0.049 0.250 0.480 0.046 -0.011 Hepatitis C
JAK1 hsa-miR-30d 0.003 0.076 0.380 0.046 -0.059 Pathways in cancer
JAK1 hsa-miR-30d 0.004 0.076 0.380 0.046 -0.059 Jak-STAT signaling pathway
JAK1 hsa-miR-30d 0.005 0.076 0.380 0.046 -0.059 Hepatitis C
JAK1 hsa-miR-30d 0.008 0.076 0.380 0.046 -0.059 Osteoclast differentiation
JAK1 hsa-miR-30d 0.010 0.076 0.380 0.046 -0.059 Toxoplasmosis
JAK1 hsa-miR-30d 0.010 0.076 0.380 0.046 -0.059 Pancreatic cancer
LCLAT1 hsa-miR-125b 0.034 0.170 0.071 0.005 -0.250 Metabolic pathways
LCLAT1 hsa-miR-130a 0.010 0.069 0.095 0.005 -0.220 Metabolic pathways
LCLAT1 hsa-miR-181d 0.022 0.099 0.290 0.005 -0.100 Metabolic pathways
M6PR hsa-miR-125b 0.018 0.170 0.008 0.029 -0.390 Lysosome
M6PR hsa-miR-130a 0.005 0.069 0.130 0.029 -0.200 Phagosome
M6PR hsa-miR-130a 0.009 0.069 0.130 0.029 -0.200 Lysosome
MTHFD2 hsa-miR-25 0.002 0.031 0.170 0.043 -0.170 Metabolic pathways
ORC2 hsa-miR-30b 0.039 0.250 0.078 0.024 -0.240 Cell cycle
ORC2 hsa-miR-30d 0.009 0.076 0.170 0.024 -0.160 Cell cycle
PDPK1 hsa-miR-181b 0.047 0.240 0.140 0.006 -0.190 Non-small cell lung cancer
PDPK1 hsa-miR-181b 0.049 0.240 0.140 0.006 -0.190 Endometrial cancer
PDPK1 hsa-miR-181d 0.020 0.099 0.055 0.006 -0.270 Endometrial cancer
PDPK1 hsa-miR-181d 0.020 0.099 0.055 0.006 -0.270 Non-small cell lung cancer
PDPK1 hsa-miR-181d 0.027 0.099 0.055 0.006 -0.270 mTOR signaling pathway
PDPK1 hsa-miR-181d 0.036 0.099 0.055 0.006 -0.270 Insulin signaling pathway
PER3 hsa-miR-30d 0.017 0.076 0.073 0.041 -0.240 Circadian rhythm - mammal
PFN2 hsa-miR-30b 0.035 0.250 0.500 0.002 -0.003 Shigellosis
PFN2 hsa-miR-30b 0.040 0.250 0.500 0.002 -0.003 Regulation of actin cytoskeleton
PFN2 hsa-miR-30d 0.003 0.076 0.320 0.002 -0.084 Shigellosis
PFN2 hsa-miR-30d 0.004 0.076 0.320 0.002 -0.084 Regulation of actin cytoskeleton
PIP4K2A hsa-miR-30b 0.040 0.250 0.390 0.021 -0.051 Regulation of actin cytoskeleton
PIP4K2A hsa-miR-30d 0.004 0.076 0.220 0.021 -0.130 Regulation of actin cytoskeleton
PLXNC1 hsa-miR-30d 0.004 0.076 0.480 0.002 -0.014 Axon guidance
PPCS hsa-miR-25 0.002 0.031 0.076 1.3E-04 -0.240 Metabolic pathways
PPP2R5C hsa-miR-125b 0.044 0.170 0.210 0.022 -0.140 mRNA surveillance pathway
PPT1 hsa-miR-125b 0.018 0.170 0.073 0.002 -0.240 Lysosome
PPT1 hsa-miR-125b 0.034 0.170 0.073 0.002 -0.240 Metabolic pathways
PRKAG2 hsa-miR-181d 0.020 0.099 0.004 0.020 -0.420 Adipocytokine signaling pathway
PRKAG2 hsa-miR-181d 0.036 0.099 0.004 0.020 -0.420 Insulin signaling pathway
PRKAR1A hsa-miR-30d 0.010 0.076 0.280 0.043 -0.100 Insulin signaling pathway
PRKAR1A hsa-miR-30d 0.046 0.076 0.280 0.043 -0.100 Apoptosis
RNF7 hsa-miR-30b 0.049 0.250 0.230 0.043 -0.130 Ubiquitin mediated proteolysis
RNF7 hsa-miR-30d 0.006 0.076 0.420 0.043 -0.040 Ubiquitin mediated proteolysis
SAR1B hsa-miR-125b 0.034 0.170 0.180 0.041 -0.160 Protein processing in endoplasmic reticulum
SAR1B hsa-miR-130a 0.010 0.069 0.070 0.041 -0.250 Protein processing in endoplasmic reticulum
STX7 hsa-miR-130a 0.005 0.069 0.210 4.1E-04 -0.140 Phagosome
TAOK1 hsa-miR-130a 0.010 0.069 0.014 0.026 -0.360 MAPK signaling pathway
TAOK1 hsa-miR-30b 0.035 0.250 0.270 0.026 -0.110 MAPK signaling pathway
TAOK1 hsa-miR-30d 0.004 0.076 0.200 0.026 -0.140 MAPK signaling pathway
TBPL1 hsa-miR-130a 0.010 0.069 0.170 0.019 -0.160 Huntington's disease
TRAF6 hsa-miR-125b 0.023 0.170 0.260 0.011 -0.120 Small cell lung cancer
TRAF6 hsa-miR-125b 0.034 0.170 0.260 0.011 -0.120 Chagas disease (American trypanosomiasis)
TRAF6 hsa-miR-125b 0.038 0.170 0.260 0.011 -0.120 Ubiquitin mediated proteolysis
TRAF6 hsa-miR-125b 0.043 0.170 0.260 0.011 -0.120 Neurotrophin signaling pathway
TRAF6 hsa-miR-125b 0.043 0.170 0.260 0.011 -0.120 Hepatitis C
TRAF6 hsa-miR-125b 0.047 0.170 0.260 0.011 -0.120 Pathways in cancer
TRIT1 hsa-miR-370 0.037 0.110 0.410 0.012 -0.042 Metabolic pathways
UBE2D3 hsa-miR-30d 0.006 0.076 0.400 0.019 -0.050 Ubiquitin mediated proteolysis
UBE2D3 hsa-miR-30d 0.014 0.076 0.400 0.019 -0.050 Protein processing in endoplasmic reticulum
VPS37A hsa-miR-130a 0.024 0.069 0.120 0.002 -0.200 Endocytosis
YWHAB hsa-miR-181d 0.042 0.099 0.240 0.050 -0.130 Neurotrophin signaling pathway
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Gene Symbol ID miRNA Integrative Score Probability of miRNA DE Probability of correlation Probability of gene DE miRNA-gene correlation KEGG Pathway
ACVR1B hsa-let-7a 0.021 0.180 0.200 0.035 -0.150 Cytokine-cytokine receptor interaction
ACVR1B hsa-let-7b 0.030 0.230 0.120 0.035 -0.200 Cytokine-cytokine receptor interaction
ACVR1B hsa-let-7c 0.006 0.100 0.130 0.035 -0.190 Cytokine-cytokine receptor interaction
ACVR1B hsa-let-7d 0.025 0.053 0.120 0.035 -0.200 Cytokine-cytokine receptor interaction
ACVR1B hsa-let-7f 0.045 0.170 0.290 0.035 -0.100 Cytokine-cytokine receptor interaction
ACVR1B hsa-miR-9 0.041 0.230 0.190 0.035 -0.150 Cytokine-cytokine receptor interaction
ADCY6 hsa-miR-9 0.046 0.230 0.370 0.002 -0.063 Gap junction
ADPGK hsa-miR-9 0.046 0.230 0.130 0.032 -0.190 Metabolic pathways
ARHGEF6 hsa-miR-30c 0.012 0.087 0.049 0.048 -0.280 Regulation of actin cytoskeleton
B3GAT3 hsa-let-7b 0.040 0.230 0.320 0.044 -0.084 Metabolic pathways
B3GAT3 hsa-let-7c 0.021 0.100 0.370 0.044 -0.060 Metabolic pathways
B3GAT3 hsa-let-7d 0.025 0.053 0.410 0.044 -0.043 Metabolic pathways
B3GAT3 hsa-let-7i 0.019 0.091 0.240 0.044 -0.120 Metabolic pathways
CCL3 hsa-let-7a 0.021 0.180 0.004 0.010 -0.430 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7a 0.021 0.180 0.004 0.010 -0.430 Toll-like receptor signaling pathway
CCL3 hsa-let-7a 0.035 0.180 0.004 0.010 -0.430 Chemokine signaling pathway
CCL3 hsa-let-7a 0.035 0.180 0.004 0.010 -0.430 Chagas disease (American trypanosomiasis)
CCL3 hsa-let-7b 0.030 0.230 0.002 0.010 -0.460 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7c 0.006 0.100 0.001 0.010 -0.490 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7c 0.010 0.100 0.001 0.010 -0.490 Chemokine signaling pathway
CCL3 hsa-let-7c 0.010 0.100 0.001 0.010 -0.490 Toll-like receptor signaling pathway
CCL3 hsa-let-7d 0.025 0.053 0.200 0.010 -0.140 Cytokine-cytokine receptor interaction
CCL3 hsa-let-7d 0.027 0.053 0.200 0.010 -0.140 Toll-like receptor signaling pathway
CCL3 hsa-let-7f 0.039 0.170 0.034 0.010 -0.300 Toll-like receptor signaling pathway
CCL3 hsa-let-7f 0.045 0.170 0.034 0.010 -0.300 Cytokine-cytokine receptor interaction
CCL3 hsa-miR-98 0.038 0.130 0.120 0.010 -0.200 Toll-like receptor signaling pathway
CCL3 hsa-miR-98 0.040 0.130 0.120 0.010 -0.200 Chemokine signaling pathway
CHST7 hsa-miR-23c 0.031 0.020 0.068 0.013 -0.250 Glycosaminoglycan biosynthesis - chondroitin sulfate
CLCF1 hsa-miR-30c 0.012 0.087 0.021 0.036 -0.330 Cytokine-cytokine receptor interaction
CLCF1 hsa-miR-30c 0.019 0.087 0.021 0.036 -0.330 Jak-STAT signaling pathway
COL4A2 hsa-let-7a 0.024 0.180 0.140 0.033 -0.190 Pathways in cancer
COL4A2 hsa-let-7b 0.038 0.230 0.072 0.033 -0.250 Pathways in cancer
COL4A2 hsa-let-7b 0.039 0.230 0.072 0.033 -0.250 Protein digestion and absorption
COL4A2 hsa-let-7c 0.010 0.100 0.096 0.033 -0.220 Pathways in cancer
COL4A2 hsa-let-7c 0.021 0.100 0.096 0.033 -0.220 Protein digestion and absorption
COL4A2 hsa-let-7c 0.034 0.100 0.096 0.033 -0.220 Focal adhesion
COL4A2 hsa-let-7c 0.046 0.100 0.096 0.033 -0.220 Small cell lung cancer
COL4A2 hsa-let-7d 0.006 0.053 0.100 0.033 -0.220 Pathways in cancer
COL4A2 hsa-let-7d 0.010 0.053 0.100 0.033 -0.220 Focal adhesion
COL4A2 hsa-let-7d 0.011 0.053 0.100 0.033 -0.220 ECM-receptor interaction
COL4A2 hsa-let-7d 0.013 0.053 0.100 0.033 -0.220 Amoebiasis
COL4A2 hsa-let-7d 0.016 0.053 0.100 0.033 -0.220 Protein digestion and absorption
COL4A2 hsa-let-7d 0.024 0.053 0.100 0.033 -0.220 Small cell lung cancer
COL4A2 hsa-let-7f 0.030 0.170 0.150 0.033 -0.180 Pathways in cancer
COL4A2 hsa-let-7g 0.045 0.063 0.230 0.033 -0.130 Pathways in cancer
COL4A2 hsa-miR-9 0.034 0.230 0.250 0.033 -0.120 Focal adhesion
COL4A2 hsa-miR-9 0.034 0.230 0.250 0.033 -0.120 ECM-receptor interaction
COL4A2 hsa-miR-9 0.037 0.230 0.250 0.033 -0.120 Pathways in cancer
COL4A2 hsa-miR-9 0.037 0.230 0.250 0.033 -0.120 Small cell lung cancer
COL4A2 hsa-miR-98 0.014 0.130 0.160 0.033 -0.170 Pathways in cancer
COL4A2 hsa-miR-98 0.028 0.130 0.160 0.033 -0.170 Focal adhesion
COL4A2 hsa-miR-98 0.031 0.130 0.160 0.033 -0.170 ECM-receptor interaction
COL4A2 hsa-miR-98 0.031 0.130 0.160 0.033 -0.170 Amoebiasis
COL4A2 hsa-miR-98 0.034 0.130 0.160 0.033 -0.170 Small cell lung cancer
COL4A2 hsa-miR-98 0.039 0.130 0.160 0.033 -0.170 Protein digestion and absorption
EPN2 hsa-miR-30c 0.036 0.087 0.037 0.003 -0.300 Endocytosis
FAM125B hsa-miR-30c 0.036 0.087 0.430 0.029 -0.035 Endocytosis
FGF2 hsa-miR-23c 0.049 0.020 0.210 0.014 -0.140 Pathways in cancer
FZD2 hsa-miR-30c 0.008 0.087 0.095 0.002 -0.220 Pathways in cancer
FZD2 hsa-miR-30c 0.014 0.087 0.095 0.002 -0.220 Melanogenesis
FZD2 hsa-miR-30c 0.017 0.087 0.095 0.002 -0.220 Wnt signaling pathway
IDH2 hsa-let-7b 0.040 0.230 0.110 0.006 -0.210 Metabolic pathways
IDH2 hsa-let-7c 0.021 0.100 0.087 0.006 -0.230 Metabolic pathways
IDH2 hsa-let-7d 0.025 0.053 0.097 0.006 -0.220 Metabolic pathways
IDH2 hsa-let-7i 0.019 0.091 0.099 0.006 -0.220 Metabolic pathways
IDH2 hsa-miR-98 0.042 0.130 0.067 0.006 -0.250 Metabolic pathways
IKBKE hsa-let-7a 0.021 0.180 0.160 4.4E-04 -0.170 Toll-like receptor signaling pathway
IKBKE hsa-let-7a 0.046 0.180 0.160 4.4E-04 -0.170 Hepatitis C
IKBKE hsa-let-7c 0.010 0.100 0.059 4.4E-04 -0.260 Toll-like receptor signaling pathway
IKBKE hsa-let-7c 0.021 0.100 0.059 4.4E-04 -0.260 Hepatitis C
IKBKE hsa-let-7d 0.016 0.053 0.095 4.4E-04 -0.220 Hepatitis C
IKBKE hsa-let-7d 0.027 0.053 0.095 4.4E-04 -0.220 Toll-like receptor signaling pathway
IKBKE hsa-let-7f 0.039 0.170 0.250 4.4E-04 -0.120 Toll-like receptor signaling pathway
IKBKE hsa-miR-98 0.034 0.130 0.350 4.4E-04 -0.069 Hepatitis C
IKBKE hsa-miR-98 0.038 0.130 0.350 4.4E-04 -0.069 Toll-like receptor signaling pathway
ITGA11 hsa-let-7d 0.010 0.053 0.250 0.007 -0.120 Focal adhesion
ITGA11 hsa-let-7d 0.011 0.053 0.250 0.007 -0.120 ECM-receptor interaction
ITGA11 hsa-let-7d 0.015 0.053 0.250 0.007 -0.120 Regulation of actin cytoskeleton
ITGA11 hsa-miR-98 0.028 0.130 0.430 0.007 -0.036 Focal adhesion
ITGA11 hsa-miR-98 0.031 0.130 0.430 0.007 -0.036 ECM-receptor interaction
ITGA11 hsa-miR-98 0.040 0.130 0.430 0.007 -0.036 Regulation of actin cytoskeleton
ITGB3 hsa-let-7d 0.010 0.053 0.210 0.034 -0.140 Focal adhesion
ITGB3 hsa-let-7d 0.011 0.053 0.210 0.034 -0.140 ECM-receptor interaction
ITGB3 hsa-let-7d 0.015 0.053 0.210 0.034 -0.140 Regulation of actin cytoskeleton
ITGB3 hsa-miR-30c 0.004 0.087 0.072 0.034 -0.250 Hematopoietic cell lineage
ITGB3 hsa-miR-30c 0.004 0.087 0.072 0.034 -0.250 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ITGB3 hsa-miR-30c 0.004 0.087 0.072 0.034 -0.250 ECM-receptor interaction
ITGB3 hsa-miR-30c 0.004 0.087 0.072 0.034 -0.250 Hypertrophic cardiomyopathy (HCM)
ITGB3 hsa-miR-30c 0.004 0.087 0.072 0.034 -0.250 Dilated cardiomyopathy
ITGB3 hsa-miR-30c 0.008 0.087 0.072 0.034 -0.250 Focal adhesion
ITGB3 hsa-miR-30c 0.012 0.087 0.072 0.034 -0.250 Regulation of actin cytoskeleton
ITGB3 hsa-miR-30c 0.023 0.087 0.072 0.034 -0.250 Osteoclast differentiation
ITGB3 hsa-miR-98 0.028 0.130 0.300 0.034 -0.094 Focal adhesion
ITGB3 hsa-miR-98 0.031 0.130 0.300 0.034 -0.094 ECM-receptor interaction
ITGB3 hsa-miR-98 0.040 0.130 0.300 0.034 -0.094 Regulation of actin cytoskeleton
LAMP1 hsa-miR-23c 0.031 0.020 0.012 0.004 -0.370 Lysosome
LAMP1 hsa-miR-23c 0.049 0.020 0.012 0.004 -0.370 Phagosome
LAMP1 hsa-miR-9 0.046 0.230 0.066 0.004 -0.250 Phagosome
MBOAT2 hsa-miR-92b 0.023 0.098 0.370 0.010 -0.064 Metabolic pathways
MGLL hsa-let-7c 0.021 0.100 0.290 0.030 -0.100 Metabolic pathways
MGLL hsa-let-7d 0.025 0.053 0.094 0.030 -0.220 Metabolic pathways
MGLL hsa-let-7i 0.019 0.091 0.380 0.030 -0.059 Metabolic pathways
MGLL hsa-miR-98 0.042 0.130 0.220 0.030 -0.140 Metabolic pathways
NDST1 hsa-miR-23c 0.049 0.020 0.250 0.037 -0.120 Metabolic pathways
PAK1 hsa-let-7d 0.010 0.053 0.460 0.028 -0.022 Focal adhesion
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PAK1 hsa-let-7d 0.015 0.053 0.460 0.028 -0.022 Regulation of actin cytoskeleton
PAK1 hsa-let-7d 0.021 0.053 0.460 0.028 -0.022 ErbB signaling pathway
PANK1 hsa-miR-211 0.039 0.210 0.190 0.029 -0.160 Metabolic pathways
PDGFB hsa-let-7a 0.021 0.180 0.054 0.005 -0.270 Cytokine-cytokine receptor interaction
PDGFB hsa-let-7a 0.021 0.180 0.054 0.005 -0.270 Prostate cancer
PDGFB hsa-let-7a 0.024 0.180 0.054 0.005 -0.270 Pathways in cancer
PDGFB hsa-let-7a 0.032 0.180 0.054 0.005 -0.270 Melanoma
PDGFB hsa-let-7a 0.034 0.180 0.054 0.005 -0.270 Glioma
PDGFB hsa-let-7b 0.029 0.230 0.011 0.005 -0.370 Prostate cancer
PDGFB hsa-let-7b 0.030 0.230 0.011 0.005 -0.370 Cytokine-cytokine receptor interaction
PDGFB hsa-let-7b 0.030 0.230 0.011 0.005 -0.370 Melanoma
PDGFB hsa-let-7b 0.035 0.230 0.011 0.005 -0.370 Glioma
PDGFB hsa-let-7b 0.038 0.230 0.011 0.005 -0.370 Pathways in cancer
PDGFB hsa-let-7c 0.006 0.100 0.009 0.005 -0.390 Cytokine-cytokine receptor interaction
PDGFB hsa-let-7c 0.006 0.100 0.009 0.005 -0.390 Prostate cancer
PDGFB hsa-let-7c 0.006 0.100 0.009 0.005 -0.390 Melanoma
PDGFB hsa-let-7c 0.008 0.100 0.009 0.005 -0.390 Glioma
PDGFB hsa-let-7c 0.010 0.100 0.009 0.005 -0.390 Pathways in cancer
PDGFB hsa-let-7c 0.030 0.100 0.009 0.005 -0.390 Regulation of actin cytoskeleton
PDGFB hsa-let-7c 0.034 0.100 0.009 0.005 -0.390 Focal adhesion
PDGFB hsa-let-7d 0.006 0.053 0.110 0.005 -0.210 Pathways in cancer
PDGFB hsa-let-7d 0.006 0.053 0.110 0.005 -0.210 Prostate cancer
PDGFB hsa-let-7d 0.006 0.053 0.110 0.005 -0.210 Melanoma
PDGFB hsa-let-7d 0.010 0.053 0.110 0.005 -0.210 Focal adhesion
PDGFB hsa-let-7d 0.010 0.053 0.110 0.005 -0.210 Glioma
PDGFB hsa-let-7d 0.015 0.053 0.110 0.005 -0.210 Regulation of actin cytoskeleton
PDGFB hsa-let-7d 0.025 0.053 0.110 0.005 -0.210 Cytokine-cytokine receptor interaction
PDGFB hsa-let-7f 0.030 0.170 0.087 0.005 -0.230 Pathways in cancer
PDGFB hsa-let-7f 0.030 0.170 0.087 0.005 -0.230 Prostate cancer
PDGFB hsa-let-7f 0.030 0.170 0.087 0.005 -0.230 Melanoma
PDGFB hsa-let-7f 0.039 0.170 0.087 0.005 -0.230 Glioma
PDGFB hsa-let-7f 0.045 0.170 0.087 0.005 -0.230 Cytokine-cytokine receptor interaction
PDGFB hsa-let-7g 0.007 0.063 0.110 0.005 -0.210 Melanoma
PDGFB hsa-let-7g 0.015 0.063 0.110 0.005 -0.210 Prostate cancer
PDGFB hsa-let-7g 0.027 0.063 0.110 0.005 -0.210 Glioma
PDGFB hsa-let-7g 0.045 0.063 0.110 0.005 -0.210 Pathways in cancer
PDGFB hsa-let-7i 0.005 0.091 0.150 0.005 -0.180 Melanoma
PDGFB hsa-let-7i 0.006 0.091 0.150 0.005 -0.180 Prostate cancer
PDGFB hsa-let-7i 0.007 0.091 0.150 0.005 -0.180 Glioma
PDGFB hsa-let-7i 0.021 0.091 0.150 0.005 -0.180 Pathways in cancer
PDGFB hsa-miR-98 0.014 0.130 0.083 0.005 -0.230 Pathways in cancer
PDGFB hsa-miR-98 0.016 0.130 0.083 0.005 -0.230 Prostate cancer
PDGFB hsa-miR-98 0.016 0.130 0.083 0.005 -0.230 Melanoma
PDGFB hsa-miR-98 0.020 0.130 0.083 0.005 -0.230 Glioma
PDGFB hsa-miR-98 0.028 0.130 0.083 0.005 -0.230 Focal adhesion
PDGFB hsa-miR-98 0.040 0.130 0.083 0.005 -0.230 MAPK signaling pathway
PDGFB hsa-miR-98 0.040 0.130 0.083 0.005 -0.230 Regulation of actin cytoskeleton
PIAS3 hsa-miR-9 0.037 0.230 0.420 0.044 -0.038 Pathways in cancer
PIAS3 hsa-miR-9 0.037 0.230 0.420 0.044 -0.038 Small cell lung cancer
PIP5K1C hsa-miR-92b 0.023 0.098 0.180 0.039 -0.160 Metabolic pathways
PIP5K1C hsa-miR-92b 0.023 0.098 0.180 0.039 -0.160 Focal adhesion
PLCG1 hsa-miR-34a 0.010 0.064 0.320 0.012 -0.087 Non-small cell lung cancer
PLCG1 hsa-miR-34a 0.026 0.064 0.320 0.012 -0.087 Pathways in cancer
PLCG1 hsa-miR-34a 0.027 0.064 0.320 0.012 -0.087 Glioma
POLR2F hsa-miR-211 0.039 0.210 0.480 0.049 -0.011 Metabolic pathways
POLR2F hsa-miR-211 0.045 0.210 0.480 0.049 -0.011 Huntington's disease
RPS6KA4 hsa-miR-9 0.046 0.230 0.170 0.019 -0.170 MAPK signaling pathway
RXRA hsa-miR-9 0.037 0.230 0.018 0.046 -0.350 Pathways in cancer
RXRA hsa-miR-9 0.037 0.230 0.018 0.046 -0.350 Small cell lung cancer
SDC2 hsa-miR-9 0.034 0.230 0.310 0.030 -0.091 ECM-receptor interaction
SEMA4B hsa-miR-23c 0.049 0.020 0.250 0.001 -0.120 Axon guidance
SMAD3 hsa-miR-23c 0.049 0.020 0.150 0.038 -0.180 TGF-beta signaling pathway
SMAD3 hsa-miR-23c 0.049 0.020 0.150 0.038 -0.180 Pathways in cancer
SMAD3 hsa-miR-23c 0.049 0.020 0.150 0.038 -0.180 Chronic myeloid leukemia
SP1 hsa-miR-211 0.024 0.210 0.004 0.031 -0.430 TGF-beta signaling pathway
SP1 hsa-miR-211 0.045 0.210 0.004 0.031 -0.430 Huntington's disease
SP1 hsa-miR-92b 0.024 0.098 0.120 0.031 -0.200 TGF-beta signaling pathway
SRC hsa-miR-9 0.034 0.230 0.200 0.005 -0.150 Focal adhesion
SRC hsa-miR-9 0.046 0.230 0.200 0.005 -0.150 Gap junction
SRGAP1 hsa-miR-23c 0.049 0.020 0.110 0.011 -0.210 Axon guidance
ST3GAL1 hsa-let-7b 0.040 0.230 0.340 0.002 -0.076 Metabolic pathways
ST3GAL1 hsa-let-7c 0.021 0.100 0.260 0.002 -0.110 Metabolic pathways
ST3GAL1 hsa-let-7d 0.025 0.053 0.140 0.002 -0.180 Metabolic pathways
ST3GAL1 hsa-let-7i 0.019 0.091 0.110 0.002 -0.210 Metabolic pathways
ST3GAL1 hsa-miR-98 0.042 0.130 0.210 0.002 -0.140 Metabolic pathways
TIAM2 hsa-miR-365 0.050 0.007 0.017 0.031 -0.350 Chemokine signaling pathway
TLN1 hsa-miR-9 0.034 0.230 0.270 0.007 -0.110 Focal adhesion
TNFRSF21 hsa-miR-9 0.041 0.230 0.290 0.027 -0.100 Cytokine-cytokine receptor interaction
XYLT1 hsa-miR-197 0.002 0.044 0.094 0.004 -0.220 Metabolic pathways
XYLT1 hsa-miR-23c 0.031 0.020 0.420 0.004 -0.038 Glycosaminoglycan biosynthesis - chondroitin sulfate
XYLT1 hsa-miR-23c 0.049 0.020 0.420 0.004 -0.038 Metabolic pathways
XYLT1 hsa-miR-9 0.041 0.230 0.440 0.004 -0.030 Glycosaminoglycan biosynthesis - chondroitin sulfate
XYLT1 hsa-miR-9 0.046 0.230 0.440 0.004 -0.030 Metabolic pathways
ZMAT3 hsa-let-7d 0.006 0.053 0.340 0.038 -0.074 p53 signaling pathway
ZMAT3 hsa-miR-98 0.016 0.130 0.340 0.038 -0.075 p53 signaling pathway
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Supplementary Table 4A
Genes (Symbol ID) down-
regulated in association with PP
miRNAs up-regulated in 
association with PP
Does the direction of gene expression reported in the 
present study accord with prior reports about the 
gene's behaviour in cancer(s)?
Literature summary Supporting references (PMID)
CCND2 hsa-let-7a, hsa-let-7c, hsa-miR-211, hsa-miR-506 Does not accord
Down-regulation of CCND2  by hsa-miR-29 and hsa-miR-206 inhibited tumor formation of gastric and 
prostate cancers respectively 24130168, 23466356
CCR2 hsa-miR-125b Does not accord Knockdown of CCR2  gene expression induces apoptosis and inhibits the proliferation, migration, and invasion of prostate cancer cells 24406043
CCR7 hsa-let-7a, hsa-let-7c Does not accord High CCR7  expression in gastric cancer cells was significantly associated with poor overall survival 24040244
CTSC hsa-let-7a Does not accord Elevated expression of CTSC  has been reported squamous cell carcinoma growth 24065739
CYLD hsa-miR-30b Accords Overexpression of CYLD  inhibited melanoma cell proliferation and migration in vitro  and subcutaneous tumor growth in vivo 22832488
DUSP5 hsa-miR-181b Accords Down-regulation of DUSP5  in gastric cancers by promoter CpG island hypermethylation resulted in cell proliferation 23402999
ETV6 hsa-miR-181b Does not accord Inhibition of ETV6 expression resulted in increased Stat3-dependent transcriptional activity and stronger Stat3 anti-proliferative activity 15229229
GCH1 hsa-miR-9 Does not accord Silencing of GCH1  reduced tumor cell proliferation and survival 22753274
GNAI2 hsa-miR-30b, hsa-miR-506 Accords Knockdown of the GNAI2  expression enhanced hepatocellular carcinoma cell migration and invasion, indicating that GNAI2  functions as a metastasis suppressor 20054866
IFNAR2 hsa-miR-30b Does not accord Overexpressed in aggressive lung cancers 22236545
MTHFD2 hsa-miR-9 Does not accord Anti-proliferative and pro-apoptotic activity of hsa-miR-9 and targeting of MTHFD2  contributed to tumor suppressor-like activity in breast cancer cells 22761433
PPP2R5C hsa-miR-125b Does not accord Overexpression of PPP2R5C in T-cell malignancy and in myeloid leukaemia cells was related to proliferation and differentiation 21548944
PRKCD hsa-miR-181a, hsa-miR-181b Accords hsa-miR-181a conferred resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD  gene 22847611
PTEN hsa-miR-92b, hsa-miR-363 Accords Loss of PTEN  function led to cell proliferation, via activation of Akt, and survival, via down-regulation of pro-apoptotic machinery and up-regulation of anti-apoptotic proteins such as Bcl-2 12782594
RASGRP3 hsa-miR-30b Does not accord RASGRP3  suppression inhibited cell proliferation and reduced both colony formation in melanoma 21602881
RUNX1 hsa-miR-30b, hsa-miR-9, hsa-miR-181b Does not accord RUNX1  may act as a skin oncogene by directly promoting proliferation 20308320
SGPL1 hsa-miR-125b, hsa-miR-211 Accords
SGPL1  deficiency led to increased cell proliferation, anchorage-independent cell growth, and 
formation of tumors in nude mice…transcriptomic studies showed that SGPL1  expression was down-
regulated in human melanoma cell lines
19934311
SH2B3 hsa-miR-30b, hsa-miR-125b Does not accord Silencing of SH2B3 /LNK decreased ovarian cancer cell growth in vitro  and in vivo . 24704825
SH3GLB1 hsa-miR-9, hsa-miR-30b Does not accord Overexpression of autophagy-related proteins such as Bfi/ SH3GLB1 were independently associated with poor prognosis pancreatic ductal adenocarcinoma 23429496
SOCS1 hsa-miR-30b Accords Down-regulation of SOCS1  expression by hsa-miR-155 promoted hep-2 cell growth, migration and invasion in laryngeal squamous cell carcinoma 23437123
THSB2 hsa-let-7a, hsa-let-7c Accords Lower expression of THSB2  mRNA in invasive cervical cancer correlated with angiogenesis and prognosis 23470460
TNC hsa-miR-9 Does not accord TNC  promoted cancer invasiveness via epithelial to mesenchymal transition (EMT) regulation 23645740
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Supplementary Table 4B
Genes (Symbol ID) up-regulated 
in association with PP
miRNAs down-regulated in 
association with PP
Does the direction of gene expression reported in the 
present study accord with prior reports about the 
gene's behaviour in cancer(s)?
Literature summary Supporting references (PMID)
CANT1 hsa-let-7g Does not accord In prostate cancer, high CANT1  levels were associated with better prognosis 21435463
NME1 hsa-miR-141 Does not accord Reduction or loss of nm23-H1 expression correlated with tumor progression and metastasis 11768314
XPO5 hsa-miR-29a, hsa-miR-29b, hsa-miR-29c Accords XO5 expression levels were higher in high-grade carcinomas than in low-grade bladder carcinomas 22766726
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Genes (Symbol ID) down-
regulated in association with 
BRAF  mutation
miRNAs up-regulated in 
association with BRAF 
mutation
Does the direction of gene expression reported in the 
present study accord with prior reports about the 
gene's effect on proliferation?
Literature summary Supporting references (PMID)
C1GALT1 hsa-miR-181d Does not accord C1GALT1  mRNA and protein was frequently overexpressed in hepatocellular carcinoma tumors where it correlated with advanced tumor stage, metastasis, and poor survival 8736698
CDC42 hsa-miR-25 Does not accord Higher expression was observed in thick melanomas and associated with poor outcome 17970806
CDK2 hsa-miR-520d-3p Does not accord Loss of Cdk2 and cyclin A2 impaired cell proliferation and tumorigenesis 24802190
CPEB1 hsa-miR-19b, hsa-miR-130a Does not accord
Several CPEB -regulated mRNAs governed cell cycle progression, regulated senescence, and promoted 
tumorigenesis and metastasis 23446545
CSNK1A1 hsa-miR-30d Does not accord Higher expression of CSNK1A1  was seen in melanoma cell lines and tissues compared to nevi…in non-small cell lung cancer (NSCLC) high expression of CSNK2A1  was predictive of poor prognosis 20671611, 21566537
DUSP10 hsa-miR-25, hsa-miR-181d Does not accord
Expression levels of DUSP10  were increased in cancerous tissue by 5-fold compared to the non-
cancerous region of the same samples in colon carcinoma...in lung, breast, and glioblastoma samples, 
there was no significant change in the expression between tumor and normal samples
22711061
GCNT2 hsa-miR-181d Uninformative Knockdown of GCNT2 expression decreased cell migration and invasion in vitro and lung metastasis and breast cancer 21750175
GNA13 hsa-miR-30d Uninformative Cells depended on GNA13  expression for their invasion and migration via high expression in many cancers 23329838
IGF2R hsa-miR-30d Uninformative Reduced expression of IGF2R  by hsa-miR-211 repressed IGF2R and led to the reduction of the invasive potential of melanomas 21109473
MTHFD2 hsa-miR-25 Uninformative Knockdown of MTHFD2  by overexpression of hsa-miR-9 decreased cell viability and increased apoptotic activity in breast cancer cells 22761433
PDPK1 hsa-miR-181b, hsa-miR-181d Does not accord Knockdown of PDK1  inhibited cell proliferation and invasion and promoted apoptosis in esophageal cancer 23098536
PER3 hsa-miR-30d Accords PER3  played a suppressive role in colorectal cancer cells 24393525
PFN2 hsa-miR-30d Uninformative In oral squamous cell carcinoma tumors with weak PFN2  expression were associated with a significantly worse prognosis than strongly expressed tumours 21725608
PPP2R5C hsa-miR-125b Does not accord Overexpression of PPP2R5C in T-cell malignancy and in myeloid leukaemia cells was related to proliferation and differentiation 21548944
STX7 hsa-miR-130a Accords Decreased expression of STX7  was associated with more aggressive melanomas 19714869
TRAF6 hsa-miR-125b Uninformative Knockdown expression of TRAF6  inhibited the migration and metastasis of esophageal squamous cell carcinoma 24026882
TRIT1 hsa-miR-370 Uninformative TRIT1  was proposed as a candidate lung tumor suppressor 15870694
Supplementary Table 4C
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Genes (Symbol ID) up-regulated in 
association with BRAF  mutation
miRNAs down-regulated in 
association with BRAF  mutation
Does the direction of gene expression reported in 
the present study accord with prior reports about 
the gene's effect on proliferation?
Literature summary Supporting references (PMID)
ACVR1B hsa-let-7a, hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7f, hsa-miR-9 Uninformative
Up-regulation promoted cell migration, triggered the process of epithelial-to-mesenchymal transition 
and thereby aided in the aggressiveness and progression of prostate cancers 23159635
COL4A2
hsa-let-7a, hsa-let-7b, hsa-let-7c, 
hsa-let-7d, hsa-let-7g, hsa-miR-9, 
hsa-miR-98
Uninformative Down-regulation of COL4A2  by miR-29b contribute to the invasion ability of MCF-7 cells in breast cancer 22864815
FGF2 hsa-miR-23c Accords Overexpression of FGF2 melanocytes resulted in marked proliferation, upwards migration, and cluster formation 12823444
FZD2 hsa-miR-30c Accords  Up-regulated in melanoma cell lines 19946729
IDH2 hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7i, hsa-miR-98 Uninformative
Higher expression of IDH2  was associated with favorable prognosis after curative resection of 
hepatocellular carcinoma 24716838
IKBKE hsa-let-7a, hsa-let-7c, hsa-let-7d, hsa-miR- 98 Uninformative
Up-regulation in glioma, oncogenic protein IKBKE  over-expression inhibited cell apoptosis induced 
by UV irradiation by inducing Bcl-2 expression 21171089
ITGA11 hsa-let-7d, hsa-miR-98 Uninformative Up-regulation correlated with lymph node metastasis and poor prognosis in non-small cell lung cancer 17016581
ITGB3 hsa-let-7d, hsa-miR-30c, hsa-miR-98 Uninformative
Increased expression associated with invasive melanoma in small cell lung cancer hsa-let-7c acted 
as a metastatic suppressor by repressing the expression of ITGB3 and MAP4K3 18679415, 23981581
MBOAT2 hsa-miR-92b Uninformative Overexpression appeared to be inversely correlated with patient survival in pancreatic ductal adenocarcinoma 19260470
NDST1 hsa-miR-23c Does not accord NDST1  played an inhibitory role and could suppress cell proliferation in gastric carcinoma 21947487
PAK1 hsa-let-7d Uninformative PAK1  was overexpressed during tumorigenic progression and its up-regulation correlated with malignant properties mainly relevant to invasion and metastasis 24236193
PDGFB hsa-let-7a, hsa-let-7b, hsa-let-7c, hsa-miR-98 Uninformative Overexpression enabled tumour survival in association with NRAS  mutation 23327964
PIAS3 hsa-miR-9 Does not accord Overexpression of PIAS3  in melanoma and prostate cancer cell lines was found to inhibit cell growth and suppressed STAT3  activity 19201870
POLR2F hsa-miR-211 Uninformative High expression levels of POLR2F  correlated with improved 3-year survival in colorectal cancer 18505059
SDC2 hsa-miR-9 Uninformative High expression of syndecan-2 supported high migration in melanoma expression 22493442
SEMA4B hsa-miR-23c Uninformative Ectopic expression of SEMA4B  abolished invasion of hypoxia-induced non-small cell lung cancer cells 24474252
SMAD3 hsa-miR-23c Uninformative Up-regulated SMAD3  promoted epithelial-mesenchymal transition and predicted poor prognosis in pancreatic ductal adenocarcinoma 24709776
SRC hsa-miR-9 Uninformative SRC  regulates cell adhesion, invasiveness and motility in cancer cells when overexpressed in melanoma 17150037
TIAM2 hsa-miR-365 Accords Increased expression of TIAM2S  promoted epithelial-to-mesenchymal transition and resulted in proliferation and invasion in liver cancer cells 21469146
TLN1 hsa-miR-9 Uninformative hsa-miR-9 played a role as a tumor suppressor in OSC by suppressing TLN1  expression 23722670
Supplementary Table 4D
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Chapter 5 
 
The melanoma-enriched microRNA miR-4731 regulates genes involved 
in cell cycle and the melanosome 
 
Mitchell S. Stark, Glen M. Boyle, Vanessa F. Bonazzi, Adrian C. Herington, Pamela M. 
Pollock, Nicholas K. Hayward. The melanoma-enriched microRNA miR-4731 regulates 
genes involved in cell cycle and the melanosome. (2015) Submitted Manuscript (Under 
Review). 
 
5.1. Relevance to thesis aims 
This chapter primarily focuses on Aim 4. miR-4731-5p (miR-4731) was identified as being 
melanoma-enriched after performing the miRNA microarray analysis which formed the 
basis of Chapter 2 along with providing the melanoma-related panel investigated in 
Chapter 3. In Chapter 3, miR-4731 was found to be down-regulated in stage IV tissues 
and in stage IV patient-derived serum (relative to stage III tissues and patient derived 
serum respectively). We sought to identify gene-specific targets of miR-4731 that were 
relevant for melanoma development (Aim 4). 
 
5.2. Contribution of the candidate 
I developed the concept and initial study design which was agreed upon and refined by my 
supervisors. I performed the majority of the experimental work, data analysis and 
interpretation, and writing of the manuscript. 
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author who accepts overall responsibility for the publication; 
3. there are no other authors of the publication according to these criteria;  
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Abstract 
We previously identified miR-4731-5p (miR-4731) as a melanoma-enriched microRNA 
following comparison of melanoma with other cell lines from solid malignancies. 
Additionally, miR-4731 has been found in serum from melanoma patients and expressed 
less abundantly in metastatic melanomas from stage IV patients relative to stage III 
patients. As miR-4731 has no known function, we used biotin-labelled miRNA duplex pull-
down to identify binding targets of miR-4731 in three melanoma cell lines. Using the 
miRanda miRNA binding algorithm, all pulled-down transcripts common to the three cell 
lines (n=1092) were predicted to be targets of miR-4731 and gene-set enrichment analysis 
of these (via STRING v9.1) highlighted significantly associated genes related to the ‘cell 
cycle’ and ‘melanosome’ pathways. Following miR-4731 overexpression, a selection 
(n=81) of pull-down transcripts underwent validation using a custom qRT-PCR array. 
These data revealed that miR-4731 regulates multiple genes associated with the cell cycle 
(e.g. CCNA2, ORC5L, and PCNA) and melanosome (e.g. RAB7A, CTSD, and GNA13). 
Furthermore, members of the synovial sarcoma X breakpoint family (SSX) (melanoma 
growth promoters) were also down-regulated (e.g. SSX2, SSX4, and SSX4B) as result of 
miR-4731 overexpression. We therefore speculate that loss of miR-4731 expression 
supports melanoma growth by, in part; reducing its regulatory control of SSX expression 
levels together with members of the cell cycle pathway, which warrants further 
investigation. 
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Introduction 
In our previous study, miR-4731-5p (miR-4731) was identified as a melanoma-enriched 
(mean 24-fold ; P(cor)=1.47E-04) miRNA following a comprehensive analysis of a large 
panel of melanoma cell lines (expressed in 37/55) in comparison with other cell lines 
derived from solid malignancies (expressed in 5/34) [1]. In a separate study, we also found 
miR-4731 to be down-regulated (23-fold mean; P(cor)=0.004) in metastatic melanoma 
spread to distant sites (stage IV) compared with loco-regional metastases (stage III) [2]. 
Moreover, together with the expression of another miRNA (miR-204), miR-4731 was able 
to distinguish stage III from stage IV tumours (p=0.003, OR=3.0, CI 1.45-6.2; AUC=0.89) 
[2]. The expression of miR-4731 was later found, in serially-collected serum from stage IV 
patients (at diagnosis and at higher disease burden), to be increased (1.7-23,925 fold) at 
disease progression, which indicates that it is likely to be tumour-derived and reflective of 
higher tumour burden [2]. 
 miR-4731 is located at chr17p12 (chr17:15,154,944-15,155,013) in an intron (>5 kb from 
intron-exon border) of  the peripheral myelin protein 22 gene (PMP22), which is commonly 
associated with hereditary Charcot-Marie-Tooth disease type 1A (CMT1A). PMP22 is 
expressed primarily in neural crest derived cell lineages (including melanocytes), however 
expression of PMP22 has also been associated with cell proliferation and survival in breast 
cancer [3-5]. To date no target genes of miR-4731 have been functionally validated. 
Given the association of miR-4731 with melanoma in our previous studies, we sought to 
identify the genes regulated by this miRNA. We employed the optimised biotin-labelled 
miRNA duplex pull-down procedure [1, 6, 7] to identify binding targets of miR-4731, 
followed by gene-set enrichment analysis (GSEA) to help elucidate significant pathways 
and biological processes regulated by miR-4731. A selection of pull-down target genes 
(n=81) underwent validation via qRT-PCR following over-expression of a miR-4731-5p 
mimic in several melanoma cell lines. We report here that miR-4731 has the potential to 
regulate multiple genes involved in the cell cycle and melanosome pathways.  
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Results and Discussion 
The verification of miR-4731 as a melanoma-enriched miRNA 
miR-4731 was identified following a comprehensive miRNA microarray (miRBase v18) 
analysis of a panel of melanoma cell lines (n=55) compared with other solid malignancies 
(n=34) [1]. In the current study, the microarray expression data for miR-4731 was validated 
using qRT-PCR in an extended panel of cell lines derived from melanoma (n=100; 
including 55 that were initially assayed) and other solid cancers (n=34) (Supp Table 1). 
The mean expression level of miR-4731 is significantly higher (Mann-Whitney U-test; 
P≤0.0001) in melanomas compared to other cancers (Figure 1). The expression of PMP22 
(miR-4731 host gene) was assessed in relation to that of miR-4731 to identify any 
correlations. In 14/43 (32%) melanoma cell lines with no detectable miR-4731 expression, 
PMP22 was expressed above background (data not shown). This is suggestive that miR-
4731 is not under the same transcriptional control as its host gene and is independently 
regulated. In the remaining samples (29/43), there was an inverse correlation observed 
(Pearson’s R2= -0.25) which suggests that expression of PMP22 may be negatively 
regulated by miR-4731 (data not shown). 
Target gene identification via biotin-labelled miRNA duplex ‘pull-down’ of mRNA transcripts 
To identify genes potentially regulated by miR-4731, we used the unbiased biotin-labelled 
pull-down procedure [1, 6, 7], which harnesses the conventional AGO2-directed binding of 
the mature miRNA to the mRNA transcript. By modifying the miRNA sequence with a 
biotin label, miRNA:mRNA bound transcripts can be ‘pulled-down’ using streptavidin-
coated magnetic beads. This procedure was applied to three melanoma cell lines (MM96L, 
MM253, and HT144), chosen based on their low, yet detectable endogenous expression of 
miR-4731, together with transfection ability. As we were looking for enrichment of biotin-
labelled transcripts, we only considered transcripts that were up-regulated in each sample 
compared to the biotin-labelled negative control (Neg-Scr) (see Materials and Methods).  
There are numerous targets (887-2496 transcripts) specific to each cell line, likely due to 
inherent differences between them, such as global gene expression profiles and 
mutational background. Due to these differences we focussed on common transcripts 
between all three cell lines (Supp Figure 1). Obsolete and duplicate transcripts were 
removed, which left 1154 unique transcripts (Supp Table 2) representing 1092 different 
genes (see Materials and Methods). 
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Verification of ‘pulled-down’ genes using prediction algorithms 
Full-length (5' UTR, protein coding sequence, and 3' UTR) FASTA sequences were 
collated for each transcript (n=1154) and parsed through the prediction algorithm 
miRanda-3.3a (see Materials and Methods). All pulled-down transcripts were predicted to 
be targets of miR-4731 by the program when the binding threshold was set at 100 (data 
not shown). However by reducing the stringency threshold, the algorithm may allow for an 
increased number of false positives. The reduced threshold was used to highlight that 
miR-4731 had the capacity to bind to the transcript given the right biological conditions. It 
is interesting to note that when the miRanda algorithm was instructed to only call ‘seed’ 
binding occurrences, believed to be the most common binding type, 505/1154 (44%) 
transcripts were called.   Therefore, the majority of the pull-down (PD) transcripts had a 
mixture of ‘non-seed’ binding present (e.g. centred, 3' supplementary, and bulged sites [8-
10]), which indicates that there was no bias toward particular sites based on fold 
enrichment. This observation may in part be explained by experimental bias previously 
observed in the procedure [6] as it has been observed that the biotin tag on the synthetic 
miRNA duplexes may actually prevent their 3' end from binding to AGO [6]. It is believed 
that the biotin-labelled miRNAs interact more readily with mRNAs and alleviate the 
reliance on ‘seed’ binding from the 5' end [6]. As we found that 44% of binding sites can be 
attributed to seed binding (which compares well to a previous estimate of 41%  [6]), we 
can also conclude that the pull-down procedure has a slight bias away from seeded sites 
[6]. As previously mentioned, miRanda 3.3a was used to confirm the binding of the PD 
transcripts using a lower stringency threshold score (100) but if stringent default settings 
were used, (binding threshold =140) only 668/1154 (58%) of transcripts were called. Other 
commonly used prediction programs (with default parameters applied) performed poorly 
when compared to the PD transcripts and miRanda 3.3a; TargetScan (27%), TargetMiner 
(23%), DIANA-microT-CDS (19%), and miRDB (2%). These prediction issues are 
complex, therefore it is important, as we have highlighted, to use many overlapping pieces 
of data to draw a more reliable picture. On the other hand, the discrepancy observed 
between the PD transcripts and the prediction algorithms may be due to a high number of 
false-positives present in the dataset. It has been previously observed that a proportion of 
PD transcripts may arise via non-specific interaction with the magnetic streptavidin beads, 
or by association with endogenous biotin, and not the intended biotinylated miRNA [6]. 
However, as all PD transcripts were compared those generated using a negative, 
scrambled sequence, and given the high concordance with the miRanda prediction 
algorithm, it seems unlikely that this is the case.  Another possibility is that the rules 
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applied for commonly used prediction algorithms are too strict, thus making them unable to 
predict accurately what occurs biologically. Based upon our data, miRanda-3.3a appears 
to offer more reflective of what may occur biologically. 
Network analysis reveals enrichment for key signalling pathways and Gene Ontology 
terms 
It is widely accepted that a single miRNA has the potential to regulate a multitude of 
signalling pathways, achieved by the direct targeting of individual genes, which in turn elicit 
their function on their next interacting partner. The understanding of a miRNA’s target 
gene(s) is not only important for understanding their contribution to the disease process, it 
is crucial when it comes to utilizing miRNAs as therapeutic agents [11]. Rather than 
individual mRNA:miRNA pairings in a signalling pathway, many genes within a 
pathway/process may undergo regulation by a single miRNA (or cluster).  
Of the miR-4731 PD transcripts, we hypothesized that some signalling pathways may be 
over-represented. In steps to identify interacting partners contained within our dataset, we 
used the network analysis program STRING (v9.1) [12] which identifies known and 
predicted protein-protein interactions. Using default settings, there were 4225 interactions, 
with many genes being over-represented as they were involved in >1 connection 
(visualised in Figure 2). It could be postulated that the pull-down genes were not randomly 
selected by the miRNA, given the high number of interactions observed. Gene-set 
enrichment analysis (GSEA) was next used to identify statistically significant pathways 
(KEGG) and Gene Ontology (GO) terms. The top three KEGG pathways of note were 
related to ‘Metabolic pathways’ (109 genes; P(cor)=8.94E-11) the ‘Cell cycle’ (25 genes; 
P(cor)=9.24E-08) and ‘Oxidative phosphorylation’ (22 genes; P(cor)=3.98E-05) (Supp 
Table 3). Notably, of particular relevance to the melanocytic lineage, was the GO term 
‘Melanosomes’ (Supp Table 3), consisting of 22 miR-4731 target genes (P(cor)=3.15E-07) 
. 
Overexpression of a miR-4731 mimic and regulation of pull-down transcripts 
Given that 1154 transcripts (1092 genes) were common to all 3 melanoma cell lines, it was 
not feasible to validate all of these genes via reporter assays, qRT-PCR or Western 
blotting. We did however assess 81 (7%) transcripts (Supp Table 4) using a custom qRT-
PCR array (QIAGEN). The criteria for transcript selection are detailed in the Materials and 
Methods but can be summarised as follows: 1) the host gene of miR-4731, PMP22 was 
selected to confirm if it was under transcriptional control of miR-4731; 2) all genes that had 
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≥2 fold enrichment in 3/3 cell lines (n=37); 3) significant pathways were selected based 
upon a priori relevance to melanoma (selected pathways were ‘cell cycle’, ‘oxidation 
phosphorylation’, and ‘melanosomes’). These pathways had further restrictions imposed in 
an attempt to be more stringent (n=43) (see Materials and Methods).  We over-expressed 
a miR-4731 mimic or a negative control mimic (Neg-scr), in the same melanoma cell lines 
(MM96L, MM253, and HT144) that were used to perform the pull-down procedure. Supp 
Figure 2 highlights that a consistent over-expression was achieved in all cell lines tested. 
After a 72 hr transfection, subsequent qRT-PCR revealed that PMP22 (miR-4731 host 
gene) was downregulated (1.4-2.2 fold) in 3/3 cell lines upon miR-4731 overexpression 
(Supp Table 4). These data support the previously observed inverse correlation between 
expression levels of PMP22 and miR-4731. All other validated target genes related to ‘cell 
cycle’, ‘oxidative phosphorylation’, and ‘melanosomes’ can be found in Supp Table 4) and 
summarised in Supp Table 5: those that were down regulated in 3/3 (n=19), 2/3 (n=12) 
and 1/3 (n=19); both up and down regulated (n=5); up regulated (n=5); and not observably 
changed at the mRNA level (≤1.2 fold up or down regulated) (n=21). These data provide 
validation of the binding effect of miR-4731 to up to 74% of the assessed transcripts. The 
26% (21/81) of transcripts that were not observably changed at the mRNA level may be 
false positives. To confirm the absolute effect on the target genes, assessment at the 
protein level must occur to confirm these findings. 
Key members of the melanosome and cell cycle pathways are regulated by miR-4731 
Melanosome pathway genes 
In melanocytes, a melanosome’s primary purpose is to package and deliver melanin to 
keratinocytes [13]. A total of 11/13 genes showed differential expression by ≥1.3 fold in 
≥1/3 cell lines (Supp Table 4). The binding of miRNAs to mRNA transcripts commonly 
results in down-regulation of the transcript; however up-regulation is also possible. 
Interestingly, the overexpression of miR-4731 caused both an up- (MM253 and HT144) 
and down-regulation (MM96L) of the assessed transcripts to be observed (Supp Table 4).  
For example, in relation to melanoma, the up-regulation of CTSD (cathepsin D) has been 
suggested to be involved in the malignant transformation and progression of melanocytic 
tumors [14]. RAB7A was also found to be both up- (MM253) and down-regulated (MM96L) 
upon overexpression of miR-4731 (Supp Table 4). RAB7A (a member of the RAS 
oncogene family) has recently been shown to control melanoma progression and the effect 
of RAB7A is known to be gene dosage dependent [15]. To further support the effect of 
miR-4731 expression in the melanosome pathway, we next assessed the expression of 
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other key members of this process (FSCN1, MLPH, RAB27A, and TYR). Given these 
melanosome-related genes were not present in the pull-down data, any observed 
expression differences as a result of miR-4731 overexpression must be considered as an 
indirect effect. Nevertheless, FSCN1, MLPH, RAB27A, and TYR all showed fold changes 
≥1.3 fold in 1/3 (FSCN1) and 2/3 (MLPH, RAB27A, and TYR) cell lines (Supp Table 6). 
These additional data strengthen the association of the other confirmed melanosome-
enriched genes (Supp Table 4). The highest observed fold changes were for MLPH (or 
melanophilin) with 8.2 and 1.7 down-regulation in HT144 and MM96L respectively. MLPH 
is known to bind directly to both RAB27A and MYO5A (miR-4731 target gene; Supp Table 
4), all of which are considered integral components of melanosome transport [16]. 
Cell cycle pathway genes 
According to Hanahan and Weinberg, the most fundamental trait of cancer cells is their 
inherent ability to sustain chronic proliferation which, in part, can be attributed to defects in 
the cell cycle [17]. In our dataset, we confirmed the strongest associated genes, present in 
3/3 cell lines, were CCNA2, ORC5L, and PCNA (Supp Table 4). CCNA2 and PCNA have 
been identified as potential biomarkers for melanoma based upon a comprehensive 
assessment of publically available gene expression datasets [18]. Moreover, in a 
systematic review of melanoma immunohistochemical (IHC) and gene microarray studies, 
increased PCNA expression was consistently identified as being associated with worse 
clinical outcome in melanoma patients [19]. In 2/3 cell lines, BUB3, CDC45L, CDK4, and 
SKP1A were also found to be down-regulated. In total, 13/13 genes were down-regulated 
in ≥1.3 fold in ≥1/3 cell lines (Supp Table 4). In the KEGG ‘cell cycle’ pathway shown in 
Figure 3, the miR-4731 target genes (red star) are represented at almost every critical 
stage of the cell cycle – indicating that the dysregulation of miR-4731 could be critical to its 
regulation. A greater in depth analysis is therefore warranted to elucidate this hypothesis. 
Oxidative phosphorylation genes 
Oxidative phosphorylation is an important biological process. Recently, dysfunctional 
oxidative phosphorylation has been shown to be driven by the commonly mutated BRAF 
oncogene (V600E), allowing malignant melanoma cells to become addicted to glycolysis 
[20]. Subsequent qRT-PCR showed that 11/15 genes were down-regulated ≥1.3 fold in 
≥1/3 cell lines (Supp Table 4). However, given that the highest fold-change was -1.6, it is 
likely that miR-4731 regulation of the pathway is of a relatively minor nature. 
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The synovial sarcoma X breakpoint family is regulated by miR-4731 
The synovial sarcoma X breakpoint family (SSX) is a cluster of cancer/testis (CT) antigens 
that have restricted expression in germ cells and is reactivated in tumours [21]. Given this 
selective expression, particularly in melanoma, it has long been suggested that they would 
be prime candidates for immunotherapeutic treatment which has now recently been shown 
in vitro to have promising results [22]. SSX2 was the first to be identified as being 
expressed in melanoma tumours (50%) [23] and in a follow-up study Gure et al [24] 
discovered that the other SSX family members were also expressed at varying levels in 
both tumour and melanoma patient-derived serum. SSX expression has also been found 
to be an early event in melanocytic neoplasia with 2/24 naevi showing nuclear staining 
[25]. 
 
Early indications that the SSX family members (SSX1-4, SSX4B, and SSX5) were 
regulated by miR-4731 can be observed in Supp Table 2, which shows that these genes 
were pulled down in 3/3 cell lines with fold changes ranging from 2.3 to 56.86. As a 
general rule, the fold change enrichment does not necessarily reflect the biological 
consequence of the binding of the biotinylated miRNA, however in these cases, all 
transcripts (except SSX5) were associated as being under transcriptional control of miR-
4731. The strongest evidence for this was with SSX4B, which was down-regulated 6 to 
85.6 fold (Supp Table 4). In MM96L and HT144, the large fold change observed was via 
ablation of the transcript, likely as a result of miR-4731 binding causing degradation of the 
message. Importantly, knockdown of SSX4 and SSX4B by siRNAs has previously been 
shown to result in marked reduction (~50%) in 2D colony formation in SK-MEL-37 
melanoma cells [26]. Strikingly, cell proliferation and migration were unaffected by the lack 
of SSX4 or SSX4B expression [26]. Furthermore, in A375 cells, induction of SSX2 
expression using a lentiviral construct (above endogenous tumour levels) led to a 
reduction of cell viability and colony formation, and induced cell cycle G1 checkpoint arrest 
[27]. SSX2 expression was further found to induce DNA damage response which 
promoted genomic instability [27]. The authors also showed that knockdown of SSX2 
expression had a similar effect to the overexpressed constructs, with cell growth being 
diminished [27]. Therefore, based on these data, the authors concluded that melanoma 
appears dependent on an optimal level of SSX2 expression [27]. Taken together, as a 
miRNAs primary function is to ‘fine-tune’ the expression of its given target gene, we 
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speculate that miR-4731 expression contributes to melanoma growth by controlling SSX 
expression levels. 
 
Conclusions 
What is apparent from the GSEA of the pulled-down miR-4731 target genes is that a single 
miRNA has the potential to have multiple effects, being involved in regulating genes 
involved in key pathways/processes related to melanocyte biology and/or melanoma. The 
identification of these enriched processes was enhanced by the use of high-throughput 
techniques such as the synthetic biotinylated miRNA-duplex pull-down procedure used 
here [6, 7] combined with an integrated network analysis programs such as STRING [12] 
which provided novel insights into our dataset. The validated pathways that we have 
highlighted, together with the commonly pulled down genes such as the SSX family, 
provide a significant insight into the role of miR-4731 in melanomagenesis. In our previous 
publication [2], we found that the expression of miR-4731 was significantly lower in tissues 
derived from stage IV patients compared with stage III tissues. These data suggests that 
miR-4731-5p may have a tumour suppressive function (with loss of a tumour suppressor 
being favourable to the metastatic tumour). As an example, the target gene, CDK4, is well 
known as potent oncogene in melanoma which is normally regulated via the tumour 
suppressor CDKN2A. Upon overexpression of miR-4731, we have shown that CDK4 
expression levels are reduced in 2/3 cell lines which is supportive of miR-4731 having a 
tumour suppressive role. Further work is warranted, to functionally validate these findings 
particularly at the protein level. In the future, we may see melanoma-related miRNAs like 
miR-4731 being used for therapeutic purposes – i.e. specifically targeted to melanoma 
with the aim of restoring miRNA levels, and in turn their interacting partners, to 
homeostasis. Finally, identification of target genes of ‘tissue-specific’ miRNAs like miR-
4731 may allow a greater understanding of the tumourigenic process, unique to each 
cancer type. Armed with this knowledge, we envisage that better tailored therapeutic 
options could be devised. 
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Materials and Methods 
Cell Culture and Total RNA extraction 
All melanoma cell lines (Supp Table 1) have been previously described [1, 28, 29]. 
Cell lines were cultured in RPMI-1640 (#31800-089, Life Technologies, Foster City, CA, 
USA) supplemented with 10% fetal bovine serum (FBS) (Life Technologies), HEPES, 100 
U/ ml penicillin and 100 µg/ml streptomycin (Life Technologies), and incubated at 37°C 
(5% CO2). All cell lines were periodically authenticated via short tandem repeat profiling 
according to the manufacturer’s instructions (AmpFISTR Profiler Plus ID kit; Life 
Technologies). 
Cells were harvested from the plate and column-purified using the miRNeasy Kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. Ethical approval 
for the study was granted by the QIMR Berghofer's Human Research Ethics Committee 
(HREC), approval number P1237. 
miScript quantitative RT-PCR validation 
Cell lines were reverse transcribed using miScript II RT Kits (QIAGEN) according to the 
manufacturer’s instructions. Real-time PCR was subsequently performed with a miScript 
SYBR Green PCR Kit (QIAGEN) using the 7900HT Fast Real Time PCR System (Life 
Technologies). Data were analysed in Microsoft Excel using the ΔCT method compared to 
RNU6 which was assessed in each sample. ΔCT values were plotted and statistical 
analysis performed in GraphPad Prism (v6.04). 
Biotin pull-downs and microarray hybridizations and data analysis 
Melanoma cell lines (MM96L, MM253, and HT144) were selected based on their high 
transfection ability together with having endogenous miR-4731 expression.  Synthetic 
biotinylated microRNA-duplexes were designed for miR-4731 (Sequence 1: 
/5Phos/rUrGrCrUrGrGrGrGrGrCrCrArCrArUrGrArGrUrGrUrG/3Bio/ Sequence 2: 
/5Phos/rCrArCrArCrArArGrUrGrGrCrCrCrCrCrArArCrArUrU) along with a scrambled 
control (Sequence 1: /5Phos/rUrArUrCrCrCrCrUrUrUrGrCrCrUrGrCrUrUrUrUrCrC/3Bio/ 
Sequence 2: /5Phos/rUrArArGrCrUrArGrArCrCrGrGrArGrGrArGrGrGrC) according to 
specifications detailed in the methodology devised by Cloonan and collegues [6, 7] (and 
optimised for melanoma cell lines [1]) and purchased from Integrated DNA Technologies 
(Coralville, USA).  
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In an effort to be inclusive, gene lists from each cell line were generated if the transcript 
occurred at an increased level (≥1.15 fold; ranged up to 51 fold) in the miR-4731 ‘pull-
down’ as compared to the Neg-Scr. Next, each gene list was compared using a Venn 
diagram in GeneSpring GX 12.5 (Agilent Technologies) to identify overlapping transcripts. 
If a transcript was present in 3/3 cell lines, it was carried forward into subsequent analysis 
(Supp Figure 1).  
Network Analysis 
Transcripts present in 3/3 cell lines were used to identify relationships amongst each gene 
along with enrichment for key signalling pathways. First, obsolete accession numbers, 
identified using Batch Entrez (http://www.ncbi.nlm.nih.gov/sites/batchentrez) were 
removed from the dataset as they were no longer associated with a bona fide gene. A list 
of unique gene names was then generated which could be imported into STRING v9.1 
(http://string-db.org/) which allowed for the identification and visualisation of known and 
predicted protein-protein interactions [12]. Enrichment for significant pathways (KEGG; 
http://www.kegg.jp/kegg/pathway.html) and GO terms (Gene Ontology; 
http://geneontology.org/) were also performed using STRING v9.1. False discovery rates 
(FDR) (i.e. corrected Bonferroni P-value) were applied against a genome-wide level, to the 
associated pathway. 
microRNA target site prediction 
All transcripts that were present in 3/3 cell lines were confirmed to be a potential target 
gene using the binding algorithm miRanda v3.3a [30] downloaded from 
http://www.microrna.org/microrna/getDownloads.do (miRanda-Aug2010 version). FASTA 
formatted sequences were obtained for miR-4731 from miRBASE 
(http://www.mirbase.org/) and target genes were identified using a batch query from the 
NCBI (http://www.ncbi.nlm.nih.gov/sites/batchentrez). The program was run using default 
conditions with exceptions (binding threshold was set to 100). TargetScan [31] (Release 
6.2: June 2012), miRDB [32], TargetMiner [33], and DIANA-microT-CDS [34] predicted 
transcripts were identified via online databases and compared to miRanda v3.3a.  
 
Criteria for selecting genes for qRT-PCR validation 
First, the host gene of miR-4731, PMP22 was selected to confirm if it was under 
transcriptional control of miR-4731. It is important to note that PMP22 was also a pull-
down target in 3/3 cell lines. Second, all genes that had ≥2 fold enrichment in 3/3 cell lines 
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(n=37) were selected. Third following the input of the 1092 unique Gene Names into 
STRING v9.1 (n=1076 were identified and present in the database), gene set enrichment 
was performed (GSEA) for KEGG pathways (cell cycle and oxidative phosphorylation), 
and the gene ontology (GO) terms: ‘Biological Process’, ‘Molecular Function’, and ‘Cellular 
Components’ (melanosomes). Significant pathways were selected based upon a priori 
relevance to melanoma and/or melanocyte biology. The significant pathways selected 
(‘cell cycle’, ‘oxidation phosphorylation’, and ‘melanosomes’) had further restrictions 
imposed in an attempt to be more stringent. I.e. all genes present in these pathways must 
have been pulled down in ≥1.5 fold, in ≥2/3 cell lines (n=43). In addition, considering the 
importance of the melanosome pathway in melanomagenesis, we selected additional 
genes (not present in the pull-down) relevant to this pathway (FSCN1, MLPH, RAB27A, 
and TYR), to observe the effect of miR-4731 overexpression.  
 
Transient transfection of miR-4731 mimic and negative scrambled control in melanoma 
cell lines 
 
Transfection conditions have been previously described [1]. miR-4731-5p mimic 
(#MSY0019853), and Negative Allstars control (#1027280; miR-NEG-scr) were purchased 
from QIAGEN. A final concentration of 5 nM of mimic Negative control were reverse-
transfected into MM96L, MM253, and HT144 (30,000 cells/6-well) using Lipofectamine® 
RNAiMAX (Life Technologies) and harvested for RNA at 72 hrs. RNA was extracted as 
previously discussed. Each biological sample was a pool of three transfected wells from a 
6-well plate from two independent experiments. 
 
Custom RT2 Profiler PCR Array 
 
First, 400 ng of RNA from duplicate biological samples (individual transfections), 
underwent cDNA synthesis using the RT2 First Strand Kit (QIAGEN) followed by qRT-PCR 
using the RT2 SYBR® Green qPCR Mastermix (QIAGEN) and the Custom RT2 Profiler 
PCR Array (QIAGEN) which contained the pre-designed primer assays for all selected 
pull-down transcripts (n=83) (Supp Table 7). The parameters were as per manufacturer’s 
instructions. The array also had the endogenous controls HPRT1, RPLP0, ACTB (also a 
target of miR-4731), GAPDH, B2M and TFRC together with controls for assessing gDNA 
contamination and technical reproducibility (triplicate wells of reverse-transcription controls 
(RTC) and a positive PCR control (PPC)). These controls allow for testing of the PCR 
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efficiency, with the replicates testing for inter-well, and intra-plate consistency. Each 384 
well plate had duplicate samples for the overexpression of miR-4731 and the negative 
control (i.e. 4 biological samples per plate). Real-Time PCR was performed using the 
ViiA™ 7 Real-Time PCR System (Life Technologies) as per manufacturer’s instructions. 
CT values were extracted using ViiA™ 7 Software v1.2.4 (Life Technologies) and analysed 
using the RT² Profiler PCR Array Data Analysis software (QIAGEN).  
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Figure Legends 
Figure 1 
miR-4731-5p expression is significantly (Mann-Whitney U-test; ****= P≤0.0001) associated 
with melanoma cell lines as compared to other solid cancers. ΔCT values are plotted 
following comparison with endogenous levels of RNU6 assessed in each sample. Error 
bars represent one SD from the mean. 
Figure 2 
Visualisation of the numerous protein-protein network connections observed after STRING 
analysis (larger font indicates genes with the most interactions with others in the geneset) 
and following subsequent enriched analysis, significant (corrected P≤0.05) pathways and 
GO terms were identified. 
Figure 3 
The ‘Cell Cycle’ KEGG pathway is represented with miR-4731 target genes (red stars). 
This highlights that miR-4731 has the potential to play a critical role in modulating cell 
cycle progression. 
 
 
 
184
Figure 1 
 
  
185
Figure 2 
 
186
)LJXUH
187
SUPPLEMENTARY MATERIAL 
The melanoma-enriched microRNA miR-4731 regulates genes 
involved in cell cycle and the melanosome 
 
Mitchell S. Stark1, 2*, Glen M. Boyle1, Vanessa F. Bonazzi2, Adrian C. Herington2, 
Pamela M. Pollock2, Nicholas K. Hayward1 
 
1.  QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, 
Australia 
2. School of Biomedical Sciences, Institute of Health and Biomedical Innovation, 
Queensland University of Technology, at the Translational Research Institute, 
Brisbane, QLD 4102, Australia 
 
 
 
 
 
 
* Corresponding author 
Mitchell Stark 
QIMR Berghofer Medical Research Institute 
Herston, Brisbane, QLD 4029, Australia. 
Tel: +61733620323 
Fax: +61738453508 
Email: mitchell.stark@qimr.edu.au 
188
SUPPLEMENTARY TABLE LEGENDS 
Supplementary Table 1  
Summary of all cell line names and associated tissue type that were used in the 
discovery (microarray) [1] and validation cohorts (qRT-PCR). 
Supplementary Table 2 
Unique transcripts common in 3/3 cell lines derived from GeneSpring 12.5 GX 
analysis. ‘PULL-DOWN DATA’ shows the respective fold changes in each cell line 
relative to the negative control mimic.  
Supplementary Table 3 
Significant (corrected P≤0.05) KEGG pathways and GO Terms (Biological Process, 
Molecular Function, and Cellular Component) were found following GSEA using 
STRING v9.1 analysis [2]. 
Supplementary Table 4 
The ‘RATIONALE FOR VALIDATION’ is noted together with the ‘qRT-PCR 
VALIDATION’ fold changes for each cell line. 
Supplementary Table 5 
Summarises the genes that were; down regulated in 3/3 (n=19), 2/3 (n=12) and 1/3 
(n=19); both up and down regulated (n=5); up regulated (n=5); and no observable 
change at the mRNA level (≤1.2 fold up or down regulated) (n=21). A relationship 
(based upon Pubmatrix searches) with ‘Melanoma’ and ‘Cancer’ is noted as ‘Novel’ 
or Y (Yes or Known). 
Supplementary Table 6 
Respective fold-changes observed in MM96L, MM253, and HT144 in melanosome-
related genes upon overexpression with miR-4731 (relative to negative control). All 
genes list are not direct targets of miR-4731, as such are downstream of its 
regulation. 
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Supplementary Table 7 
Assay IDs (QIAGEN) used for qRT-PCR validation. 
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SUPPLEMENTARY FIGURE LEGENDS 
SUPPLEMENTARY FIGURE 1 
Venn diagram showing the overlap of genes pulled-down in 3/3 cell lines. 
SUPPLEMENTARY FIGURE 2 
Endogenous expression (Neg) of miR-4731 is low in MM96L, MM253, and HT144 
and is highly expressed upon transient overexpression with a miR-4731 mimic (miR-
4731).  
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SUPPLEMENTARY FIGURE 1 
 
 
192
SUPPLEMENTARY FIGURE 2 
  
193
References 
 
1. Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan C, 
Schimdt C, Herington A, Ballotti R, Pollock PM and Hayward NK. miR-514a 
regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. 
Oncotarget. 2015; (Advance Publications). 
2. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin 
J, Minguez P, Bork P, von Mering C and Jensen LJ. STRING v9.1: protein-protein 
interaction networks, with increased coverage and integration. Nucleic Acids Res. 
2013; 41(Database issue):D808-815. 
 
194
Sample ID Type Cohort qRT PCR validation
C001 Melanoma Discovery Yes
C002 Melanoma Discovery Yes
C003 Melanoma Discovery Yes
C004 Melanoma Discovery Yes
C006 Melanoma Discovery Yes
C008 Melanoma Discovery Yes
C011 Melanoma Discovery Yes
C012 Melanoma Discovery Yes
C013 Melanoma Discovery Yes
C016 Melanoma Discovery Yes
C017 Melanoma Discovery Yes
C021 Melanoma Discovery Yes
C022 M l Di Ye anoma scovery es
C025 Melanoma Discovery Yes
C027 Melanoma Discovery Yes
C028 Melanoma Discovery Yes
C037 Melanoma Discovery Yes
C038 Melanoma Discovery Yes
C042 Melanoma Discovery Yes
C043 Melanoma Discovery Yes
C044 Melanoma Discovery Yes
C045 Melanoma Discovery Yes
C050 Melanoma Discovery Yes
C052 Melanoma Discovery Yes
C054 Melanoma Discovery Yes
C057 Melanoma Discovery Yes
C058 Melanoma Discovery Yes
C060 Melanoma Discovery Yes
C062 Melanoma Discovery Yes
C065 Melanoma Discovery Yes
C067 Melanoma Discovery Yes
C071 Melanoma Discovery Yes
C074 Melanoma Discovery Yes
C076 Melanoma Discovery Yes
C077 Melanoma Discovery Yes
C078 Melanoma Discovery Yes
C079 Melanoma Discovery Yes
C080 Melanoma Discovery Yes
C081 Melanoma Discovery Yes
C083 Melanoma Discovery Yes
C084 Melanoma Discovery Yes
C086 Melanoma Discovery Yes
C088 Melanoma Discovery Yes
C089 Melanoma Discovery Yes
C091 Melanoma Discovery Yes
C092 Melanoma Discovery Yes
C094 Melanoma Discovery Yes
C096 Melanoma Discovery Yes
C097 Melanoma Discovery Yes
C100 Melanoma Discovery Yes
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Sample ID Type Cohort qRT PCR validation
C106 Melanoma Discovery Yes
C108 Melanoma Discovery Yes
A02 Melanoma Discovery Yes
A04 Melanoma Discovery Yes
A06 Melanoma Validation Yes
A13 Melanoma Validation Yes
A15 Melanoma Validation Yes
AF6 Melanoma Validation Yes
C‐32 Melanoma Validation Yes
CJM Melanoma Validation Yes
D01 Melanoma Validation Yes
D04 Melanoma Validation Yes
D05 M l V lid ti Ye anoma a a on es
D08 Melanoma Validation Yes
D10 Melanoma Validation Yes
D11 Melanoma Validation Yes
D14 Melanoma Validation Yes
D17 Melanoma Validation Yes
D20 Melanoma Validation Yes
D22 Melanoma Validation Yes
D24 Melanoma Validation Yes
D25 Melanoma Validation Yes
D28 Melanoma Validation Yes
D29 Melanoma Validation Yes
D32 Melanoma Validation Yes
D35 Melanoma Validation Yes
D36 Melanoma Validation Yes
D40 Melanoma Validation Yes
D41 Melanoma Validation Yes
D59 Melanoma Discovery Yes
HT144 Melanoma Validation Yes
MM127 Melanoma Validation Yes
MM200 Melanoma Validation Yes
MM229 Melanoma Validation Yes
MM253 Melanoma Validation Yes
MM329 Melanoma Validation Yes
MM370 Melanoma Validation Yes
MM386 Melanoma Validation Yes
MM415 Melanoma Validation Yes
MM426 Melanoma Validation Yes
MM466 Melanoma Validation Yes
MM473 Melanoma Validation Yes
MM485 Melanoma Validation Yes
MM537 Melanoma Validation Yes
MM540 Melanoma Validation Yes
MM548 Melanoma Validation Yes
MM649 Melanoma Validation Yes
MM96L Melanoma Validation Yes
SKMEL28 Melanoma Validation Yes
SKMEL5 Melanoma Validation Yes
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Sample ID Type Cohort qRT PCR validation
BT474 Other(BREAST) Discovery Yes
MCF‐7 Other(BREAST) Discovery Yes
MDAMB231 Other(BREAST) Discovery Yes
SKBR3 Other(BREAST) Discovery Yes
T47D Other(BREAST) Discovery Yes
Co115 Other(COLORECTAL) Discovery Yes
HT29 Other(COLORECTAL) Discovery Yes
LIM1899 Other(COLORECTAL) Discovery Yes
LIM2405 Other(COLORECTAL) Discovery Yes
SW48 Other(COLORECTAL) Discovery Yes
LN‐18 Other(GLIOMA) Discovery Yes
T46 Other(GLIOMA) Discovery Yes
T50 Oth (GLIOMA) Di Yer scovery es
U118 Other(GLIOMA) Discovery Yes
CaOV‐3 Other(OVARIAN) Discovery Yes
OAW28 Other(OVARIAN) Discovery Yes
OVCAR‐3 Other(OVARIAN) Discovery Yes
PE04 Other(OVARIAN) Discovery Yes
SK‐OV‐3 Other(OVARIAN) Discovery Yes
BxPC‐3 Other(PANCREATIC) Discovery Yes
CAPAN‐1 Other(PANCREATIC) Discovery Yes
CAPAN‐2 Other(PANCREATIC) Discovery Yes
PANC‐1 Other(PANCREATIC) Discovery Yes
PL45 Other(PANCREATIC) Discovery Yes
22rV‐1 Other(PROSTATE) Discovery Yes
ALVA‐1 Other(PROSTATE) Discovery Yes
Du145 Other(PROSTATE) Discovery Yes
LNCAP Other(PROSTATE) Discovery Yes
PC‐3 Other(PROSTATE) Discovery Yes
786‐O Other(RENAL) Discovery Yes
CAKI‐1 Other(RENAL) Discovery Yes
CAKI‐2 Other(RENAL) Discovery Yes
SN12K‐1 Other(RENAL) Discovery Yes
SW839 Other(RENAL) Discovery Yes
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RefSeq Accession Gene Name MM96L Fold Change Upregulated vs SCR Control
MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_153321 PMP22 1.92 1.36 1.95
NM_001101 ACTB 3.25 2.30 2.58
NM_001136 AGER 2.38 2.66 15.71
NM_020959 ANO8 2.93 3.97 3.19
NM_020531 C20orf3 5.02 2.25 12.40
NM_018584 CAMK2N1 5.88 3.65 14.34
NM_207352 CYP4V2 3.49 3.12 14.62
NM_024819 DCAKD 7.93 2.70 11.34
NM_021923 FGFRL1 7.31 5.13 21.68
NM_005476 GNE 6.82 4.45 12.92
NM_013434 KCNIP3 4.39 2.12 7.59
NM_005780 LHFP 7.39 4.12 11.75
NM_032485 MCM8 11.70 7.39 23.46
NM_001014839 NCDN 4.61 2.62 10.48
NM_001004720 NCK2 5.48 2.19 9.79
NM_032569 N‐PAC 6.17 3.54 6.86
NM_148906 OSBPL9 4.04 2.50 4.83
NM_016395 PTPLAD1 5.32 2.18 5.36
NM_005669 REEP5 15.38 2.58 33.05
NM_005866 SIGMAR1 21.26 7.31 23.13
NM_014096 SLC43A3 6.57 2.32 7.57
NM_003068 SNAI2 6.78 2.35 6.13
NM_004782 SNAP29 24.53 4.52 15.08
NM_003100 SNX2 8.69 13.49 9.80
NM_003795 SNX3 3.56 2.07 4.84
NM_024592 SRD5A3 4.83 2.41 9.01
NM_005635 SSX1 30.09 17.27 20.15
NM_003147 SSX2 3.77 2.30 12.20
NM_021014 SSX3 21.31 12.63 21.20
NM_005636 SSX4 10.73 4.53 56.86
NM_001034832 SSX4B 26.76 15.95 26.36
NM_021015 SSX5 19.38 17.50 29.72
NM_014178 STXBP6 3.69 2.25 6.61
NM_001039141 TRIOBP 8.76 4.70 16.45
NM_145049 UBLCP1 10.02 4.25 12.22
NM_006297 XRCC1 3.78 3.47 12.58
NM_003435 ZNF134 2.90 2.96 8.86
NM_080603 ZSWIM1 9.72 4.87 25.25
NM_015391 ANAPC13 2.02 1.23 2.03
NM_001007793 BUB3 2.24 1.30 1.57
NM_001237 CCNA2 2.05 1.26 1.83
NM_001760 CCND3 1.70 1.23 2.24
NM_003504 CDC45L 2.27 1.27 4.58
NM_001798 CDK2 2.54 1.87 2.15
NM_000075 CDK4 2.19 1.39 2.72
NM_001429 EP300 2.26 1.37 2.88
NM_006341 MAD2L2 1.56 1.20 1.63
NM_002553 ORC5L 2.49 1.23 2.24
NM_182649 PCNA 3.17 1.65 2.46
NM_006930 SKP1A 1.78 1.23 1.51
NM_007111 TFDP1 1.56 1.34 1.67
NM_001909 CTSD 2.15 1.50 2.59
NM_004104 FASN 3.21 1.23 2.02
NM_003878 GGH 2.47 1.52 1.73
NM_006572 GNA13 2.38 1.41 1.91
NM_001005340 GPNMB 2.84 1.62 2.49
NM_005561 LAMP1 1.87 1.47 1.78
NM_000259 MYO5A 1.58 1.28 1.20
NM_181696 PRDX1 2.01 1.39 1.56
NM_201434 RAB5C 1.77 1.17 2.15
NM_004637 RAB7A 10.44 2.58 4.59
NM_006908 RAC1 2.38 1.36 2.35
NM_006325 RAN 1.96 1.57 1.76
NM_004099 STOM 2.48 1.36 2.07
NM_006754 SYPL1 2.05 1.25 1.81
NM_003234 TFRC 1.91 1.30 1.73
NM_004046 ATP5A1 2.36 1.33 1.52
NM_005176 ATP5G2 2.45 1.28 2.15
NM_001003785 ATP5H 1.58 1.26 1.58
PULL‐DOWN DATA
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RefSeq Accession Gene Name MM96L Fold Change Upregulated vs SCR Control
MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_001697 ATP5O 1.54 1.42 2.16
NM_004691 ATP6V0D1 1.95 1.35 1.88
NM_145230 ATP6V0E2 2.15 1.22 2.24
NM_001690 ATP6V1A 2.68 1.36 1.99
NM_001303 COX10 2.16 1.23 1.95
NM_004074 COX8A 1.67 1.23 2.14
NM_005003 NDUFAB1 2.32 1.56 2.25
NM_019056 NDUFB11 1.68 1.19 2.97
NM_002492 NDUFB5 2.13 1.33 2.43
NM_176866 PPA2 2.01 1.31 1.95
NM_003002 SDHD 2.04 1.27 1.69
NM_006003 UQCRFS1 2.57 1.47 2.34
NM_005174 ATP5C1 1.62 1.50 1.37
NM_002495 NDUFS4 1.43 1.66 1.56
NM_004725 BUB3 1.72 1.26 2.03
NM_002510 GPNMB 2.14 1.32 1.81
NM_004583 RAB5C 2.10 1.25 2.34
NM_182715 SYPL1 2.68 1.43 1.73
NM_022662 ANAPC1 1.45 1.23 1.63
NM_004336 BUB1 1.52 1.24 1.29
NM_001239 CCNH 1.57 1.19 1.31
NM_001078645 CDC16 1.24 1.19 1.33
NM_003903 CDC16 1.21 1.17 1.34
NM_004358 CDC25B 1.43 1.19 1.74
NM_004526 MCM2 1.48 1.26 1.48
NM_006739 MCM5 1.42 1.21 1.48
NM_005915 MCM6 1.87 1.36 1.28
NM_002467 MYC 2.25 1.22 1.44
NM_182687 PKMYT1 1.35 1.42 1.90
NM_006265 RAD21 1.25 1.62 1.24
NM_139323 YWHAB 2.21 1.40 1.17
NM_001679 ATP1B3 1.40 1.35 1.68
NM_001007067 SDCBP 1.94 1.41 1.18
NM_005628 SLC1A5 1.32 1.20 1.47
NM_006516 SLC2A1 1.47 1.23 1.42
NM_001013251 SLC3A2 1.35 1.29 1.17
NM_006356 ATP5H 1.33 1.22 1.33
NM_001039457 ATP6V0B 1.89 1.35 1.42
NM_001867 COX7C 1.25 1.24 1.65
NM_002489 NDUFA4 1.24 1.21 2.00
NM_003000 SDHB 1.47 1.22 1.51
NM_001693 ATP6V1B2 1.91 1.27 1.34
NM_015665 AAAS 1.26 1.29 1.34
NM_182662 AADAT 1.18 1.17 1.58
NM_005692 ABCF2 1.42 1.32 1.66
NM_001042472 ABHD12 1.31 1.19 1.19
NM_152924 ABHD2 1.23 1.15 1.32
NM_022060 ABHD4 1.24 1.18 1.43
NM_020676 ABHD6 1.28 1.22 1.56
NM_001092 ABR 2.07 1.73 2.93
NM_022914 ACD 1.79 1.29 2.03
NM_001096 ACLY 1.75 1.42 1.51
NM_001098 ACO2 1.38 1.24 1.33
NM_007274 ACOT7 2.47 1.26 1.43
NM_007099 ACP1 1.41 1.20 1.45
NM_001040649 ACP1 1.30 1.42 1.59
NM_001614 ACTG1 2.13 1.98 1.80
NM_001102 ACTN1 1.87 1.18 1.52
NM_138289 ACTRT1 1.90 1.50 2.61
NM_001105 ACVR1 1.67 1.20 2.00
NM_000666 ACY1 1.65 1.44 1.28
NM_015840 ADAR 1.72 1.19 2.59
NM_001111 ADAR 1.89 1.28 2.97
NM_021116 ADCY1 1.64 1.24 1.37
NM_001116 ADCY9 1.39 1.20 1.51
NM_015999 ADIPOR1 1.99 1.20 1.37
NM_181442 ADNP 1.50 1.17 1.36
NM_014913 ADNP2 1.44 1.27 1.53
NM_018238 AGK 1.62 1.40 1.76
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RefSeq Accession Gene Name MM96L Fold Change Upregulated vs SCR Control
MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_006411 AGPAT1 2.06 1.27 1.64
NM_001040194 AGTRAP 1.45 1.19 1.23
NM_006303 AIMP2 1.85 1.19 1.17
NM_001625 AK2 1.41 1.25 1.65
NM_018064 AKIRIN2 2.06 1.25 1.55
NM_001628 AKR1B1 1.49 1.21 1.43
NM_003689 AKR7A2 1.52 1.33 1.66
NM_012067 AKR7A3 1.63 1.42 1.72
NM_184041 ALDOA 2.34 1.36 2.10
NM_184043 ALDOA 2.48 1.29 2.38
NM_005165 ALDOC 2.46 1.28 1.72
NM_001007027 ALG8 1.50 1.20 1.30
NM_001097577 ANG 2.04 1.36 3.27
NM_019004 ANKIB1 1.67 1.32 2.11
NM_182608 ANKRD33 2.57 1.21 2.02
NM_001039888 ANKRD34A 1.27 1.26 1.70
NM_015245 ANKS1A 1.22 1.16 2.02
NM_001154 ANXA5 2.96 1.36 1.91
NM_004069 AP2S1 1.77 1.60 1.48
NM_014481 APEX2 1.75 1.19 1.53
NM_144772 APOA1BP 1.74 1.26 2.26
NM_024122 APOO 1.73 1.50 1.37
NM_000485 APRT 1.38 1.39 1.61
NM_001655 ARCN1 1.94 1.16 1.19
NM_001024227 ARF1 1.76 1.25 1.63
NM_001024228 ARF1 1.40 1.26 1.67
NM_001660 ARF4 2.89 1.43 2.13
NM_004308 ARHGAP1 2.27 1.24 2.09
NM_139135 ARID1A 1.53 1.52 2.01
NM_152641 ARID2 1.46 1.15 1.32
NM_012106 ARL2BP 2.31 1.19 1.73
NM_015161 ARL6IP1 2.31 1.31 1.22
NM_018184 ARL8B 2.30 1.40 2.25
NM_031905 ARMC10 1.49 1.36 1.41
NM_001024959 ARPC4 1.71 1.31 1.55
NM_006628 ARPP19 2.05 1.20 1.30
NM_032810 ATAD1 1.41 1.16 1.16
NM_001880 ATF2 1.28 1.24 1.30
NM_015104 ATG2A 1.16 1.31 1.49
NM_001077198 ATG9A 1.46 1.16 3.15
NM_004044 ATIC 1.61 1.18 1.55
NM_015251 ATMIN 1.54 1.22 2.08
NM_004045 ATOX1 1.82 1.27 2.55
NM_022089 ATP13A2 1.26 1.16 1.29
NM_001677 ATP1B1 1.64 1.17 1.44
NM_018035 ATP5SL 3.50 1.52 4.07
NM_005765 ATP6AP2 2.44 1.29 1.31
NM_000054 AVPR2 1.36 1.16 1.27
NM_004048 B2M 1.29 1.30 1.23
NM_006876 B3GNT6 1.41 1.27 1.28
NM_003779 B4GALT3 1.53 1.32 1.72
NM_138992 BACE2 1.92 1.23 2.04
NM_018842 BAIAP2L1 1.34 1.19 1.59
NM_080686 BAT2 1.29 1.16 2.17
NM_080703 BAT3 1.82 1.19 1.70
NM_080702 BAT3 1.32 1.32 1.85
NM_001190 BCAT2 1.39 1.24 1.60
NM_005881 BCKDK 1.85 1.28 2.12
NM_138578 BCL2L1 2.07 1.30 1.62
NM_017745 BCOR 1.45 1.17 1.43
NM_016561 BFAR 2.17 1.44 1.45
NM_001031827 BOLA2 1.48 1.20 1.37
NM_015201 BOP1 1.52 1.19 1.49
NM_199191 BRE 2.05 1.32 1.57
NM_199192 BRE 1.79 1.32 1.70
NM_015379 BRI3 1.36 1.29 1.51
NM_015695 BRPF3 1.19 1.24 1.53
NM_001007246 BRWD1 1.54 1.32 1.56
NM_001011885 BTBD1 1.71 1.18 1.26
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MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_017797 BTBD2 1.56 1.27 2.11
NM_014962 BTBD3 1.34 1.26 1.54
NM_001731 BTG1 1.48 1.17 1.23
NM_006806 BTG3 1.93 1.25 1.18
NM_147147 BVES 5.22 1.79 13.55
NM_014038 BZW2 1.59 1.35 1.25
NM_025125 C10orf57 1.21 1.19 1.57
NM_014206 C11orf10 1.49 1.26 2.57
NM_022338 C11orf24 1.49 1.17 1.67
NM_145018 C11orf82 1.43 1.23 1.45
NM_024738 C12orf49 2.06 1.16 1.23
NM_025138 C13orf23 1.49 1.17 1.72
NM_001071775 C13orf37 1.83 1.24 2.18
NM_016468 C14orf112 1.39 1.31 2.16
NM_080664 C14orf126 1.18 1.19 1.29
NM_016472 C14orf129 1.31 1.19 1.47
NM_022495 C14orf135 1.33 1.23 1.32
NM_031210 C14orf156 1.28 1.29 2.14
NR_023922 C14orf167 1.91 1.19 2.05
NR_023921 C14orf167 1.21 1.20 1.44
NM_004894 C14orf2 1.28 1.16 1.66
NM_015492 C15orf39 1.60 1.18 1.60
NM_032499 C15orf41 2.03 1.34 2.15
NM_052849 C15orf57 3.81 1.24 2.35
NM_001080791 C15orf57 2.15 1.28 2.73
NM_001039476 C16orf35 1.51 1.29 2.50
NM_024598 C16orf57 1.83 1.18 1.71
NM_024683 C17orf42 1.16 1.16 1.17
NM_001077498 C17orf63 1.68 1.18 1.65
NM_018149 C17orf71 1.53 1.27 1.36
NM_001008239 C18orf25 1.60 1.18 1.47
NM_013326 C18orf8 1.54 1.24 1.23
NM_024069 C19orf50 1.55 1.20 1.45
NM_016145 C19orf56 1.51 1.27 2.06
NM_207356 C1orf174 1.50 1.23 1.28
NM_032324 C1orf57 1.16 1.25 1.18
NM_144580 C1orf85 2.02 1.39 1.97
NM_182533 C1orf86 1.29 1.29 2.31
NM_152371 C1orf93 1.19 1.21 1.16
NM_001212 C1QBP 2.36 1.40 2.09
NM_016470 C20orf111 1.19 1.47 1.76
NM_199181 C20orf117 1.30 1.22 1.78
NM_199483 C20orf24 1.43 1.17 1.20
NM_018840 C20orf24 1.23 1.17 1.31
NM_001039140 C20orf27 1.62 1.18 1.58
NM_001009923 C20orf30 2.11 1.34 1.91
NM_001009924 C20orf30 1.94 1.41 1.94
NM_032261 C21orf56 1.19 1.23 1.49
NM_031444 C22orf13 1.86 1.22 1.82
NM_015680 C2orf24 1.34 1.26 1.16
NM_015702 C2orf25 1.80 1.30 1.52
NM_080592 C2orf28 1.60 1.15 1.35
NM_021925 C2orf43 1.30 1.21 1.28
NM_025203 C2orf44 1.66 1.26 1.53
NM_024520 C2orf47 1.91 1.36 1.23
NM_001013663 C2orf79 3.54 1.88 10.04
NM_152531 C3orf21 1.51 1.33 1.92
NM_173654 C3orf64 1.91 1.85 3.17
NM_032313 C4orf14 1.70 1.31 1.27
NM_016613 C4orf18 1.70 1.26 1.50
NM_018356 C5orf22 1.95 1.31 1.19
NM_032412 C5orf32 1.48 1.32 1.88
NM_032385 C5orf4 3.17 1.39 6.17
NM_175921 C5orf51 2.50 1.54 2.04
NM_001008704 C6orf1 1.83 1.33 2.84
NM_052831 C6orf192 1.27 1.23 1.34
NM_030939 C6orf62 1.66 1.29 1.40
NM_024315 C7orf23 1.17 1.18 1.16
NM_138446 C7orf30 1.65 1.47 1.80
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NM_017994 C7orf42 1.81 1.22 1.51
NM_053279 C8orf13 2.53 1.28 1.71
NM_023080 C8orf33 1.81 1.36 1.49
NM_016446 C9orf127 1.19 1.16 1.44
NM_153045 C9orf91 1.68 1.31 1.35
NM_138793 CANT1 1.43 1.33 1.52
NM_006366 CAP2 1.97 1.34 1.55
NM_001749 CAPNS1 2.26 1.32 1.81
NM_004930 CAPZB 1.74 1.29 1.53
NM_007359 CASC3 3.45 1.77 18.19
NM_032983 CASP2 1.26 1.29 1.50
NM_032982 CASP2 1.50 1.28 1.95
NM_001753 CAV1 2.40 1.25 1.83
NM_003655 CBX4 1.20 1.18 1.32
NM_199246 CCNG1 1.74 1.24 1.38
NM_006835 CCNI 4.37 1.38 3.59
NM_139029 CD151 1.42 1.18 1.38
NM_001039490 CD151 1.30 1.20 1.40
NM_139030 CD151 1.28 1.20 1.89
NM_006016 CD164 1.82 1.36 1.23
NM_001024736 CD276 1.61 1.31 1.94
NM_001001392 CD44 1.94 1.28 1.68
NM_001779 CD58 1.60 1.18 1.42
NM_000611 CD59 1.25 1.23 1.23
NM_004356 CD81 2.59 1.23 1.99
NM_078481 CD97 1.23 1.17 1.68
NM_080668 CDCA5 1.32 1.39 2.03
NM_003818 CDS2 1.72 1.16 1.20
NM_001024912 CEACAM1 1.27 2.03 1.27
NM_001042426 CENPA 1.69 1.23 1.67
NM_018132 CENPQ 1.49 1.26 1.32
NM_014914 CENTG2 1.57 1.25 1.24
NM_005441 CHAF1B 1.44 1.26 1.46
NM_213720 CHCHD10 1.96 1.21 2.89
NM_016139 CHCHD2 2.56 1.29 2.12
NM_005197 CHES1 6.20 1.75 5.96
NM_004067 CHN2 1.34 1.26 1.16
NM_017444 CHRAC1 1.85 1.26 1.30
NM_130468 CHST14 1.56 1.21 1.72
NM_032830 CIRH1A 2.27 1.36 2.49
NM_018464 CISD1 1.62 1.24 1.26
NM_006079 CITED2 1.48 1.17 1.20
NM_001008938 CKAP5 1.24 1.17 1.29
NM_001823 CKB 1.22 1.27 2.34
NM_001015001 CKMT1A 1.36 1.26 1.19
NM_001826 CKS1B 1.69 1.24 1.72
NM_001827 CKS2 1.49 1.61 2.04
NM_012129 CLDN12 1.59 1.31 1.37
NM_001040181 CLDND1 2.09 1.26 1.42
NM_015226 CLEC16A 1.28 1.22 1.54
NM_015526 CLIP3 1.34 1.19 1.79
NM_000086 CLN3 1.15 1.19 1.35
NM_001293 CLNS1A 1.53 1.22 1.26
NM_001294 CLPTM1 2.04 1.26 2.46
NM_052995 CLRN1 1.48 1.23 1.56
NM_181472 CMTM7 2.06 1.26 3.76
NM_178868 CMTM8 2.04 1.30 2.29
NM_018235 CNDP2 1.73 1.16 1.15
NM_005776 CNIH 1.58 1.40 1.89
NM_201277 CNN2 3.56 1.27 4.74
NM_017623 CNNM3 1.21 1.19 1.35
NM_018366 CNO 1.22 1.38 1.67
NM_014516 CNOT3 1.33 1.15 1.30
NM_013354 CNOT7 1.84 1.23 1.18
NM_004779 CNOT8 1.60 1.21 1.31
NM_016094 COMMD2 1.47 1.40 1.19
NM_014186 COMMD9 1.77 1.19 1.65
NM_007310 COMT 1.35 1.28 1.34
NM_016451 COPB1 1.92 1.17 1.52
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NM_199444 COPE 1.44 1.18 1.20
NM_016128 COPG 1.48 1.34 1.42
NM_022730 COPS7B 1.18 1.17 1.68
NM_006710 COPS8 2.07 1.31 1.61
NM_021149 COTL1 1.87 1.24 2.01
NM_004373 COX6A1 1.32 1.22 2.70
NM_001304 CPD 1.36 1.15 1.44
NM_003909 CPNE3 1.87 1.16 1.19
NM_194071 CREB3L2 5.53 1.76 7.10
NM_182898 CREB5 1.33 1.32 1.47
NM_003851 CREG1 2.60 1.38 2.49
NM_019095 CRLS1 1.54 1.23 1.21
NM_006371 CRTAP 2.64 1.47 2.72
NM_004077 CS 2.14 1.18 2.20
NM_001316 CSE1L 3.32 1.58 3.34
NM_004383 CSK 1.88 1.22 2.14
NM_001895 CSNK2A1 1.49 1.27 1.62
NM_001896 CSNK2A2 1.42 1.20 1.29
NM_000099 CST3 1.92 1.35 2.55
NM_000100 CSTB 1.82 1.27 2.01
NM_021198 CTDSP1 1.49 1.18 1.59
NM_005730 CTDSP2 1.61 1.34 2.14
NM_000308 CTSA 1.26 1.24 1.55
NM_001814 CTSC 1.41 1.60 1.16
NM_004390 CTSH 1.56 1.24 1.47
NM_206833 CTXN1 1.70 1.15 1.39
NM_003591 CUL2 1.34 1.29 1.48
NM_001014840 CUTA 1.63 1.19 1.62
NM_001014838 CUTA 2.20 1.39 1.89
NM_001122716 CXorf64 1.60 1.28 1.20
NM_016243 CYB5R1 1.47 1.30 1.68
NM_007326 CYB5R3 3.04 1.26 2.20
NM_153611 CYBASC3 1.72 1.16 1.45
NM_014376 CYFIP2 2.09 1.18 1.73
NM_177538 CYP20A1 1.34 1.29 1.53
NM_001343 DAB2 2.01 1.16 1.40
NM_145056 DACT3 1.22 1.18 1.52
NM_001344 DAD1 2.20 1.29 1.91
NM_014764 DAZAP2 2.44 1.38 1.76
NM_005828 DCAF7 2.03 1.21 1.66
NM_016221 DCTN4 1.72 1.27 1.53
NM_012137 DDAH1 2.12 1.17 1.40
NM_003887 DDEF2 1.20 1.41 1.78
NM_013993 DDR1 1.18 1.17 1.66
NM_001355 DDT 1.57 1.28 1.79
NM_016355 DDX47 1.42 1.34 1.25
NM_133328 DEDD2 2.10 1.31 2.39
NM_003676 DEGS1 1.94 1.29 1.68
NM_017779 DEPDC1 1.48 1.19 1.26
NM_018369 DEPDC1B 1.45 1.22 1.32
NM_024295 DERL1 1.82 1.15 1.42
NM_080916 DGUOK 1.59 1.22 1.97
NM_001358 DHX15 1.44 1.36 1.71
NM_014473 DIMT1L 1.76 1.29 1.42
NM_173602 DIP2B 1.98 1.29 1.75
NM_016941 DLL3 1.49 1.29 1.85
NM_006145 DNAJB1 1.38 1.25 1.65
NM_012266 DNAJB5 1.24 1.25 1.31
NM_018981 DNAJC10 1.17 1.18 1.17
NM_013238 DNAJC15 2.54 1.56 3.71
NM_052951 DNTTIP1 1.35 1.23 1.38
NM_033407 DOCK7 2.17 1.20 1.25
NM_020438 DOLPP1 1.45 1.16 1.51
NM_017613 DONSON 1.30 1.16 1.51
NM_206831 DPH3 1.15 1.35 1.60
NM_001047434 DPH3 1.18 1.32 1.66
NM_006052 DSCR3 1.47 1.36 1.59
NM_001943 DSG2 1.48 1.22 1.25
NM_015343 DULLARD 2.05 1.35 4.09
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NM_003584 DUSP11 1.76 1.41 1.36
NM_007026 DUSP14 1.82 1.37 2.12
NM_001025249 DUT 1.91 1.18 1.51
NM_017653 DYM 2.17 1.18 1.42
NM_014183 DYNLRB1 1.56 1.36 1.90
NM_024680 E2F8 1.32 1.15 1.94
NM_007265 ECD 1.54 1.28 1.17
NM_004092 ECHS1 1.86 1.26 1.58
NM_018098 ECT2 1.17 1.47 1.68
NM_021783 EDA2R 1.96 1.44 1.26
NM_014674 EDEM1 1.89 1.24 1.65
NM_000115 EDNRB 1.57 1.45 1.19
NM_001402 EEF1A1 2.06 1.71 1.46
NM_004429 EFNB1 1.64 1.44 2.54
NM_004247 EFTUD2 1.57 1.23 1.46
NM_005801 EIF1 1.61 1.33 1.71
NM_005875 EIF1B 1.62 1.30 1.44
NM_001414 EIF2B1 1.74 1.29 1.97
NM_012199 EIF2C1 1.21 1.30 1.28
NM_003754 EIF3F 2.16 1.89 2.98
NM_013234 EIF3K 1.92 1.42 1.70
NM_016091 EIF3L 1.88 1.32 1.60
NM_006360 EIF3M 2.25 1.93 1.85
NM_001416 EIF4A1 2.06 1.23 1.45
NM_004096 EIF4EBP2 1.84 1.20 1.39
NM_001418 EIF4G2 2.01 1.43 1.68
NM_005229 ELK1 2.05 1.30 1.69
NM_021204 ENOPH1 1.80 1.39 1.18
NM_001430 EPAS1 1.32 1.18 1.18
NM_005702 ERAL1 1.81 1.18 2.41
NM_198398 ERGIC3 1.53 1.33 1.74
NM_153332 ERI1 1.38 1.26 1.35
NM_001017420 ESCO2 2.94 1.37 3.62
NM_015292 ESYT1 1.43 1.23 3.21
NM_001986 ETV4 1.67 1.35 2.15
NM_004454 ETV5 1.98 1.23 2.01
NM_018199 EXD2 1.18 1.21 1.22
NM_000401 EXT2 1.48 1.34 1.54
NM_001439 EXTL2 1.46 1.22 1.60
NM_012151 F8A1 1.48 1.16 1.31
NM_005449 FAIM3 2.00 1.23 1.81
NM_173511 FAM117B 2.90 1.33 2.68
NM_033446 FAM125B 1.32 1.18 1.44
NM_001078171 FAM127A 2.11 1.26 2.13
NM_001078172 FAM127B 1.56 1.18 2.21
NM_032648 FAM167B 1.40 1.24 1.53
NM_032042 FAM172A 1.24 1.16 1.16
NM_006589 FAM189B 1.93 1.48 3.00
NM_024792 FAM57A 1.70 1.40 2.32
NM_001135811 FAM60A 1.50 1.74 1.44
NM_024519 FAM65A 1.19 1.24 2.46
NM_030919 FAM83D 2.04 1.24 1.86
NM_024622 FASTKD1 1.35 1.19 1.21
NM_014929 FASTKD2 1.33 1.22 1.19
NM_024091 FASTKD3 1.23 1.28 1.23
NM_024963 FBXL18 1.71 1.30 1.78
NM_032875 FBXL20 1.75 1.20 2.93
NM_015176 FBXO28 1.55 1.18 1.32
NM_001033024 FBXO7 1.66 1.43 2.36
NM_004462 FDFT1 1.80 1.23 1.20
NM_018708 FEM1A 2.05 1.20 1.92
NM_015322 FEM1B 1.48 1.20 1.27
NM_005102 FEZ2 1.49 1.27 1.40
NM_004463 FGD1 1.47 1.19 1.59
NM_002006 FGF2 1.19 1.30 1.37
NM_001004358 FGFRL1 2.58 3.12 17.07
NM_201557 FHL2 1.85 1.73 2.36
NM_201555 FHL2 1.42 1.49 1.80
NM_004214 FIBP 1.99 1.31 1.86
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NM_000801 FKBP1A 2.26 1.24 1.79
NM_054014 FKBP1A 1.58 1.20 1.67
NM_152424 FLJ39827 3.34 1.31 5.39
NM_024619 FN3KRP 1.27 1.19 1.57
NM_001079673 FNDC3A 1.42 1.33 1.46
NM_001135095 FNDC3B 1.97 1.63 2.33
NM_022763 FNDC3B 2.27 1.77 2.45
NM_005252 FOS 1.30 1.24 1.66
NM_004472 FOXD1 1.79 1.18 1.72
NM_014947 FOXJ3 1.24 1.17 1.31
NM_002158 FOXN2 1.91 1.44 1.80
NM_001085471 FOXN3 1.82 1.42 1.47
NM_024955 FOXRED2 1.58 1.21 1.68
NM_014489 FRAG1 1.41 1.26 1.51
NM_152330 FRMD6 1.56 1.16 2.22
NR_002201 FTHL3 1.93 1.24 1.47
NM_000146 FTL 2.04 1.17 1.41
NM_014164 FXYD5 1.56 1.28 2.27
NM_144779 FXYD5 1.83 1.19 2.27
NM_138387 G6PC3 1.92 1.24 3.00
NM_181427 GABPB1 1.28 1.19 1.45
NM_016655 GABPB2 1.59 1.24 1.67
NM_000156 GAMT 1.22 1.18 1.53
NM_002046 GAPDH 2.17 1.26 2.96
NM_002047 GARS 2.04 1.24 1.84
NM_001005742 GBA 1.34 1.23 1.26
NM_002061 GCLM 2.22 1.26 1.57
NM_001493 GDI1 1.20 1.35 1.64
NM_202468 GIPC1 1.18 1.18 1.44
NM_001014999 GIYD1 1.20 1.20 1.19
NM_024044 GIYD2 1.30 1.34 1.17
NM_000404 GLB1 1.21 1.25 2.17
NM_001079811 GLB1 1.34 1.26 2.24
NM_015554 GLCE 1.19 1.42 1.24
NM_014905 GLS 1.48 1.17 1.34
NM_016433 GLTP 1.71 1.25 1.32
NM_005271 GLUD1 1.65 1.29 1.26
NM_004124 GMFB 2.10 1.19 1.54
NM_003875 GMPS 1.78 1.51 1.40
NM_002070 GNAI2 1.97 1.15 1.97
NM_138736 GNAO1 1.18 1.15 1.47
NM_006578 GNB5 1.76 1.17 1.30
NM_001098721 GNG4 1.52 1.33 1.52
NM_014236 GNPAT 1.46 1.19 1.40
NM_005471 GNPDA1 2.84 1.26 2.55
NM_002076 GNS 1.86 1.45 1.80
NM_022130 GOLPH3 1.63 1.33 1.27
NM_016072 GOLT1B 1.96 1.20 1.58
NM_002079 GOT1 2.08 1.24 1.36
NM_000175 GPI 2.72 1.40 2.38
NM_001001995 GPM6B 2.38 1.46 1.16
NM_007266 GPN1 1.64 1.16 1.61
NM_032777 GPR124 1.15 1.17 1.24
NM_003272 GPR137B 1.64 1.56 1.75
NM_201525 GPR56 2.39 1.58 2.92
NM_201524 GPR56 2.34 1.37 3.65
NM_001009184 GRINA 1.67 1.35 1.70
NM_000837 GRINA 1.61 1.23 2.02
NM_004492 GTF2A2 1.37 1.26 1.70
NR_002206 GTF2IP1 1.19 1.42 1.75
NM_002097 GTF3A 2.01 1.19 2.06
NM_004130 GYG1 2.32 1.23 1.73
NM_005327 HADH 1.91 1.30 1.61
NM_000183 HADHB 1.84 1.23 1.31
NM_006118 HAX1 1.50 1.17 1.36
NM_005334 HCFC1 1.60 1.20 1.87
NM_006037 HDAC4 1.35 1.30 1.23
NM_016063 HDDC2 1.74 1.32 1.73
NM_004494 HDGF 1.77 1.20 1.43
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NM_012080 HDHD1A 2.01 1.26 1.85
NM_032558 HIATL1 2.03 1.26 1.64
NM_138820 HIGD2A 1.94 1.19 2.14
NM_022740 HIPK2 1.57 1.31 1.58
NM_002116 HLA‐A 1.23 1.31 1.51
NM_145899 HMGA1 1.80 1.41 1.37
NM_003484 HMGA2 1.15 1.24 1.45
NM_003483 HMGA2 1.15 1.31 2.34
NM_032383 HPS3 4.54 1.81 7.18
NM_016142 HSD17B12 1.76 1.27 1.36
NM_016299 HSPA14 1.38 1.15 1.22
NM_001540 HSPB1 2.23 1.20 2.13
NM_012267 HSPBP1 1.48 1.27 1.27
NR_023919 HSPC157 1.19 1.32 1.20
NR_023918 HSPC157 1.22 1.20 1.21
NM_002775 HTRA1 1.64 1.15 1.35
NM_002161 IARS 2.06 1.37 2.07
NM_016513 ICK 1.50 1.24 1.79
NM_002167 ID3 1.39 1.16 1.85
NM_005896 IDH1 1.61 1.45 1.62
NM_000202 IDS 1.64 1.15 1.62
NM_006123 IDS 1.37 1.20 1.54
NM_001136265 IFFO2 1.39 1.31 1.39
NM_021034 IFITM3 2.52 1.24 2.70
NM_005534 IFNGR2 1.50 1.19 1.86
NM_002182 IL1RAP 1.30 1.27 1.54
NM_198336 INSIG1 2.96 1.43 1.90
NM_023015 INTS3 1.33 1.23 1.31
NM_014425 INVS 3.52 1.51 5.21
NM_024658 IPO4 1.49 1.26 1.44
NM_018085 IPO9 1.52 1.47 1.96
NM_003749 IRS2 1.31 1.22 1.57
NM_024710 ISOC2 1.26 1.17 1.51
NM_002205 ITGA5 1.18 1.24 1.86
NM_002213 ITGB5 1.55 1.21 1.62
NM_021999 ITM2B 2.03 1.26 1.61
NM_001012516 ITM2C 1.34 1.16 1.20
NM_033397 ITPRIP 1.73 1.27 1.40
NM_032801 JAM3 1.77 1.46 1.98
NM_175061 JAZF1 2.09 1.21 1.27
NM_006694 JTB 1.79 1.30 1.69
NM_003884 KAT2B 1.54 1.27 1.92
NM_001014380 KATNAL1 4.20 1.82 5.85
NM_005886 KATNB1 1.29 1.25 2.47
NM_001034914 KCNIP3 2.44 1.40 2.50
NM_153331 KCTD6 1.21 1.16 1.44
NM_006801 KDELR1 1.99 1.28 2.04
NM_014761 KIAA0174 1.19 1.24 1.39
NM_014846 KIAA0196 1.55 1.41 1.35
NM_014774 KIAA0494 1.77 1.34 2.05
NM_001040715 KIAA0895L 1.90 2.94 9.63
NM_001018000 KIAA1026 1.26 1.21 1.26
NM_001079685 KIAA1191 1.38 1.26 1.34
NM_020444 KIAA1191 1.29 1.17 1.37
NM_015074 KIF1B 2.61 1.31 1.95
NM_017658 KLHL28 1.19 1.27 1.35
NM_002266 KPNA2 2.02 1.26 1.44
NM_138417 KTI12 1.40 1.16 1.39
NM_002294 LAMP2 1.76 1.47 1.27
NM_006055 LANCL1 1.28 1.26 1.19
NM_018407 LAPTM4B 2.41 1.85 1.88
NM_004737 LARGE 1.29 1.27 1.63
NM_015155 LARP4B 1.61 1.17 1.56
NM_022075 LASS2 1.38 1.19 1.82
NM_182551 LCLAT1 1.59 1.15 1.58
NM_001002257 LCLAT1 2.16 1.32 1.89
NM_001135239 LDHA 1.65 1.15 1.18
NM_016269 LEF1 1.66 1.22 1.52
NM_018192 LEPREL1 2.26 1.47 9.52
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NM_005567 LGALS3BP 1.21 1.32 1.52
NM_001008530 LGMN 1.38 1.29 1.44
NM_004987 LIMS1 1.16 1.25 1.22
NM_004862 LITAF 2.98 1.46 1.83
NM_022458 LMBR1 1.70 1.31 1.25
NM_018368 LMBRD1 1.30 1.23 1.33
NM_001134693 LOC100128731 1.58 1.28 2.38
NM_001017980 LOC203547 2.70 1.22 2.12
NM_199337 LOC374395 1.91 1.27 2.56
NR_002144 LOC407835 1.22 1.23 1.60
XM_929503 LOC646567 1.96 1.41 2.22
NR_003040 LOC649946 1.35 1.58 1.89
NM_005578 LPP 4.62 1.53 6.39
NM_024509 LRFN3 1.54 1.22 2.51
NM_014045 LRP10 1.58 1.19 1.54
NM_144598 LRRC28 2.01 1.27 2.52
NM_052940 LRRC42 1.80 1.17 1.30
NM_001099678 LRRC58 2.05 1.18 1.65
NM_012322 LSM5 1.77 1.32 1.69
NM_002346 LY6E 2.28 1.26 2.05
NM_006330 LYPLA1 1.36 1.25 1.44
NM_020408 LYRM4 1.48 1.21 1.28
NM_001001660 LYRM5 1.30 1.15 1.40
NM_181705 LYRM7 4.17 1.38 2.42
NM_153374 LYSMD2 1.69 1.28 2.18
NM_014628 MAD2L1BP 1.74 1.35 1.43
NM_005882 MAEA 1.47 1.45 1.38
NM_021048 MAGEA10 1.40 1.15 1.46
NM_005367 MAGEA12 1.21 1.33 1.53
NM_175868 MAGEA6 1.16 1.16 1.16
NM_001005332 MAGED1 2.26 1.39 1.77
NM_006986 MAGED1 1.82 1.21 1.44
NM_018174 MAP1S 1.68 1.20 1.57
NM_030662 MAP2K2 1.46 1.21 1.38
NM_015093 MAP3K7IP2 1.25 1.16 1.15
NM_138957 MAPK1 1.47 1.29 1.38
NM_002746 MAPK3 1.59 1.18 1.98
NM_001040056 MAPK3 1.68 1.19 1.64
NM_023009 MARCKSL1 1.78 1.34 1.52
NM_138395 MARS2 1.34 1.20 1.15
NM_207296 MBNL1 1.62 1.17 1.36
NM_144778 MBNL2 1.57 1.25 1.19
NM_024298 MBOAT7 1.45 1.22 1.73
NM_014060 MCTS1 1.79 1.28 1.50
NM_005917 MDH1 2.38 1.56 1.22
NM_002395 ME1 1.40 1.24 1.52
NM_002396 ME2 1.74 1.23 1.43
NM_005481 MED16 1.92 1.17 1.77
NM_004275 MED20 1.74 1.18 1.56
NM_017592 MED29 1.75 1.21 1.16
NM_080651 MED30 1.29 1.19 1.22
NM_016060 MED31 1.73 1.28 2.19
NM_005466 MED6 1.72 1.19 1.89
NM_002397 MEF2C 2.36 1.22 3.81
NM_015955 MEMO1 1.59 1.21 1.42
NM_130799 MEN1 1.39 1.21 1.35
NM_015143 METAP1 1.32 1.22 1.32
NM_024042 METRN 1.23 1.18 1.34
NM_001077180 METTL9 1.30 1.40 1.20
NM_016025 METTL9 1.57 1.48 1.32
NM_054013 MGAT4B 1.31 1.23 1.99
NM_015246 MGRN1 2.08 1.91 3.65
NM_004528 MGST3 1.83 1.42 1.78
NM_002415 MIF 1.71 1.22 2.27
NR_031597 MIR1228 1.89 1.26 1.69
NR_030313 MIR586 1.74 1.22 1.45
NM_199054 MKNK2 1.20 1.27 1.21
NM_005439 MLF2 1.48 1.39 1.62
NM_012329 MMD 2.30 1.29 1.77
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NM_002437 MPV17 1.78 1.20 2.49
NM_145255 MRPL10 1.84 1.37 2.01
NM_002949 MRPL12 1.28 1.22 1.57
NM_014078 MRPL13 1.68 1.41 1.44
NM_007208 MRPL3 1.56 1.17 1.23
NM_146387 MRPL4 1.44 1.23 1.43
NM_020409 MRPL47 1.27 1.31 1.26
NM_014046 MRPS18B 1.78 1.19 1.83
NM_016034 MRPS2 1.79 1.28 2.14
NM_016640 MRPS30 3.03 1.20 1.47
NM_032476 MRPS6 1.60 1.32 1.57
NM_016542 MST4 1.23 1.20 1.34
NM_015440 MTHFD1L 1.42 1.16 1.33
NM_001040446 MTMR12 1.62 1.15 1.25
NM_004687 MTMR4 1.27 1.27 1.69
NM_145808 MTPN 2.43 1.23 1.36
NM_033375 MYO1C 1.54 1.17 1.65
NM_001012643 MYPOP 1.24 1.25 3.16
NM_006766 MYST3 1.86 5.94 2.69
NM_001018160 NAE1 1.61 1.33 1.73
NM_020443 NAV1 1.59 1.16 3.54
NM_145117 NAV2 1.65 1.24 1.33
NM_005380 NBL1 1.70 1.37 1.50
NM_182744 NBL1 1.85 1.38 1.86
NM_001040626 NCALD 1.31 1.37 1.29
NM_014284 NCDN 7.26 5.27 16.99
NM_003581 NCK2 2.14 1.21 6.38
NM_005437 NCOA4 2.26 1.27 1.68
NR_015427 NCRNA00094 1.50 1.29 1.50
NM_199069 NDUFAF3 2.08 1.33 1.73
NM_002499 NEO1 1.19 1.22 1.35
NM_018092 NETO2 1.39 1.21 1.20
NM_000434 NEU1 1.46 1.15 1.30
NM_021824 NIF3L1 1.61 1.27 1.63
NM_003634 NIPSNAP1 1.63 1.28 1.56
NM_020202 NIT2 1.26 1.36 1.39
NM_016231 NLK 1.65 1.31 1.75
NM_021077 NMB 1.39 1.19 1.28
NM_015938 NMD3 1.60 1.55 1.77
NM_015039 NMNAT2 1.54 1.20 3.31
NM_024078 NOC4L 1.19 1.16 1.54
NM_015462 NOL11 1.39 1.32 1.77
NM_014287 NOMO1 1.25 1.31 1.48
NM_018648 NOP10 1.79 1.33 2.11
NM_002514 NOV 1.28 1.25 1.15
NM_006310 NPEPPS 1.34 1.18 1.28
NM_006993 NPM3 1.43 1.19 1.50
NM_017455 NPTN 1.89 1.18 1.97
NM_012428 NPTN 1.46 1.39 1.67
NM_021005 NR2F2 1.55 1.23 1.56
NM_002525 NRD1 1.17 1.22 1.22
NM_018534 NRP2 1.78 1.25 2.32
NM_201266 NRP2 1.57 1.24 2.52
NM_201264 NRP2 1.76 1.28 3.37
NM_017615 NSMCE4A 1.23 1.16 1.27
NM_001002010 NT5C3 1.67 1.23 1.23
NM_152729 NT5DC1 1.85 1.43 1.55
NM_015135 NUP205 1.23 1.29 1.72
NM_024057 NUP37 2.26 1.44 1.80
NM_016553 NUP62 1.38 1.16 1.71
NM_000274 OAT 2.31 1.44 1.29
NM_000276 OCRL 1.69 1.19 1.87
NM_002539 ODC1 1.65 1.32 1.38
NR_002171 OR7E156P 1.38 1.37 1.54
NM_021227 OSTC 2.07 1.39 2.05
NM_005015 OXA1L 1.15 1.22 2.22
NM_002568 PABPC1 2.04 1.53 1.44
NM_003819 PABPC4 1.72 1.28 1.74
NM_006452 PAICS 2.18 1.23 1.22
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NM_002577 PAK2 1.96 1.24 1.71
NM_001014832 PAK4 1.54 1.22 1.49
NM_024675 PALB2 1.27 1.22 1.18
NM_138821 PAM 1.43 1.26 1.16
NM_001040202 PAQR3 1.77 1.25 1.23
NM_032510 PARD6G 1.53 1.41 1.18
NM_013327 PARVB 2.03 1.35 1.70
NM_152716 PATL1 1.22 1.32 1.78
NM_000281 PCBD1 1.40 1.32 1.35
NM_006196 PCBP1 2.17 1.21 1.60
NM_000532 PCCB 1.80 1.18 1.16
NM_005391 PDK3 2.00 1.28 1.39
NM_020315 PDXP 2.06 1.15 2.26
NM_020651 PELI1 1.28 1.21 1.43
NM_148172 PEMT 1.75 1.18 1.71
NM_000285 PEPD 2.13 1.42 1.61
NM_003846 PEX11B 1.60 1.48 2.09
NM_002627 PFKP 1.65 1.28 1.34
NM_002629 PGAM1 1.86 1.53 1.78
NM_001029891 PGAM4 1.70 1.25 1.55
NM_000291 PGK1 1.36 1.46 1.34
NM_006667 PGRMC1 2.30 1.31 1.95
NM_007350 PHLDA1 4.24 1.76 5.91
NM_006608 PHTF1 1.18 1.26 1.33
NM_015886 PI15 1.38 1.18 1.17
NM_015937 PIGT 1.58 1.40 1.89
NM_001042616 PIGY 1.93 1.68 1.57
NM_182470 PKM2 2.08 1.26 1.84
NM_182471 PKM2 2.18 1.16 1.90
NM_002654 PKM2 1.82 1.24 1.36
NM_022062 PKNOX2 1.90 1.23 1.26
NM_002657 PLAGL2 1.37 1.54 2.06
NM_000930 PLAT 1.42 1.43 1.32
NM_021200 PLEKHB1 1.26 1.17 1.26
NM_199478 PLP1 1.54 1.18 1.45
NM_021105 PLSCR1 2.30 1.20 1.43
NM_006227 PLTP 1.20 1.33 1.24
NM_182676 PLTP 1.31 1.22 1.91
NM_022572 PNKD 1.51 1.33 1.69
NM_002689 POLA2 1.32 1.16 1.43
NM_000937 POLR2A 1.22 1.25 1.78
NM_001099415 POM121C 1.91 1.16 3.74
NM_017739 POMGNT1 1.56 1.30 1.77
NM_000305 PON2 1.24 1.36 1.51
NM_198202 POP5 1.38 1.16 1.50
NM_022825 PORCN 4.40 1.85 8.51
NM_176895 PPAP2A 1.53 1.19 1.62
NM_005729 PPIF 1.31 1.22 1.17
NM_152329 PPIL5 1.23 1.16 1.19
NM_001008709 PPP1CA 1.39 1.20 1.57
NM_002715 PPP2CA 2.02 1.17 1.64
NM_021131 PPP2R4 1.39 1.17 1.47
NM_005134 PPP4R1 1.18 1.24 1.75
NM_002721 PPP6C 2.32 1.23 1.61
NM_016076 PPPDE1 1.79 1.26 1.61
NM_000310 PPT1 2.32 1.19 1.21
NM_138717 PPT2 1.34 1.22 1.53
NM_152391 PQLC3 1.50 1.28 1.21
NM_006793 PRDX3 2.99 1.34 2.40
NM_006406 PRDX4 1.54 1.49 1.51
NM_013397 PRICKLE4 1.26 1.53 1.52
NM_003690 PRKRA 1.19 1.16 1.22
NM_001080121 PRNP 1.67 1.32 1.17
NM_183079 PRNP 1.17 1.29 1.47
NM_006445 PRPF8 2.99 1.35 2.86
NM_002764 PRPS1 1.74 1.28 1.24
NM_001039091 PRPS2 1.84 1.33 1.40
NM_025263 PRR3 1.21 1.23 1.40
NM_012486 PSEN2 1.20 1.20 1.18
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NM_002786 PSMA1 1.31 1.24 1.34
NM_148976 PSMA1 1.66 1.48 1.45
NM_002790 PSMA5 3.11 1.35 2.44
NM_002794 PSMB2 2.14 1.54 2.35
NM_002796 PSMB4 2.09 1.44 1.81
NM_148919 PSMB8 1.17 1.18 1.43
NM_002806 PSMC6 1.60 1.28 1.21
NM_005805 PSMD14 1.53 1.21 1.18
NM_014614 PSME4 2.40 1.23 2.01
NM_020232 PSMG2 1.92 1.59 2.22
NM_004878 PTGES 1.75 1.23 1.27
NM_006601 PTGES3 1.98 1.68 1.44
NM_198402 PTPLB 1.75 1.15 1.37
NM_002827 PTPN1 2.35 1.34 1.55
NM_002835 PTPN12 1.45 1.17 1.25
NM_004339 PTTG1IP 1.76 1.49 1.51
NM_002859 PXN 1.32 1.26 2.17
NM_002862 PYGB 1.24 1.55 1.63
NM_012413 QPCT 2.13 1.58 1.18
NM_001002814 RAB11FIP1 1.88 1.26 1.26
NM_030981 RAB1B 1.26 1.18 1.29
NM_001035230 RABGAP1L 1.22 1.17 1.42
NM_182836 RABGGTA 1.26 1.15 1.17
NM_003610 RAE1 1.22 1.21 1.35
NM_015577 RAI14 1.96 1.19 1.47
NM_000964 RARA 1.83 1.45 4.28
NM_133452 RAVER1 1.58 1.22 2.23
NM_006606 RBBP9 1.64 1.26 1.24
NM_018047 RBM22 1.63 1.24 2.19
NM_002897 RBMS1 1.35 1.16 1.29
NM_002902 RCN2 2.33 1.39 1.64
NM_007033 RER1 1.50 1.33 1.19
NM_001042682 RERE 1.23 1.28 1.46
NM_002915 RFC3 1.52 1.22 1.51
NM_022841 RFX7 1.92 1.27 2.72
NM_015149 RGL1 1.34 1.24 1.63
NM_001040456 RHBDD2 2.10 1.18 2.41
NM_001005498 RHBDF2 1.53 1.27 2.46
NM_024599 RHBDF2 1.34 1.23 1.95
NM_001665 RHOG 2.82 1.34 2.24
NM_033103 RHPN2 1.70 1.33 1.58
NM_003821 RIPK2 1.89 1.15 1.24
NM_024945 RMI1 1.48 1.16 1.34
NM_001004333 RNASEK 1.69 1.30 1.94
NM_018683 RNF114 1.20 1.31 1.63
NM_014746 RNF144 1.79 1.26 1.46
NM_016494 RNF181 1.37 1.23 1.53
NM_007219 RNF24 1.40 1.25 1.42
NM_002938 RNF4 1.43 1.15 1.62
NM_203385 RNH1 1.56 1.30 1.86
NM_144563 RPIA 1.32 1.16 1.36
NM_007104 RPL10A 1.24 1.31 1.76
NM_000980 RPL18A 1.24 1.16 1.39
NM_000984 RPL23A 2.35 1.41 1.93
NM_000988 RPL27 1.22 1.21 1.60
NM_001024921 RPL9 1.41 1.37 1.75
NM_001002 RPLP0 2.18 1.71 1.85
NM_053275 RPLP0 1.36 1.16 1.57
NM_001017 RPS13 1.40 1.49 1.93
NM_022551 RPS18 1.46 1.26 1.43
NM_002952 RPS2 1.45 1.52 1.23
NM_001030001 RPS29 1.15 1.51 1.29
NM_001005 RPS3 1.80 1.24 1.37
NM_001009 RPS5 1.45 1.23 1.74
NM_001006944 RPS6KA4 1.20 1.28 1.43
NM_001011 RPS7 1.28 1.22 1.43
NM_001013 RPS9 1.23 1.24 1.19
NM_006570 RRAGA 2.48 1.26 2.21
NM_006511 RSC1A1 1.62 1.16 1.44
PULL‐DOWN DATA
210
RefSeq Accession Gene Name MM96L Fold Change Upregulated vs SCR Control
MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_201430 RTN3 2.00 1.19 1.58
NM_004350 RUNX3 1.53 1.23 1.75
NM_005620 S100A11 2.24 1.18 2.83
NM_022753 S100PBP 1.19 1.16 1.55
NM_018028 SAMD4B 1.66 1.18 2.70
NM_015380 SAMM50 1.31 1.20 1.55
NM_015278 SASH1 1.77 1.18 1.26
NM_015265 SATB2 1.63 1.18 1.80
NM_001017369 SC4MOL 2.43 1.35 1.44
NM_006918 SC5DL 2.68 1.43 1.58
NM_005698 SCAMP3 2.01 1.20 2.73
NM_016240 SCARA3 1.92 1.26 2.95
NR_004387 SCARNA10 1.17 1.17 1.43
NM_001031694 SCMH1 1.46 1.22 2.28
NM_020680 SCYL1 1.48 1.15 1.83
NM_032970 SEC22C 1.43 1.18 1.21
NM_032985 SEC23B 2.05 1.26 1.21
NM_014302 SEC61G 1.16 1.18 1.17
NM_080430 SELM 1.20 1.18 2.15
NM_020796 SEMA6A 1.91 1.45 2.09
NM_152699 SENP5 1.32 1.16 1.53
NM_001008491 SEPT2 2.09 1.21 1.63
NM_145799 SEPT6 1.65 1.58 1.50
NM_145800 SEPT6 1.29 1.41 1.69
NM_006811 SERINC3 1.54 1.17 1.83
NM_198941 SERINC3 1.25 1.18 1.27
NM_007165 SF3A2 1.43 1.15 1.75
NM_016047 SF3B14 1.16 1.36 1.55
NM_012426 SF3B3 1.67 1.27 1.17
NM_005850 SF3B4 2.76 1.26 2.61
NM_032102 SFRS2B 1.58 1.60 1.29
NM_005627 SGK1 2.10 1.29 2.17
NM_005475 SH2B3 2.04 1.16 2.03
NM_003022 SH3BGRL 1.78 1.24 1.30
NM_031286 SH3BGRL3 2.37 1.23 2.94
NM_014521 SH3BP4 2.09 1.39 1.57
NM_001009555 SH3D19 1.26 1.16 1.38
NM_030974 SHARPIN 1.27 1.28 1.64
NM_004169 SHMT1 1.62 1.15 1.60
NM_018130 SHQ1 1.49 1.17 1.33
NM_005067 SIAH2 1.23 1.22 1.58
NM_147157 SIGMAR1 15.69 7.41 26.90
NM_015477 SIN3A 1.93 1.31 1.37
NM_001040023 SIRPA 1.94 1.17 2.31
NM_080792 SIRPA 1.40 1.23 1.26
NM_203327 SLC23A2 1.28 1.39 3.09
NM_002635 SLC25A3 1.83 1.32 1.99
NM_001152 SLC25A5 1.43 1.43 1.19
NM_001859 SLC31A1 2.72 1.57 1.82
NM_080670 SLC35A4 3.23 1.18 3.20
NM_017945 SLC35A5 1.87 1.34 1.32
NM_018389 SLC35C1 1.54 1.33 1.79
NM_014437 SLC39A1 1.42 1.20 1.46
NM_015359 SLC39A14 1.41 1.32 1.68
NM_144564 SLC39A3 1.30 1.18 1.30
NM_017611 SLC43A3 11.39 2.24 7.92
NM_003040 SLC4A2 1.26 1.39 1.74
NM_021095 SLC5A6 1.17 1.30 2.13
NM_003045 SLC7A1 1.95 1.22 2.13
NM_003047 SLC9A1 1.42 1.30 2.26
NM_004252 SLC9A3R1 1.98 1.23 2.06
NM_005903 SMAD5 1.31 1.21 1.71
NM_001007468 SMARCB1 1.25 1.31 1.76
NM_003076 SMARCD1 1.71 1.24 2.51
NM_001007593 SMPD1 1.60 1.16 1.18
NM_003096 SNRPG 1.42 1.17 2.38
NM_001042581 SNUPN 1.45 1.21 1.28
NM_013322 SNX10 2.33 1.64 1.67
NM_022133 SNX16 1.17 1.18 1.34
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NM_014748 SNX17 1.63 1.31 1.93
NM_030918 SNX27 1.69 1.26 1.71
NM_013321 SNX8 1.50 1.29 1.25
NM_014041 SPCS1 1.62 1.49 1.76
NM_021928 SPCS3 1.25 1.18 1.72
NM_016630 SPG21 1.66 1.25 1.73
NM_001040058 SPP1 1.49 1.46 1.16
NM_152594 SPRED1 1.61 1.15 1.79
NM_181784 SPRED2 1.85 1.25 2.24
NM_199327 SPRY1 1.17 1.19 1.63
NM_030964 SPRY4 1.80 3.05 12.30
NM_025106 SPSB1 1.54 1.16 1.62
NM_006415 SPTLC1 1.31 1.19 1.18
NM_015326 SRGAP2 2.67 1.45 5.86
NM_003133 SRP9 2.19 1.46 2.11
NM_003139 SRPR 1.81 1.23 1.55
NM_006307 SRPX 2.41 1.81 1.60
NM_016305 SS18L2 1.28 1.38 1.57
NM_003145 SSR2 1.69 1.28 2.03
NM_006396 SSSCA1 1.75 1.16 1.18
NM_175729 SSX4 1.79 1.25 22.41
NM_001042437 ST3GAL5 1.35 1.29 2.04
NM_006100 ST3GAL6 1.29 1.20 1.66
NM_003032 ST6GAL1 2.47 1.53 2.07
NM_018412 ST7 1.61 1.17 1.16
NM_003473 STAM 2.02 1.38 1.44
NM_020151 STARD7 1.58 1.20 1.27
NM_003576 STK24 2.13 1.27 1.80
NM_032017 STK40 1.48 1.26 1.74
NM_203401 STMN1 1.70 1.27 1.64
NM_003165 STXBP1 1.62 1.16 1.51
NM_001032221 STXBP1 1.95 1.29 1.55
NM_003168 SUPT4H1 1.78 1.36 2.31
NM_003171 SUPV3L1 1.41 1.17 1.24
NM_033161 SURF4 1.43 1.30 1.51
NM_014849 SV2A 1.17 1.22 1.23
NM_033025 SYDE1 1.58 1.25 2.01
NM_003184 TAF2 1.29 1.23 1.38
NM_015975 TAF9L 1.47 1.23 1.24
NM_006755 TALDO1 1.56 1.33 1.44
NM_018201 TBC1D13 1.37 1.18 1.36
NM_014832 TBC1D4 1.25 1.26 1.34
NM_016495 TBC1D7 2.83 1.33 2.25
NM_004865 TBPL1 1.52 1.23 1.38
NM_207037 TCF12 2.36 1.21 1.53
NM_207038 TCF12 2.53 1.31 1.71
NM_138501 TECR 1.57 1.17 2.25
NM_001042425 TFAP2A 2.15 1.41 2.79
NM_001032280 TFAP2A 1.21 1.28 1.44
NM_003223 TFAP4 1.44 1.25 3.00
NM_022366 TFB2M 1.99 1.49 1.41
NM_001007565 TFG 1.88 1.33 2.49
NM_006070 TFG 1.45 1.32 1.83
NM_001024847 TGFBR2 1.32 1.18 1.96
NM_004613 TGM2 1.43 1.17 2.79
NM_198951 TGM2 1.44 1.26 1.45
NM_005834 TIMM17B 1.18 1.18 1.89
NM_012460 TIMM9 1.47 1.22 1.90
NM_003254 TIMP1 2.55 1.29 2.49
NM_003255 TIMP2 1.60 1.31 1.47
NM_003258 TK1 2.06 1.27 2.25
NM_005077 TLE1 1.40 1.20 1.47
NM_032027 TM2D1 1.59 1.48 2.02
NM_016551 TM7SF3 1.27 1.43 1.41
NM_016056 TMBIM4 2.13 1.43 2.92
NM_003217 TMBIM6 2.79 1.44 2.55
NR_002807 TMED10P 1.78 1.54 1.46
NM_016040 TMED5 1.82 1.22 1.87
NM_018374 TMEM106B 1.44 1.16 1.78
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NM_032814 TMEM118 2.07 1.31 1.18
NM_018480 TMEM126B 1.35 1.23 1.45
NM_015348 TMEM131 1.20 1.25 1.16
NM_016464 TMEM138 1.17 1.15 2.01
NM_014051 TMEM14A 1.49 1.34 1.45
NM_015444 TMEM158 1.68 1.31 1.51
NM_018475 TMEM165 1.50 1.19 1.36
NM_174909 TMEM167A 1.17 1.21 1.22
NM_030577 TMEM177 1.40 1.22 1.51
NM_012264 TMEM184B 1.74 1.25 2.03
NM_199129 TMEM189 2.21 1.27 2.48
NM_018279 TMEM19 1.59 1.21 1.49
NM_015257 TMEM194 1.15 1.26 1.41
NM_001010866 TMEM201 1.34 1.30 1.42
NM_018252 TMEM206 1.36 1.21 1.34
NM_032842 TMEM209 1.67 1.21 1.16
NM_018087 TMEM48 1.80 1.28 1.63
NM_018022 TMEM51 1.31 1.20 1.30
NM_018710 TMEM55A 1.78 1.25 1.50
NM_004872 TMEM59 1.60 1.29 1.29
NM_032936 TMEM60 1.21 1.23 1.26
NM_001008495 TMEM64 1.96 1.16 1.60
NM_016486 TMEM69 1.32 1.24 1.68
NM_021259 TMEM8 1.22 1.20 1.55
NM_014573 TMEM97 1.87 1.19 1.76
NM_001033504 TMEM98 1.63 1.17 1.84
NM_014452 TNFRSF21 1.94 1.34 2.57
NM_005488 TOM1 1.17 1.20 1.31
NM_006809 TOMM34 1.79 1.32 2.03
NM_001134493 TOMM6 1.23 1.36 1.47
NM_007027 TOPBP1 1.27 1.22 1.29
NM_015602 TOR1AIP1 1.79 1.38 1.60
NM_003596 TPST1 1.38 1.23 1.88
NM_001008566 TPST2 1.68 1.19 1.61
NM_032271 TRAF7 1.34 1.20 1.24
NM_025195 TRIB1 2.38 1.31 2.79
NM_021158 TRIB3 1.76 1.16 1.91
NM_005762 TRIM28 1.49 1.19 2.02
NM_015906 TRIM33 1.25 1.20 1.28
NM_033091 TRIM4 1.35 1.18 1.65
NM_004237 TRIP13 1.82 1.34 2.06
NM_016404 TRMT112 1.55 1.23 1.31
NM_006022 TSC22D1 1.72 1.25 1.89
NM_030935 TSC22D4 1.45 1.62 4.14
NM_018718 TSGA14 1.64 1.17 1.32
NM_031945 TSPAN10 2.15 1.50 1.16
NM_030927 TSPAN14 1.57 1.21 1.40
NM_003270 TSPAN6 1.31 1.38 1.24
NM_000714 TSPO 1.36 1.16 2.15
NM_003310 TSSC1 1.52 1.35 1.63
NM_153712 TTL 1.55 1.15 1.60
NM_006009 TUBA1A 2.41 1.87 1.44
NM_032704 TUBA1C 2.32 1.59 1.59
NM_178014 TUBB 3.20 1.31 2.89
NM_006086 TUBB3 2.45 1.26 1.84
NM_001070 TUBG1 2.77 1.15 3.14
NM_014444 TUBGCP4 1.31 1.25 1.62
NM_003321 TUFM 1.28 1.29 1.76
NM_003324 TULP3 1.62 1.22 1.47
NM_015959 TXNDC14 1.91 1.34 2.39
NM_006472 TXNIP 1.24 1.43 2.04
NM_001071 TYMS 2.30 1.53 1.65
NM_014847 UBAP2L 1.47 1.30 2.32
NM_003334 UBE1 1.65 1.41 1.64
NM_182666 UBE2E1 1.68 1.17 1.18
NM_006357 UBE2E3 2.27 1.44 1.99
NM_003342 UBE2G1 1.31 1.28 1.15
NM_016021 UBE2J1 2.52 1.16 1.33
NM_004223 UBE2L6 1.83 1.33 2.57
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RefSeq Accession Gene Name MM96L Fold Change Upregulated vs SCR Control
MM253 Fold Change 
Upregulated vs SCR Control
HT144 Fold Change 
Upregulated vs SCR Control
NM_173469 UBE2Q2 1.41 1.17 1.32
NM_018299 UBE2W 1.33 1.19 1.28
NM_014671 UBE3C 1.98 1.23 2.10
NM_004788 UBE4A 1.55 1.21 1.57
NM_007106 UBL3 1.72 1.49 1.24
NM_183008 UBXN11 1.21 1.15 3.65
NM_006002 UCHL3 1.44 1.25 1.33
NM_175866 UHMK1 2.12 1.16 1.45
NM_003362 UNG 1.23 1.24 1.44
NM_014777 URB2 1.25 1.27 1.33
NM_030914 URM1 1.33 1.40 2.06
NM_012475 USP21 1.57 1.29 1.53
NM_032172 USP42 1.21 1.32 1.43
NM_004781 VAMP3 2.24 1.29 1.45
NM_020335 VANGL2 1.19 1.33 1.58
NM_003374 VDAC1 1.90 1.24 1.60
NM_003377 VEGFB 1.44 1.18 1.41
NM_003378 VGF 1.29 1.44 1.18
NM_003380 VIM 2.92 1.43 1.98
NM_020746 VISA 1.62 1.20 1.50
NM_024006 VKORC1 1.99 1.20 2.02
NM_032353 VPS25 1.47 1.31 1.93
NM_152415 VPS37A 1.18 1.17 1.16
NM_001025778 VRK3 1.27 1.19 1.16
NM_198315 VWA5A 1.20 1.16 1.73
NM_006646 WASF3 1.70 1.30 1.40
NM_012478 WBP2 2.41 1.28 2.37
NM_005112 WDR1 1.49 1.22 1.37
NM_024100 WDR18 1.41 1.27 1.73
NM_139281 WDR36 1.50 1.16 1.71
NM_018024 WDYHV1 1.55 1.39 1.60
NM_018639 WSB2 2.09 1.18 1.21
NM_015472 WWTR1 1.29 1.15 1.76
NM_005080 XBP1 1.83 1.44 1.47
NM_020383 XPNPEP1 1.37 1.44 1.41
NM_015171 XPO6 1.96 1.22 3.30
NM_001040436 YARS2 2.15 1.35 1.55
NM_001039673 YIF1B 1.67 1.48 1.78
NM_032312 YIPF4 1.68 1.16 1.42
NM_016061 YPEL5 1.41 1.44 1.21
NM_016258 YTHDF2 1.59 1.26 1.36
NM_032283 ZDHHC18 1.20 1.16 1.36
NM_021943 ZFAND3 1.29 1.15 1.33
NM_006885 ZFHX3 1.35 1.27 1.65
NM_019103 ZMAT5 1.18 1.17 1.21
NM_001032293 ZNF207 1.74 1.16 1.67
NM_012482 ZNF281 1.33 1.38 1.40
NM_152493 ZNF362 1.53 1.16 1.58
NM_016535 ZNF581 1.64 1.25 2.18
NM_025040 ZNF614 1.29 1.15 1.30
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Pathway Kegg Pathway NumberOfGenes p-value p-value_fdr p-value_bonferroni
hsa01100 Metabolic pathways 109 3.77E-13 8.94E-11 8.94E-11
hsa04110 Cell cycle 25 3.90E-10 4.62E-08 9.24E-08
hsa00190 Oxidative phosphorylation 22 1.68E-07 1.33E-05 3.98E-05
hsa05016 Huntington's disease 26 4.71E-07 2.57E-05 1.12E-04
hsa05012 Parkinson's disease 21 5.42E-07 2.57E-05 1.29E-04
hsa04520 Adherens junction 15 7.00E-07 2.77E-05 1.66E-04
hsa05010 Alzheimer's disease 22 9.73E-06 3.30E-04 2.31E-03
hsa04142 Lysosome 18 1.57E-05 4.65E-04 3.72E-03
hsa03013 RNA transport 20 2.14E-05 5.46E-04 5.08E-03
hsa05110 Vibrio cholerae infection 11 2.30E-05 5.46E-04 5.46E-03
hsa04914 Progesterone-mediated oocyte maturation 14 3.12E-05 6.73E-04 7.40E-03
hsa04145 Phagosome 18 1.64E-04 2.90E-03 3.90E-02
hsa00030 Pentose phosphate pathway 7 1.65E-04 2.90E-03 3.90E-02
hsa04114 Oocyte meiosis 15 1.71E-04 2.90E-03 4.05E-02
GO_id Biological Process NumberOfGenes p-value p-value_fdr p-value_bonferroni
GO:0032268 regulation of cellular protein metabolic process 140 3.60E-18 4.54E-14 4.54E-14
GO:0008219 cell death 122 1.92E-16 1.05E-12 2.42E-12
GO:0016265 death 122 2.49E-16 1.05E-12 3.14E-12
GO:0048523 negative regulation of cellular process 215 8.75E-14 2.76E-10 1.10E-09
GO:0044281 small molecule metabolic process 175 1.58E-13 3.99E-10 1.99E-09
GO:0051246 regulation of protein metabolic process 146 9.14E-13 1.73E-09 1.15E-08
GO:0044267 cellular protein metabolic process 178 9.90E-13 1.73E-09 1.25E-08
GO:0048519 negative regulation of biological process 224 1.22E-12 1.73E-09 1.54E-08
GO:0051338 regulation of transferase activity 83 1.23E-12 1.73E-09 1.55E-08
GO:0071840 cellular component organization or biogenesis 265 4.11E-12 5.17E-09 5.17E-08
GO:0044710 single-organism metabolic process 243 8.52E-12 9.76E-09 1.07E-07
GO:0045184 establishment of protein localization 102 1.06E-11 1.12E-08 1.34E-07
GO:0012501 programmed cell death 95 1.54E-11 1.50E-08 1.95E-07
GO:0031399 regulation of protein modification process 103 1.67E-11 1.50E-08 2.10E-07
GO:0044237 cellular metabolic process 392 2.36E-11 1.76E-08 2.98E-07
GO:0044419 interspecies interaction between organisms 75 2.37E-11 1.76E-08 2.99E-07
GO:0044403 symbiosis, encompassing mutualism through parasitism 75 2.37E-11 1.76E-08 2.99E-07
GO:0016043 cellular component organization 255 4.63E-11 3.07E-08 5.83E-07
GO:0006915 apoptotic process 93 4.63E-11 3.07E-08 5.84E-07
GO:0048522 positive regulation of cellular process 223 5.42E-11 3.42E-08 6.83E-07
GO:0015031 protein transport 96 6.08E-11 3.65E-08 7.66E-07
GO:0008104 protein localization 117 7.59E-11 4.35E-08 9.56E-07
GO:0043067 regulation of programmed cell death 104 9.88E-11 5.41E-08 1.25E-06
GO:0042981 regulation of apoptotic process 103 1.16E-10 6.08E-08 1.46E-06
GO:0031325 positive regulation of cellular metabolic process 155 1.46E-10 7.37E-08 1.84E-06
GO:0010941 regulation of cell death 106 1.75E-10 8.51E-08 2.21E-06
GO:0009893 positive regulation of metabolic process 161 1.92E-10 8.95E-08 2.42E-06
GO:0000278 mitotic cell cycle 72 2.11E-10 9.52E-08 2.67E-06
GO:0016032 viral process 68 2.29E-10 9.75E-08 2.88E-06
GO:0022403 cell cycle phase 44 2.32E-10 9.75E-08 2.93E-06
GO:0044848 biological phase 46 2.60E-10 1.03E-07 3.28E-06
GO:0044764 multi-organism cellular process 68 2.63E-10 1.03E-07 3.31E-06
GO:1903047 mitotic cell cycle process 66 3.08E-10 1.18E-07 3.89E-06
GO:0033554 cellular response to stress 102 3.34E-10 1.22E-07 4.20E-06
GO:0007049 cell cycle 101 3.38E-10 1.22E-07 4.25E-06
GO:0032269 negative regulation of cellular protein metabolic process 55 4.57E-10 1.60E-07 5.77E-06
GO:0070727 cellular macromolecule localization 81 8.95E-10 3.05E-07 1.13E-05
GO:0065009 regulation of molecular function 156 9.78E-10 3.24E-07 1.23E-05
GO:0006886 intracellular protein transport 60 1.21E-09 3.91E-07 1.53E-05
GO:0051248 negative regulation of protein metabolic process 59 1.35E-09 4.24E-07 1.70E-05
GO:0050790 regulation of catalytic activity 135 1.60E-09 4.65E-07 2.01E-05
GO:0000075 cell cycle checkpoint 35 1.60E-09 4.65E-07 2.02E-05
GO:0019538 protein metabolic process 196 1.62E-09 4.65E-07 2.04E-05
GO:0034613 cellular protein localization 80 1.62E-09 4.65E-07 2.05E-05
GO:0010033 response to organic substance 151 1.76E-09 4.94E-07 2.22E-05
GO:0032270 positive regulation of cellular protein metabolic process 82 1.87E-09 5.12E-07 2.36E-05
GO:0051329 mitotic interphase 27 2.08E-09 5.36E-07 2.62E-05
GO:0006996 organelle organization 155 2.08E-09 5.36E-07 2.63E-05
GO:0044248 cellular catabolic process 126 2.43E-09 6.12E-07 3.06E-05
GO:0022402 cell cycle process 80 2.52E-09 6.20E-07 3.18E-05
GO:1902582 single-organism intracellular transport 81 2.56E-09 6.20E-07 3.22E-05
GO:0010604 positive regulation of macromolecule metabolic process 145 2.82E-09 6.71E-07 3.56E-05
GO:0033036 macromolecule localization 125 3.76E-09 8.79E-07 4.75E-05
GO:0033365 protein localization to organelle 50 3.92E-09 8.98E-07 4.94E-05
GO:0048518 positive regulation of biological process 237 4.28E-09 9.64E-07 5.40E-05
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GO:0044711 single-organism biosynthetic process 84 4.63E-09 1.02E-06 5.84E-05
GO:0006793 phosphorus metabolic process 138 5.47E-09 1.19E-06 6.89E-05
GO:0006796 phosphate-containing compound metabolic process 136 6.14E-09 1.31E-06 7.74E-05
GO:0072594 establishment of protein localization to organelle 39 6.70E-09 1.41E-06 8.45E-05
GO:1901564 organonitrogen compound metabolic process 118 1.06E-08 2.20E-06 1.34E-04
GO:0043066 negative regulation of apoptotic process 63 1.27E-08 2.57E-06 1.60E-04
GO:0006950 response to stress 190 1.40E-08 2.81E-06 1.77E-04
GO:0051247 positive regulation of protein metabolic process 85 1.44E-08 2.84E-06 1.82E-04
GO:0000084 mitotic S phase 23 1.73E-08 3.28E-06 2.18E-04
GO:0044260 cellular macromolecule metabolic process 300 1.74E-08 3.28E-06 2.20E-04
GO:0006605 protein targeting 42 1.81E-08 3.33E-06 2.29E-04
GO:0043069 negative regulation of programmed cell death 63 1.82E-08 3.33E-06 2.30E-04
GO:0006807 nitrogen compound metabolic process 291 2.01E-08 3.62E-06 2.53E-04
GO:0043549 regulation of kinase activity 65 2.10E-08 3.72E-06 2.64E-04
GO:1901575 organic substance catabolic process 129 2.40E-08 4.20E-06 3.02E-04
GO:0006091 generation of precursor metabolites and energy 42 2.55E-08 4.40E-06 3.21E-04
GO:0071702 organic substance transport 119 2.70E-08 4.56E-06 3.41E-04
GO:0044085 cellular component biogenesis 121 2.71E-08 4.56E-06 3.42E-04
GO:0007093 mitotic cell cycle checkpoint 26 2.87E-08 4.76E-06 3.62E-04
GO:0006417 regulation of translation 34 3.22E-08 5.27E-06 4.05E-04
GO:0051641 cellular localization 125 3.35E-08 5.41E-06 4.22E-04
GO:0060548 negative regulation of cell death 64 5.70E-08 9.10E-06 7.19E-04
GO:0045859 regulation of protein kinase activity 61 5.84E-08 9.21E-06 7.37E-04
GO:0031401 positive regulation of protein modification process 71 6.94E-08 1.08E-05 8.75E-04
GO:0061024 membrane organization 62 7.59E-08 1.17E-05 9.57E-04
GO:0044772 mitotic cell cycle phase transition 37 7.84E-08 1.19E-05 9.88E-04
GO:0009056 catabolic process 138 8.15E-08 1.22E-05 1.03E-03
GO:0043436 oxoacid metabolic process 70 8.95E-08 1.33E-05 1.13E-03
GO:0046907 intracellular transport 87 9.46E-08 1.39E-05 1.19E-03
GO:0006082 organic acid metabolic process 71 9.91E-08 1.44E-05 1.25E-03
GO:0044770 cell cycle phase transition 37 1.02E-07 1.46E-05 1.29E-03
GO:0042325 regulation of phosphorylation 86 1.06E-07 1.51E-05 1.34E-03
GO:1901135 carbohydrate derivative metabolic process 99 1.12E-07 1.57E-05 1.41E-03
GO:0051348 negative regulation of transferase activity 34 1.14E-07 1.57E-05 1.43E-03
GO:0019752 carboxylic acid metabolic process 63 1.15E-07 1.57E-05 1.45E-03
GO:0031323 regulation of cellular metabolic process 274 1.16E-07 1.58E-05 1.47E-03
GO:0006464 cellular protein modification process 128 1.22E-07 1.61E-05 1.53E-03
GO:0044249 cellular biosynthetic process 232 1.28E-07 1.68E-05 1.62E-03
GO:0009057 macromolecule catabolic process 70 1.34E-07 1.74E-05 1.69E-03
GO:0044802 single-organism membrane organization 51 1.44E-07 1.85E-05 1.82E-03
GO:0009058 biosynthetic process 237 1.79E-07 2.28E-05 2.26E-03
GO:1901576 organic substance biosynthetic process 234 1.89E-07 2.39E-05 2.39E-03
GO:0044238 primary metabolic process 376 1.96E-07 2.44E-05 2.47E-03
GO:0019637 organophosphate metabolic process 89 1.98E-07 2.44E-05 2.49E-03
GO:0000082 G1/S transition of mitotic cell cycle 25 2.17E-07 2.61E-05 2.73E-03
GO:0034641 cellular nitrogen compound metabolic process 268 2.18E-07 2.61E-05 2.75E-03
GO:0001932 regulation of protein phosphorylation 74 2.53E-07 3.01E-05 3.19E-03
GO:1901991 negative regulation of mitotic cell cycle phase transition 26 3.37E-07 3.98E-05 4.25E-03
GO:0043412 macromolecule modification 132 3.48E-07 4.06E-05 4.39E-03
GO:0022411 cellular component disassembly 41 3.94E-07 4.56E-05 4.97E-03
GO:0031324 negative regulation of cellular metabolic process 107 4.28E-07 4.91E-05 5.40E-03
GO:0007399 nervous system development 122 4.65E-07 5.28E-05 5.87E-03
GO:1901360 organic cyclic compound metabolic process 266 4.82E-07 5.42E-05 6.07E-03
GO:0006613 cotranslational protein targeting to membrane 19 5.07E-07 5.65E-05 6.39E-03
GO:0010948 negative regulation of cell cycle process 30 5.53E-07 6.12E-05 6.97E-03
GO:1901988 negative regulation of cell cycle phase transition 26 5.86E-07 6.42E-05 7.38E-03
GO:0010608 posttranscriptional regulation of gene expression 44 6.50E-07 7.06E-05 8.19E-03
GO:0044265 cellular macromolecule catabolic process 61 6.78E-07 7.30E-05 8.54E-03
GO:0009117 nucleotide metabolic process 71 7.68E-07 8.21E-05 9.68E-03
GO:0051179 localization 212 7.82E-07 8.28E-05 9.85E-03
GO:0019222 regulation of metabolic process 290 8.10E-07 8.50E-05 1.02E-02
GO:2001233 regulation of apoptotic signaling pathway 37 9.03E-07 9.41E-05 1.14E-02
GO:2001235 positive regulation of apoptotic signaling pathway 20 1.00E-06 1.04E-04 1.27E-02
GO:0008285 negative regulation of cell proliferation 53 1.05E-06 1.08E-04 1.33E-02
GO:0055114 oxidation-reduction process 74 1.10E-06 1.12E-04 1.39E-02
GO:0071704 organic substance metabolic process 377 1.13E-06 1.14E-04 1.43E-02
GO:0015980 energy derivation by oxidation of organic compounds 34 1.17E-06 1.17E-04 1.47E-02
GO:0010646 regulation of cell communication 152 1.26E-06 1.25E-04 1.58E-02
GO:0031400 negative regulation of protein modification process 39 1.32E-06 1.30E-04 1.66E-02
GO:0006974 cellular response to DNA damage stimulus 52 1.36E-06 1.33E-04 1.71E-02
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GO:0051649 establishment of localization in cell 104 1.41E-06 1.37E-04 1.78E-02
GO:0023051 regulation of signaling 151 1.58E-06 1.52E-04 1.99E-02
GO:0009966 regulation of signal transduction 138 1.73E-06 1.66E-04 2.19E-02
GO:0006614 SRP-dependent cotranslational protein targeting to membrane 18 1.97E-06 1.87E-04 2.48E-02
GO:0051128 regulation of cellular component organization 107 2.06E-06 1.94E-04 2.60E-02
GO:0060255 regulation of macromolecule metabolic process 251 2.22E-06 2.06E-04 2.79E-02
GO:0009892 negative regulation of metabolic process 111 2.22E-06 2.06E-04 2.79E-02
GO:1901990 regulation of mitotic cell cycle phase transition 29 2.23E-06 2.06E-04 2.82E-02
GO:0043933 macromolecular complex subunit organization 98 2.34E-06 2.14E-04 2.95E-02
GO:0019439 aromatic compound catabolic process 70 2.35E-06 2.14E-04 2.97E-02
GO:0051726 regulation of cell cycle 64 2.75E-06 2.48E-04 3.47E-02
GO:0022613 ribonucleoprotein complex biogenesis 31 2.77E-06 2.48E-04 3.49E-02
GO:0046483 heterocycle metabolic process 252 2.91E-06 2.58E-04 3.67E-02
GO:0000209 protein polyubiquitination 24 3.28E-06 2.89E-04 4.13E-02
GO:0045047 protein targeting to ER 18 3.45E-06 3.02E-04 4.35E-02
GO:0072599 establishment of protein localization to endoplasmic reticulum 18 3.95E-06 3.43E-04 4.98E-02
GO:0043086 negative regulation of catalytic activity 57 4.06E-06 3.51E-04 5.12E-02
GO_id Molecular Function NumberOfGenes p-value p-value_fdr p-value_bonferroni
GO:0005515 protein binding 512 3.80E-28 1.46E-24 1.46E-24
GO:0044822 poly(A) RNA binding 107 2.99E-12 5.74E-09 1.15E-08
GO:0019899 enzyme binding 104 8.21E-09 1.05E-05 3.15E-05
GO:0003824 catalytic activity 234 2.85E-08 2.73E-05 1.09E-04
GO:0003723 RNA binding 106 1.66E-07 1.27E-04 6.36E-04
GO:0005488 binding 513 2.30E-07 1.47E-04 8.83E-04
GO:0015078 hydrogen ion transmembrane transporter activity 17 5.46E-07 2.99E-04 2.09E-03
GO:0003712 transcription cofactor activity 46 1.23E-06 5.91E-04 4.72E-03
GO:0016829 lyase activity 19 1.62E-06 6.92E-04 6.23E-03
GO:0000988 protein binding transcription factor activity 47 1.95E-06 6.95E-04 7.50E-03
GO:0042802 identical protein binding 82 1.99E-06 6.95E-04 7.65E-03
GO:0016787 hydrolase activity 119 2.53E-06 8.10E-04 9.72E-03
GO:0000989 transcription factor binding transcription factor activity 46 4.46E-06 1.32E-03 1.71E-02
GO_id Cellular Components NumberOfGenes p-value p-value_fdr p-value_bonferroni
GO:0043230 extracellular organelle 271 1.44E-42 7.70E-40 2.14E-39
GO:0070062 extracellular vesicular exosome 271 1.56E-42 7.70E-40 2.31E-39
GO:0044446 intracellular organelle part 432 2.16E-29 7.97E-27 3.19E-26
GO:0044444 cytoplasmic part 440 9.31E-29 2.76E-26 1.38E-25
GO:0044422 organelle part 435 3.65E-28 9.00E-26 5.40E-25
GO:0005829 cytosol 243 1.17E-27 2.48E-25 1.73E-24
GO:0005737 cytoplasm 556 1.84E-27 3.41E-25 2.73E-24
GO:0031988 membrane-bounded vesicle 267 2.49E-27 4.09E-25 3.68E-24
GO:0031982 vesicle 268 1.46E-26 2.15E-24 2.15E-23
GO:0043231 intracellular membrane-bounded organelle 564 3.94E-26 5.30E-24 5.83E-23
GO:0044421 extracellular region part 273 9.77E-25 1.20E-22 1.45E-21
GO:0043227 membrane-bounded organelle 599 1.03E-23 1.17E-21 1.52E-20
GO:0005739 mitochondrion 147 1.11E-20 1.17E-18 1.64E-17
GO:0031090 organelle membrane 216 3.03E-20 2.99E-18 4.49E-17
GO:0043226 organelle 598 5.90E-20 5.46E-18 8.73E-17
GO:0043229 intracellular organelle 565 3.94E-19 3.43E-17 5.83E-16
GO:0031974 membrane-enclosed lumen 227 2.23E-18 1.83E-16 3.30E-15
GO:0043233 organelle lumen 222 7.58E-18 5.90E-16 1.12E-14
GO:0070013 intracellular organelle lumen 218 9.95E-18 7.36E-16 1.47E-14
GO:0005576 extracellular region 290 1.86E-16 1.31E-14 2.76E-13
GO:0044424 intracellular part 595 1.17E-15 7.89E-14 1.74E-12
GO:0044428 nuclear part 192 2.65E-15 1.71E-13 3.93E-12
GO:0005634 nucleus 370 5.23E-14 3.22E-12 7.74E-11
GO:0005622 intracellular 585 1.74E-13 1.03E-11 2.58E-10
GO:0098588 bounding membrane of organelle 160 2.48E-13 1.41E-11 3.67E-10
GO:0031981 nuclear lumen 164 2.42E-12 1.32E-10 3.58E-09
GO:0044429 mitochondrial part 78 4.76E-12 2.51E-10 7.04E-09
GO:0012505 endomembrane system 212 3.28E-11 1.68E-09 4.86E-08
GO:0042470 melanosome 22 2.13E-10 1.02E-08 3.15E-07
GO:0032991 macromolecular complex 250 6.92E-10 3.20E-08 1.02E-06
GO:0005654 nucleoplasm 116 1.25E-09 5.59E-08 1.84E-06
GO:0005759 mitochondrial matrix 41 1.87E-09 8.13E-08 2.76E-06
GO:0030529 ribonucleoprotein complex 56 6.68E-09 2.82E-07 9.88E-06
GO:0005743 mitochondrial inner membrane 42 3.55E-08 1.43E-06 5.26E-05
GO:0019866 organelle inner membrane 45 3.58E-08 1.43E-06 5.30E-05
GO:0031967 organelle envelope 75 4.85E-08 1.89E-06 7.18E-05
GO:0016020 membrane 407 5.63E-08 2.14E-06 8.33E-05
GO:0031975 envelope 75 6.22E-08 2.30E-06 9.21E-05
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GO:0044437 vacuolar part 38 4.16E-07 1.50E-05 6.16E-04
GO:0043228 non-membrane-bounded organelle 195 8.16E-07 2.81E-05 1.21E-03
GO:0043232 intracellular non-membrane-bounded organelle 195 8.16E-07 2.81E-05 1.21E-03
GO:0005774 vacuolar membrane 32 8.81E-07 2.96E-05 1.30E-03
GO:0031966 mitochondrial membrane 48 1.35E-06 4.44E-05 2.00E-03
GO:0043234 protein complex 209 1.93E-06 6.21E-05 2.86E-03
GO:0005740 mitochondrial envelope 49 2.20E-06 6.89E-05 3.26E-03
GO:0005765 lysosomal membrane 29 2.23E-06 6.89E-05 3.31E-03
GO:0005794 Golgi apparatus 89 2.98E-06 9.01E-05 4.41E-03
GO:0044455 mitochondrial membrane part 21 3.55E-06 1.05E-04 5.26E-03
GO:0005753 mitochondrial proton-transporting ATP synthase complex 7 7.10E-06 2.06E-04 1.05E-02
GO:0005789 endoplasmic reticulum membrane 67 7.66E-06 2.18E-04 1.13E-02
GO:0042175 nuclear outer membrane-endoplasmic reticulum membrane network 68 8.67E-06 2.42E-04 1.28E-02
GO:0005783 endoplasmic reticulum 97 1.58E-05 4.33E-04 2.34E-02
GO:0016469 proton-transporting two-sector ATPase complex 9 1.71E-05 4.60E-04 2.53E-02
GO:0005730 nucleolus 58 1.76E-05 4.65E-04 2.60E-02
GO:0000139 Golgi membrane 50 2.20E-05 5.71E-04 3.25E-02
GO:0010008 endosome membrane 36 2.67E-05 6.82E-04 3.96E-02
GO:0035770 ribonucleoprotein granule 16 3.33E-05 8.22E-04 4.93E-02
GO:0036464 cytoplasmic ribonucleoprotein granule 16 3.33E-05 8.22E-04 4.93E-02
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a
2/3celllines
>1.5fold
enrichm
ent
FoldRegulation
M
M
96L+m
iRͲ4731
m
im
icv.s.M
M
96L+
NegͲSCR
FoldRegulation
M
M
253+m
iRͲ4731
m
im
icv.s.M
M
253
+
NegͲSCR
FoldRegulation
HT144+m
iRͲ4731
m
im
icv.s.HT144+
NegͲSCR
Changein
m
RNA
expression
detetcted?
ValidationType
NM
_020959
ANO8
>2fold3/3
.
.
Ͳ1.2
Ͳ1.2
Ͳ1.1
N
<1.2fold
NM
_020531
C20orf3
>2fold3/3
.
.
1.0
Ͳ1.0
Ͳ1.0
N
<1.2fold
NM
_024819
DCAKD
>2fold3/3
.
.
1.2
Ͳ1.1
Ͳ1.1
N
<1.2fold
NM
_005476
GNE
>2fold3/3
.
.
Ͳ1.0
1.0
1.1
N
<1.2fold
NM
_005780
LHFP
>2fold3/3
.
.
Ͳ1.2
Ͳ1.1
1.0
N
<1.2fold
NM
_032569
NͲPAC
>2fold3/3
.
.
1.1
Ͳ1.0
Ͳ1.1
N
<1.2fold
NM
_016395
PTPLAD1
>2fold3/3
.
.
Ͳ1.1
Ͳ1.0
1.2
N
<1.2fold
NM
_005669
REEP5
>2fold3/3
.
.
Ͳ1.0
Ͳ1.2
1.0
N
<1.2fold
NM
_003068
SNAI2
>2fold3/3
.
.
Ͳ1.0
Ͳ1.1
1.1
N
<1.2fold
NM
_003795
SNX3
>2fold 3/3
.
.
Ͳ1.1
Ͳ1.0
Ͳ1.2
N
<1.2fold
NM
_021015
SSX5
>2fold3/3
.
.
1.1
1.0
Ͳ1.0
N
<1.2fold
NM
_001039141
TRIOBP
>2fold3/3
.
.
1.1
Ͳ1.2
Ͳ1.2
N
<1.2fold
NM
_003435
ZNF134
>2fold3/3
.
.
1.1
1.1
Ͳ1.1
N
<1.2fold
NM
_018584
CAM
K2N1
>2fold3/3
.
.
1.0
Ͳ1.2
1.4
Y
1/3upregulated
NM
_021923
FGFRL1
>2fold3/3
.
.
1.5
Ͳ1.1
1.0
Y
1/3upregulated
NM
_013434
KCNIP3
>2fold3/3
.
.
1.1
Ͳ1.0
1.4
Y
1/3upregulated
NM
_001136
AGER
>2fold3/3
.
.
Ͳ1.1
1.0
Ͳ1.7
Y
1/3validated
NM
_003100
SNX2
>2fold3/3
.
.
Ͳ1.4
Ͳ1.0
Ͳ1.1
Y
1/3 validated
NM
_014178
STXBP6
>2fold3/3
.
.
Ͳ1.2
Ͳ1.2
Ͳ1.4
Y
1/3validated
NM
_207352
CYP4V2
>2fold3/3
.
.
Ͳ1.0
1.5
1.5
Y
2/3upregulated
NM
_001101
ACTB
>2fold3/3
.
.
Ͳ1.3
1.0
Ͳ1.6
Y
2/3validated
NM
_032485
M
CM
8
>2fold3/3
.
.
Ͳ2.0
Ͳ1.0
Ͳ1.3
Y
2/3validated
NM
_005635
SSX1
>2fold3/3
.
.
Ͳ1.7
8.3
Ͳ2.3
Y
2/3validated
NM
_021014
SSX3
>2fold3/3
.
.
Ͳ1.8
1.1
Ͳ3.1
Y
2/3validated
NM
_145049
UBLCP1
>2fold3/3
.
.
Ͳ1.1
Ͳ1.4
Ͳ1.5
Y
2/3validated
NM
_153321
PM
P22
HOSTGENE
.
.
Ͳ1.4
Ͳ1.5
Ͳ2.2
Y
3/3validated
NM
_001014839
NCDN
>2fold3/3
.
.
Ͳ1.3
Ͳ1.7
Ͳ1.6
Y
3/3validated
NM
_148906
OSBPL9
>2fold3/3
.
.
Ͳ1.3
Ͳ1.4
Ͳ1.4
Y
3/3validated
NM
_005866
SIGM
AR1
>2fold3/3
.
.
Ͳ1.5
Ͳ1.6
Ͳ1.8
Y
3/3validated
NM
_014096
SLC43A3
>2fold3/3
.
.
Ͳ1.8
Ͳ1.6
Ͳ1.6
Y
3/3validated
NM
_004782
SNAP29
>2fold3/3
.
.
Ͳ1.3
Ͳ1.4
Ͳ1.4
Y
3/3validated
NM
_003147
SSX2
>2fold3/3
.
.
Ͳ2.0
Ͳ1.8
Ͳ3.1
Y
3/3validated
NM
_005636
SSX4
>2fold3/3
.
.
Ͳ2.5
Ͳ4.4
Ͳ14.1
Y
3/3validated
NM
_001034832
SSX4B
>2fold3/3
.
.
Ͳ85.6
Ͳ6.0
Ͳ35.1
Y
3/3validated
NM
_006297
XRCC1
>2fold3/3
.
.
Ͳ1.4
Ͳ1.4
Ͳ1.5
Y
3/3validated
NM
_001004720
NCK2
>2fold3/3
.
.
Ͳ1.6
5.7
Ͳ1.2
Y
Upanddow
n
NM
_024592
SRD5A3
>2fold3/3
.
.
1.1
Ͳ1.5
1.4
Y
Upanddow
n
NM
_080603
ZSW
IM
1
>2fold3/3
.
.
Ͳ1.2
Ͳ1.3
1.4
Y
Upanddow
n
NM
_015391
ANAPC13
.
CellCycle
Y
Ͳ1.1
Ͳ1.6
Ͳ1.2
Y
1/3validated
NM
_001760
CCND3
.
CellCycle
Y
Ͳ1.4
Ͳ1.0
1.1
Y
1/3validated
NM
_001798
CDK2
.
CellCycle
Y
Ͳ1.1
Ͳ1.0
Ͳ1.5
Y
1/3validated
NM
_001429
EP300
.
CellCycle
Y
Ͳ 1.1
Ͳ1.4
Ͳ1.1
Y
1/3validated
NM
_006341
M
AD2L2
.
CellCycle
Y
1.0
Ͳ1.2
Ͳ1.3
Y
1/3validated
NM
_007111
TFDP1
.
CellCycle
Y
Ͳ1.1
Ͳ1.1
Ͳ1.3
Y
1/3validated
NM
_001007793
BUB3
.
CellCycle
Y
Ͳ1.2
Ͳ1.3
Ͳ1.3
Y
2/3validated
NM
_003504
CDC45 L
.
CellCycle
Y
Ͳ1.5
Ͳ1.2
Ͳ2.3
Y
2/3validated
NM
_000075
CDK4
.
CellCycle
Y
Ͳ1.4
Ͳ1.1
Ͳ1.6
Y
2/3validated
NM
_006930
SKP1A
.
CellCycle
Y
Ͳ1.2
Ͳ1.4
Ͳ1.5
Y
2/3validated
NM
_001237
CCNA2
.
CellCycle
Y
Ͳ1.4
Ͳ1.4
Ͳ2.0
Y
3/3validated
NM
_002553
ORC5L
.
CellCycle
Y
Ͳ1.8
Ͳ1.4
Ͳ1.3
Y
3/3validated
NM
_182649
PCNA
.
CellCycle
Y
Ͳ1.7
Ͳ1.6
Ͳ2.0
Y
3/3validated
RATIO
NALEFO
RVALIDATIO
N
qRTͲPCRVALIDATIO
N
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RefSeqAccession
GeneNam
e
STRINGDBRelevantPathw
ayfor
m
elanom
a
2/3celllines
>1.5fold
enrichm
ent
FoldRegulation
M
M
96L+m
iRͲ4731
m
im
icv.s.M
M
96L+
NegͲSCR
FoldRegulation
M
M
253+m
iRͲ4731
m
im
icv.s.M
M
253
+
NegͲSCR
FoldRegulation
HT144+m
iRͲ4731
m
im
icv.s.HT144+
NegͲSCR
Changein
m
RNA
expression
detetcted?
ValidationType
NM
_005561
LAM
P1
.
M
elanosom
e
Y
1.0
1.1
Ͳ1.1
N
<1.2fold
NM
_006908
RAC1
.
M
elanosom
e
Y
Ͳ1.2
Ͳ1.0
1.0
N
<1.2fold
NM
_006754
SYPL1
.
M
elanosom
e
Y
Ͳ1.1
Ͳ1.2
Ͳ1.1
N
<1.2fold
NM
_003234
TFRC
.
M
elanosom
e
Y
1.1
Ͳ1.0
1.0
N
<1.2fold
NM
_000259
M
YO5A
.
M
elanosom
e
Y
Ͳ1.2
1.3
1.0
Y
1/3upregulated
NM
_004104
FASN
.
M
elanosom
e
Y
Ͳ1.3
Ͳ1.1
Ͳ1.1
Y
1/3validated
NM
_003878
GGH
.
M
elanosom
e
Y
Ͳ1.2
Ͳ1.1
Ͳ1.3
Y
1/3validated
NM
_181696
PRDX1
.
M
elanosom
e
Y
Ͳ1.1
Ͳ1.6
1.0
Y
1/3validated
NM
_201434
RAB5C
.
M
elanosom
e
Y
1.1
Ͳ1.3
Ͳ1.2
Y
1/3validated
NM
_001005340
GPNM
B
.
M
elanosom
e
Y
Ͳ1.4
Ͳ1.0
Ͳ1.3
Y
2/3validated
NM
_004099
STOM
.
M
elanosom
e
Y
Ͳ4.4
Ͳ1.1
Ͳ1.6
Y
2/3validated
NM
_006572
GNA13
.
M
elanosom
e
Y
Ͳ1.6
Ͳ1.4
Ͳ1.8
Y
3/3validated
NM
_006325
RAN
.
M
elanosom
e
Y
Ͳ1.3
Ͳ 1.4
Ͳ1.3
Y
3/3validated
NM
_001909
CTSD
.
M
elanosom
e
Y
Ͳ1.3
1.3
1.3
Y
Upanddow
n
NM
_004637
RAB7A
.
M
elanosom
e
Y
Ͳ1.3
1.8
1.1
Y
Upanddow
n
NM
_005176
ATP5G2
.
Oxidativephosphorylation
Y
1.0
Ͳ1.1
1.0
N
<1.2fold
NM
_001690
ATP6V1A
.
Oxidativephosphorylation
Y
1.0
Ͳ1.1
1.1
N
<1.2fold
NM
_001303
COX10
.
Oxidativephosphorylation
Y
Ͳ1.1
Ͳ1.2
Ͳ1.2
N
<1.2fold
NM
_176866
PPA2
.
Oxidativephosphorylation
Y
1.1
Ͳ1.2
Ͳ1.2
N
<1.2fold
NM
_004046
ATP5A1
.
Oxidativephosphorylation
Y
Ͳ1.2
Ͳ1.2
Ͳ1.3
Y
1/3validated
NM
_004691
ATP6V0D1
.
Oxidativephosphorylation
Y
Ͳ1.2
1.1
Ͳ1.3
Y
1/3validated
NM
_145230
ATP6V0E2
.
Oxidativephosphorylation
Y
Ͳ1.1
1.1
Ͳ1.3
Y
1/3validated
NM
_004074
COX8A
.
Oxidativephosphorylation
Y
Ͳ1.2
Ͳ1.0
Ͳ1.3
Y
1/3validated
NM
_002492
NDUFB5
.
Oxidative phosphorylation
Y
Ͳ1.2
Ͳ1.4
Ͳ1.2
Y
1/3validated
NM
_003002
SDHD
.
Oxidativephosphorylation
Y
1.1
Ͳ1.5
1.2
Y
1/3validated
NM
_005003
NDUFAB1
.
Oxidativephosphorylation
Y
Ͳ1.3
Ͳ1.2
Ͳ1.5
Y
2/3validated
NM
_001003785
ATP5H
.
Oxidativephosphorylation
Y
Ͳ1.3
Ͳ1.3
Ͳ1.3
Y
3/3validated
NM
_001697
ATP5O
.
Oxidativephosphorylation
Y
Ͳ1.3
Ͳ1.6
Ͳ1.6
Y
3/3validated
NM
_019056
NDUFB11
.
Oxidativephosphorylation
Y
Ͳ1.3
Ͳ1.3
Ͳ1.4
Y
3/3validated
NM
_006003
UQ
CRFS1
.
Oxidativephosphorylation
Y
Ͳ1.3
Ͳ1.3
Ͳ1.3
Y
3/3validated
RATIO
NALEFO
RVALIDATIO
N
qRTͲPCRVALIDATIO
N
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3/3 Validated
GENE NAME Melanoma related Cancer related
ATP5H NOVEL Y
ATP5O NOVEL Y
CCNA2 Y Y
GNA13 Y Y
NCDN NOVEL NOVEL
NDUFB11 NOVEL Y
ORC5L NOVEL Y
OSBPL9 NOVEL NOVEL
PCNA Y Y
PMP22 Y Y
RAN Y Y
SIGMAR1 Y Y
SLC43A3 NOVEL Y
SNAP29 NOVEL Y
SSX2 Y Y
SSX4 Y Y
SSX4B NOVEL NOVEL
UQCRFS1 NOVEL Y
XRCC1 Y Y
2/3 Validated
GENE NAME Melanoma related Cancer related
UBLCP1 NOVEL NOVEL
SSX3 Y Y
SSX1 Y Y
ACTB Y Y
MCM8 NOVEL Y
SKP1A NOVEL Y
BUB3 Y Y
CDC45L Y Y
CDK4 Y Y
STOM NOVEL
GPNMB Y Y
NDUFAB1 NOVEL NOVEL
1/3 Validated
GENE NAME Melanoma related Cancer related
AGER Y Y
STXBP6 NOVEL Y
SNX2 NOVEL Y
CDK2 Y Y
TFDP1 Y Y
MAD2L2 NOVEL Y
ANAPC13 NOVEL Y
EP300 Y Y
CCND3 Y Y
GGH NOVEL Y
RAB5C NOVEL Y
221
PRDX1 Y Y
FASN Y Y
ATP6V0D1 NOVEL NOVEL
ATP5A1 NOVEL Y
COX8A NOVEL Y
ATP6V0E2 NOVEL NOVEL
NDUFB5 NOVEL NOVEL
SDHD Y Y
Up and Down‐regulated
GENE NAME Melanoma related Cancer related
SRD5A3 NOVEL Y
ZSWIM1 NOVEL NOVEL
NCK2 Y Y
RAB7A NOVEL Y
CTSD Y Y
Upregulated
GENE NAME Melanoma related Cancer related
FGFRL1 NOVEL Y
KCNIP3 Y Y
CAMK2N1 NOVEL Y
CYP4V2 NOVEL Y
MYO5A Y Y
<1.2fold up or down
GENE NAME Melanoma related Cancer related
SNX3 NOVEL Y
TRIOBP NOVEL Y
ANO8 NOVEL Y
DCAKD NOVEL NOVEL
N‐PAC NOVEL NOVEL
ZNF134 NOVEL NOVEL
SSX5 Y Y
C20orf3 NOVEL Y
REEP5 NOVEL Y
LHFP NOVEL Y
SNAI2 Y Y
GNE Y Y
PTPLAD1 NOVEL Y
SYPL1 NOVEL Y
LAMP1 Y Y
TFRC NOVEL Y
RAC1 Y Y
COX10 NOVEL Y
PPA2 NOVEL Y
ATP5G2 NOVEL Y
ATP6V1A NOVEL Y
222
Melanosome‐
realted genes MM96L MM253 HT144
FSCN1 -1.0 -1.5 1.2
MLPH -1.7 1.1 -8.2
RAB27A -1.5 1.2 -1.0
TYR -1.3 1.1 -1.5
≥1.3 fold
223
*HQH6\PERO
$OLDV
5HIVHT
2IILFLDO)XOO1DPH
57&DWDORJ1XPEHU
PM
P22
CM
T1A/CM
T1E/DSS/GASͲ3/HM
SNIA/HNPP/Sp110
NM
_000304
Peripheralm
yelinprotein22
PPH02152
AGER
RAGE
NM
_001136
AdvancedglycosylationendproductͲspecificreceptor
PPH06984
ANO8
KIAA1623/TM
EM
16H
NM
_020959
Anoctam
in8
PPH19903
APM
AP
BSCv/C20orf3
NM
_020531
Chrom
osom
e20openreadingfram
e3
PPH08393
CAM
K2N1
PRO1489/RP11Ͳ401M
16.1
NM
_018584
Calcium
/calm
odulinͲdependentproteinkinaseIIinhibitor1
PPH14215
CYP4V2
BCD/CYP4AH1
NM
_207352
Cytochrom
eP450,fam
ily4,subfam
ilyv,polypeptide2
PPH14808
DCAKD
Ͳ
NM
_024819
DephosphoͲCoAkinasedom
aincontaining
PPH14029
FGFRL1
FGFR5/FHFR
NM
_021923
Fibroblastgrow
thfactorreceptorͲlike1
PPH01285
GNE
DM
RV/GLCNE/IBM
2/NM
/Uae1
NM
_005476
Glucosam
ine(UDPͲNͲacetyl)Ͳ2Ͳepim
erase/NͲacetylm
annosam
inekinase
PPH07367
KCNIP3
CSEN/DREAM
/KCHIP3
NM
_013434
Kvchannelinteractingprotein3,calsenilin
PPH16645
LHFP
Ͳ
NM
_005780
Lipom
aHM
GICfusionpartner
PPH10530
M
CM
8
C20orf154/dJ967N21.5
NM
_182802
M
inichrom
osom
em
aintenancecom
plexcom
ponent8
PPH24209
NCDN
Ͳ
NM
_014284
Neurochondrin
PPH11567
NCK2
GRB4/NCKbeta
NM
_003581
NCKadaptorprotein2
PPH01626
GLYR1
BM
045/HIBDL/NͲPAC/NP60
NM
_032569
Glyoxylatereductase1hom
olog(Arabidopsis)
PPH07640
OSBPL9
ORPͲ9/ORP9
NM
_024586
OxysterolbindingproteinͲlike9
PPH08362
PTPLAD1
BͲIND1/HACD3/HSPC121
NM
_016395
ProteintyrosinephosphataseͲlikeAdom
aincontaining1
PPH22223
REEP5
C5orf18/D5S346/DP1/TB2/YOP1
NM
_005669
Receptoraccessoryprotein5
PPH02167
SIGM
AR1
ALS16/OPRS1/SIGͲ1R/SRͲBP/SRͲBP1/SRBP/hSigm
aR1/sigm
a1R
NM
_005866
Sigm
anonͲopioidintracellularreceptor1
PPH08535
SLC43A3
EEG1/FOAPͲ13/PRO1659/SEEEGͲ1
NM
_199329
Solutecarrierfam
ily43,m
em
ber3
PPH10816
SNAI2
SLUG/SLUGH1/SNAIL2/W
S2D
NM
_003068
Snailhom
olog2(Drosophila)
PPH02475
SNAP29
CEDNIK/SNAPͲ29
NM
_004782
Synaptosom
alͲassociatedprotein,29kDa
PPH14125
SNX2
TRGͲ9
NM
_003100
Sortingnexin2
PPH07780
SNX3
Grd19/M
COPS8/SDP3
NM
_003795
Sortingnexin3
PPH07825
SRD5A3
CDG1P/CDG1Q
/KRIZI/SRD5A2L/SRD5A2L1
NM
_024592
Steroid5alphaͲreductase3
PPH09114
SSX1
CT5.1/SSRC
NM
_005635
Synovialsarcom
a,Xbreakpoint1
PPH20270
SSX2
CT5.2/CT5.2A/HD21/HOMͲM
ELͲ40/SSX
NM
_175698
Synovialsarcom
a,Xbreakpoint2
PPH16204
SSX3
CT5.3
NM
_175711
Synovialsarcom
a,Xbreakpoint3
PPH13708
SSX4
CT5.4
NM
_175729
Synovialsarcom
a,Xbreakpoint4
PPH15690
SSX4B
CT5.4
NM
_001034832
Synovialsarcom
a,Xbreakpoint4B
PPH63498
SSX5
Ͳ
NM
_175723
Synovialsarcom
a,Xbreakpoint5
PPH13329
STXBP6
am
isyn
NM
_014178
Syntaxinbindingprotein6(am
isyn)
PPH10773
TRIOBP
DFNB28/TARA/dJ37E16.4
NM
_007032
TRIOandFͲactinbindingprotein
PPH09126
UBLCP1
CPUB1
NM
_145049
UbiquitinͲlikedom
aincontainingCTDphosphatase1
PPH09170
XRCC1
RCC
NM
_006297
XͲrayrepaircom
plem
entingdefectiverepairinChineseham
stercells1
PPH01741
ZNF134
pHZͲ15
NM
_003435
Zincfingerprotein134
PPH21915
ZSW
IM
1
C20orf162
NM
_080603
Zincfinger,SW
IMͲtypecontaining1
PPH22275
ANAPC13
APC13/SW
M
1
NM
_015391
Anaphaseprom
otingcom
plexsubunit13
PPH11045
BUB3
BUB3L/hBUB3
NM
_004725
Buddinguninhibitedbybenzim
idazoles3hom
olog(yeast)
PPH19836
CCNA2
CCN1/CCNA
NM
_001237
CyclinA2
PPH00125
CCND3
Ͳ
NM
_001760
CyclinD3
PPH00130
CDC45
CDC45L/CDC45L2/PORCͲPIͲ1
NM
_003504
Celldivisioncycle45hom
olog(S.cerevisiae)
PPH00915
CDK2
p33(CDK2)
NM
_001798
CyclinͲdependentkinase2
PPH00117
CDK4
CM
M
3/PSKͲJ3
NM
_000075
CyclinͲdependentkinase4
PPH00118
EP300
KAT3B/RSTS2/p300
NM
_001429
E1Abindingproteinp300
PPH00319
M
AD2L2
M
AD2B/POLZ2/REV7
NM
_006341
M
AD2m
itoticarrestdeficientͲlike2(yeast)
PPH00936
ORC5
ORC5L/ORC5P/ORC5T
NM
_181747
Originrecognitioncom
plex,subunit5
PPH12872
PCNA
Ͳ
NM
_182649
Proliferatingcellnuclearantigen
PPH00216
SKP1
EM
C19/OCPͲII/OCP2/SKP1A/TCEB1L/p19A
NM
_006930
SͲphasekinaseͲassociatedprotein1
PPH00231
TFDP1
DP1/DRTF1/DpͲ1
NM
_007111
TranscriptionfactorDpͲ1
PPH00360
*HQH6\PERO
$OLDV
5HIVHT
2IILFLDO)XOO1DPH
57&DWDORJ1XPEHU
224
CTSD
CLN10/CPSD/HELͲSͲ130P
NM
_001909
CathepsinD
PPH00112
FASN
FAS/OAͲ519/SDR27X1
NM
_004104
Fattyacidsynthase
PPH01012
GGH
GH
NM
_003878
Gam
m
aͲglutam
ylhydrolase(conjugase,folylpolygam
m
aglutam
ylhydrolase)
PPH10118
GNA13
G13
NM
_006572
Guaninenucleotidebindingprotein(Gprotein),alpha13
PPH02844
GPNM
B
HGFIN/NM
B
NM
_002510
Glycoprotein(transm
em
brane)nm
b
PPH18941
LAM
P1
CD107a/LAM
PA/LGP120
NM
_005561
Lysosom
alͲassociatedm
em
braneprotein1
PPH05794
PRDX1
M
SP23/NKEFͲA/NKEFA/PAG/PAGA/PAGB/PRX1/PRXI/TDPX2
NM
_002574
Peroxiredoxin1
PPH01700
RAB5C
L1880/RAB5CL/RAB5L/RABL
NM
_004583
RAB5C,m
em
berRASoncogenefam
ily
PPH07004
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Chapter 6 
Discussion and Future Directions 
6.1- Discussion 
Discussed below is a timeline of events that occurred prior to and during this PhD project. 
It is written in such a way as to best portray the rationale of the studies and major 
discussion points of each Chapter (2-5) in the order of events. Following on from these 
discussions will be the envisaged future directions and development of this project. 
 
6.1.1- Study Design Rationale 
Prior to the commencement of this PhD project, I was involved in several projects relating 
to microRNAs [1, 2]. In one of these projects, we assayed melanoma cell lines (AJCC 
stage IV; n=52), along with melanocytes, using both miRNA and mRNA (whole genome) 
microarrays [1]. The miRNA arrays were ‘first generation’ arrays with ~400 human miRNAs 
(miRBase v9), of which a total of 299 miRNAs were found to be present in at least one 
sample. We found that miR-211 was expressed in melanocytes ~50 fold higher than the 
average for the melanoma cell lines. This miRNA was subsequently shown to be a 
melanocytic lineage-specific miRNA, through assessment of a set of normal tissues. We 
next sought to identify specific targets of miR-211. In an effort to make more informed 
choices as to what target genes may be involved, we combined our miRNA and mRNA 
datasets to identify inversely correlated genes, thereby potentially identifying mRNAs that 
may be controlled directly or indirectly by individual miRNAs. The combined dataset 
underwent ‘supervised’ hierarchical clustering analysis based upon the expression level of 
miR-211 (classified as high, medium, low, or nil). We found that miR-211 was co-
expressed with the melanocyte-specific genes MITF and TRPM1, an expected result given 
that miR-211 is located within intron 6 of TRPM1 and MITF is a known transcriptional 
regulator of TRPM1.  Following this co-expression analysis, our search was refined to only 
include inversely correlated genes that were involved with MITF, in order to find the best 
candidates for follow up studies. We discovered POU3F2 (BRN2), which encodes a 
transcriptional regulator of MITF, to be inversely correlated with miR-211. The relationship 
between miR-211, POU3F2, and MITF was experimentally characterised and published in 
Pigment Cell and Melanoma Research (PCMR) [1].  
The lineage-specific nature of miR-211, explored in the PCMR study, prompted a new 
study which aimed to discover additional pigment cell lineage miRNAs not present in 
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miRBase. At the time, this study involved the newly developed next-generation sequencing 
to assess different malignant melanoma subtypes (acral, mucosal, cutaneous  and uveal) 
[2]. This allowed for the comprehensive and unbiased identification of novel and known 
miRNAs present in a given sample. We assayed a panel (n=12) of normal pigment cells 
(melanoblasts and melanocytes), pre-cancerous cells (naevus cell line) and 539 of the 847 
canonical miRNAs (mature and mature star) that were present in miRBase [3] (v12, 
September 2008), to be expressed in at least one of the samples. We also identified 722 
expressed sequences predicted to be novel miRNAs and following strict filtering criteria, 
the list was reduced to 389 novel candidate miRNAs. The majority of these are now 
present in the current miRBase registry (v21, June 2014), which lists more than 2500 
human miRNAs. This study, in which we proposed that some of the novel miRNAs may be 
specific to the melanocytic lineage, was published in PLOS One [2]. 
 
Just prior to the commencement of my PhD project, I co-wrote a comprehensive literature 
review on melanoma and miRNAs [4]. This review allowed for a refinement of the concept 
and design of the PhD project. What was evident from previous studies (including our first 
study [1]), was that whilst some significant data had been presented, most miRNA array-
based studies were limited by the use of early iterations of miRBase and as such, 
numerous melanoma-miRNA associations remained to be elucidated. 
 
6.1.2 - Current PhD project 
As previously discussed (Chapter 1), the central theme of this PhD project was to identify 
a ‘lineage-specific’ or a ‘melanoma-specific’ panel of miRNAs that could be deemed more 
directly related to melanomagenesis and in turn could be of benefit for use as biomarkers 
for disease prognosis or have the potential to be useful for ‘early’ diagnosis. Moreover, 
identification of melanoma-related miRNAs may help to improve our understanding of 
melanoma development by elucidating gene targets that may provide new avenues for 
future therapies. 
 
In steps toward identifying a panel of melanoma-related miRNAs, we assayed a large set 
of cell lines from melanoma (n=55) and other solid malignancies (n=34) (e.g. breast, 
ovarian, prostate, colorectal) using an array platform that contained the most current (at 
time of project design) miRBase version (v18, November 2011). Upon comparison of 
‘melanoma’ vs. ‘other’ cancers, 233 miRNAs were found to be differentially expressed 
(Aim 1). These data are discussed in more detail in Chapter 2. Additional samples on the 
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array included a melanocyte pool, a melanoblast culture, and a naevus cell line, along with 
serum/plasma derived RNA from melanoma patients. The latter were included to see if 
miRNAs were detectable in serum, prior to collection of large cohorts of patient sera (See 
Chapter 3). The former were used for comparative purposes to see which of the 
melanoma-miRNAs, were predominant in melanoma compared to a range of normal 
pigment cell types (See Chapter 3). Importantly, the top ranked over-expressed miRNA 
was miR-211, being significantly enriched (P (corr) = 3.43E-07; fold change = 276) in 
melanoma. This finding validates our previous work [1] and that of others [5, 6] on the 
association of miR-211 and melanoma. However, miR-211, whilst specific to the 
melanocytic lineage, is not expressed in all melanomas (up to 30% do not express miR-
211, including this current dataset) [1]. In fact, many of the melanoma-related miRNAs 
exhibit the same type of expression in this dataset (e.g. miR-514a-3p), i.e. predominantly 
expressed in melanoma albeit not absolute. Due to this variable expression, in terms of 
biomarker identification, a ‘panel’ of melanoma-related miRNAs was considered 
more robust for serum measurement than a single miRNA. 
 
As previously mentioned, following the determination of a panel of melanoma-related 
miRNAs, large cohorts of melanoma patient sera (and healthy control sera) and tissue 
would need to be recruited to establish if a miRNA panel would be useful for 
diagnostic/prognostic purposes (Aims 2 and 3). Early on in the project, it was evident that 
a prospective recruitment of large numbers of participants would be not possible within the 
confines of the project timeframe. As such, alternate arrangements and new collaborations 
were made so as to ascertain sufficient patient material for biomarker validation. Specific 
details of sample recruitment can be found in Chapter 3. During the 1-3 years taken to 
receive all patient serum and tissue, I commenced work on the identification of target 
genes of some melanoma-related miRNAs (Aim 4). Chapters 2 and 5 present data from 
these studies. 
 
With miR-211 being the most highly upregulated miRNA in melanoma, the next best was 
miR-514a-3p (see Chapter 2). This miRNA is a member of a cluster of miRNAs on 
chromosome X which have been shown to be involved in melanocyte transformation along 
with promotion of melanoma growth [7]. The authors were able to distinguish two distinct 
sub-populations within this cluster: sub-cluster A (miR-506, miR-507, miR-508, miR-513a, 
b, and c), and sub-cluster B (miR-509, miR-510, and miR-514). Inhibiting sub-cluster A led 
to significant inhibition of cell growth, invasiveness, and colony formation in soft agar, 
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along with increased apoptosis. The authors showed further that sub-cluster A was critical 
for maintaining the cancer phenotype; however, over-expression of the full cluster (A and 
B) was necessary for transformation of melanocytes. As mentioned, this particular miRNA 
cluster was significantly over-expressed in the dataset produced as part of this PhD 
project. The cluster as a whole showed highly significant fold change differences when 
‘melanomas’ were compared to ‘other cancers’, with sub-cluster A showing 2.5 - 65 fold 
higher expression and sub-cluster B showing 2.5 - 204 fold higher expression. The two 
greatest fold-changes were for miR-514a-3p (204 fold) and miR-509-3p (139 fold). miR-
514a-3p was selected for further investigation as it showed the highest fold change 
difference and had not had described any functionally validated gene targets to date (see 
Chapter 2).  
 
In addition to identifying targets for miR-514a, a novel miRNA (present in miRBase, but not 
currently mentioned in the literature) was also assayed.  Target genes for miR-4731-5p are 
discussed in more detail in Chapter 5. Using a biotin-labelled pull down procedure, target 
genes for both miR-514a-3p and miR-4731-5p were determined (Chapters 2 and 5). 
 
As for many other malignancies being studied worldwide, NGS technology is being used to 
identify and catalogue mutational events in melanoma. During this PhD project, some 
significant publications in this space occurred which describe the ‘landscape’ of mutations 
in melanoma [8-10]. Along with the highly mutated genes (BRAF and NRAS) commonly 
occurring in melanoma, many inactivating mutations in NF1 were documented. NF1 
(neurofibromin 1) has long been associated as a tumour suppressor in melanoma [11] . 
Recently, in an elegant paper by Maertens et al.[12], NF1 was shown to be integral to 
melanoma formation. The authors highlighted a mechanism for overcoming oncogene-
induced senescence (OIS) which is required for tumourigenesis to continue following 
BRAF mutations (~50% of all melanomas harbour a BRAF V600E mutation). 
Following target gene identification of miR-514a-3p (biotin pull-down), it was revealed that 
the NF1 transcript was a potential binding target and was subsequently proven as such 
using reporter assays (Chapter 2). During the target gene validation process, it was 
revealed that loss of NF1 protein was one of the reasons for resistance to occur in 
melanoma patients undergoing targeted therapy to with BRAFV600E inhibitors [12, 13]. I 
subsequently showed supportive evidence of miR-514-3p regulation of NF1 in these 
processes (Chapter 2). Whilst this was not an original aim of the project, these findings 
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were of particular importance to the melanoma field. As the primary function of NF1 is to 
inhibit RAS (specifically HRAS and KRAS), its downstream effectors lie in both the MAPK 
and PI3K pathways. These are key signalling pathways in melanoma and, as such, it was 
considered necessary to follow-up the relationship between miR-514-3p and NF1. As 
discussed in Chapter 2, in combination with currently used targeted therapies of the 
MAPK, PI3K, and mTOR pathways, pharmacological intervention of miRNAs like miR-
514a-3p, may allow for more durable outcome in late stage melanoma patients. 
The miRNA panel selection and data generated from patient material (serum and tissue) 
that encompasses Aims 2 and 3 are detailed in Chapter 3. This chapter describes the 
multi-centre study, which evolved over the course of the project. Based upon the 
microarray data presented in Chapter 2, a panel of melanoma-related miRNAs (‘MELmiR-
18’) was validated in an independent cohort of tissue derived from AJCC stage III and IV 
patients, in serum derived from AJCC patients of stages I/II, III, and IV, as well as in 
controls (participants with no history of melanoma; prior melanoma history; and high 
naevus count). What was immediately evident was that expression of miRNA was readily 
detectable in FFPE tissue, as well as in serum. This was made possible using the HD 
Biomark (Fluidigm) real-time PCR system. This ultra-sensitive methodology, using ‘gold-
standard’ miRNA-specific Taqman assays, was able to detect differences between lowly 
expressed transcripts. These often subtle changes are what are required for biomarker 
identification. However, not all of the miRNAs measureable in tissue were detectable in 
serum. Many of the undetectable miRNAs in serum were members of the miR-506-514 
cluster (see Chapter 2). Those members that were undetectable in serum included: miR-
508-3p, miR-508-5p, miR-513b, and miR-513c. It could be postulated that the other 
members that were expressed in serum: miR-506-3p, miR-509-3p, miR-509-5p, and miR-
514a-3p are the ‘drivers’ amongst the cluster with the remainder being ‘passengers’.  
The assaying of the ‘MELmiR-18’ panel in serum revealed a highly significant and 
discriminatory panel of miRNAs (‘MELmiR-7’) that were both diagnostic (detection) and 
prognostic (predictive) for melanoma (see Chapter 3 for detailed discussion). miR-211, a 
member of the ‘MELmiR-7’ panel, was individually associated with patient survival. The 
diagnostic and prognostic nature of the ‘MELmiR-7’ panel thus makes it a powerful tool for 
monitoring disease burden in patients undergoing surveillance for recurrence. Moreover, 
measurement of the panel in patients with AJCC stage III disease (regional metastases), 
may allow for better triaging of patients i.e. patients could be up-staged prior to gross 
metastatic spread, and as such, may qualify earlier for targeted and/or systemic therapies. 
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 The strength of the ‘MELmiR-18’ panel, along with the assay methodology was next 
assessed using an independently derived panel of miRNAs and was the primary reason 
for becoming involved in the study with my collaborators from the Melanoma Institute of 
Australia (MIA). 
 
Following on from our ‘miR-211 project’ (discussed previously) and using similar 
methodology, a new study initiated by our collaborators was commenced. This study was 
later expanded upon with the data presented in Chapter 4 as part of this current PhD 
project. This study used global expression profiling of both mRNA (whole genome) and 
miRNA (miRBase v16) in matched fresh-frozen metastatic melanomas (AJCC stage III). 
All samples (n=45) used had excellent clinical follow-up information and as such were able 
to be classified into GP (good prognosis) and PP (poor prognosis). This stratification of 
samples was used to identify which miRNAs were differentially expressed between each 
group. Four miRNAs were found to be associated with prognosis (miR-142-3p, miR-142-
5p, miR-146b-5p, and miR-150-5p), some of which were identified by Segura et al. [14]. 
These miRNAs were subsequently validated by real-time PCR and later (as part of this 
PhD project) in an independent cohort of FFPE tumours (AJCC stage III and IV) and 
serum derived from melanoma patients (AJCC stage III and IV). Many of these samples 
were the same as those used in Chapter 3. Using this well-defined panel of miRNAs, I 
was able to utilise the fully optimised methodology I implemented in Chapter 3. With my 
primary focus firmly on miRNA expression in serum derived from melanoma patients, the 
miRNAs identified by the MIA group, using stage III GP vs. PP, did not perform as well as 
the ‘MELmiR-18’ or ‘MELmiR-7’ panels. In summary, only 2/4 MIA miRNAs (miR-150-5p 
and miR-142-3p) had significant (P = 0.05 - <0.01) expression differences in serum 
(Chapter 4), both with AUC scores of <0.70. In comparison, the ‘MELmiR-7’ panel 
achieved a much higher significance (P= 0.05 - ≤0.0001) and had AUC scores ranging 
from 0.64 – 0.78 when assayed in the same sample types. This increased significance and 
discriminatory ability of the ‘MELmiR-7’ panel validates the original identification and 
selection process (upregulated melanoma-related miRNAs). 
 
Aim 4 of this PhD project was to identify gene specific targets of miRNAs relevant to 
melanoma development. In an effort to address this aim, along with data presented in 
Chapter 2 (miR-514a-3p regulation of NF1), the biotin-pull-down methodology was used 
with miR-4731-5p. This miRNA had no known association with melanoma and as such 
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was an attractive candidate. The array data (Chapter 2) shows a >24 fold enrichment  in 
melanoma as compared to other cancers however it is important to note that whilst it 
appears to be predominantly expressed in melanoma, it is not highly expressed. Protein-
coding tumour suppressor genes (e.g. CDKN2A) often exhibit loss of expression, which is 
a normal tumourigenic event ‘favouring’ the tumour. The data presented in Chapter 3 
shows that the serum expression levels of miR-4731-5p were actually significantly lower in 
‘melanomas’ when compared with ‘controls’. Additionally, in FFPE tissue (Chapter 3), 
expression of miR-4731-5p is significantly down-regulated in stage IV tumours compared 
with stage III tumours. This suggests that loss of expression could be involved in tumour 
progression and that miR-4731-5p may have a tumour suppressive function. The target 
genes found to associate with miR-4731-5p are shown and discussed in detail in Chapter 
5. The network analysis function of STRING [15] was used to look for associations 
between genes that were pulled-down in the melanoma cell lines assayed. The gene lists 
were then assessed by gene set enrichment analysis to reveal significantly over-
represented pathways (via KEGG) and Gene Ontology (GO) Terms. As discussed in 
Chapter 5, it is widely accepted that a single miRNA has the potential to regulate a 
multitude of signalling pathways, achieved by the direct targeting of individual genes, 
which in turn elicit their function (or lack of) on their next interacting partner. The genes 
involved in the ‘Cell Cycle’ KEGG pathway were one of the clear stand-outs from the 
enrichment analysis. What is immediately apparent is that each gene in this pathway 
(present from the pull down list), appears to be related to cell cycle progression (G1 
through to Mitosis). As the primary role of an miRNA is to down-regulate its target genes, 
the loss of expression seen in stage IV tumours and in melanoma patient serum, suggests 
that the dysregulation of miR-4731-5p is far reaching, directly affecting a great number of 
key genes involve in this key biological pathway. 
 
 
6.1.3 - Summary 
With the benefit of hindsight and access to additional funding, this study could have been 
strengthened by performing a comprehensive screen of cohorts of melanoma patient-
derived serum (stages I-IV) using the same microarray platform used in Chapter 2. Larger 
panels of 'other' solid tumours together with serum cohorts, would have provided a 
thoroughly comprehensive study to be of benefit not only for greater understanding of 
melanoma, but for all other cancers analysed. These data would have thus allowed a 
unique insight by providing a direct comparison of blood-borne miRNA expression relative 
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to tumour (cell line)- derived expression. Nevertheless, this PhD project has successfully 
achieved the original aims by firstly identifying a panel of melanoma-related miRNAs that 
are highly discriminatory for melanoma not only in the ‘discovery data’ (Chapter 2) but 
also in melanoma patient tissue and serum (Chapter 3) which correlated with tumour 
progression. The strength of the panel was then highlighted following comparison with 
data from an independent miRNA panel (Chapter 4). Finally, gene specific targets of a 
circulating miRNA were identified (Chapter 5) which have relevance to melanoma 
development. 
 
 
6.2- Future Directions 
 
The data produced during this thesis was generated to answer specific research questions 
within a defined set of aims. Whilst the major themes have been addressed throughout the 
course of the project, the study is by no means complete as further investigation is 
required to thoroughly explore all of the new and exciting avenues that have arisen since 
commencing the study. 
 
6.2.1 - miRNA expression profiling: tissue 
The miRNA array platform selected for this study was chosen as it contained all known 
human miRNAs present in the online repository miRBase (v18). The trade-off was that 
newly identified miRNAs would not be assessed which would have only have been 
detected using miRNA-seq. However, with the number of specimens to be assayed 
(n=102), this was cost prohibitive and as such the array methodology was the most cost 
effective choice. The LC Sciences (TX, USA) array has 1898 miRNA sequences and 
combined with the large panel of melanoma cell lines, this study is the most complete 
survey to date.  
 
Recently, the TCGA (The Cancer Genome Atlas) has published its first landmark paper 
studying cutaneous melanoma [10]. Amongst the voluminous data that has been 
generated (e.g. DNA-seq, RNA-seq, methylome); the project has produced miRNA data 
using miRNA-seq.  Due to the use of the Illumina HiSeq, read numbers are high (>10 
million/sample) and once complete, these data will supersede all other datasets due to its 
high sample numbers (~300 melanoma tumours) and comprehensiveness. Early release, 
analysed data is available, however, the miRNA data presented is limited to those present 
233
in miRBase v16 (1047 miRNAs). It remains to be seen if the raw data will be made 
publically available to allow for comparison with current miRBase versions (v21) as well as 
prediction of novel miRNAs. Nevertheless, the TCGA is actively studying 33 tumour types, 
and combined with the previously published studies hosted in cBioPortal, a total of 20,958 
specimens (from 89 studies) have been analysed thus far (April 2015).  Once completed, 
these studies will have produced sufficient data to provide the global research community 
with enough analytical material for years to come.  
 
6.2.1.1 - Lineage-specific miRNA expression 
This PhD study identified 233/1898 miRNAs that were differentially expressed between 
melanomas and other solid cancer types (Chapter 2). This was achieved by grouping all 
of the solid cancers together rather than being separated into each cancer type. Due to the 
costs involved in acquiring additional material from cell line repositories, this study was 
unable to identify lineage-specific expression in the other solid cancers. Future 
interrogation of the TCGA miRNA-seq data from all cancers studied would provide a 
wealth of opportunity to discover lineage-specific expression present in each tissue type. 
Until then, the data presented in Chapter 2 satisfied the Aim 1 of this study which was 
melanoma-centric. 
 
6.2.2 - miRNA expression profiling: serum 
Using the array data presented in Chapter 2, a panel of melanoma-related miRNAs were 
selected to measure in serum derived from melanoma patients (AJCC stage I-IV) along 
with controls (see Chapter 3 for selection process). The miRNAs chosen provided 
excellent discriminatory power in a large collection of melanoma patients (Chapter 3) and 
as such warrants further development. The success of this panel (‘MELmiR-7’) will be 
explored further beyond the timeframe of this current project. Some of the future plans are 
outlined below. 
 
6.2.2.1 - Will the ‘MELmiR-7’ panel allow for more precise risk 
stratification of AJCC stage III patients? 
According to the AJCC staging committee, stage III patients have a 50% chance of 
survival beyond 5 years [16]; these patients remain the most difficult for whom to provide 
effective treatments/surveillance regimens and accurate survival estimates. A mutation in 
the BRAF gene, causing an amino acid substitution at the V600 location is currently the 
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best way to stratify patients with stage IV disease for treatment. Those patients with this 
mutation present in their tumours will qualify for treatment with the BRAF inhibitors (e.g. 
Dabrafenib) or to be enrolled in clinical trials for new therapies targeting the BRAF 
signaling pathway, including next generation RAF inhibitors and combination therapies that 
inhibit the pathway at multiple points (e.g. MEK and ERK inhibitors). In some cases, 
unresectable stage III tumours may qualify patients for these trials, but at present, the 
majority of stage III patients with BRAF-mutated tumours are not eligible to receive 
targeted therapies. 
 
6.2.2.1.1 - Strategy and Aims 
It has been planned to further expand on the extensive data collected and discussed in 
Chapter 3 by examining an extended cohort of stage III patients. This will serve to 
strengthen and assess if the data is clinically relevant in these earlier stage patients. All 
the retrospectively collected sera that were used in preliminary miRNA studies have FFPE 
tumour samples available from various pathology centres. An additional larger cohort of 
100 stage III patients for whom a wealth of clinical data has been collected, including 
prognosis, as well as matched serum and tumour, via a collaboration with the MIA, will 
complete the stage III cohort. This equates to a total of 150 stage III retrospective and 
prospectively collected patients with matched serum, tumour and clinical information. 
Correlations with miRNA expression, mutation status, and patient outcome will be 
determined via routine statistical methods. 
6.2.2.1.2 - Methodology 
Following genomic DNA and total RNA extraction from FFPE tissue (n=150) and RNA 
extraction from serum (n=100) from MIA patient material, the same panel of 18 miRNAs 
identified in Chapter 3 will be accessed via the high-throughput method of detection 
described previously (Biomark HD, Fluidigm in combination with TaqMan® MicroRNA 
Assays, Life Technologies). This approach maximizes the chance of detecting low 
abundance miRNAs and maintains consistency across the study. The genomic DNA will 
be required to investigate the BRAF and NRAS genes for mutations as these are the most 
commonly mutated genes in melanoma. 
6.2.2.1.3 - Questions addressed and conclusions drawn 
The following questions will be addressed: 
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• Does the expression of the miRNA panel in serum show a correlation with the 
matched tumour material? 
• Is there a relationship between miRNA expression in serum and/or tumour that is 
associated with prognosis? 
• Does mutation status of the tumour show a relationship with prognosis? 
• Does the combination of miRNA expression strengthen the prognostic ability of 
mutation status or does it offer better predictive power when used in isolation? 
 
This proposed study will, at completion, have determined if measurement of the ‘MELmiR-
7’ panel allows for a more precise risk-stratification in the stage III patients. In addition, the 
study will have determined if the combination of BRAF/NRAS mutation status and miRNA 
expression profile enhances the prognostication of stage III patients. 
 
 
6.2.2.2 - Is it possible to have a more rapid and cost effective method of 
determining miRNA expression in patient derived serum? 
 
6.2.2.2.1 - Strategy and Aims 
In order to develop a blood test that could be widely used by clinicians and diagnostic 
laboratories, several features need to be taken into consideration. A clinically useful test 
would need to be rapid and cost effective whilst achieving high sensitivity and specificity. 
Using the specimens that formed the basis of the data presented in Chapter 3, along with 
the additional cohort of patients ascertained for completion of the previous aim, it is 
planned to investigate the potential use of the SmartRNAplex™ miRNA Assay, which is a 
rapid, low cost per sample per marker methodology. This method has been developed by 
Firefly Bioworks (Cambridge, MA, USA) and is run using standard benchtop flow-
cytometers. 
 
6.2.2.2.2 - SmartRNAplex™ miRNA Assay Methodology 
The SmartRNAplex™ miRNA Assay is a multiplexed assay for miRNA expression 
analysis, allowing up to 68 miRNA targets to be analysed simultaneously. The assay, 
based on encoded hydrogel particles, can be completed in about 4 hours. The assay is 
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highly sensitive and has capability of measuring expression from crudely extracted 
serological or tissue material. 
The data generated from the previous aim, along with statistically significant data 
generated in stage I-IV patients (Chapter 3) is considered the ‘gold standard’ and will be 
used to compare results generated using this method, to allow an informed decision to be 
made on the potential use of this technique in the clinical/diagnostic setting. 
6.2.2.2.3 - Outcomes and significance 
After completing this proposed study, we will have demonstrated whether the ‘MELmiR-7’ 
panel can be used to stratify stage III patients into good or bad prognosis groups. 
Additionally, the miRNA serum and tumour expression levels at different stages of 
melanoma progression will provide a better understanding of the process of melanoma 
development and will highlight other avenues for further investigation into the fundamental 
mechanisms of cellular growth regulation of this cancer type.  
We aim to develop a minimally invasive blood test that will measure expression levels of 
the ‘melanoma-specific’ miRNA panels that can be used clinically/diagnostically. This 
biomarker panel will have the potential to assist in the early detection of disease in patients 
undergoing surveillance for recurrence, as well as increasing the predictive power of other 
prognostic indicators such as BRAF/NRAS mutation status in late stage patients. 
 
6.2.2.3 -  ‘MELmiR-7’ panel assessment for disease recurrence 
 
6.2.2.3.1 - Screening for recurrence following melanoma excision 
Current treatment guidelines (e.g. NCCN) recommend comprehensive physical 
examination every 3 to 12 months following excision.  While serum- and imaging-tests 
exist, they are not recommended due to poor sensitivity and high false positive rates.  
Therefore, a significant medical need and commercial market exists for a serum test that 
demonstrates acceptable sensitivity and specificity.  It is estimated that approximately 
100,000 new melanoma cases per year are diagnosed worldwide at stages I – III, who will 
require monitoring for recurrence following excision of the primary tumour.  The actual 
number of patients requiring follow-up testing in any year is much larger than this figure, 
since patients require regular monitoring for several years after diagnosis and surgery. 
Melanoma patients undergoing surveillance for disease recurrence by their clinician would 
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Figure 6.1: miR-514a-3p 
expression correlates with 
increased BRAFi treatment. 
therefore greatly benefit from a minimally invasive blood test to assess the presence of 
such. The data presented in Chapter 3 would be strengthened by assessing the panel in 
larger cohorts of stage I/II patients (NSR vs. REC) and stage III patients (NSR vs. REC). 
 
6.2.3 - miR-514a-3p 
 
6.2.3.1 - miR-514a-3p expression relative to RAF inhibitor therapy 
miR-514a-3p was proven to be a direct regulator of the tumour suppressor gene NF1 and 
was subsequently shown to be involved in the resistance mechanism following RAF 
inhibitor treatment (Chapter 2). Some new data has since been generated which was not 
included in the original manuscript submission.  
In a BRAFV600E mutant melanoma cell line, sensitive to RAF inhibitor therapy, we have 
shown that the expression level of miR-514a-3p appears to be induced following in vitro 
drug treatment (Figure 6.1). 
This implies that endogenous levels of 
this lineage-specific miRNA may 
actually increase following repeated 
doses of RAF-inhibitor in patients 
undergoing therapy. To test this 
hypothesis, two melanoma patients that 
were actively being treated with BRAF 
inhibitors each had a cell line derived 
from one of their stage IV tumours. 
During the course of treatment,  the patients developed resistance to the therapy. At this 
juncture, another cell line was derived, this time from the resistant tumour. Expression 
levels of miR-514a-3p were then determined in both the ‘sensitive’ and ‘resistant’ cell lines 
(Figure 6.2). 
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Figure 6.2: miR-514a-3p 
expression increases 
dramatically in BRAFi 
resistant cell line relative to 
the matched sensitive cell line 
It is clear from these data 
represented in Figure 6.2, that 
miR-514-3p expression is induced 
in patients with resistance to RAF 
inhibitors (Dabrafenib and 
Vemurafenib (PLX)). There is therefore a need to test this in a larger collection of patient 
material, however these resources are very difficult to collect and as such the material is 
limited. Nevertheless, taken together with the data presented in Chapter 2, we have 
shown that increased endogenous levels of miR-514-3p occurring in resistant tumours 
implies that an even greater regulation of NF1 protein  (and other target genes like CDK2) 
could occur, thus allowing for over-activation of MEK-ERK and the PI3K pathways. 
 
6.2.3.2 - Why does miR-514a-3p increase in expression following 
BRAFi treatment? 
In an attempt to explain why BRAFi treatment leads to an upregulation of miR-514a-3p, a 
search was performed for transcription factor binding sites in the putative promoter region 
of miR-514a-3p using TFSEARCH (threshold=90) [17]. There were numerous potential 
transcription factor binding sites including a FOXD3 (HFH-2) binding site between -215 
and -226 (GAATATTTCTTT) upstream from the start of the pre-miR-514a-3p sequence. 
FOXD3 is a forkhead box (FOX) transcription factor which is specific to the neural crest 
lineage (from which melanocytes arise) and has recently been shown to be upregulated 
following depletion of BRAF via siRNA [18] and PLX4032/PLX4720 [19, 20] inhibition of 
BRAFV600E mutant melanomas in vitro. Moreover, the induction of FOXD3 via its 
upregulation of ERBB3 [19] has provided another mechanism for resistance to occur. We 
propose that the induction of FOXD3 may also lead to an upregulation of miR-514a-3p, 
which in turn down-regulates NF1 and others, thus allowing for MEK-ERK and PI3-K 
signalling to continue. Considering the large upregulation of miR-514a following 
PLX4032/Dabrafenib treatment (Figure 1), and given the endogenous expression of miR-
514a in ~70% of melanoma cell lines, we propose that miR-514a should be considered a 
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major player in the inherent and acquired resistance to BRAF mutant targeted therapy, 
which warrants further investigation. 
 
6.2.3.3 - miR-514a-3p target genes and their involvement in 
melanomagenesis 
The biotin-labelled pull-down procedure identified over 1000 target genes common to 2 
melanoma cell lines (Chapter 2). Given the binding ability of miRNAs, this high number is 
not unexpected. Functional validation of all binding targets is however cost prohibitive 
using currently available methodologies. As such, refinement of the gene-list for only those 
known to be associated with ‘melanoma’ was one way to identify the ‘best’ candidates for 
validation. This method was used to identify NF1 as a binding target. Additional genes that 
were also of note, and will be the subject of future interrogation, include MC1R and 
CTNNB1 (β-catenin).  
 
6.2.3.3.1 - MC1R and miR-514-3p 
MC1R (melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)) is the 
master regulator of the pigmentation process. It is well known that that certain germline 
variants (single-nucleotide polymorphisms or SNPs) in MC1R are significantly associated 
with red-hair colour (RHC), fair skin, and poor tanning ability. Moreover, people with the 
RHC trait are more likely to developed melanoma. Recently, in a study by Cao et al [21], 
the underlying mechanism was revealed. The authors showed that upon UV exposure, the 
tumour suppressor gene, PTEN, interacts with MC1R which prevents degradation of PTEN 
thus allowing AKT to be inactivated. The authors revealed that RHC-associated MC1R 
variants (unlike wild-type MC1R) were unable to suppress AKT (via PI3K) leading to 
elevated PI3K/AKT signalling. In addition, in the presence of BRAFV600E, this led to 
oncogenic transformation. 
 
6.2.3.3.2 - CTNNB1 and miR-514-3p 
CTNNB1 (β-catenin) is a member of the WNT signalling pathway which is frequently 
activated in melanoma.  However, it has recently been shown that activation of β-catenin 
actually reduced the migratory nature of melanocytes and melanoma cell lines [4]. 
Although, in a murine mouse model, the presence of an NRAS mutation combined with 
increased β-catenin signalling, promoted lung metastasis [22]. Moreover, using 
immunohistochemistry, β-catenin expression has been associated with tumour progression 
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and patient survival [23-27]. The Wnt/β-catenin pathway has further been shown to 
regulate BRAF-mediated signalling and in turn undergoes negative regulation following 
BRAFV600E mutation [28]. Additionally, treatment of BRAFV600E mutant melanoma cell lines 
with BRAFi long-term leads to a reduction in Wnt/β-catenin signalling [29].  
 
Given the importance of both MC1R and CTNNB1 in these key signalling pathways, it 
would therefore be of importance to investigate if miR-514a-3p plays a role in the 
regulation process. 
 
6.2.3.3.3 – Future miR-514a-3p target-gene studies 
First, it would be interesting to see if the effect of miR-514a-3p binding to MC1R leads to 
elevated PI3K/AKT levels - similar to the effect of RHC-variants [21]. Further, the decrease 
in CTNNB1 expression, often observed in metastatic melanoma [26], may be the 
consequence of miR-514a-3p binding. In addition, as 69% of melanoma cell lines have 
endogenous expression of miR-514a-3p (Chapter 2), it is reasonable to suggest that it 
may play a significant role in modulating both the PI3K and WNT/β-catenin pathways. 
Furthermore, as we have shown that this miRNA can also regulate the MAPK pathway (via 
its direct regulation of NF1), the notion that it also has the potential to be involved in other 
key signalling pathways, warrants further investigation. 
 
6.2.4 - Concluding statement 
For melanoma patients with metastatic disease, the 5-year overall survival rates remain 
poor despite the improvement in objective clinical response rates due to current targeted 
therapies. However, if disease is detected and fully excised in stages I/II, then 5-year 
survival is one of the highest for all cancers. In patients with metastatic disease, survival 
differs depending on the extent of disease spread. Patients with metastases confined to 
regional lymph nodes (stage III disease) have 5-year survival of ~50%, whereas patients 
with widely disseminated metastases (stage IV disease) have 5-year survival of <15%. 
Until relatively recently, metastatic melanoma patients, had no viable treatment options for 
disseminated melanoma. The advent of targeted therapies has resulted in dramatically 
improved progression-free survival and objective clinical response rates. However, in the 
majority of cases, a complete response to therapy is still uncommon, with most patients 
succumbing to disease relapse. This can be attributed to inherent and acquired resistance 
to these new therapies.  
241
Thus, improved monitoring of a patient’s tumour burden is a potential method to increase 
survival rates, by allowing earlier therapeutic intervention. However, in clinical practice, 
there is currently a lack of reliable, sensitive and specific predictive biomarkers for 
detecting early melanoma progression. 
 
In melanoma, primary prevention strategies (e.g. sunscreen, protective clothing, and sun 
avoidance) and early detection of primary lesions offers the best outcome but relies 
heavily on self-monitoring and the expertise of medical professionals (G.P.s and 
Dermatologists). Yet, in Australia, these practices have proven to be highly effective; 
evidenced by increased detection of early stage tumours and high overall survival of 
patients with stage 0-II disease. Nevertheless, these practices are not absolute and 
disease can be missed, reoccur, or manifest as metastatic disease without the observation 
of a primary lesion.  
Therefore, there is currently an unmet need for highly specific and predictive biomarkers of 
melanoma burden and treatment resistance. The data presented in this thesis aimed to 
address these important issues by firstly identifying potential biomarkers in the form of 
‘melanoma-related’ miRNAs. This comprehensive assessment successfully yielded a 
highly specific and sensitive panel of miRNAs (MELmiR-7) that have the potential to be 
used as a primary screening tool for clinically undetected metastatic melanoma, as well as 
monitoring of disease recurrence/burden in patients undergoing surveillance. This miRNA 
panel, in combination with newly identified panels (from other recent studies), enables 
more precise measurement of disease progression, and in conjunction with current 
therapy options, may herald an increase in overall survival. 
 
In addition, for patients undergoing treatment with targeted therapies, better prediction of 
treatment resistance may aid treatment decisions for using first-line single- or combined-
agent therapy. Armed with an improved surveillance methodology, we hope to see better 
clinical management of metastatic disease, which in turn could increase objective clinical 
responses and survival times. Given the advances presented in this thesis, future 
melanoma treatment regimens should consider the utility of miRNAs as a prognostic aid in 
the clinical setting. 
  
242
6.3 - References 
1. Boyle, G.M., et al., Melanoma cell invasiveness is regulated by miR-211 
suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res, 2011. 
24(3): p. 525-37. 
2. Stark, M.S., et al., Characterization of the Melanoma miRNAome by Deep 
Sequencing. PLoS One, 2010. 5(3): p. e9685. 
3. Griffiths-Jones, S., The microRNA Registry. Nucleic Acids Res, 2004. 32(Database 
issue): p. D109-11. 
4. Bonazzi, V.F., M.S. Stark, and N.K. Hayward, MicroRNA regulation of melanoma 
progression. Melanoma Res, 2012. 22(2): p. 101-13. 
5. Bell, R.E., et al., Transcription factor/microRNA axis blocks melanoma invasion 
program by miR-211 targeting NUAK1. J Invest Dermatol, 2014. 134(2): p. 441-51. 
6. Levy, C., et al., Intronic miR-211 assumes the tumor suppressive function of its host 
gene in melanoma. Mol Cell, 2010. 40(5): p. 841-9. 
7. Streicher, K.L., et al., A novel oncogenic role for the miRNA-506-514 cluster in 
initiating melanocyte transformation and promoting melanoma growth. Oncogene, 
2012. 31(12): p. 1558-70. 
8. Hodis, E., et al., A landscape of driver mutations in melanoma. Cell, 2012. 150(2): 
p. 251-63. 
9. Krauthammer, M., et al., Exome sequencing identifies recurrent somatic RAC1 
mutations in melanoma. Nat Genet, 2012. 44(9): p. 1006-14. 
10. Cancer Genome Atlas Network. Electronic address, i.m.o. and N. Cancer Genome 
Atlas, Genomic Classification of Cutaneous Melanoma. Cell, 2015. 161(7): p. 1681-
96. 
11. Andersen, L.B., et al., Mutations in the neurofibromatosis 1 gene in sporadic 
malignant melanoma cell lines. Nat Genet, 1993. 3(2): p. 118-21. 
12. Maertens, O., et al., Elucidating distinct roles for NF1 in melanomagenesis. Cancer 
Discov, 2013. 3(3): p. 338-49. 
13. Whittaker, S.R., et al., A genome-scale RNA interference screen implicates NF1 
loss in resistance to RAF inhibition. Cancer Discov, 2013. 3(3): p. 350-62. 
14. Segura, M.F., et al., Melanoma MicroRNA signature predicts post-recurrence 
survival. Clin Cancer Res, 2010. 16(5): p. 1577-86. 
15. Franceschini, A., et al., STRING v9.1: protein-protein interaction networks, with 
increased coverage and integration. Nucleic Acids Res, 2013. 41(Database issue): 
p. D808-15. 
16. Balch, C.M., et al., Final version of 2009 AJCC melanoma staging and 
classification. J Clin Oncol, 2009. 27(36): p. 6199-206. 
17. Heinemeyer, T., et al., Databases on transcriptional regulation: TRANSFAC, TRRD 
and COMPEL. Nucleic Acids Res, 1998. 26(1): p. 362-7. 
18. Abel, E.V. and A.E. Aplin, FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S 
progression in melanoma cells. Cancer Res, 2010. 70(7): p. 2891-900. 
19. Abel, E.V., et al., Melanoma adapts to RAF/MEK inhibitors through FOXD3-
mediated upregulation of ERBB3. J Clin Invest, 2013. 123(5): p. 2155-68. 
20. Basile, K.J., E.V. Abel, and A.E. Aplin, Adaptive upregulation of FOXD3 and 
resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. 
Oncogene, 2012. 31(19): p. 2471-9. 
21. Cao, J., et al., MC1R is a potent regulator of PTEN after UV exposure in 
melanocytes. Mol Cell, 2013. 51(4): p. 409-22. 
22. Gallagher, S.J., et al., Beta-catenin inhibits melanocyte migration but induces 
melanoma metastasis. Oncogene, 2013. 32(17): p. 2230-8. 
243
23. Bachmann, I.M., et al., Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled 
for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin 
Cancer Res, 2005. 11(24 Pt 1): p. 8606-14. 
24. Chien, A.J., et al., Activated Wnt/beta-catenin signaling in melanoma is associated 
with decreased proliferation in patient tumors and a murine melanoma model. Proc 
Natl Acad Sci U S A, 2009. 106(4): p. 1193-8. 
25. Gould Rothberg, B.E., et al., Melanoma prognostic model using tissue microarrays 
and genetic algorithms. J Clin Oncol, 2009. 27(34): p. 5772-80. 
26. Kageshita, T., et al., Loss of beta-catenin expression associated with disease 
progression in malignant melanoma. Br J Dermatol, 2001. 145(2): p. 210-6. 
27. Maelandsmo, G.M., et al., Reduced beta-catenin expression in the cytoplasm of 
advanced-stage superficial spreading malignant melanoma. Clin Cancer Res, 2003. 
9(9): p. 3383-8. 
28. Biechele, T.L., et al., Wnt/beta-catenin signaling and AXIN1 regulate apoptosis 
triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci 
Signal, 2012. 5(206): p. ra3. 
29. Chien, A.J., et al., Targeted BRAF inhibition impacts survival in melanoma patients 
with high levels of Wnt/beta-catenin signaling. PLoS One, 2014. 9(4): p. e94748. 
 
 
  
244
